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Abstract 
The pir genes comprise the largest multi-gene family in Plasmodium, with members 
found in P. vivax, P. knowlesi and rodent malaria species. Despite their almost universal 
presence, little is known about the functions of the PIR proteins. To investigate the role 
PIR proteins play during the erythrocytic stages of infection, the P. chabaudi model was 
chosen, where this gene family is termed cir. 198 cir genes were identified in the P. 
chabaudi genome, 86% of which clustered to form two major sub-families on the basis 
of sequence similarity.  
Quantitative RT-PCR and Illumina RNA sequencing were used to investigate cir 
transcription during P. chabaudi infection. Both methods detected many cir genes 
transcribed at low levels, as shown previously for other pirs.  
Three of the transcribed cir genes were selected for recombinant protein expression in 
the yeast Pichia pastoris: PCHAS_000100, PCHAS_070130 and PCHAS_040110. 
Soluble PCHAS_000100 was used for measurements of CIR secondary structure. 
Conserved and sub-family specific peptides were also synthesized. Antibodies present in 
the sera of P. chabaudi immune mice recognized all CIR proteins and peptides.  
Polyclonal antibodies were used to determine CIR localization by confocal microscopy 
and flow cytometry. Whilst most CIRs were located within the parasites, some CIRs 
were also found on the infected erythrocyte surface of mature trophozoites. In addition, 
CIRs were detected at the apical end of merozoites. 
These results imply that CIR proteins are exposed to the immune system during P. 
chabaudi infection and are antigenic, yet immunization with most CIR proteins and 
peptides did not protect mice from P. chabaudi infection. Upon P. chabaudi challenge 
of mice immunized with CIR sub-family specific reagents, increased levels of cir 
transcripts belonging to the other major sub-family were detected. This may explain why 
few differences in parasitaemia were observed. The exception was observed during P. 
chabaudi challenge of mice immunized with PCHAS_000100, which were able to clear 
parasitaemia earlier than controls.  
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Western blot wash buffer 
PBS containing 0.05% Tween 20 
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List of media 
BMGY medium  
Liquid broth containing 1% yeast extract, 2% peptone, 100 mM potassium 
phosphate pH 6.0, 1.34 % yeast nitrogen base, 4x10-5 % biotin and 0.5 % 
glycerol 
 
BMMY medium  
Liquid broth containing 1% yeast extract, 2% peptone, 100 mM potassium 
phosphate pH 6.0, 1.34 % yeast nitrogen base, 4x10-5 % biotin and 0.5 % 
methanol 
 
LB broth  
1% tryptone, 0.5% yeast extract, 1% NaCl, pH 7.0 
 
Minimal methanol medium  
Liquid broth containing 1.34% yeast nitrogen base, 4x10-5% biotin and 0.5% 
methanol 
 
RPMI 1640 (Gibco) complete medium 
To which 6 mM HEPES, 0.5 mM sodium pyruvate, 2 mM L-glutamine, 50 µM 
β-Mercapto-ethanol (Invitrogen) and 10% heat inactivated foetal calf serum 
(PAA laboratories, Pasching, Austria) were added 
 
RPMI 1640 (Gibco) incomplete medium 
To which 6 mM HEPES and 2 mM L-glutamine (both Invitrogen) were added 
 
Yeast extract peptone medium  
Containing 1% yeast extract, 2% peptone and 2% dextrose 
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List of antibodies used  
Capture goat anti-mouse Ig (Southern Biotechnology) used for ELISA: 2 µg/ml 
 
Primary Abs: 
Ter119 conjugated to biotin (Biolegend) 
- Recognizes a M. musculus Glycophorin A associated protein (Kina et al., 2000) 
- Western blot: 32 pg/ml 
- Immuno-fluorescence: 50 µg/ml 
 
NIMP23 
- Recognizes P. chabaudi MSP1p21 (Kina et al., 2000, Boyle et al., 1982, McKean 
et al., 1993) 
- Western blot: 18 µg/ml 
- Immuno-fluorescence: 50 µg/ml 
 
Anti-histidine tag (Novagen) 
- Western blot: 0.5 µg/ml 
 
Purified mouse IgM, IgG1, IgG2a, IgG2b, and IgG3 (Sigma-Aldrich)  
used for ELISA: 2 µg/ml 
 
Polyclonal Anti-CIR Abs generated in mice 
- Flow cytometry: diluted 1/50 
 
Polyclonal Anti-CIR Abs generated in rabbit 
- Western blot: diluted 1/500 
- ELISA: diluted 1/10,000 
- Immuno-fluorescence: diluted 1/50 
 
Secondary Abs for ELISA: 
- Goat anti-mouse IgM (Southern Biotechnology): 2 µg/ml 
- Goat anti-mouse IgG1 (Southern Biotechnology): 2 µg/ml 
- Goat anti-mouse IgG2a (Southern Biotechnology): 2 µg/ml 
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- Goat anti-mouse IgG2b (Southern Biotechnology): 2 µg/ml 
- Goat anti-mouse IgG3 (Southern Biotechnology): 2 µg/ml 
 
Secondary reagents for flow cytometry: 
- Goat anti-mouse IgG conjugated to FITC (Southern Biotechnology): 10 µg/ml 
- Hoechst 33342 (Invitrogen): 10 µg/ml 
 
Secondary reagents for immuno-fluorescence: 
- Goat anti-rabbit IgG conjugated to Alexa 680 (Molecular Probes): 10 µg/ml 
- Goat anti-mouse IgG conjugated to Alexa 594 (Molecular Probes): 10 µg/ml 
- Streptavidin conjugated to Alexa 750-Allophycocyanin (Molecular Probes): 10 
µg/ml 
- 4',6-Diamidino-2-phenylindole (DAPI, Sigma Aldrich): 1 mg/ml 
 
Secondary Abs for Western blot: 
- Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG, (Southern 
Biotechnology): 1:10,000 dilution 
- Horseradish peroxidase (HRP)-conjugated Abs: goat anti-rabbit IgG, goat anti-
mouse IgG and goat anti-rat igG (Biorad): 1:10,000 dilution 
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Chapter 1: Introduction 
1.1 Malaria is a global burden  
Half of the world’s population is at risk of malaria infection and the disease results in 
over a million deaths every year (WHO, 2008). The incidence is particularly high in 
children under five years of age, with an estimated 0.8% infant mortality in Africa alone 
(Rowe et al., 2006). 
Malaria is caused by Plasmodium parasites, of which four have been historically known 
to infect humans: P. falciparum, P. vivax, P. ovale and P. malariae. Infection is 
characterized by relapsing fever, however there are severe syndromes that can also 
manifest. P. falciparum is widely attributed as the most deadly species, because these 
infections have a high propensity to develop into the severe syndromes listed in Table 1. 
The other Plasmodium species have been considered more benign, however, reports 
have emerged in recent years not only that P. vivax is capable of causing severe disease 
[reviewed by (Price et al., 2009)], but also a fifth human malaria exists: P. knowlesi 
(White, 2008). 
 
Table 1: Severe malaria disease syndromes.  
Syndromes Clinical features Disease mechanisms References 
Severe 
anaemia 
Shock,  
Respiratory distress 
Increased erythrocyte destruction 
(phagocytosis, parasite- and complement- lysis) 
Reduced erythrocyte production 
(Menendez et al., 2000, 
Phillips et al., 1986, Stoute et 
al., 2003, Devine, 1991, 
Sexton et al., 2004) 
Cerebral 
malaria 
(CM) 
Impaired 
consciousness 
Convulsions, 
Long term 
neurological 
deficits 
Microvascular obstruction  
(parasites, platelets, rosettes, microparticles) 
Pro-inflammatory cytokines, 
Parasite toxins (eg glycosylphosphatidylinositol) 
(Taylor et al., 2004, Grau et 
al., 1987, Xiao et al., 1999, 
MacPherson et al., 1985, 
Newbold et al., 1997, Pain et 
al., 2001, Grau et al., 2003, 
Wassmer et al., 2004, Allen et 
al., 1999, Rowe et al., 1995, 
Cockburn et al., 2004), 
(Rogerson et al., 1999)1 
Metabolic 
acidosis 
Respiratory distress, 
Hypoxia,  
Acidaemia, 
Reduced CVP. 
Reduced tissue perfusion (eg hypovolaemia), 
Parasite products, 
Pro-inflammatory cytokines, 
Pulmonary pathology (eg airway obstruction) 
(Marsh et al., 1995, English et 
al., 1996, Clark and Cowden, 
2003), (Grau et al., 1989)2, 
(Kwiatkowski, 1990)3, (Day 
et al., 1999)4, 
Other 
Hypoglycaemia, 
 Disseminated intra 
vascular 
coagulation 
Parasite products and/or toxins, 
Pro-inflammatory cytokines,  
Cytoadherance 
(Clark and Cowden, 2003, 
Grau et al., 1989, Luty et al., 
1999, Anstey et al., 1996, 
Clark et al., 2003) 1 2 3 4 
Adapted from (Mackintosh et al., 2004). Central venous pressure was abbreviated to CVP. 
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It appears that in South East Asia, P. vivax infection is capable of progressing to severe 
disease as often as P. falciparum, with a similar proportion of fatal infections (Genton et 
al., 2008, Kochar et al., 2005, Tjitra et al., 2008, Anstey et al., 2009). In addition, P. 
vivax infection during pregnancy can cause miscarriage or decreased full term birth 
weight (Nosten et al., 1999). P. knowlesi is classed as an ‘emerging human pathogen’, 
transmitted zoonotically from its natural hosts: the long- and pig-tailed macaques 
(Macaca fasicularis and Macaca nemestrina). In fact, almost a third of malaria cases in 
Sarawak, Malaysia, were due to P. knowlesi infection, rising to 77% in some regions 
(Cox-Singh et al., 2008).  
The repeated nature of infection means that malaria exerts an enormous socio-economic 
cost to endemic countries - estimates suggest that P. falciparum malaria may have 
reduced the Gross Domestic Product of some African countries by almost 10% (Gallup 
and Sachs, 2001), and P. vivax malaria could have a global burden of US $1.4 - 4.0 
billion per year (Price et al., 2009). 
In developed countries, malaria has largely been eradicated by widespread drainage  and 
the use of toxic insecticides such as DDT, which purged the vector population: female 
Anopheles mosquitoes, in the mid 20th century. However, such insecticides are now 
known to be environmentally hazardous and mosquitoes have developed resistance to 
those still in common usage, thus alternative approaches are sought to control the 
prevalence of this disease in the 99 countries where malaria remains endemic (Feachem 
et al., 2010). 
Not only have malaria vectors developed resistance to insecticides, but increased drug 
resistance of parasites is also a growing problem. Resistance to chloroquine first 
emerged in East Africa in 1978 (Trape, 2001), a phenomenon now found worldwide 
and foci of artemisinin resistant parasites have been detected recently on the Cambodia-
Thailand border (Yeung et al., 2009). This is particularly worrying since artemisinin 
based combination therapy is the frontline defence for patients with severe P. 
falciparum malaria (WHO, 2008). Clearly, multiple and coordinated approaches will be 
required for future malaria control in the face of such drug resistance, even if the 
desired ‘elimination era’ is not attainable, particularly in Africa (Moonen et al., 2010, 
Tatem et al., 2010). A major advantage in this struggle would be the development of a 
malaria vaccine, which ideally would not only protect individuals from infection, or at 
least from severe disease, but would also reduce the possibility of parasite transmission 
and therefore re-infection. 
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1.2  Plasmodium  
1.2.1 The parasite life-cycle 
Plasmodium parasites have a complex life cycle, involving two hosts and development 
into several morphologically distinct forms, summarized in Figure 1.  
 
 
Figure 1: The Plasmodium life-cycle.  
Adapted from: http://www.cdc.gov/malaria/biology/life_cycle.htm. Sporozoites injected from an infected 
Anopheles mosquito migrate to the liver, where they invade hepatocytes and merozoites develop. Upon 
release from the liver, merozoites enter the bloodstream where they undergo asexual multiplication in the 
erythrocytes. After infecting red blood cells, parasites mature into ring stages, trophozoites and then into 
schizonts, which rupture releasing further merozoites. During the erythrocytic replicative stages, some 
parasites also differentiate into gametocytes, which undergo sexual maturation when taken up by an 
Anopheles host. Within the mosquito, sexual reproduction occurs, producing a motile zygote known as an 
ookinete. Following penetration of the gut wall, ookinetes differentiate into oocysts, which, rupture on 
maturity to release sprorozoites. The sporozoites migrate to the mosquito salivary glands, where they may 
be injected into another mammalian host.   
 
The definitive host, where sexual reproduction takes place, is the female Anopheles 
mosquito, which injects infective sporozoites into the skin of the second, mammalian 
host during a blood meal. In the second host, sporozoites migrate through the skin for 
several hours (Yamauchi et al., 2007), with up to 80% reaching the blood vasculature 
and completing their migration to the liver (Frevert et al., 2005), where they invade 
hepatocytes. Plasmodium development within a single hepatocyte results in the 
production of thousands of merozoites, which are released into the blood stream. 
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Recently, it has been discovered that, at least in the rodent model P. yoelii, merozoites 
are released into the bloodstream within a protective membrane, the merozome, which 
protects the new merozoites from liver resident phagocytes. Merozomes were observed 
to sequester in the lung, where they ruptured to release the merozoites (Baer et al., 
2007). 
Certain species such as P. vivax are able to form quiescent uni-nucleate hyponozoites 
after hepatocyte invasion, such that the parasites may re-enter the cell cycle and give 
rise to infective parasites several months after initial sporozoite injection (Krotoski et 
al., 1982). This adaptation likely facilitates Plasmodium transmission in areas where the 
dry season prevents continual breeding of the mosquito vector. 
Once released into the blood stream, merozoites begin red blood cell (RBC) invasion, 
involving attachment of parasites to the RBC surface, followed by re-orientation and 
invagination of the RBC membrane to form a parasitophorous vacuole [PV; reviewed 
by (Cowman and Crabb, 2006)]. Within the PV parasites develop first into ring stages, 
then trophozoites, and finally multi-nucleate schizonts. Rupture of schizonts releases 
more merozoites to continue cycling through this asexual development process. During 
this time, some parasites will begin to differentiate into pre-sexual stages: the male and 
female gametocytes. When these are taken up in the blood meal of an Anopheles 
mosquito, gametocytes mature into reproductively capable gametes and sexual 
reproduction may occur. This process eventually results in the generation of further 
infective sporozoites for continuation of the parasite life-cycle. 
The repeated cycles of erythrocytic infection, intracellular growth, rupture and re-
infection give rise to clinical symptoms and pathology. Infected RBCs (iRBCs) and 
released parasitic material is thought to be involved in the induction of the host immune 
response. Malarial anaemia occurs as a result of RBC destruction and reduced RBC 
synthesis, which is partly due to the diversion of new erythroid progenitors towards 
myeloid/lymphoid development in the haematopoietic pathway (Belyaev et al., 2010). 
During development within iRBCs, Plasmodium parasites adapt their host cell in order 
to gain access to nutrients and export waste products. As a result, the surfaces of 
infected erythrocytes are extensively modified with parasite proteins. However, the 
presence of these molecules also makes iRBCs a target for innate and adaptive immune 
responses and clearance by the reticulo-endothelial system of the spleen.  
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1.2.2 Cyto-adherance 
Patients experiencing severe malaria often have vascular occlusion by iRBCs, which 
may obstruct blood flow and cause pathology [reviewed by: (Rogerson et al., 2007, 
Mackintosh et al., 2004, Rasti et al., 2004, Van der Heyde et al., 2006, Dondorp et al., 
2008, Maude et al., 2009a, Maude et al., 2009b)]. Whilst this has not been definitively 
proven as the cause of severe malaria, iRBCs are known to accumulate in the brains of 
patients dying from cerebral malaria (Montgomery et al., 2007), and cyto-adherant 
parasite phenotypes have a strong correlation with severe disease (Ockenhouse et al., 
1991, Smith et al., 2000) [and reviewed by (Berendt et al., 1994, De Souza et al., 
2009)].  
Plasmodium iRBCs are known to cytoadhere to both endothelium and to uninfected 
RBCs; these phenomena are known as sequestration and rosetting, respectively. The 
formation of rosettes may conceal iRBCs from immune responses. Observations that P. 
knowlesi iRBCs no longer sequestered after host splenectomy (Barnwell et al., 1982, 
Barnwell et al., 1983) have led to the theory that sequestration of iRBCs in the deep 
vasculature prevents their clearance by the spleen. Several host receptors have been 
determined which mediate sequestration, including: cluster determinant 36 (CD36), 
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 
(ICAM1), E-selectin, platelet-endothelial cell adhesion molecule c1 (PECAM-1/CD31), 
P-selectin, chondroitin sulphate A (CSA) and hyaluronic acid (HA; (Barnwell et al., 
1989, Ockenhouse et al., 1992, Berendt et al., 1989, Fried and Duffy, 1996, Rogerson et 
al., 1995, Treutiger et al., 1997, Beeson et al., 2000, Ockenhouse et al., 1989, Ho et al., 
1998).  
 
1.2.3 Models of malaria 
Plasmodium parasites usually have a limited host range, and the five species infecting 
humans will only grow in higher primates or in vitro RBC culture for some species. 
This often makes dissection of key components for immunity to the human-infecting 
Plasmodium species unethical or inaccessible for researchers.  
Fortunately, some of the features of human malaria are represented in rodent-infecting 
Plasmodium species, which may be used to model the human disease. Among these, 
Plasmodium chabaudi was isolated from Thamnomys rutilans thicket rats in the African 
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Congo (Landau, 1965, Landau and Boulard, 1978). Other rodent malarias include P. 
berghei, P. yoelii and P. vinckei.  
Infection by different Plasmodium species can cause different pathologies - either acute 
(where the primary infection results in death or parasite clearance) or chronic (long-
term) infections, which may recrudesce (forming secondary peaks of infection). The 
features of these rodent malarias are highly dependent upon the parasite strain used 
(McKenzie et al., 2008), in combination with the host genetic background, this is 
summarized in Table 2. 
 
Table 2: Features of rodent malaria models.  
Species, 
sub species, 
clone 
RBC 
invasion 
pref. 
Susceptibility 
to anaemia 
Susceptibility 
to cerebral 
malaria 
Organs of 
iRBC seq. 
(acc.)  
References 
P. berghei 
ANKA RE 
C57BL/6: L 
CD-1: L 
C57BL/6J: NL 
C57BL/6: S 
CBA: S 
BALB/c: R 
Lungs, 
Adipose 
tissue & 
Spleen 
(Brain) 
(Franke-Fayard et al., 
2005b, Engwerda et al., 
2005, Asami et al., 1992, 
Maggio-Price et al., 1985, 
Franke-Fayard et al., 2006, 
Spaccapelo et al., 2010) 
P. yoelii 
yoelii 17X RE & E BALB/c: NL Most strains R (Spleen) 
(Asami et al., 1992, 
Landau and Boulard, 1978, 
Martin-Jaular et al., 2011) 
P. yoelii 
yoelii 17XL RE & E 
BALB/c: L 
C57BL/6: L Most strains S  (Weiss et al., 1989) 
P. chabaudi 
chabaudi AS E 
A/J: L 
C57BL/6: NL 
C57BL/6 IL-
10 KO: S 
Liver 
 (Spleen & 
Brain) 
(Gilks et al., 1990b, Mota 
et al., 2000, Yap and 
Stevenson, 1992, Sanni et 
al., 2004) 
P. chabaudi 
adami DS E 
C3H: L 
C57BL/6: NL 
  (Villeval et al., 1990) 
P. vinckei 
vinckei E    (Silverman et al., 1987) 
Adapted from: (Lamb et al., 2006). Preference was abbreviated to pref., reticulocytes and erythrocytes 
were abbreviated to RE and E, lethal and non-lethal were abbreviated to L and NL, resistant and 
susceptible were abbreviated to R and S, sequestration and accumuation were abbreviated to seq. and 
acc., respectively.  
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1.3  Protective immunity to malaria  
1.3.1 Cells of the immune response  
The immune system is divided into the innate and adaptive responses. Cells of the 
innate immune system comprise a host of leukocytes, which recognize and respond to 
pathogens non-specifically. These include mast cells, eosinophils and basophils, which 
produce histamine amongst their responses; Natural killer (NK) cells, which primarily 
target host cells that have down-regulated MHC class I, and the phagocytic neutrophils, 
macrophages, and dendritic cells. The latter two cell types are capable of presenting 
processed antigens to cells of the adaptive response, stimulating antigen-specific 
responses, and are thus known as antigen presenting cells (APCs). 
The adaptive immune response is comprised of lymphocytes, all of which first develop 
in the bone marrow. T cells then migrate to the thymus, where they are exposed to the 
full host peptide repertoire and self-recognizing cells are deleted. Thymic development 
results in T cell subsets possessing the surface receptor CD8, also known as cytotoxic 
lymphocytes; and CD4, which are T helper (Th) cells.  
Lymphocytes completing their development in the bone marrow are known as B cells. 
Once activated by a Th cell specific for the same antigen, B cells proliferate and 
differentiate into plasma cells, whose primary purpose is the production of antibody 
(Ab). Abs provide the basis for humoral immunity and consist of a variable, antigen 
specific region, and a constant region. The constant region provides different effector 
functions, according to which C-region gene segment is incorporated: IgA, IgD, IgE, 
IgG or IgM.  
 
1.3.2 Immune response overview  
Upon infection with a typical pathogen, the innate immune response is the first line of 
defence. Recognition of pathogen-associated molecular patterns (PAMPs) by pattern 
recognition receptors (PRRs) causes macrophages, dendritic cells and neutrophils to 
raise the alarm by secreting inflammatory cytokines and chemokines. This promotes 
migration of other leukocytes to the site of infection, and at the same time APCs 
migrate to lymphoid tissues to stimulate an antigen specific, adaptive response. 
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Antigen presenting cells process antigens into short peptides and present these in the 
context of MHC class II molecules to T helper cells [reviewed by (Jenkins et al., 2001)]. 
T helper cells recognizing their cognate antigen, in the presence of co-stimulatory 
molecules derived from the APC, are stimulated to divide and secrete different 
cytokines, depending upon the conditions under which they were activated [for 
example: (Hugues et al., 2004, Shakhar et al., 2005)]. The Th subsets are summarized in 
Figure 2.  
 
 
Figure 2: The major T helper cell subsets.  
Adapted from (Brand, 2009). Naïve CD4+ T helper (Th) cells, once activated by presentation of their 
cognate antigen, differentiate into four major subsets: Th1, Th2, Th17 and T regulatory cells, which may 
develop within the thymus (Treg) or be induced in the periphery (iTreg). A fifth subset has been recently 
described, Th9 (Veldhoen et al., 2008), not included in this diagram. Different conditions dispose CD4 T 
cells to differentiate into the different subsets, indicated by red arrows and text. The cytokines produced 
by the different subsets are shown with blue arrows and text. 
 
At first, B cells produce both IgM Abs and membrane bound IgD. The function of IgD 
is unknown, and animals lacking IgD appear to retain fully functional immune 
responses (Blattner and Tucker, 1984, Roes and Rajewsky, 1991). IgM Abs individually 
tend to bind antigen with low affinity, but high avidity; they can form pentamers which 
allows multi-point binding, and also efficiently activate the complement cascade, 
described below.  
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After B cell activation, the B cells and their cognate Th cells migrate into follicles 
within the lymphoid tissue where the B cells proliferate, forming germinal centres. 
Within the germinal centre further genetic refinement occurs via the processes of 
somatic hyper mutation and class switching. Somatic hyper mutation involves the 
accumulation of point mutations within the variable region, and enables more avid 
antigen recognition; whilst class switching involves physical recombination to change 
the constant region of the antibodies produced to either IgG, IgA and IgE Ab isotypes. 
These act in different tissues, IgG being the major isotype found in the blood and extra 
cellular fluid. IgG Abs may comprise one of four sub-classes, termed 1 - 4 in humans, 
and 1, 2a, 2b (BALB/c, or 2c in C57BL/6) and 3 in mice.  
Antibody functions can be broadly divided into three types, examples of which are 
shown in Figure 3. All Ab isotypes can perform neutralization and opsonization 
functions to different degrees, whilst complement can be activated most efficiently by 
IgM, but also by IgG.  
- Where pathogens are not recognized by pattern recognition receptors present on 
innate immune cells, antibodies can bind to the pathogen surface and signal for 
their phagocytosis, a process known as opsonization.  
- Neutralization involves direct antigen binding, thus inhibiting pathogen invasion 
or the action of their products. This may be mediated by agglutination of Abs to 
each other, a process that can also aid opsonization. 
- Complement is a cascade of plasma proteins that can directly kill certain 
pathogens, and can also promote opsonization. The complement cascade may be 
activated in a variety of ways, including the classical pathway by Ab: antigen 
complexes (Cooper, 1985). 
The key advantage of the adaptive response over innate responses is the ability to 
generate memory of an infection. Memory T and B lymphocytes can divide and respond 
more quickly and effectively to a subsequent infection, whilst the residual presence of 
long-lived plasma cells in bone marrow provides a threshold level of serum-antibody 
that should prevent establishment of a subsequent infection.  
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Figure 3: The three major functions of antibodies.  
Adapted from (Janeway, 2007). These examples show three of the possible antibody functions during 
bacterial infection, although the same responses also occur during Plasmodium infection. The left panels 
show neutralization of a bacterial toxin, which may then be ingested by macrophages. This could equally 
apply to Plasmodium toxins, such as glycosylphosphatidylinisotol. The centre panels show opsonization 
of whole bacteria, followed by phagocytosis, this process may occur for merozoites or iRBC during the 
erythrocytic stages of Plasmodium infection. Finally, the right panels show the binding of complement to 
the bacterial cell, followed by direct complement-mediated lysis. This mechanism acts on Plasmodium 
gametocytes (Healer et al., 1997), however in vivo, iRBC appear to be protected from complement 
mediated lysis (Kawamoto et al., 1997, Wiesner et al., 1997).   
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1.3.3 Defining immune responses to malaria 
Selective experimental removal of cell populations (either by depletion or the use of 
knock-out animals) has allowed investigation into which cell types are essential for 
resolving Plasmodium infection and providing immune memory. Many of these studies 
have used intra-peritioneal infection of mice with P. chabaudi, a model for the blood 
stages of malaria. 
In this model, C57BL/6 and BALB/c mice experience a peak of parasitaemia around 
day 7 when injected with an infectious dose of 105 iRBCs. At the peak, 20-40% of 
RBCs may be infected; this is quickly controlled, and develops into a chronic infection 
where parasites may remain at sub-patent levels for several months (Wargo et al., 
2006). Recrudescences occur on day 25 and around day 30, each comprising iRBCs 
with different surface phenotypes than those observed previously in the infection 
(McLean et al., 1982). A typical course of parasitaemia is illustrated in Figure 4, along 
with immune characteristics important for resolution of infection. 
 
 
Figure 4: Characteristics of P. chabaudi infection in mice.  
Adapted from (Langhorne et al., 2004). The percentage of RBC infected is shown in black. During the 
first few days of infection, interleukin 12 is produced by macrophages and dendritic cells, thereby 
inducing development of a Th1 response, characterized by high levels of interferon-γ (IFN-γ) and tumour 
necrosis factor-α (TNF-α).  This inflammatory environment aids control of peak parasitaemia around day 
10 of infection. To prevent immune-mediated pathology and provide help for Ab production, the CD4 
positive population then switches to become predominantly Th2 type, allowing the production of the high 
Ab titres required for parasite clearance.  
 
During the initial stages of infection, cells of the innate response act in various ways to 
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inhibit parasite growth, including the release of parasitocidal mediators and receptor-
mediated phagocytosis by macrophages and monocytes (Stevenson and Riley, 2004). 
Other innate cells such as NK, natural killer T- (NKT), and gamma delta T- (γδT) cells 
may also be important for early control of parasitaemia (Mohan et al., 1997, Seixas et 
al., 2002, Artavanis-Tsakonas and Riley, 2002, Roetynck et al., 2006). 
Resolution of P. chabaudi infection, however, requires both T and B lymphocytes: in 
their absence, mice were unable to control the peak of parasitaemia and succumbed to 
infection. Equally, when CD4+ cells were adoptively transferred into these animals, 
they were able to control the acute phase of infection but not to eliminate the parasites 
(Meding and Langhorne, 1991). 
Control of the peak of infection is characterized by inflammation, predominantly high 
levels of interferon gamma (IFN-γ), and the signalling cascade that it induces (Meding 
et al., 1990, Stevenson et al., 1990, van der Heyde et al., 1997, Favre et al., 1997, Tsuji 
et al., 1995). This is typical of a Th1 response, which is known to activate macrophages. 
Indeed, it has recently been shown that inflammatory monocytes, which differentiate 
into macrophages, aid parasite clearance around day 10 of infection (Sponaas et al., 
2009). After the acute phase of parasitaemia is resolved, CD4 responses convert 
towards a Th2 phenotype, producing IL-4, IL-5, IL-6, and IL-10, and stimulating B 
cells to produce antibody (Langhorne, 1989). Importantly, in the absence of B cells, 
mice were able to control the peak of parasitaemia to sub-patent levels but unable to 
eliminate parasites (Grun and Weidanz, 1983).  
It is likely that all of the three mechanisms described in Figure 3 are involved in parasite 
removal. In P. chabaudi, the absence of complement did not affect the ability of mice to 
resolve primary infection, but increased susceptibility to re-infection (Taylor et al., 
2001). Evidence from P. falciparum implies that neutralizing Abs inhibit RBC invasion 
(Blackman et al., 1990), and that opsonization aids iRBC clearance from both blood and 
placenta, although it is not required for complete parasite elimination (Bull et al., 1998, 
Keen et al., 2007, Rotman et al., 1998). Abs generated to antigens displayed on the 
iRBC surface enhance phagocytosis and destruction of iRBC in vitro (Mota et al., 
1998), and the presence of opsonising Abs is associated with protection (Groux and 
Gysin, 1990). Importantly, passive transfer of Abs from clinically immune adults has 
been successfully used to treat patients with severe malaria (Cohen et al., 1961, 
Sabchareon et al., 1991), demonstrating the crucial role of Abs in immunity to severe 
disease. 
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1.3.4 Generation of immune memory to Plasmodium 
The acquisition of immunity to malaria in humans is complicated by many factors, 
including infection with different Plasmodium species and strains, host genetic variation 
and transmission intensity. For example, both in Kenya and the Gambia, the risks of 
developing cerebral malaria or severe malaria anemia in childhood were reported to be 
lowest among populations experiencing the highest transmission intensities, and vice 
versa (Mbogo et al., 1993, Mbogo et al., 1995, McElroy et al., 1997, Snow et al., 1997).  
Nonetheless, malaria infection follows a common pattern in most endemic areas of sub-
Saharan Africa: Infants are initially protected from parasitaemia, and severe disease, 
probably due to the presence of maternal IgG. Around 3-4 months old, children begin to 
experience clinical episodes and are extremely vulnerable to severe disease and 
mortality. Cerebral malaria (CM) commonly develops in children between 2 and 4 years 
of age, the risk of this complication usually subsides after age 5. After puberty, severe 
disease is rare, although clinical episodes may occur several times per year. This 
situation is maintained throughout adult life in endemic areas, and many people appear 
to develop immunity to clinical disease, whilst maintaining asymptomatic parasitaemia 
(Doolan et al., 2009).  
There is an important exception to the above: pregnancy associated malaria [PAM, 
(Rogerson et al., 2007, Hviid et al., 2010)]. Women otherwise clinically immune to 
malaria may experience severe disease, predominantly during their first pregnancy, after 
which immunity to the condition begins to develop. This is caused in part by the 
accumulation of iRBCs in the placenta, reducing birth weight or leading to miscarriage.  
For reasons awaiting discovery, individuals living in malaria-endemic areas appear 
never to develop protection from infection, otherwise known as sterilizing immunity 
(Sergent and Parrot, 1935, Obi et al., 2011). Therefore, naturally acquired immunity to 
pre-erythrocytic stages has been considered ineffective (Hoffman et al., 1987). In 
contrast, deliberate exposure to pre-erythrocytic antigens by vaccination is capable of 
inducing protective responses (Mueller et al., 2005, Hoffman et al., 2002, Alonso, 
2006). 
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1.4  Factors influencing the outcome of malaria 
The generation of protective immunity and the severity of disease during Plasmodium 
infection may be affected by several factors, which are considered below. 
Firstly, epidemiological data suggest that in endemic areas, almost a quarter of the risk 
of developing severe malaria is due to host genetic factors (Mackinnon et al., 2005). For 
example, many protective traits affect the ability of parasites to invade and replicate 
within RBCs, and as such have been preserved in populations continually exposed to 
malaria infection, whilst these factors have been removed by selection in non-malaria 
exposed populations. Examples include sickle cell trait, thalassaemia, glucose-6-
phosphate deficiency and ovalocytosis, which provide protection for heterozygous 
individuals (Allen et al., 1997, Gilles et al., 1967, Miller, 1999, Ruwende et al., 1995). 
Also the Duffy negative trait common in African peoples prevents RBC invasion by P. 
vivax (Miller et al., 1976), resulting in Africans comprising less than 4% of the global 
population at risk of P. vivax infection (Guerra et al., 2010). Considerable host genetic 
variability also lies in the composition of each individual’s immune response. For 
example, whilst inflammatory Th1 responses are required to control parasitaemia and 
for generation of protective immunity (Sam et al., 1999, Su et al., 2002), over-
production of inflammatory cytokines such as TNFα and IFNγ cause immuno-
pathology (Kwiatkowski et al., 1990, Lyke et al., 2004). The regulatory cytokine IL10 
reduces inflammation, to the extent that P. chabaudi infection in mice lacking IL10 is 
frequently lethal (Li et al., 1999). Therefore polymorphisms in the genes or regulation 
of IL10, TNFα and IFNγ (Juliger et al., 2003, Carpenter and al., 2007, Bayley et al., 
2004, Henri and al., 2002) could play a critical role in the ability to clear infection, and 
the extent of immuno-pathology experienced (Li et al., 2003, Omer et al., 2003, 
Kurtzhals, 1999). 
Secondly, people who leave malaria-endemic areas appear to lose their previously 
established immunity, such that upon moving back to the endemic area, they are equally 
susceptible to infection as naïve individuals (Jennings et al., 2006). This has led to 
conjectures that immune memory may be somehow defective - a hypothesis 
investigated in our laboratory using antigen specific responses to Merozoite Surface 
Protein 1 (MSP1) in the model P. chabaudi, outlined below: 
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‐ The generation of humoral responses appeared intact, as MSP1 specific memory 
B cells and IgG secreting long-lived plasma cells were detectable for more than 
eight months following primary infection. Upon homologous challenge, 
functional memory B-cell and long-lived plasma cell responses were induced 
(Ndungu et al., 2009). These memory B cells could be detected in peripheral 
blood throughout infection, but plasma cells were only transiently detected in 
the blood during acute infection, possibly reflecting their migration to bone 
marrow (Nduati and Ng, 2010). These data support the finding that P. 
falciparum specific memory B cells can persist in adults in the absence of 
exposure for over eight years (Migot et al., 1993), and suggest that deficiencies 
in the generation and maintenance of the humoral response do not contribute to 
prolonged susceptibility to malaria. 
 ‐ CD4+ T cells specific for malarial antigen MSP1 have been shown to protect 
immuno-deficient RAG2-/- mice from an otherwise lethal P. chabaudi infection, 
providing that a threshold of anti-parasite Abs was also present (Stephens et al., 
2005). After experiencing a primary P. chabaudi infection, these CD4+ T cells 
could be visualized in three subsets: central memory, and early and late effector 
memory cells, based on the relative expression of the following surface markers: 
CD44, IL-7Rα, CD62L and CD27, and the cytokines IFNγ and IL10 (Stephens 
and Langhorne, 2010). Adoptive transfer of each of these sorted subsets, isolated 
from a chronically infected mouse, was able to protect RAG2-/- mice both from 
excessive parasitaemia and pathology, better than the same cells isolated from 
drug-cured mice (Stephens and Langhorne, 2010). These data suggest that 
chronic antigen stimulation aids protective memory CD4+ responses. 
In the field, humoral immunity generated to MSP1 after infection correlates with 
substantial protection against homologous challenge (Weir and Cockerham, 1984, Riley 
et al., 1992, Egan et al., 1996, Su and Wellems, 1996, Branch et al., 1998, Anderson et 
al., 1999, Dodoo et al., 1999, Kitua et al., 1999, Conway et al., 2000, Metzger et al., 
2003, Polley et al., 2004, Perrant et al., 2005, Nebie et al., 2008, Osier et al., 2010, 
Stanisic et al., 2009). Whilst it is possible that responses to MSP1 may not be 
representative of the total immune response to other antigens, these data suggest that 
established immune memory to Plasmodium can persist. This is supported by evidence 
from Madagascar, where malaria was eradicated for 30 years, before re-emergence. 
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Adults who were immune before eradication remained more resistant to clinical disease 
than naïve individuals (Deloron and Chougnet, 1992).  
Data acquired from field studies where P. falciparum infection was dominant (Marsh 
and Kinyanjui, 2006) indicate that there are three phases of susceptibility to malaria, 
which are shown in Figure 5.  
 
 
Figure 5: The different types of malaria experienced by endemic populations.  
 
Adapted from (Marsh and Kinyanjui, 2006). The percentage of individuals in the endemic area of Kilifi, 
Kenya, experiencing severe malaria (green), ‘mild’ uncomplicated malaria (blue), or asymptomatic 
Plasmodium infection (orange), are shown, along with the ages at which these syndromes manifest. 
 
Immunity to severe disease and morbidity and may be acquired fairly quickly in life. 
Gupta and colleagues used mathematical modelling to suggest that this phase of 
immunity (non-cerebral severe malaria defined as “Plasmodium falciparum infection 
requiring hospital admission”) may be acquired after only one or two infections (Gupta 
et al., 1999). Immunity to clinical symptoms takes longer to develop and is often 
negatively associated with high parasite load during infection (Marsh and Snow, 1997). 
The acquisition of immunity to clinical malaria nonetheless allows chronic Plasmodium 
infection to occur, resulting in asymptomatic parasitaemia (Sergent and Parrot, 1935, 
Koch, 1900a, Koch, 1900b, Koch, 1900c, Koch, 1900d).    
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There are two plausible reasons for this three-phase pattern of Plasmodium infection:  
i) Qualitatively different immune responses are required at each stage of malaria.  
ii) Certain parasite phenotypes are disposed towards causing infection with 
different characteristics. In this case immunity would need to be generated 
towards different parasite strains or variants, in order to prevent their associated 
pathologies. 
There is evidence to support both theories, and they may not be mutually exclusive. 
Whilst the content of qualitatively different immune responses is not clear, different 
states of immuno-modulation appear to associate with severe and uncomplicated 
disease. Severe malarial disease syndromes are often associated with high levels of 
inflammation, giving rise to immuno-pathology [reviewed by (Mackintosh et al., 2004, 
Combes et al., 2010, Moxon et al., 2010)]. Endothelial cells respond to inflammation by 
up-regulating expression of receptors such as ICAM-1 and VCAM-1, to which iRBCs 
can cyto-adhere. This response is more pronounced in endothelium from patients with 
severe disease than uncomplicated malaria (Wassmer et al., 2011). A further mechanism 
which may contribute to severe disease has been recently been put forward, whereby 
activated endothelial cells produce long strings of von Willebrand Factor, to which 
platelets and iRBCs can adhere, thus enhancing the capacity of iRBCs to sequester 
(Bridges et al., 2010). 
The inflammation state affects other features, such as the activation status of platelets 
and intravascular accumulation of leukocytes, both of which are complications during 
cerebral malaria [for example (Grau et al., 2003, Taylor et al., 2004, Medana and 
Turner, 2006, Miu et al., 2008)]. In addition, different forms of severe malaria have 
been linked to particular cytokine profiles (Prakash et al., 2006); for example IL10 can 
be associated with either severe anaemia, at low levels (Kurtzhals et al., 1998), or 
respiratory distress, at high levels (Awandare et al., 2006). Factors such as prior 
exposure to Plasmodium infection, nutritional status and co-infection context may 
influence an individual’s inflammation status and cytokine profile during different 
malaria episodes. 
An alternate explanation for the tendency towards severe or uncomplicated disease has 
been put forward regarding parasite retention by the splenic architecture (Safeukui et 
al., 2008). In this argument iRBCs not retained within the spleen would have the 
potential to sequester in different organs, causing severe disease; whilst if the majority 
 Chapter 1.4 Factors influencing the outcome of malaria 
 40 
of parasite biomass were retained in the spleen, fewer iRBCs would have the capacity to 
sequester. The latter scenario would result in splenomegaly, and probably contribute to 
malarial anaemia, yet would allow the infection to progress in an uncomplicated 
fashion. The factors influencing such splenic retention are unclear, but it is likely that 
possession of immunity to a previous infection would enhance the ability of the spleen 
to behave in this way. Buffet and colleagues have proposed that the splenic retention of 
iRBCs is more stringent in infants, allowing their spleens to retain more iRBCs during a 
primary infection, than the spleens of naïve adults (Buffet et al., 2011). This may 
explain observations in S. E. Asia that naïve adults are more susceptible to severe 
disease than naïve young children [for example (Baird et al., 2003)]. However, 
immunity to P. falciparum may not be acquired in the same way as immunity to P. 
vivax and other species prevalent in different regions. Immune memory may also not be 
acquired in the same way in areas of high and low or seasonal transmission, making 
parallels difficult to draw between different populations. Another factor is that children 
may have a different capacity to generate immunity than adults. For example, children 
develop short lived Ab responses following infection and fail to boost Ab titres upon re-
infection (Kinyanjui et al., 2007). It has been suggested that the onset of puberty aids 
generation of widespread immunity to malaria (Kurtis et al., 2001). 
Whilst different immune responses could contribute to the three phases of malaria 
shown in Figure 5, they do not explain observations of strain specific immunity. 
Primary malaria infection results in protective immunity to homologous but not 
heterologous challenge in monkey and rodent models (Cadigan Jr and Chaicumpa, 
1969, Jones et al., 2000, Jarra and Brown, 1985). This has also been observed in 
experimental human infections (Pombo et al., 2002, Krause et al., 2007), and when 
malaria infection was used as a treatment for patients suffering from neurosyphilis 
(Yorke and Macfie, 1924, Ciuca et al., 1934, James and Ciuca, 1938, Jeffery, 1966). 
From these data, the dominant hypothesis has emerged that individuals become immune 
to clinical symptoms only after being exposed to the majority of locally circulating 
Plasmodium strains (Garnham, 1966, Wilson and Phillips, 1976, Day and Marsh, 1991, 
Bruce et al., 2000). This could be due either to polymorphism in conserved antigens 
(Conway et al., 2000, Healer et al., 2004, Coley et al., 2006, Hodder and al., 2001, 
Kennedy et al., 2002, Miura et al., 2007, Tanabe et al., 1987, Polley and Conway, 
2001), or the differential expression of antigens, including members of diverse multi-
gene families. 
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1.5  Protective immunity against parasite variants 
Studies undertaken in Kenya have shown that sera taken from children and adults have 
differential abilities to recognize and agglutinate iRBCs isolated from different 
Plasmodium infections. Typically, a child’s serum could only agglutinate parasites 
isolated from their own infection, whilst sera from immune adults could agglutinate a 
range of parasite isolates (Bull et al. 1999, 2000). In addition, parasites isolated from 
severe malaria cases were more likely to be recognized by sera from semi-immune 
children and adults, having a higher agglutination frequency, depicted in Figure 6, (Bull 
et al., 2000). These observations support the hypothesis that immunity to different 
parasite strains is the reason for increased protection from severe disease or clinical 
symptoms.  
 
 
Figure 6: Frequency of iRBC agglutination by host immune serum, according to 
the age at which parasites were isolated from infected children.  
Adapted from (Bull et al., 2000). P. falciparum isolates were taken from 70 children, in Kilifi, Kenya. 
Each isolate is plotted as a single point according to the age of the child from whom it was taken, shown 
on the X-axis. The frequency of agglutination of these parasites by the sera of all 70 children is shown in 
the Y-axis.   
 
Because children develop immunity to severe disease fairly rapidly, as discussed above, 
the parasite variants encountered during these early infections must be associated with 
severe disease. Therefore, the acquisition of immunity to different parasite antigens and 
their variants must be important. 
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There is no evidence that particular alleles of polymorphic antigens, such as apical 
membrane antigen 1 (AMA1) and MSP1, are associated with severe disease. Although 
immunization with these antigens is able to induce protection against re-infection in 
model systems (Daly and Long, 1993, Ling et al., 1997, Crewther et al., 1996, 
Hirunpetcharat et al., 1997, Tian et al., 1997, Anders et al., 1998, Burns et al., 2003, 
Burns et al., 2004, Alaro et al., 2010), recent phase II vaccine trials have not shown 
particular efficacy (Ogutu et al., 2009, Sagara et al., 2009). This suggests that 
acquisition of immunity to conserved antigens, whilst important for control of 
parasitaemia, is not the crucial factor determining the characteristics of malaria 
infection - whether severe, uncomplicated or asymptomatic.  
It is important to note that very few Plasmodium antigens have been studied so far, 
approximately 1% from a predicted proteome of over 5000 proteins (Gardner et al., 
2002, Langhorne et al., 2008). Scant success has been achieved to date using conserved 
antigens in vaccine trials, highlighted by the number of discontinued vaccines in Table 
3. Clearly, there is an urgent need to identify new potential vaccine targets: antigens that 
are associated with parasites causing severe disease and to which protective immune 
responses are directed. 
 
Table 3: A summary of current vaccine studies. 
Antigen (s) Pre-clinical Clinical Discontinued 
   Pre-erythrocytic stages 
Circumsporozoite protein (CSP) 3 4 8 
Liver stage antigen 1 0 0 2 
Thrombospondin related anonymous protein (TRAP) 0 0 4 
Liver stage antigen 3 0 0 3 
CSP & another antigen 1 1 5 
Whole sporozoite antigens 1 1 0 
   Erythrocytic stages 
Apical membrane antigen 1 1 3 4 
Merozoite surface protein 1 1 2 3 
Merozoite surface protein 2 0 0 1 
Glutamate rich protein 0 0 1 
Merozoite surface protein 3 0 2 0 
Erythrocyte binding antigen 175 0 1 0 
VAR-2-CSA 2 0 0 
Combinations of these antigens 1 0 3 
   Sexual stages 
P. falciparum surface protein 25 (Pfs25) 1 0 1 
P. vivax surface protein 25 0 0 1 
Pfs25 & another antigen 1 0 0 
Whole gametocyte antigens 0 2 0 
   Multiple stages 1 1 1 
 Adapted from from WHO data 2009: www.who.int/malaria/world_malaria_report_2009/en/index.html 
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Support for the idea that particular parasite variants are associated with severe disease 
comes from typical parasitaemia courses observed in human and model infections, 
whereby after resolution of the acute phase, primary infections are not resolved for 
some time. Instead, several recrudescences occur, an example of which is displayed in 
Figure 7. In this experimental human infection, there were repeated peaks of infection, 
and although the intensity of parasitaemia diminished over time, the infection had still 
not been cleared by day 260, whereupon drug cure was administered [described by 
(Miller et al., 1994)]. 
 
 
Figure 7: Experimental P. falciparum infection of a naïve human volunteer.  
Adapted from data described in (Miller et al., 1994). Peripheral parasitaemia, defined as the number of 
iRBC per µl blood x 106, was monitored during the course of infection, until chloroquine drug-cure was 
administered on day 260 of infection, denoted by *. 
 
The crucial factor in this example is that the experimental infection was known to be a 
single parasite strain, inoculated via mosquito bite, yet repeated immune responses were 
evaded for a considerable length of time (Miller et al., 1994). This could not be due to 
induction of expression of different alleles of a conserved protein, because the parasite 
genome could not evolve so rapidly. Instead, this points to the differential expression of 
variants encoded within the genome, each of which could be novel to the ongoing 
immune response, allowing continued parasite growth. 
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1.6 Antigenic variation 
The capacity to change surface antigens in the face of dynamic host immune responses, 
is an advantage for pathogens, and has been termed antigenic variation [reviewed by 
(Deitsch et al., 2009, Turner, 2002)]. This phenomenon does not include permanent 
genetic change and probably occurs by immune selection of spontaneously changed 
surface antigens (Roberts et al., 1992, Brannan et al., 1994). 
Two types of antigenic variation have been described. Phase variation refers to the 
ability to switch antigen expression on or off. This was first described for flagellar 
expression by Salmonella (Zeig et al., 1977), and is in fact a mechanism common to all 
pathogens. Antigenic variation in the true sense refers to the ability to express 
alternative forms of an antigen. This can occur within a gene by alternative splicing 
events, or by expression of different members of multi-gene families. Protozoan 
parasite genomes contain diverse multi-gene families, examples are shown in Table 4.  
 
Table 4: Comparison of variant antigens encoded by protozoan multi-gene families. 
Parasite Trypanosoma brucei Giardia lamblia Babesia bovis 
Lifestyle 
Initially blood and haemolymph 
dwelling, followed by CNS* 
invasion. 
Intestinal dwelling trophozoites Sporozoites directly infect RBC 
Host Human Human Cattle (human zoonosis) 
Trans-
mission Tsetse fly 
Environmentally resistant 
infectious cysts 
Tick 
Disease 
African sleeping sickness 
(headache, fever, swollen 
lymph nodes and neurological 
symptoms) 
Abdominal cramps, diarrhoea 
and nausea 
Fever, malaise, and hemolytic 
anemia 
Gene family 
Variant surface glycoprotein 
(VSG) 
Variant surface protein 
(VSP) 
Variant erythrocyte surface 
antigen 1 (VESA1) 
Copy no. ≥ 1250-1500  > 190 ~130-160 
Regulation 
of gene 
expression 
Partial genes recombine into a 
single active expression site, 
whose activity is epigenetically 
regulated 
Several vsp genes are 
transcribed but ‘silent’ 
transcripts are degraded via the 
RNAi pathway. 
The two subunits are encoded 
by the ves1a and b genes, 
whose expression is regulated 
like the vsg genes. 
Other 
Hydrodynamic flow directs Ig-
VSG complexes to the cell 
posterior where they are 
endocytosed, allowing growth 
in the face of low-level humoral 
responses. 
Disruption of the RNAi 
pathway allows all VSP to be 
expressed simultaneously, 
permitting generation of 
effective immune memory. 
VESA1 proteins are located in 
iRBC membrane knobs and 
mediate both cytoadhesion to 
endothelium and antigenic 
variation 
References 
(Bernards et al., 1981, Cross, 
1996, Engstler et al., 2007) 
*Central Nervous System 
(Prucca et al., 2008, Rivero et 
al., 2010) 
(Allred et al., 2000, Al-Khedery 
and Allred, 2006, Xiao et al., 
2010) 
Estimates of copy number downloaded from http://www.vardb.org/vardb/families.html, March 2011. 
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The major benefit of antigenic variation is that pathogens can evade immune 
recognition, which allows long-term (chronic) infection. It is important to note that 
antigenic variation may not be the primary function of such proteins, and in fact, 
varying their expression in this manner may act to preserve their real function. 
For Plasmodium parasites, chronic infections are necessary to increase their chances of 
transmission into another mosquito host and continue the life-cycle. Other benefits 
include the ability to re-infect the same hosts such that the parasite-host range is not 
decreased, and even to super-infect hosts already carrying a different Plasmodium 
infection. This is certainly true for P. falciparum, where individuals can be infected 
with 7 genetically distinct parasite populations (Montgomery et al., 2007). 
Variant antigens have been shown to be important targets of protective immunity 
(Marsh and Howard, 1986, Marsh et al., 1989), and crucially, certain variants are 
associated with different disease states (Bull et al., 2000a, Bull et al., 2008, Nielsen et 
al., 2002, Kirchgatter and Del Portillo, 2002, Kyriacou et al., 2006a, Kaestli et al., 2006, 
Rottmann et al., 2006, Normark et al., 2007). In the absence of pre-established 
immunity, parasites express these variants first so these are the proteins children 
initially make Abs against (Cham et al., 2009). Over the course of repeated infection, 
children acquire a repertoire of Abs against the variants that they have encountered, 
which correlates with the age that immunity to severe disease is acquired (Cham et al., 
2009). This is shown in Figure 8, using data acquired from a village experiencing 
medium transmission intensity (Cham et al., 2009).  
The cumulative acquisition of a broad range of Abs to an antigen expressed at the 
surface of iRBCs, P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1), is 
independent of malaria endemicity, although the pace of acquisition reflects the 
transmission intensity, with the acquisition of Abs recognizing more variants occurring 
at a younger age in areas of higher transmission (Cham et al., 2009). This would also 
correlate with the phenomenon observed in the field, that it takes much longer to 
develop immunity to clinical symptoms than to severe disease; due to the relatively 
restricted set of variants associated with the severe phenotype, compared with the much 
broader repertoire of less pathogenic variants which the parasite is obliged to express to 
evade previously established immunity (Marsh and Howard, 1986).  
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Figure 8: The percentage of individuals whose anti-sera recognized individual 
recombinant domains from the different PfEMP1 sub-groups.  
Adapted from (Cham et al., 2009). Serum samples from 1342 individuals were probed for recognition of 
25 different recombinant PfEMP1 DBL domains. 
The study population was based in Tanga, Tanzania, where different villages experience variable 
intensities of malaria transmission. The data shown here were from a population experiencing high 
transmission frequency, and were classified according to the age of indviduals.  
The percentage of individuals possessing IgG Abs recognizing each DBL domain is shown, for domains 
where >10% of individuals had a measurable response.  
Each of the 25 PfEMP1 DBL domains is shown as an individual column, coloured according to the native 
PfEMP1 group: A, red; B/A, yellow; B, C, and B/C, green; VAR1, blue.  
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1.7 Variant surface antigens in Plasmodium 
Several multi-gene families have been described in Plasmodium, some of which have 
been implicated in antigenic variation. These are introduced below. 
The SICAvar proteins were the first family of variant surface antigens (VSAs) 
discovered in Plasmodium (Brown and Brown, 1965), using an assay to measure 
agglutination of infected red blood cells by antiserum from P. knowlesi infected rhesus 
macaques, the Schizont-Infected Cell Agglutination test [SICA, (Eaton, 1938)]. During 
P. knowlesi infection, each emergent parasite population was shown to have surface 
antigens that were distinct from those previously expressed. The genes responsible were 
later shown to be encoded by the SICAvar gene family (Al-Khedery et al., 1999). In fact 
the SICAvar genes comprise the largest gene family encoding variant antigens in P. 
knowlesi, with an estimated 107 members in the H strain (Pain et al., 2008). The 
predicted proteins range in size from 53 to 247 kDa (Pain et al., 2008). 
Several variant antigen-encoding gene families have been identified in P. falciparum, in 
contrast to other Plasmodium species. The best-described family are the var genes, 
which encode the PfEMP1 antigen. Members of the PfEMP1 family are large proteins 
(200-350kDa) found in electron-dense knobs on the iRBC surface. There are 
approximately 60 var genes per parasite (Gardner et al., 2002), and the genes have a 
two-exon structure, the first exon encoding the extracellular domain (Su et al., 1995). 
All PfEMP1 variants have several domains in the encoded amino acid sequence: an N-
terminal segment; duffy binding like domains (DBL) with subtypes: α, β, γ, δ, ε and x; 
cysteine rich inter-domains (CIDR) with subtypes: α, β, γ; a trans-membrane (TM) 
domain, a C2 domain and a conserved intracellular acidic terminal segment (Kraemer 
and Smith, 2003), shown in Figure 9.  
Between different P. falciparum isolates, the var genes are highly variable but while 
they may be re-arranged, the domains themselves are conserved (albeit at low sequence 
identity). Kraemer and colleagues described 31 different PfEMP1 architectures, 7 of 
which were shared between all three sequenced isolates: 3D7 (Africa), HB3 (Central 
America) and IT4 (S. E. Asia) (Kraemer et al., 2007).  
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Figure 9: The arrangement of domains in an example PfEMP1 molecule.  
Adapted from (Kyes et al., 2007). A typical B or C-type var gene is shown with the encoded PfEMP1 
domains arranged from the N-terminal segment (NTS), followed by CIDR1α, DBL2β, C2, DBL3γ, 
DBL2β, CIDR2β, and TM domains, with a C-terminal acidic terminal segment (ATS). Within the 5’ 
flanking DNA sequence, the upstream (Ups) region by which var genes are classified is denoted by *. 
 
 
The chromosomal position, domain structure and upstream (Ups) DNA sequences of 
PfEMP1 molecules define 4 sub-groups (Kraemer and Smith, 2003, Lavstsen et al., 
2003, Gardner et al., 2002). Group A is the most complex, located sub-telomerically 
and transcribed towards the telomere, this group also incorporates var genes formerly 
named group D (Kraemer et al., 2007). A-type PfEMP1 molecules contain an N-
terminal DBL1α1 domain rather than the DBL1α domain common in other PfEMP1sub-
types. The domain arrangement of a typical B or C type PfEMP1 protein is depicted in 
Figure 9.  Group B var genes are transcribed away from the telomere and may be 
located subtelomerically or centrally, whilst group C are only found in central-
chromosomal locations. Group E is located and transcribed similarly to group A, but 
includes only the most highly conserved var, including the pregnancy associated variant 
var2csa. 
The majority of var genes are located in sub-telomeric clusters, where frequent 
recombination events take place, generating further diversity (Mu et al., 2005, Mu et al., 
2007). Both reciprocal recombination and gene conversion events have been 
experimentally detected in the var repertoire (Su et al., 1999, Taylor et al., 2000b, 
Freitas-Junior et al., 2000). Although each parasite contains approximately 60 var 
genes, there appears to be little overlap between isolates, meaning that the diversity of 
encoded PfEMP1 is vast. Indeed, in one study over 8000 variants were sequenced, yet 
the authors failed to detect significant overlap between parasite lines (Barry et al., 
2007).  
Other multi-gene families also exist in these locations, often in tandem with var genes, 
including the: rif (Repetitive Interspersed Family), stevor (Sub-Telomeric Variable 
Open Reading Frame), Pfmc-2tm (P. falciparum Maurers Cleft 2 TM) and surf genes. 
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The rif genes form the largest family in P. falciparum, containing approximately 150 
copies per haploid genome (Gardner et al., 2002). The genes consist of a short 5’ exon 
and a second exon, which encodes the majority of the RIFIN protein. Unlike the var 
genes, the rif repertoire was fairly consistent between the three sequenced P. falciparum 
isolates 3D7, HB3 and IT4 (Bultrini et al., 2009). The authors’ explanation for this was 
that whilst stochastic events may ensure the generation of novel variants, substantial 
homogenization prevents the loss of function in the encoded proteins.  
The RIFIN proteins, of 30-45kDa, were initially identified by iRBC surface protein 
radio-labelling and SDS PAGE (Cheng et al., 1998, Weber, 1988). Two putative trans-
membrane (TM) domains were predicted (Gardner et al., 1998), and the region between 
was the most variable, containing many hydrophobic amino acids, and was predicted to 
form an extracellular ‘loop’ (Cheng et al., 1998). The rif, stevor and PfMC2-TM gene 
families share a similar predicted protein structure and export motifs, so they have been 
proposed to be a super-family (Dzikowski et al., 2006, Sam-Yellowe et al., 2004). The 
33 member- stevor gene family encodes products of approximately 30 kDa (Cheng et 
al., 1998), whilst the PfMC2-TM family encodes 11 proteins, of approximately 27 kDa 
(Sam-Yellowe et al., 2004). 
Another small multi-gene family exists in P. falciparum, comprising the 10 surf genes, 
of which three are predicted pseudogenes (Winter et al., 2005). These genes, like the 
other VSA families appear to have no close orthologues in other Plasmodium species.  
Conversely, the Plasmodium interspersed repeat (pir) genes are present in many 
Plasmodium species but not P. falciparum, and were first described in P. vivax, where 
they were named vir (Del Portillo et al., 2001). The name was coined as an analogy for 
P. vivax variant genes, upon the discovery of 32 novel genes within a chromosome end 
from a P. vivax field isolate (Del Portillo et al., 2001). Subsequently orthologues were 
also identified in primate (P. knowlesi, kir. (Pain et al., 2008)) and rodent malaria 
species (P. berghei, bir; P. chabaudi, cir; P. yoelii, yir. (Janssen et al., 2002)). These 
genes form the largest multi-gene family within each genome, with the exception of P. 
knowlesi, encoding up to 5% of the total genes.  
pir genes are typically found in sub-telomeric locations (vir, bir, cir and yir), although 
non-sub-telomeric yir family members are also found (Fonager et al., 2007). The kir 
genes however, are dispersed throughout the chromosomes, associated with interstitial 
telomeric repeat sequences (Pain et al., 2008), suggesting that the kir distribution was 
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created by recombination (Lin and Yan, 2008). 
Most pir genes share the structure identified by del Portillo and colleagues, comprising 
a short first exon, long second exon and a highly conserved final exon (Del Portillo et 
al., 2001). PIR proteins contain most variability in their N-terminal sequence, although 
conserved cysteine residues exist, followed by a predicted trans-membrane domain (Del 
Portillo et al., 2001, Janssen et al., 2002).  
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1.8  P. falciparum variant surface antigens 
 
In accordance with the long-held view that that P. falciparum infection alone caused 
severe malaria syndromes (described above), efforts to characterize and investigate the 
function of VSAs have predominantly concentrated on the PfEMP1, RIFIN and 
STEVOR proteins. These efforts have focussed on particular aspects to elucidate 
possible functions, namely the proteins’ cellular localization, regulation, adhesive 
properties and immune recognition, which will be discussed below. 
 
 
1.8.1 VSA protein export 
As indicated by the name ‘variant surface antigens’, most of the VSA families in P. 
falciparum have been located at or near the surface of iRBCs. Transport of these 
proteins from the developing parasite to the iRBC surface requires translocation across 
three plasma membranes, the parasite membrane, the parasitophorous vacuole 
membrane and the iRBC membrane. This will be briefly described before the 
localizations of P. falciparum VSAs are discussed. 
Wickham and colleagues have shown that a recessed amino-terminal endoplasmic 
reticulum (ER) signal sequence is sufficient to cross the parasite plasma membrane, but 
not beyond (Wickham et al., 2001). In addition, the Plasmodium export element 
(PEXEL) or vacoular transport signal (VTS) sequence: RXLXE/Q/D is found in many 
exported proteins, approximately 35 amino acids downstream of the signal sequence 
(Marti et al., 2004, Hiller et al., 2004). This sequence alone has been shown to be 
sufficient for protein export in P. falciparum [for example: (Bhattacharjee et al., 2006)], 
hence several groups have searched for the presence of a PEXEL motif to predict the 
malaria ‘secretome’ (Sargeant et al., 2006, Van Ooij et al., 2008). The PEXEL motif is 
also cleaved in the ER, creating a new N-terminal sequence beginning with XE/Q/D, 
with an acetyl group at the terminal residue (Chang et al., 2008, Boddey et al., 2009). 
Following PEXEL-cleavage, protein export is mediated, at least in part, by the novel 
‘Plasmodium translocon for protein export’ (PTEX) machinery identified by de Koning-
Ward and colleagues (De Koning-Ward et al., 2009). The authors hypothesize that 
proteins are recognized by members of the PTEX complex as they reach the vacuolar 
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space, whereupon the HSP100/ClpA/B chaperone-related protein (HSP101) mediates 
unfolding, and the protein passes through a central pore, most probably provided by 
‘exported protein-2’ (EXP2). On the cytosolic face of the PVM, host and / or other 
exported parasite proteins may contribute to protein refolding (De Koning-Ward et al., 
2009, Gehde et al., 2009).  
Not all exported proteins appear to contain a PEXEL motif however (Blisnick et al., 
2000, Spycher et al., 2003, Hawthorne et al., 2004). It could be that these ‘PEXEL-
negative exported proteins’ (PNEPs) actually contain PEXEL-equivalent motifs, that 
there are other properties of the N-terminus which are required for export across the 
PVM using the PTEX translocon, or that alternative export mechanisms are involved 
[reviewed by (Spielmann and Gilberger, 2010)].  
Once across the PVM, proteins bound for export probably enter a secretory vesicular 
pathway to reach the iRBC membrane, which may include the membranous structures 
known as Maurer’s Clefts (Hanssen et al., 2008). The possession of a TM domain 
appears to aid this process (Spycher et al., 2006, Saridaki et al., 2009).  
 
1.8.2 Cellular localization 
PfEMP1 proteins bind to the electron-dense conical knobs of the iRBC membrane via 
KAHRP (Aikawa et al., 1985, Waller et al., 1999). PfEMP1 proteins were identified 
following their detection at the surface of iRBC by cell-surface radio-iodination 
experiments (Howard et al., 1988). RIFINs were initially detected at the iRBC surface, 
appearing to be transit via the Maurer’s clefts (MC) in association with PfEMP1 
(Fernandez et al., 1999, Kyes et al., 1999, Haeggström et al., 2004).  
Two sub-types of RIFINs have since been identified (Joannin et al., 2008), where 
approximately two thirds of the RIFINs contain a 25 amino acid insertion sequence 
(Gardner et al., 2002, Pizzi and Frontali, 2001), located approximately 66 amino acids 
downstream from the PEXEL protein export motif, (Marti et al., 2004). RIFINs 
containing this sequence were designated type A (Joannin et al., 2008) and have been 
shown to display different cellular localizations to members of the other sub-family, B. 
In merozoites, A type RIFINs were located at the apical end, next to AMA1, whilst B-
types were more dispersed throughout the cell, but not in the uniform distribution of 
MSP1 (Petter et al., 2007), Figure 10. Petter and colleagues showed that in ring, 
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trophozoite and schizont stages, A type RIFINs were both associated with the parasite 
and transported to the iRBC surface via MC, whilst the B type were retained within the 
parasite (Petter et al., 2007), Figure 10.  A study using GFP-tagged RIFINs confirmed 
the localization pattern of B-types and suggested that the C-terminus was a crucial 
determinant for whether they were exported beyond the PV (Sijwali and Rosenthal, 
2010).  
 
 
Figure 10: Cellular localization of VSA family members in different stages of P. 
falciparum intra-erythrocytic development.  
 
Adapted from (Petter et al., 2007, Blythe et al., 2008, Winter et al., 2005). P. falciparum parasites of ring, 
trophozoite, schizont and merozoite stages are shown, stained with Abs generated against proteins from 
the VSA families RIFIN A- and B- types, STEVOR and SURFIN 4.1, in green. Parasite nuclei were 
stained with Hoechst 33342, blue (RIFIN and STEVOR), or propidium iodide, red (SURFIN). In 
addition, merozoite localization of VSAs was compared to other proteins, shown in red: MSP1, for 
RIFINs, and AMA1, for STEVOR.  
 
STEVOR proteins and transcripts have also been detected in many stages of the 
Plasmodium lifecycle: in merozoites, in gametocytes and sporozoites (Florens et al., 
2002, Florens et al., 2004, Le Roch et al., 2003, Le Roch et al., 2004, Bozdech et al., 
2003b, Lavazec et al., 2006, McRobert et al., 2004, Khattab et al., 2008, Khattab and 
Meri, 2011). In trophozoite and schizont stage parasites, STEVORs have been observed 
both at the iRBC surface and in the MC, during trafficking (Kaviratne et al., 2002, 
McRobert et al., 2004, Przyborski et al., 2005, Blythe et al., 2008, Niang et al., 2009, 
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Khattab and Meri, 2011). Whilst STEVOR proteins display different localizations to the 
RIFINs in trophozoite stages, the apical expression observed in merozoites is similar to 
A-type RIFINs (Blythe et al., 2008), Figure 10. 
Recent bio-informatic analyses suggest that in fact the two-TM domain gene model is 
wrong for A-type RIFINs and only one TM domain exists (Bultrini et al., 2009). The 
authors also predicted that these proteins have an ‘armadillo-like’ structural fold, which 
is found in diverse circumstances, facilitating protein-protein interactions (Coates, 
2003). In line with the suggestions that the 2-TM model may not best represent the 
RIFIN repertoire (Bultrini et al., 2009), evidence has emerged that the majority of the 
STEVOR protein is also exposed on the iRBC surface, likely anchored by the C-
terminal TM domain (Niang et al., 2009). Whilst this supports the similarities 
previously observed between these multi-gene families, it remains to be seen whether 
these proteins truly form a super-family, performing similar functions.  
Within erythrocytic stages, PfMC2-TM family members have been localized to the MC 
and in the knob structures of iRBC (Lavazec et al., 2006), but iRBC surface localization 
has not been proven. The inter-TM loop in these proteins is small, only three amino 
acids (Sam-Yellowe et al., 2004) and this region may be exposed on the iRBC surface, 
as proposed by Sam-Yellowe and colleagues.  
Finally, members of the SURFIN family have been located at the surface and the PV of 
iRBCs and also in merozoites (Winter et al., 2005). Interestingly, as observed for 
members of the RIFIN family, different SURFIN variants appear to have different 
cellular localizations, for example SURFIN 4.1 was detected forming an ‘amorphous 
cap’ at the apical end of merozoites, whilst the distribution of SURFIN 4.2 was more 
discrete in the centre of the merozoite cell (Winter et al., 2005). Similarly to other VSA 
families, their function(s) are as yet unknown. 
 
1.8.3 Regulation of expression  
There has been a great deal of interest in understanding how var/PfEMP1 expression is 
regulated following early data suggesting that only one PfEMP1 is present on the 
surface of an iRBC (Biggs et al., 1991, Scherf et al., 1998, Roberts et al., 1992, Biggs et 
al., 1992, Chen et al., 1998). It seems that ring stage parasites may transcribe several 
var genes, but mutually exclusive expression is achieved during mature stages of 
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development (Duraisingh et al., 2005, Dzikowski et al., 2006, Deitsch et al., 2001), 
whereby the dominant transcript is the only one translated and exported to the iRBC 
surface (Chen et al., 1998).  
The regulation of var transcription is highly complex, involving three layers of 
regulation [reviewed by (Scherf et al., 2008, Chookajorn et al., 2008, Dzikowski and 
Deitsch, 2009)]. The first layer comprises the cis-regulatory sequences of var gene 
promoters to which transcription factors bind, such as members of the APiAP2 family 
(Llinás et al., 2006). The intron also contains a promotor that drives expression of the 
intron sequence in most var genes (Epp et al., 2009). This appears to act in silencing 
and may contribute to var recognition by the mechanism regulating their mutually 
exclusive expression (Deitsch et al., 2001, Frank et al., 2006, Dzikowski et al., 2007). 
The second layer comprises epigenetic histone marks, such as methylated H3K27 and 
tri-methylated H3K9 (Duraisingh et al., 2005, Lopez-Rubio et al., 2007), which 
maintain var genes respectively in their active or silent state for several cell cycles 
(Horrocks et al., 2004a, Frank et al., 2007). The final layer is the sub-nuclear 
localization of chromatin, whereby chromatids appear to be re-positioned into distinct 
nuclear sites to allow active transcription (Ralph et al., 2005). 
Importantly, the majority of iRBCs also express the same PfEMP1 as the schizont from 
which they were derived (Roberts et al., 1992). In general this leads to expression of the 
same PfEMP1 by the majority of iRBCs during P. falciparum infection (Marsh and 
Howard, 1986, Bull et al., 1998, Giha et al., 1999, Ofori et al., 2002), and the major 
variant may switch over a period of weeks (Staalsoe et al., 2002). Recent data obtained 
from modelling var transcription patterns during in vitro culture indicate that certain 
variants dominate in the parasite population due to a high likelihood of switching to 
these variants when other var genes are switched off in combination with these genes 
having slow switching-off rates (Recker et al., 2011).  
After RBC invasion, the first VSA transcripts produced are var, followed by rifin and 
then stevor (Kyes et al., 2001, Kaviratne et al., 2002), whilst PfMC2-TM genes were 
transcribed between the times of rifin and stevor genes (Sam-Yellowe et al., 2004). No 
co-expression with var genes has been observed either for stevor (Sharp et al., 2006), or 
rifin genes (Tham et al., 2007). This indicates that, despite their chromosomal proximity 
to var genes and the presence of similar promoter sequences, the rifin and stevor genes 
are independently regulated.  
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Between four and 10 PfMC2-TM proteins have been detected from trophozoite stage 
samples of iRBC, indicating that at the population level, several of these genes were 
expressed at the same time (Sam-Yellowe et al., 2004). This has also been observed for 
the stevor genes, where several different transcripts were detected within individual 
iRBCs (Kaviratne et al., 2002). Recent data however, indicate that although several 
STEVORs may be expressed within iRBCs, only one is exposed at the surface of 
trophozoite stages (Khattab and Meri, 2011). This suggests that STEVORs may also 
mediate mutually exclusive expression at the iRBC surface like PfEMP1 family 
members, a phenomenon which may extend to the other VSA families.  
 
1.8.4  Cyto-adhesion: rosetting and sequestration 
The severe disease syndromes of pregnancy associated malaria and cerebral malaria 
have been associated with cytoadhesion to the receptors CSA, HA, and ICAM1, 
respectively (Fried and Duffy, 1996, Newbold et al., 1999, Newbold et al., 1997, 
Ochola et al., 2011), whilst CD36 binding is a characteristic of many clinical isolates, 
and may be associated with less severe disease outcomes (Ockenhouse et al., 1992, 
Reeder et al., 1994, Ochola et al., 2011). At present it is not clear exactly how the 
phenomenon of iRBC sequestration occurs, although the process is better understood in 
the placenta, than for example, in cerebral malaria. P. falciparum adhesion to placenta 
has been shown to involve the semi-conserved VAR2CSA PfEMP1 protein binding to 
CSA (Fried and Duffy, 1996, Salanti et al., 2004), present in the intervillous space of 
placental tissue. This blocks blood supply to the foetus, which is exacerbated by the 
infiltration of monocytes (Walter et al., 1982). The development of novel technologies, 
such as whole mouse imaging (Franke-Fayard et al., 2005), multi-photon imaging 
(Ortolano et al., 2009), and transcriptional profiling (Vignali et al., 2011) are likely to 
elucidate the mechanisms underlying parasite cyto-adhesion and cell:cell interactions.  
PfEMP1 proteins have the capacity to cyto-adhere via several host receptors: CD36 
(Baruch et al., 1996, Robinson et al., 2003, Mo et al., 2008), ICAM 1, thrombospondin 
(Baruch et al., 1996), CSA (Fried and Duffy, 1996), and to form rosettes by binding to 
uninfected RBCs (Rowe et al., 1997, Chen et al., 1998). Certain binding phenotypes 
have been attributed to individual domains, for example CIDR1α domains from many 
parasite isolates bind to CD36 (Robinson et al., 2003), whilst the DBLβ domain and c2 
region are both required for binding to ICAM-1 (Springer et al., 2004). It is possible 
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that inclusion of two or more of these domains in an individual PfEMP1 molecule could 
allow binding to several host receptors, a feature that has been associated with severe 
disease (McCormick et al., 1997, Ockenhouse et al., 1992, Heddini et al., 2001) and 
also observed using selected in vitro lines (Smith et al., 2000, Chen et al., 2000). 
Due to their different domain compositions, PfEMP1 sub-groups have different binding 
capacities. Most members of the Ups B and C groups bind to CD36 (Robinson et al., 
2003), whilst the Ups A proteins do not, and may instead bind to a range of receptors 
(Kyes et al., 2007, Janes et al., 2011). It is thought that the variants associated with 
severe disease preferentially bind host receptors in, for example, brain endothelium. 
This would explain observations of iRBC accumulation in brain and heart tissue from 
post-mortem analysis of malaria fatalities (Montgomery et al., 2007). Rosetting also 
appears to contribute to severe disease since sera from children experiencing cerebral 
malaria were unable to disrupt rosettes, unlike sera from children experiencing 
uncomplicated infection (Carlson et al., 1990, Rowe et al., 1995, Horata et al., 2009). 
It has been suggested that variants appear during infection in a pre-determined pattern 
(Bull et al., 1998, Bull et al., 2000, Nielsen et al., 2002, Horrocks et al., 2004b). 
Although this is difficult to determine in the field (Bull et al., 2005a, Bull et al., 2005b), 
evidence from experimental human infections support this idea. Lavstsen and 
colleagues studied naïve adults infected with P. falciparum sporozoites, observing that 
parasites emerging into the bloodstream from the liver expressed an assortment of 
variants, but after only two or three cell cycles the majority of transcribed var genes 
belonged to the Ups A group (Lavstsen et al., 2005). The recent data from Recker and 
colleagues also supports the idea of pre-determined var expression, in the absence of 
immune selection, such that infection of naïve individuals would be more likely to 
result in the expression of a narrow range of var genes (Recker et al., 2011).  
The functions of RIFIN proteins are unknown. They were initially thought to mediate 
rosetting (Helmby et al., 1993, Kyes et al., 1999, Fernandez et al., 1999), although 
whether the RIFINs may contribute to rosette formation is unclear as PfEMP1 family 
members are now known to bind uninfected RBCs (Rowe et al., 2000, Russell et al., 
2005). Other evidence for RIFIN-mediated cyto-adhesion is lacking, although one study 
found identical rif transcription in parasite lines displaying different binding 
characteristics (Cabral and Wunderlich, 2009), suggesting that iRBC adhesion, at least 
to CD36, ICAM-1 and Selectin does not require RIFIN proteins. Conversely, 
differences in stevor transcription have been observed after selection of parasite lines 
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for adhesion to the receptors CD36 and CSA (Khattab et al., 2008), suggesting that 
these proteins may contribute to iRBC sequestration.  
 
1.8.5 Parasite survival in vivo 
It has been shown that parasite isolates down-regulate the transcription of a number of 
VSA genes upon adaptation to in vitro culture: var, rif and stevor (Mackinnon et al., 
2009). Similar down-regulation was also observed in a splenectomised patient 
experiencing severe malaria, with specific down-regulation of var, stevor and A-type rif 
but not B-type rif or PfMC 2TM genes (Bachmann et al., 2009). This indicates that 
PfEMP1, STEVOR and the A-type RIFIN proteins are not essential for parasite survival 
in the absence of splenic selection. Interestingly, the B-type RIFINs were not down-
regulated during asplenic infection (Bachmann et al., 2009), which probably indicates 
that these proteins are not exposed to selection, due to their PVM localization within 
iRBCs (Petter et al., 2007). In fact, early phylogenetic analysis of the RIFINs found 
evidence of different selective pressures applying to different subsets, which the authors 
suggested could be due to different exposure to the immune system (McInerney et al., 
2003). Following identification of the two subfamilies, Joannin and colleagues indicated 
that sub-functionalization has occurred within the RIFINs (Joannin et al., 2008), namely 
that the sequences of RIFINs belonging to the two sub-groups have significantly 
diverged, and the proteins may perform distinct functions. This is supported by their 
different cellular localizations [Figure 10, (Petter et al., 2007)]. 
Similarly, to the B-type RIFINs, PfMC 2TM proteins did not appear to be subject to 
splenic selection (Bachmann et al., 2009). Due to their MC localization within iRBC, 
these proteins have been hypothesized to involve trafficking of other VSA to the iRBC 
surface (Sam-Yellowe et al., 2004). If this were true, the PfMC 2TM and possibly B-
type RIFINs could mediate transport of those VSAs which appear essential to in vivo 
parasite survival: the PfEMP1, A-type RIFIN and STEVOR proteins. 
The functions of these proteins could be sequestration to evade splenic clearance of 
iRBCs, as discussed above. Another explanation could be that these proteins are 
required for evasion of immune selection, which would be severely limited in the 
absence of the spleen, a major lymphatic organ. In the absence of splenic selection, it is 
feasible that iRBC lacking exposed VSAs could proliferate more quickly than iRBC 
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expending energy to produce and traffic these proteins, and hence these parasites would 
come to dominate the infection. 
 
1.8.6  Immune evasion 
Although the functions of the different VSA families remain to be fully determined, it is 
evident that their variant expression acts to preserve expression of at least one member 
in the face of specific immune responses to other family members. The presence of Abs 
to different variants results in differential in vivo selection pressures within the parasite 
population. Abs recognizing VSAs are likely to play an important role in mediating 
parasite clearance, performing functions such as opsonization and complement 
mediated lysis of iRBC (Beeson et al., 2008). In addition, Abs generated against certain 
VSA, notably PfEMP1, are likely to inhibit cyto-adhesion.  
During infection, it is thought that sequestration provides a selective advantage for 
iRBC to escape splenic clearance. Thus in the absence of Abs, parasites expressing 
strong adhesive molecules will proliferate to dominate the infection. Furthermore, even 
dead iRBCs can continue to sequester (Hughes et al., 2010), meaning that vascular 
occlusion and other neurological phenomena could continue to occur after anti-malarial 
treatment.  
An important consideration for our understanding of severe malaria is how the 
generation of specific Abs to the PfEMP1 domains mediating adhesion may influence 
parasite behaviour. The presence of Abs recognizing the dominant, strongly adhesive 
domains means that iRBCs expressing these proteins would no longer be able to 
sequester, and other PfEMP1 variant-expressing iRBCs would have a selective growth 
advantage during infection (Hviid, 2010, Marsh and Howard, 1986, Giha et al., 1999, 
Ofori et al., 2002). The resulting antigenic variation may be explained by two different 
theories:  
- Phiri and colleagues have proposed that parasites expressing more effective 
adhesion molecules will out-compete other iRBCs to bind available host 
receptors, particularly within the currents of the bloodstream. This has been 
demonstrated under flow conditions in the absence of immune pressure (Phiri et 
al., 2009). Upon acquisition of immunity to the most adhesive variants, other 
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variants would experience a selective advantage, which would enable iRBC 
proliferation, and these variants would become dominant. 
- An alternative scenario is that different domains arrangements between PfEMP1 
variants means that Abs recognizing, for example, the DBL1α domain, will be 
likely to cross-react with other variants that also contain this domain, or similar 
epitopes. In this case, any PfEMP1 molecules containing domains to which 
cross-reactive responses were induced would be selected against, allowing the 
proliferation of iRBCs expressing other variants. The generation of Abs cross 
reactive with many PfEMP1 domains or variants have been described, both from 
experimental infection (Elliott et al., 2007), and in the field (Mackintosh et al., 
2008, Chattopadhyay et al., 2003). Interestingly, PfEMP1 variants belonging to 
the Ups A group have been shown to contain more cross-reactive Ab epitopes 
than variants belonging to the other sub-groups (Joergensen et al., 2006).  
Mathematical modelling has been able to reproduce both of these scenarios: Recker and 
colleagues suggested that cross reactive immune responses could effectively structure 
the PfEMP1 expression patterns observed during infection (Recker et al., 2004); whilst 
van Noort and collegues reproduced the association of different variants with severe and 
uncomplicated malaria, by combining adhesive phenotypes with cumulative Ab 
repertoires (Van Noort et al., 2010). Both mechanisms could play equally important 
roles in structuring the antigenic variation of PfEMP1 during infection. 
Evidence is increasing that other VSAs are also involved in the process of antigenic 
variation or immune evasion. The PfMC2-TM genes, along with the stevors, have also 
been shown to undergo switching of expression at rates similar to the var genes 
(Lavazec et al., 2007). Transcription of stevor genes has been detected in up to 90% of 
iRBC in fresh parasite isolates, which decreased upon adaptation to in vitro culture to 
only 10% of iRBC (Blythe et al., 2008), similar to that seen for the var and rif genes 
(Mackinnon et al., 2009). Niang and colleagues have also confirmed the iRBC surface 
exposure of STEVORs, and that changes in their expression profile directly correlated 
with the immunogenic properties of the iRBC (Niang et al., 2009).  
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1.8.7 Acquisition of immunity to P. falciparum VSAs 
Although the potential number of VSA variants is immense, they are targets of 
protective immunity (Marsh et al., 1989, Bull et al., 1998, Dodoo et al., 2001, Ofori et 
al., 2002, Kinyanjui et al., 2004a, Yone et al., 2005, Magistrado et al., 2007), and it 
seems that acquisition of immunity to a small fraction is associated with protection 
against severe disease (Bull et al., 2005b, Kaestli et al., 2006).  
Clinical malaria has been linked to the Ups A and B/A PfEMP1 groups, whilst 
asymptomatic infections have been associated with parasites expressing Ups B and C 
types (Jensen et al., 2004, Kaestli et al., 2006, Kyriacou et al., 2006, Rottmann et al., 
2006). All group A and some of the B/A PfEMP1 variants contain two cysteine residues 
within the DBLα domain, termed ‘cys 2’ (Bull et al., 2005a, Bull et al., 2007). These 
variants have been detected during infection of immuno-deficient children and in cases 
of cerebral malaria (Bull et al., 2005a, Kyriacou et al., 2006, Warimwe et al., 2009), 
appearing to be expressed in the face of a poorly developed Ab response.  
The humoral response to PfEMP1 domains has been investigated by several groups, 
finding variable responses towards different domains that tended to increase with age 
(Mackintosh et al., 2008, Vestergaard et al., 2008). Cham and colleagues have 
definitively shown that children acquire Abs to Ups A and B/A PfEMP1 variants first 
(Cham et al., 2009, Cham et al., 2010). In areas of high transmission, the Ab repertoire 
increased more quickly, but Abs were acquired to DBL-like domains in a similar order 
regardless of endemicity. Once Abs against the A/B type were acquired, a broader range 
of PfEMP1 variants was encountered, which took longer to generate effective immunity 
against, (Figure 8). This ordered acquisition of Abs neatly explains the three phases of 
Plasmodium infection that is observed in endemic areas, described in section 1.4. 
Whilst immunity to P. falciparum must comprise variant specific responses, including 
the UpsA variants of PfEMP1, it is likely that cross-reactive immune responses also 
occur, which are able to overcome antigenic variation to some degree. Indeed there have 
been reports of boosting responses during heterologous infection (Kinyanjui et al., 
2004a, Bull and Marsh, 2002, Ofori et al., 2002). In addition, certain PfEMP1 domains 
also appear capable of inducing cross-reactive immune responses (Gamain et al., 2001, 
Mackintosh et al., 2008). This finding, in concert with the association of only a small 
proportion of the PfEMP1 repertoire and severe disease, has led to proposals for 
development of PfEMP1-based vaccines (Chen, 2007).  
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Vaccine design would need to consider which epitopes may stimulate protective 
responses, particularly of T helper cells, which coordinate adaptive immunity. PfEMP1 
epitopes that elicit cross-reactive CD4 responses would thus be more likely to 
contribute to protection by stimulating the proliferation of both cross-reactive and 
variant specific B-cells. The cellular response to PfEMP1 has been investigated using 
the three most conserved domains: the extracellular DBLa, and CIDRa domains and a 
region from the intracellular region within exon 2 (Allsopp et al., 2002, Sanni et al., 
2002, Das et al., 2007, Ndungu et al., 2006). Surprisingly, CD4 T cells from both 
malaria-naïve and -exposed individuals had measurable proliferative and cytokine 
responses to the CIDR domain, suggesting that this region may contain epitopes similar 
to non-Plasmodium proteins to which the donors had all been previously exposed 
(Ndungu et al., 2006, Allsopp et al., 2002). Specific responses were observed to the 
other domains, suggesting that these regions contain T cell epitopes that may be useful 
vaccine components (Allsopp et al., 2002). In particular the peptide 
SDITSSESEYEEMDINDIYVPGS from the exon 2 region has been shown to induce 
more consistent magnitudes of proliferative, IL4 and IFNγ responses than several other 
peptides from this region, and higher proliferative and IL4 responses in immune adults 
than malaria patients [in Delhi, India (Das et al., 2007)]. 
In fact, vaccine development is underway for the unusual, conserved PfEMP1 variant 
VAR2CSA (http://cmp.ku.dk/english/research/teamvar2csa/), found in all P. falciparum 
genomes, which mediates sequestration of iRBC to the placenta during PAM (Fried and 
Duffy, 1996). Immunity to PAM specifically correlates with the presence of Abs to 
conserved regions of VAR2CSA (Rogerson et al., 2007), to which cross-reactive Abs 
may be generated by immunization (Avril et al., 2010).  
Less is known about immunity to the non-PfEMP1 VSA families in P. falciparum. 
RIFIN and STEVOR proteins are recognized by Abs present in immune serum from 
clinically immune adults (Fernandez et al., 1999, Leech et al., 1984, Schreiber et al., 
2008, Abdel-Latif et al., 2003, Abdel-Latif et al., 2002). The presence of anti-STEVOR 
Abs in Ghanian infants has been shown to correlate with the number of parasitaemia 
episodes experienced, and over time the children developed a pattern of high, transient 
or low humoral responses (Schreiber et al., 2008). It is not clear whether these Abs 
contribute to protection from clinical disease, since several studies appear to show 
either no association of anti-RIFIN or STEVOR Abs with protection (Abdel-Latif et al., 
2003, Schreiber et al., 2008) or even that the presence of these Abs could be risk factors 
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for development of higher peripheral parasitaemia or cerebral malaria (Schreiber et al., 
2006, Schreiber et al., 2008). In the latter study, the IgG2 and 4 isotypes of RIFIN 
specific Abs were exclusively detected in cerebral malaria cases, the authors suggesting 
that these Abs may play pathogenic roles during infection. An alternative explanation is 
simply that the acquisition of Abs against this vast number of VSA reflects the number 
of infections experienced, which are more likely to result in severe disease in young 
children.   
Given the long-standing dogma that P. falciparum infection alone caused severe malaria 
syndromes (described in Table 1), it is not surprising that the majority of studies 
investigating the generation of immunity to VSA have concentrated on those found in 
this species. It is likely that similar phenomena could also occur in other Plasmodium 
infections, which are not as benign as once thought.  
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1. 9  The pir / PIR ‘super-family’  
 
Non-P. falciparum species also undergo antigenic variation, mediate rosetting, and 
cytoadherance via receptors including CD36 (Mackinnon et al., 2002, Mota et al., 2000, 
Franke-Fayard et al., 2005, Carvalho et al., 2010, Brown and Brown, 1965, Gilks et al., 
1990, McLean et al., 1982), so these phenomena must be mediated by VSAs besides 
PfEMP1. The pir multi-gene family may be able to perform some of these functions, 
which has members in the majority of Plasmodium species described to date.  
 
1.9.1 Classification of the PIR superfamily 
The approach that has been widely utilized in description of multi-gene families, as 
observed earlier for the PfEMP1 and RIFIN genes, is their classification into smaller 
sub-groups, based on shared characteristics. This has also been used to define the vir 
genes, initially describing 6 clusters: A-F (Del Portillo et al., 2001), and members of 
these sub-families were detected in parasites isolated from 32 patients (Merino et al., 
2006). On completion of the P. vivax Salvador I genome sequence (Carlton et al., 
2008), further sub-families were identified, giving a total of 12 sub-families from 76% 
of VIR amino acid sequences. The yir repertoire has been analyzed in a similar way, 
with 56% of yir genes clustering to form five sub-groups (Fonager et al., 2007). 
Orthologous members of these sub-groups were also identified in the bir repertoire, 
reflecting the recent evolutionary divergence between P. yoelii and P. berghei 
(Hayakawa et al., 2008). 
A comparison of PIR sequences from the whole ‘super-family’ was carried out by 
Janssen and colleagues using approximately 8.5% of the total repertoire [157 sequences 
analyzed from an estimated 1843 total sequences, (Janssen et al., 2004)]. The 
relationships between 136 PIRs have been confirmed using different bio-informatic 
methodology (Cunningham et al., 2010), namely that PIR sequences displayed most 
similarity with their orthologues in the evolutionarily closest Plasmodium species. 
These data are summarized in Figure 11. 
RIFIN and STEVOR sequences were also included in the analyses of Janssen and 
colleagues, with the suggestion that these may be distantly related to the PIR super-
family (Janssen et al., 2004). As a consequence of the evolutionary distance between P. 
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falciparum and other Plasmodium species, these sequences did not cluster with the PIR 
sequences. The authors postulated that these families may share ancestral sequences, 
and noted that there was significant orthology between the intron of rif genes and the 
second pir intron (Janssen et al., 2004). The inclusion of the rif, stevor and PfMC-2TM 
genes within the pir super-family was based upon similarities in size, and conserved 
sequences present in the first intron, the authors proposing an ancestral relationship 
rather than necessarily conserved functions between these gene families. However, this 
inclusion has proved controversial [for example: (Joannin, 2010)], especially due to the 
divergence in amino acid structure between the P. falciparum gene families and the 
other pir. 
 
 
 
Figure 11: Sequence comparison between PIR super-family members.  
Adapted from (Cunningham et al., 2010) (Janssen et al., 2004). The left tree was created using the 
maximum parsimony algorithm, and shows the relationships between 157 PIR and RIFIN sequences 
(Janssen et al., 2004), whilst the right hand image is a NeighborNet network (Bryant and Moulton, 2004) 
which shows the relationships between 136 PIR sequences (Cunningham et al., 2010) .  
 
Indeed, since the functions of none of these multi-gene families have been elucidated, it 
could be argued that definition of any gene family purely based on their sequence 
characteristics risks being obstructive. Future experimental evidence showing 
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disparities or parallels between members of the variant antigen families should aid their 
definitive classifications.  
 
1.9.2 pir / PIR expression 
Northern blot analysis of cir transcription during the erythrocytic growth cycle 
indicated that late-trophozoite stages have most active transcription, which is reduced 
during schizogony (Janssen et al., 2002). Microarray studies carried out subsequently in 
P. vivax and P. yoelii suggest that at the population level, the pattern of pir transcription 
is more complex with many changes occurring (Bozdech et al., 2008, Cunningham et 
al., 2009). In these studies, 42% and 59% of the yir and vir repertoires were transcribed 
respectively. 
Initial reverse-transcription PCR experiments have suggested that yir sub-families may 
be differentially expressed in different parasite stages (Fonager et al., 2007), however, 
this was not confirmed by a subsequent microarray investigation (Cunningham et al., 
2009). Instead, a large proportion of yir were found transcribed at low levels, each gene 
having different transcriptional peaks at different stages of intra-erythrocytic 
development. This was the case even within cloned parasites, in the absence of 
lymphoid selection, where the expressed yir repertoire was substantially altered from 
the infecting parasite within 10–12 growth cycles (Cunningham et al., 2009).  
Similarly to the yir genes, there was also no evidence that vir transcription correlated 
with the previously identified phylogenetic groups (Bozdech et al., 2008, Del Portillo et 
al., 2001, Carlton et al., 2008). However, two non-overlapping sets of vir transcription 
were detected in different stages of P. vivax development: shortly after RBC invasion 
and in schizonts (Bozdech et al., 2008). The waves of vir transcription were associated 
with a similar pattern for the P. vivax tryptophan rich antigen genes (Pvtrag), which 
have also been postulated to be involved in immune evasion (Jalah et al., 2005). 
pir transcription has recently been compared between the erythrocytic stages of infected 
patients and their subsequent sexual stages (gametes / zygotes and ookinetes), generated 
by in vitro culture (Westenberger et al., 2010). The majority of vir genes showed lower 
expression than other genes at all stages, and strong differential regulation was only 
displayed by 9.9% of virs (Westenberger et al., 2010).  
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Using P. yoelii, it has been possible to conduct controlled experiments to investigate pir 
transcription in pre-erythrocytic stages (Williams and Azad, 2010).The transcriptome 
was compared between WT sporozoites, radiation-attenuated sporozoites and liver 
stages. Differences in yir transcription were observed in that wild-type sporozoites 
retained a higher number of expressed yir genes than radiation-attenuated sporozoites, 
and that distinct groups of yir genes were expressed by sporozoites and 48hr liver 
stages, and 24hr liver stages contained an intermediate yir profile (Williams and Azad, 
2010). 
The detection of yir transcripts in sporozoites supports earlier proteomic data which 
found BIR proteins expressed at different stages of the parasite lifecycle (Hall et al., 
2005). In this study almost 20% of the possible BIR repertoire was detected, with the 
vast majority expressed within specific, non-overlapping stages, and almost a tenth of 
BIR expressed within ookinete stage parasites (Hall et al., 2005). Together, these data 
suggest that PIR subsets may perform distinct roles within different parasite stages. 
 
1.9.3 Regulation of pir expression  
Clearly, pir genes are subject to differential gene regulation. To decipher the level of 
regulation applying to individual iRBCs, micro-manipulation has been used to separate 
single cells and investigate their pir transcription (Fernandez-Becerra et al., 2005, 
Cunningham et al., 2009).  Surprisingly, considering the large proportion of yir and vir 
genes that were transcribed in the total blood population, only 1 - 3 yir were transcribed 
in a single iRBC.  This suggests that whilst mutually exclusive pir transcription does 
not occur, transcription of these genes is under tight control. It is possible that not all 
transcribed pir are translated so mutually exclusive protein expression cannot yet be 
ruled out. 
Very little is known about regulatory factors affecting pir genes, although an informatic 
analysis has identified a motif within the yir, bir and cir promoter regions, which may 
provide general regulatory control rather than differential regulation (Fonager et al., 
2007). This study also identified alternative splicing events occurring during yir mRNA 
processing. Alternative splicing may alter the character of the translated YIR or 
contribute to regulation of expression by blocking translation of full-length yir and 
perhaps regulation upon transcription of other yirs, as postulated for other VSA families 
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(Al-Khedery et al., 1999, Taylor et al., 2000a). 
 
1.9.4 PIR protein characteristics  
In general PIRs do not appear to contain strong homology to proteins whose structures 
have been solved. Predictions of their secondary structure have identified multiple alpha 
helices (7-8) ranging from 12 to 20 amino acids in length, separated by coiled-coil 
regions (Janssen et al., 2004). Secondary structure predictions for the VIR and KIR 
repertoires reflect their diverse natures, containing more beta-stranded regions (Janssen 
et al., 2004).  
Domains found in other VSA, such as the DBL and CIDR domains of PfEMP1 
members are absent in PIR proteins. Instead, PIRs are comprised of up to three as yet 
uncharacterized PIR domains followed by a trans-membrane region (Pain et al., 2008). 
Their predicted arrangements are shown in Figure 12. Although the majority of PIRs do 
contain a predicted TM domain (Janssen et al., 2004, Pain et al., 2008), this is only 
predicted for half of the VIR proteins (Carlton et al., 2008), which may indicate that 
half of the proteins perform other functions to the other VIRs. 
 
 
Figure 12: Domain organization predicted for the KIR proteins.  
Adapted from (Pain et al., 2008). The three predicted KIR domains are shown in purple, followed by the 
TM domain, top panel. KIR proteins may contain one, two or three domains, which are thought to be 
exposed at the surface of iRBC, as indicated in the bottom panel. 
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Some PIR proteins also contain sequences similar to the PEXEL /VTS motif, associated 
with protein export to the iRBC surface in P. falciparum (Hiller et al., 2004, Marti et al., 
2004). This is found in 46% of VIR in the Sal I strain, and in 69% of VIR sequenced 
from 32 patient isolates, 11% of YIR, but not in any KIR sequences (Pain et al., 2008, 
Fonager et al., 2007, Merino et al., 2006, Carlton et al., 2008). Instead, a different, 
potential export sequence has been identified in three quarters of the KIR repertoire: 
ZLPS [where Z encodes a hydrophilic residue, (Pain et al., 2008)]. 
Several features of PIR proteins are shared with members of the RIFIN and STEVOR 
families, including the typical PIR alpha helical secondary structure. In fact, rif genes 
could be identified from the P. falciparum genome using hidden Markov models 
designed for detection of rodent pir genes [with low significance, (Janssen et al., 
2004)]. In addition, certain VIR sub-families display similarities with other P. 
falciparum multi-gene families: sub-family A members contain a cysteine rich domain 
at their N-termini, like the SURFINs (Merino et al., 2006, Winter et al., 2005), whilst 
sub-family D members share features with PfMC-2TM proteins including an N-
terminus which is weakly hydrophobic, conserved cysteine residues and proline 
residues in one of the TM domains, and a lysine rich C-terminus, (Merino et al., 2006). 
 
1.9.5 Function(s) of PIR proteins  
The function(s) of PIRs are unknown, although certain features of the proteins may 
provide an insight into their possible roles.  The cellular localization provides a crucial 
insight into protein function and several investigations have been carried out to 
elucidate the localization of PIR within erythrocytic stages. 
Numerous methodologies have been used to show that at least some PIR reside at or 
near the iRBC surface: indirect immunofluorescence assay using both fixed and live 
iRBC, flow cytometry using live iRBC and proteome analysis of detergent-resistant 
membrane-associated proteins (Fernandez-Becerra et al., 2005, Janssen et al., 2004, Del 
Portillo et al., 2001, Cunningham et al., 2005, Di Girolamo et al., 2008).  In the latter 
study, an endogenous bir gene was GFP-tagged, and maximal fluorescence intensity 
was detected in trophozoite stage parasites, confirming earlier transcriptional data which 
had suggested peak PIR expression occurred at this stage of development (Di Girolamo 
et al., 2008).  
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Surface localization of PIR proteins is perhaps surprising, since few of the proteins 
contain export motifs, as discussed above. However, reports of protein export in the 
absence of PEXEL/VTS sequences suggest that alternative export pathways exist, 
which may utilize an overall N-terminal negative charge, as observed for skeleton-
binding protein 1 (Saridaki et al., 2009). The localization of some PIRs at the iRBC 
surface, and the detection of BIR family members within detergent resistant lipid rafts, 
could indicate that PIR perform environmental interactions such as signalling and 
protein trafficking, functions of other lipid-raft associated proteins (Di Girolamo et al., 
2008). 
Given the fact that a small fraction of PIRs are found at the iRBC surface, and that 
different PIRs are expressed throughout the erythrocytic cycle, it seems likely that 
different PIRs may have distinctive cellular localizations. It could be that particular 
subsets perform individual functions, and given the similarities of certain VIR sub-
groups with SURFIN and PfMC-2TM sequences, it is possible that these proteins may 
also be found located in merozoites and at the MCs (Winter et al., 2005, Sam-Yellowe 
et al., 2004).  
As described above, the pir genes represent the largest multi-gene family in P. vivax, P. 
yoelii, P. berghei and P. chabaudi. Their function(s) must be crucial for parasite 
survival otherwise such redundancy would have been quickly lost by stabilizing 
selection. The presence of at least some PIR at the iRBC surface may well indicate that 
they are involved in host-interactions. Potential host-interactions of the PIR proteins are 
discussed below, including: antigenic variation, immune interactions and sequestration. 
 
1.9.5 i) Antigenic variation 
Requirements that must be fulfilled for a multi-gene family to truly mediate antigenic 
variation are stringent (Turner, 2002). The five major criteria proposed by Turner are 
presented here, in context with features of the pir family. 
1) Variant antigens must have the capability to express several different antigens; a 
feature easily fulfilled by the large size of the pir family.  
2) Variants should ideally be immuno-dominant over conserved antigens, each 
variant containing unique conformational determinants to which immune 
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responses are directed. The diversity of pir sequences accounts for this factor, 
VIR proteins sharing as little as 20% sequence identity (Carlton et al., 2008), 
although there is no evidence as yet that PIRs are immuno-dominant. 
3) Sub-populations of iRBCs expressing different variants must be capable of 
growth to compensate for parasites killed by effective immune responses. 
Although this has not been definitively shown regarding PIR, iRBCs isolated 
from different peaks of P. chabaudi infection express distinct surface antigens 
(McLean et al., 1982a), which are likely to be encoded by the cir genes as these 
comprise the largest multi-gene family in P. chabaudi (Janssen et al., 2002). 
4) The differential expression of variants must not affect the expression of other 
genes, for example being induced as part of a physiological response. pir 
transcription has been shown to change without associated differences in other 
genes, and in different patient isolates (Bozdech et al., 2008, Cunningham et al., 
2009, Westenberger et al., 2010, Williams and Azad, 2010). 
5) Mutually exclusive transcription should occur to prevent exposure of all variants 
to the immune response and thus exhausting the repertoire of variants. This is 
not the case for pir genes, however transcription of 1 - 3 pir genes per iRBC 
nonetheless demonstrates tight control of pir regulation (Cunningham et al., 
2009), and is similar to the number of var genes that may be transcribed in ring 
stage P. falciparum iRBCs (Chen et al., 1998). Similarly, the parasite population 
must retain the capacity to present different variants in waves with relatively 
little overlap. This has been shown within the vir repertoire (Bozdech et al., 
2008). 
Despite non mutually exclusive expression, pir transcription is highly regulated, and it 
is possible that low-level transcripts exist below the threshold required to mount an 
immune response, or alternatively, that so few iRBC are targeted by immune responses, 
that the majority of parasites remain to prolong the infection (Cunningham et al., 2009). 
Both of these proposals are possible mechanisms for the pir family to mediate immune 
evasion, even if this is not antigenic variation in the strictest sense.  
yir expression has been shown to be modulated in immuno-competent, but not immuno 
deficient mice, suggesting that YIRs are immune targets (Cunningham et al., 2009, 
Cunningham et al., 2005). In addition, few iRBCs from either laboratory infection, or 
patient isolates, are recognized by Abs generated against different sub-sets (Fernandez-
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Becerra et al., 2005, Cunningham et al., 2005), indicating that there is differential 
expression at the protein level too. Finally, the fact that there appears to be limited 
cross-reactivity between Abs generated to YIR sub-family specific peptides 
(Cunningham et al., 2005), supports the idea that distinct PIR variants could be 
maintained in the face of an active host immune response. 
 
1.9.5 ii) Immune interactions 
As described above, pir transcription is modulated in the presence of an intact immune 
response, suggesting that PIR proteins could be immune targets. Abs are indeed 
generated to PIRs during P. yoelii and P. vivax infections (Cunningham et al., 2009, Del 
Portillo et al., 2001), although the number of P. vivax episodes experienced by the 
patients did not significantly alter the repertoire of VIR that their Abs were able to 
detect (Fernandez-Becerra et al., 2005, Oliveira et al., 2006). This provides support for 
the smoke-screen hypothesis of immune evasion, whereby multiple PIRs may be 
expressed during infection, overwhelming the immune response such that some iRBCs 
always escape immune selection to proliferate and maintain the infection.   
Another potential immune interaction has been postulated for the KIR family members, 
in that several of these proteins contain regions of identical sequence to those of host 
proteins (Pain et al., 2008). Notably, the molecules CD99 and AHNAK are included in 
this phenomenon, where different KIRs contain identity to different regions of the 
proteins. KIR sequences correspond in total to over half of the extracellular domain of 
CD99, a protein expressed on all leukocytes, which aids their migration, adhesion and 
activation (Dworzak et al., 1994). Pain and colleagues suggested that KIR proteins 
mimic host CD99, which may act to inhibit iRBC recognition by leukocytes or compete 
for CD99 ligands to reduce T cell activation (Pain et al., 2008). To date similar 
sequences have not been determined in other PIR members, but it is possible that 
similar host mimicry may also occur in the other species. 
 
1.9.5 iii) Sequestration 
P. falciparum and the rodent parasites P. chabaudi and P. berghei, are known to 
sequester in various organs, to differing degrees (Montgomery et al., 2007, Mota et al., 
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2000, Franke-Fayard et al., 2005), whilst non lethal clones of P. yoelii are thought not 
to, because all intra-erythrocytic stages can be seen in peripheral blood, also the case for 
P. vivax. A recent study has questioned this dogma however, showing that P. vivax 
iRBCs can cyto-adhere via the receptors ICAM-1 and CSA (Carvalho et al., 2010). In 
this study, P. vivax iRBCs could cyto-adhere with approximately a tenth of the 
frequency of P. falciparum iRBCs, but once bound the interactions were as strong.  
The ability of only some iRBCs to sequester would explain the observation of mature 
stages in peripheral circulation, and also explains their depletion in peripheral 
circulation found in some human and monkey infections (Rudolf, 1927, Field and Reid, 
1956, Fremount and Miller, 1975). Indirect evidence exists that lung pathology may 
result from sequestered P. vivax iRBCs (Anstey and Price, 2007). Both VIR and YIR 
family members have been predicted to be adhesive (Ansari et al. 2008), and a recent 
experimental investigation of P. vivax iRBC adhesion has implicated the VIR proteins 
in this process. Anti-sera raised against the VIR sub-families A and E were both able to 
reduce cyto-adhesion to human lung endothelial cells, in vitro, by approximately 40% 
compared to iRBCs incubated with no anti-sera, and approximately 30% compared to 
iRBCs incubated with unrelated anti-sera (Carvalho et al., 2010). This is the first 
evidence that members of the PIR family could mediate cyto-adhesion, although 
further, more rigorous investigations will be required to elucidate the role of VIR 
proteins in this phenomenon. However, correlations of PIR with sequestration are 
complex, as Lovegrove and colleagues found no difference in bir transcription when 
mice were infected with different strains of P. berghei, which either did or did not elicit 
cerebral malaria (Lovegrove et al., 2006). However, 5% of bir genes were differentially 
expressed when CM-resistant and -susceptible strains of mice were compared during P. 
berghei ANKA infection (Lovegrove et al., 2006). 
The classification of cerebral malaria in patients, and its representation by rodent 
models has recently been a subject of debate [for example: (Riley et al., 2010, 
Stevenson et al., 2010)]. Some data suggest that sequestration of iRBCs is not linked 
with the pathology of experimental CM (Franke-Fayard et al., 2005), whilst other 
studies have argued that the extreme inflammation observed in this condition relies 
upon iRBC sequestration (Lovegrove et al., 2006). What is clear however, is that bir 
transcripts were detected from multiple organs in mice, implying that even if their 
involvement in CM is not clear, BIR proteins may mediate cytoadhesion in organs such 
as the lungs, liver and spleen (Lovegrove et al., 2006). 
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A further hypothesis has been put forward involving splenic sequestration, which would 
explain the partial lack of mature P. vivax iRBC in peripheral circulation, (Del Portillo, 
2004, Fernandez-Becerra et al., 2009). During malaria infection, the architecture of the 
spleen is dramatically altered (Achtman et al., 2003, Cadman et al., 2008). One of the 
changes is the development of barrier cells (Weiss et al., 1989) between the white and 
red pulp, to which Del Portillo and colleagues believe that PIR may allow sequestration 
of P. vivax iRBC (Del Portillo et al., 2004).  
Clearly there is still a great deal to learn about this large multi-gene family, particularly 
with respect to their possible host-interactions such as sequestration and immune 
evasion. These investigations are most accessible in rodent models, following which 
mechanisms can be confirmed by patient studies.  
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1.10 Investigations of the cir multi-gene family 
1.10.1   P. chabaudi  
P. chabaudi is the only well-characterised Plasmodium species that produces chronic 
infection in laboratory mice - in contrast to both P. berghei and P. yoelii, which give 
rise to an acute infection that is either resolved or results in death [reviewed by (Amante 
and Good, 1997)]. The chronicity of P. chabaudi infection produced in laboratory mice 
is likely to be perpetuated by antigenic variation. Antigenic variation has been 
demonstrated within this model (McLean et al., 1982b, McLean et al., 1982a, McLean 
et al., 1986), however the antigens responsible have not been determined.  
Besides development of chronic infection, P. chabaudi also exhibits several other 
features observed in human Plasmodium infections, including rosetting, sequestration of 
some mature iRBC stages and adhesion to endothelium via the receptor CD36 (Gilks et 
al., 1990, Mota et al., 2000, Mackinnon et al., 2002). 
Another similarity to human malaria is that mice develop some immunity to re-infection 
with the same parasite strain after only one infection (Jarra et al., 1986), otherwise 
known as homologous challenge. However, resistance to heterologous challenge, re-
infection using a different parasite strain, did not emerge even after 6 or 7 homologous 
infections (Jarra et al., 1986). The P. chabaudi model thus provides an ideal system in 
which to dissect the host immune response to Plasmodium infection, and this has been 
extensively investigated, as described in section 1.3.3. 
Since many facets of mouse infection with P. chabaudi have been elucidated or are 
experimentally accessible, this system may also be used to investigate which proteins 
could mediate antigenic variation or sequestration, and which are the targets of 
protective immune responses. 
The cir multi-gene family was chosen for the present study. Because the cir genes 
comprise the largest gene family in P. chabaudi, their products are prime candidates for 
antigenic variation, immune evasion and potentially sequestration, yet very little is 
known about their expression, function and role in stimulating or evading host 
immunity. 
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1.10.2 Objectives of this study 
To appreciate the role of CIR proteins during P. chabaudi infection several components 
had to be considered, including the gene-family composition, their expression at the 
gene and protein level, and their interactions with the host immune response. A wide 
range of approaches was required to address such different aspects, reflected in the five 
results chapters presented here: 
Firstly, cir genes were identified and annotated onto the P. chabaudi AS genome 
sequence, in collaboration with the Sanger Institute. The amino acid sequences were 
aligned to identify groups of similar sequences, which may share functional roles.  
Analysis of cir transcription was undertaken, initially by quantitative RT-PCR using 
primers designed to amplify members of the individual groups; and subsequently 
methods of purifying P. chabaudi AS infected blood were investigated to provide a 
clean template for full transcriptome sequencing by Solexa / Illumina technology. 
Highly transcribed cir genes were selected for the design of synthetic gene constructs, 
used for the expression of recombinant CIR in the methyltropic yeast Pichia pastoris. 
Polyclonal anti-sera were generated in rabbits against two recombinant CIR proteins 
and against three CIR peptides. One of these peptides was a conserved sequence found 
in the majority of CIRs, and anti-sera to this peptide was used to show the localization 
of CIR proteins within and on the surface of infected erythrocytes.  
Finally, the CIR peptides and recombinant proteins were used to determine whether 
mice make antibodies that recognize CIR proteins during infection, and whether the 
induction of high anti-CIR antibody titres by immunization might play a role during a 
subsequent P. chabaudi AS infection. 
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Chapter 2: Characterization of the cir gene family 
2.1 Introduction      
The sequencing of Plasmodium genomes has made it possible to apply bio-informatic 
methods towards characterizing novel genes. Several approaches have been used in 
efforts to identify and understand the pir genes, described below. 
The identification of thirty-two novel genes in a P. vivax yeast artificial chromosome 
library clone marked the discovery of the vir multi-gene family (Del Portillo et al., 
2001). Shortly afterwards, the cir genes were identified in P. chabaudi, by a genome 
survey sequencing project, and initially called fam3 (Janssen et al., 2001, Fischer et al., 
2003, Janssen et al., 2002). Orthologues were also detected in the available genome 
sequencing data for the rodent parasites P. berghei and P. yoelii, whereupon the whole 
‘super-family’ was called pir (Janssen et al., 2002, Janssen et al., 2004, Carlton et al., 
2002). 
These early investigations were unable to use complete genome sequences for 
identification of the full pir repertoires, and instead estimated the total copy number 
according to the distribution of pir genes within the investigated DNA and the fact that 
all chromosomes were positive by southern blots using pir specific probes. Initially, 
600- 1000 vir genes (Del Portillo et al., 2001) and 600 cir genes (Janssen et al., 2002) 
were predicted, figures which were revised closer to the true copy numbers as genome 
data accumulated: 346 vir genes, 38 kir genes, 160-200 bir and cir genes, and 838 yir 
genes were predicted (Carlton et al., 2002, Janssen et al., 2004, Pain et al., 2008).  
In addition, chromosomal location made annotation of pir genes particularly difficult. 
The majority of pir genes reside in the sub-telomeres (Fischer et al., 2003, Carlton et al., 
2008, Hall et al., 2005, Carlton et al., 2002), which are prone to repetitive sequence 
(Hall and Gardner, 2004), or associated with interstitial repeat sequences making contig 
assembly in these regions fraught with error (Hall and Gardner, 2004). For Plasmodium 
species whose genomes are still incomplete, such as P. berghei (according to 
http://www.genedb.org/Homepage/ Pberghei 4/4/2011), the pir annotation is likely to 
change as genome-finishing re-assembles contigs and accurately defines the sub-
telomeric and repetitive sequences. 
As genome-sequencing data expands, the difficulties of pir chromosomal location may 
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be resolved, such as for the vir and kir genes (Pain et al., 2008). However, automated 
gene prediction software remains unable to accurately detect all pir genes, meaning that, 
to date, the majority of pirs have been manually annotated [for example, (Carlton et al., 
2008)].  
 Whilst determination of the full genome sequence has allowed description of the vir 
and kir families in detail (Pain et al., 2008), and smaller scale investigations have 
indicated the conserved features of PIR superfamily members (Del Portillo et al., 2001, 
Janssen et al., 2002, Janssen et al., 2004, Merino et al., 2006, Fonager et al., 2007), less 
is known about the pir repertoire in rodent malarias. The P. chabaudi AS genome had 
been sequenced to 8-fold coverage at the beginning of this study, making it possible to 
update the cir repertoire from its original annotation (Janssen et al., 2002). 
The objectives of the work described in this chapter were to: 
i) Identify and annotate the full cir repertoire in the P. chabaudi AS genome. 
ii) Characterize the features of CIR amino acid sequences that may provide 
indications to the possible function(s) of these proteins 
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2.2 Methods     
2.2.1 Annotation of cir genes 
Artemis release 11 (Rutherford et al., 2000, Carver et al., 2008) was used to annotate cir 
genes onto the 8x sequence coverage of the P. chabaudi genome. This process is 
summarized in Figure 13. 
 
 
Figure 13: Strategy used for annotation of cir genes in the P. chabaudi AS genome. 
a) Flow chart demonstrating the steps taken to identify and annotate cir genes. 
b) Annotation was carried out using the genome browser Artemis (Rutherford et 
al., 2000, Carver et al., 2008). Three windows show important features of the 
selected DNA assembly: 
i. GC content is shown graphically, fluctuating around the average content 
for each DNA section under analysis.  
ii. All six possible open reading frames are shown in yellow, with stop 
codons represented by black vertical bars. Different exons often existed 
in different reading frames, as shown in the three example cir genes 
included in this DNA sequence. 
iii. All six possible reading frames are shown, as in window ii), but further 
magnified in this view, to show the individual amino acid sequences. 
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Three stages of cir gene annotation were performed, indicated in Figure 13 by 1, 2, and 
3. Open reading frames (ORFs) were identified that contained conserved features of cir 
genes from the previous (3x) genome assembly and common Plasmodium splice sites 
(Appendix 2.1). Available P. chabaudi AS transcriptome data was used to verify the 
annotated ORFs. These were then searched for similarity to the pir super-family genes 
via basic local alignment tool (BLAST). Genes that had high identity to other pir genes 
were considered to be cirs.  
110 cir genes were originally identified, which increased to 128 cirs upon genome 
finishing where contigs were re-assembled. This enabled the re-evaluation of cir genes 
which had either previously been found as partial genes at the ends of contigs, or had 
been mis-identified within poorly assembled regions of the genome. A further 71 cir 
genes were identified using a hidden Markov model [HMM, reviewed by (Eddy, 
1996)], created using the established repertoire of 128 cir genes, according to the 
methods used for Pfam classification (Sonnhammer et al., 1998, Finn et al., 2010).  
 
2.2.2  Detection of conserved motifs  
CIR amino acid sequences were uploaded to http://meme.sdsc.edu/meme/ to allow 
Multiple Expectation Maximization for Motif Elicitation analysis [MEME, (Bailey and 
Elkan, 1994)], and the program was set to identify up to 20 of the most conserved 
motifs and return the analysis as text. The average motif locations were identified and 
plotted onto each gene. WebLogos were generated using by the MEME program, using 
an adaptation of the WebLogo software [(Crooks et al., 2004), hosted at 
http://weblogo.berkeley.edu/]. 
 
2.2.3 Analysis of sequence similarity 
Three stages of annotation were performed, outlined in Figure 13; the number of 
identified cir genes increased after each stage of annotation. Amino acid sequences of 
107, 117 and 183 CIRs were aligned using the Multiple Sequence Comparison by Log- 
Expectation algorithm [Muscle, (Edgar, 2004)]. These alignments are attached in 
Appendices 2.3, 2.6 and 2.9. (In addition, alignments of PIR sequences are attached in 
Appendices 2.12 and 2.14). Certain sequences aligned poorly with the other CIRs, for 
reasons including probable incomplete annotation and extreme divergence (called ‘CIR-
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like’ sequences). These sequences were excluded from each alignment. Alignments 
were then refined by eye to ensure that all the sequence blocks identified aligned well 
together. Regions containing large insertions were deleted as these cannot be compared 
to the other sequences and are therefore uninformative. 
Several tree-building methods were applied to the first alignments of 107 and 117 CIRs, 
to ensure that the clades seen were valid. Phylogenetic trees were produced with the 
MEGA program (Kumar et al., 2004) using: un-weighted pair group method with 
arithmetic mean (UPGMA), minimum evolution, neighbour joining and maximum 
parsimony. The latter three trees used an evolutionary model for amino acid sequence, 
the Poisson correction (Zuckerkandl and Pauling, 1965).  For these methods a bootstrap 
of 500 was carried out. This calculates the proportion of times a particular branch was 
included in a tree, so a bootstrap of 50 means 50% of trees contained that branch 
(Felsenstein, 1985).  
In addition, a tree was constructed using the maximum likelihood method from the 
PhyML server (Guindon et al., 2005, Guindon and Gascuel, 2003). Here, the 
evolutionary model applied was Le Gascuel [LG, (Gascuel, 1997)] and the branch 
support was calculated by approximate likelihood ratio test [aLRT, (Anisimova and 
Gascuel, 2006)]. This method is a non-parametric branch support based on a 
Shimodaira-Hasegawa-like procedure [SH-like, (Shimodaira and Hasegawa, 1999)], 
which is less computationally intensive than bootstrapping, but not equivalent. SH-like 
aLRT assesses whether the branch being studied is more statistically likely than 
collapsing a branch, leaving the rest of the tree topology identical. The initial tree was 
created by BIONJ (Gascuel, 1997), and tree improvement was carried out by nearest 
neighbor interchanges (NNI) using the maximum likelihood method.  
Clades that were identified by all of these analyses, with high branch support values, 
contained highly CIR similar sequences; consequently these clades were called 
subfamilies A - F. The maximum likelihood algorithm implemented by PhyML 
(Guindon and Gascuel, 2003, Guindon et al., 2005), was seen to provide more 
consistent results than the other tree-building methodologies, therefore only this method 
was applied to the alignments of 117 and 183 CIRs. Maximum likelihood trees are 
attached in Appendices 2.4, 2.7 and 2.10. 
Since trees only represent a bifurcating lineage and imply phylogenetic relationships, 
reticulate networks were also created within the program Splitstree 4.0 (Bryant and 
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Moulton, 2004). All networks used the algorithms NeighborNet (Bryant and Moulton, 
2004) for calculation of distances and Equal angle (Gambette and Huson, 2008) for 
calculation of splits, as these make no assumptions about the evolutionary history of 
sequences, and are therefore suitable for creation of character display networks (Bryant 
and Moulton, 2004, Morrison, 2005). 1000 bootstrap replicates were generated. 
NeighborNet (Bryant and Moulton, 2004, Morrison, 2005) is derived from the 
Neighbour joining tree-building method, and uses agglomeration to produce 
progressively larger overlapping clusters of taxa. This algorithm is particularly suited to 
complex data sets, such as the CIRs, as fewer false negatives are produced than other 
commonly used methods of network creation, such as split decomposition (Bryant and 
Moulton, 2004, Morrison, 2005). Networks created for each CIR alignment are attached 
in Appendices 2.5, 2.8 and 2.11, whilst networks of PIR sequences are attached in 
Appendices 2.13 and 2.15. 
 
2.2.4 Evidence of recombination between cir genes 
Phylogenetic incompatibilities within the alignment of 183 CIRs, and smaller 
alignments containing members of each identified sub-family, were analysed using the 
pairwise homoplasy index (PHI) in Splitstree v4.0 (Huson, 1998).  
Phylogenetic profiling was used to detect phylogenetic inconsistencies between four 
chosen cir DNA sequences, using a hidden Markov model method within the TOPALi 
platform (Milne et al., 2009, Milne et al., 2004). The probability of generating each of 
the three possible tree topologies for the four sequences was modelled in a given 100 
nucleotide window. Possible recombination breakpoints were identified where the most 
probable topology altered at different positions along the alignment.  
 
2.2.5 Function shift analysis 
The two major CIR sub-families (U and A-F) were compared by identification of 
residues in the alignment that were differently conserved between the two groups. The 
‘FunShift’ methodology was developed using enzymes known to have different 
specificities (Abhiman and Sonnhammer, 2005), and is thus designed to predict whether 
groups of proteins may perform different functions.  
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The alignment of 183 CIRs was split into two files containing only CIR sub-family A-F 
or CIR sub-family U members. The two alignments were then used to calculate the 
following parameters, described below. Positions that contained only gaps in a 
subfamily were not counted. 
- Rate-Shifting Sites (RSS) were defined as positions conserved in one sub-
family but variable in the other, and were identified using the likelihood 
ratio test (LRT) program [(Knudsen and Miyamoto, 2001), hosted at 
http://www.daimi.au.dk/~compbio/rateshift/]. The U-values generated by 
this program indicate the likelihood of rate change for each position in the 
alignment between the two sub-families. U-values above 4.0 were 
considered significant at the 5% significance level, as previously described 
(Knudsen and Miyamoto, 2001). 
- Conservation-Shifting Sites (CSS) were defined as positions that were 
conserved in both groups, but containing different residues in each. CSS 
were detected using the method developed by Abhiman, Sonnhammer and 
colleagues [(Abhiman and Sonnhammer, 2005), hosted for proteins defined 
by PFAM domains at http://funshift.sbc.su.se/]. This calculates a Z-score 
based on the normalized cumulative relative entropy at each position of the 
alignment, between the two sub-families. Z-scores exceeding 0.5 per 
alignment position were considered significant (Abhiman and Sonnhammer, 
2005). 
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2.3 Results   
2.3.1 Identification of cir genes 
Completion of the P. chabaudi AS genome sequencing to eight fold redundancy meant 
it was possible to revisit initial cir annotation (Janssen et al., 2002, Janssen et al., 2004). 
Conserved features from initially identified cir genes, such as the relative exon lengths, 
splice sites and amino acid sequences were used to identify which ORFs in the 
assembled contigs were likely to be cir genes (This information is included in Appendix 
2.1). Three stages of annotation were performed, outlined in Figure 13; the number of 
identified cir genes increased after each stage of annotation. 
At first, 110 cir genes were identified, and 56% of these could be mapped to a specific 
chromosome. BLAST analysis found that 44% of newly annotated cirs were identical to 
cirs annotated on the previous genome assembly, which had a three-fold depth of 
sequence coverage. Some previously identified cir genes had high similarity to more 
than one newly annotated cir, in particular Pc_200009 (whose current ID is 
PCHAS_000100) matched 8 cirs with greater than 73% identity. The expectation (E-) 
value of this tBLASTn match is 7e-108, the low value indicates that this is a significant 
alignment and unlikely to have occurred by chance. 
As the final P. chabaudi AS contigs were assembled accurately, a further 18 cir genes 
were detected. Finally, a hidden markov model (HMM) was designed on the basis of the 
identified cir repertoire (Sonnhammer et al., 1998, Finn et al., 2010), which was used to 
detect more divergent cir genes, bringing the total of identified cirs to 198. These data 
are summarized in Table 5.  
 
Table 5: The status of the cir repertoire at each stage of annotation. 
Annotation stage: 1 2 3 
Number of annotated cir genes 110 128 198 
Long cirs 
Pc_040001 
Pc_990013 
Pc_990028 
Pc_990042 
PCAS_001000 
PCAS_000210 
PCAS_000140 
PCAS_040020 
PCHAS_040020 
PCHAS_000130 
PCHAS_000400 
Pseudogene Pc_070004 0 PCHAS_070090 
Number of cirs with no predicted TM domain 0 0 8 
Number of cirs with 1 predicted TM domain 110 123 143 
Number of cirs with 2 predicted TM domains 0 5 36 
Number of cirs with >2 predicted TM domains 0 0 1 (PCHAS_011490) 
The species identifiers: Pc_, PCAS_, PCHAS_ and gene names were altered at each stage of annotation. 
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Only three partial cir genes were identified in each stage of annotation, Table 5. These 
may result from poor assembly of contigs that could not be assigned to a specific 
chromosome. Long cir genes were also identified, which contained an extended first 
exon. The majority of cir genes contained one predicted TM domain, even after more 
divergent cirs were identified. Upon addition of more divergent cir genes to the 
repertoire, some amino acid sequences aligned poorly with the majority of CIRs, 
contained a long third exon or had been indentified as CIR-like sequences, containing 
some but not all expected features of cir family members. These CIR sequences were 
excluded from further analysis.  
  
2.3.2 CIR sequence similarity 
One method for further characterization of the cir repertoire is to investigate sequence 
similarity. To this end, the amino acid sequences detected at each stage of cir annotation 
were aligned using Muscle (Edgar, 2004), and refined by eye. The sequence similarity 
of each alignment was determined using Plotcon (http://emboss.bioinformatics.nl/cgi-
bin/emboss/plotcon), Figure 14. Clearly, all three alignments were similar, with more 
conserved sequences found between amino acids 250 and 600, and at the end of the 
alignment. The length of the alignments differed predominantly with respect to the 
region encoded by the end of exon two, which increased as more divergent CIRs were 
included. 
To determine the relationships between CIR sequences, both phylogenetic and non-
assumptive methods were employed. Initially, phylogenetic analysis was carried out 
using several methods from the alignment of 107 CIRs. The ability of different 
phylogenetic methods to identify clades of similar CIR sequences is compared in Figure 
16. Three distance-based phylogenetic methods were used: un-weighted pair group 
method with arithmetic mean (UPGMA), a, minimum evolution, b, and neighbour 
joining, c (Figure 15). These are simple methods that rank sequences according to the 
number of pairwise differences at each point, and then use this distance matrix to 
calculate a phylogeny. UPGMA is the simplest, followed by minimum evolution, which 
estimates the length of each branch in the tree, and chooses the ‘best’ tree as the one 
with the lowest sum of branch lengths. Neighbour joining is slightly more complex as 
an evolutionary model is applied to calculate the tree.  
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Two cladistic methods were also used: maximum parsimony, d, and maximum 
likelihood, e, (Figure 15). These methods create an initial tree directly from the multiple 
sequence alignment so no information is lost. Many trees are created by these methods, 
and the best one is chosen according to an evolutionary model. Maximum parsimony 
chooses the best tree as the one that uses the fewest evolutionary changes. Maximum 
likelihood calculates the probability of all possible tree topologies for each sequence 
unit, and chooses the most likely tree with the highest overall probability at each 
residue. All of the phylogenetic methodologies gave rise to similar tree morphologies, 
where 76% of CIRs clustered to form 6 clades, labelled A-F, Figure 15. The branches 
were coloured according to sub-family. Clades were only deemed to be sub-families if 
the bootstrap or aLRT branch support value was greater than 60%, in the majority of 
trees. This was the case for sub-families A, B, D, E and U, and the C1, C2, F1 and F2 
clades. Sub-family C, and the clades F1 and F2 were all strongly supported in the 
maximum likelihood tree, e) Figure 15, with aLRT values of 95 or greater.  
In addition, networks were created in the program Splitstree 4 (Huson and Bryant, 
2006) using the NeighborNet and Equal Angle algorithms (Bryant and Moulton, 2004, 
Gambette and Huson, 2008), for all alignments of CIR sequences. Figure 16 shows the 
trees and networks created from alignments of 117 and 183 CIRs. Unlike the 
phylogenetic analyses, the network methodology used did not assume linear evolution, 
instead allowing the complex inter-relationships between sequences to be visualized, 
which may reflect their evolutionary history or simply display character conflicts within 
the data [reviewed by (Morrison, 2005)]. The maximum likelihood trees and 
NeighborNet networks produced clades with consistent confidence values, despite being 
based on different criteria. The figures with confidence values (either calculated by 
bootstrapping, for networks, or aLRT, for maximum likelihood trees) are attached as 
appendices. 
Although the six sub-groups A-F were consistently identified (Figure 15 and Figure 16), 
their significance dropped as more divergent CIR sequences were added to the 
alignment. From the largest alignment of 183 CIR sequences, the sub-groups A-F 
comprised 44.3% of all analyzed CIRs. In contrast, the un-clustered CIR sequences, 
highlighted in black, expanded greatly upon identification of further CIR sequences by 
HMM analysis. This was expected given the divergent nature of the un-clustered CIRs, 
however clades of similar sequences were present within this group, Figure 16. Due to 
time constraints these clades were not investigated further, and the 55.7% CIRs found in 
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the un-clustered clade were termed sub-family U. The members of each identified sub-
family are shown in Table 6. 
 
Table 6: Genes present in the CIR sub-families: A, B, C, D, E, F and U. 
Sub-families 
A B C D E F U 
140030 000400 114750 120070 011510 140090 000040 083760 042020 040060 
114740 040020 000140 001130 104260 000730 000390 060050 060070 000430 
000030 120040 000070 100040 140020 030020 001100 030090 030190 104200 
000090 000130 001040 000560 070020 000360 000500 060060 060090 114720 
000270 001110 030080 000300 000720 011530 030120 130030 041980 073130 
000120 000110 060020 073180 070050 073160 114640 042030 130080 030070 
000280 120050 000020 070130 030060 070160 030180 060140 041970 137110 
000490 104250 000290 040030 000750 000580 130070 040110 060110 011490 
010020 000320 001090  000680 010030 146850 120030 041990 070060 
140130 000410   000100 110020 011500 000660 030140 070040 
000570    000310 050060 070100 040080 130100 011480 
114730    000420 000350 030110 060160 070170 000470 
140040    040040 050020 130050 146790 100060 050040 
100030    120060 073200 040050 000260 130060 000770 
001120    104230 120020 001050 083720 146860 130220 
000740    030040 000060 050070 090010 060130 114700 
011520    000340 130020 140070 114600 041950 137030 
070030     000150 000180 042070 130120 000170 
073190      001060 010040 126770 130170 
      011450 073150 130280 070070 
      030210 140140 011330 000220 
      146870 110030   
x 19 x 10 x 9 x 8 x 17 x 18 x 102 
Sub-families were identified from the alignment of 183 CIRs. The number of cirs present in each sub-
family are indicated underneath the gene names. For clarity, the species identifier PCHAS_ was excluded 
for each gene. 
 
Given that the later analyses of the CIR repertoire appeared to show two much larger 
clusters of sequences than previously identified, each comprising almost half of the 
CIRs, these may be considered to be ‘major’ sub-families. For simplicity, the major CIR 
sub-families will henceforth be referred to as sub-family U (comprising the more 
divergent CIRs) and sub-family A-F (including all six of the minor sub-groups that 
were initially identified), as shown in Figure 16. 
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2.3.3 Identification of conserved amino acid motifs 
The identification of conserved amino acid sequences may provide indications for 
possible protein function(s). 14 conserved motifs in the CIR amino acid sequences were 
identified by Multiple EM for Motif Elicitation analysis [MEME, (Bailey and Elkan, 
1994)]. These are represented as WebLogos (Crooks et al., 2004) in Table 7, where the 
height of each letter indicates the proportion of CIR sequences containing that residue. 
 
Table 7: Conserved amino acid motifs found within CIR sequences. 
Number Motif Frequency E-value 
1 
 
72.73% 2.1e-1491 
2 
 
33.84% 3.9e-939 
3 
 
72.22% 4.2e-923 
4 
 
74.24% 3.7e-1228 
5 
 
72.22% 2.2e-1262 
6 
 
39.80% 2.6e-628 
7 
 
41.41% 4.0e-800 
8 
 
15.66% 3.0e-426 
9 
 
49.49% 6.8e-391 
10 
 
59.09% 4.6e-567 
11 
 
45.45% 6.5e-462 
12 
 
29.80% 4.6e-337 
13 
 
12.63% 2.6e-326 
14 
 
14.14% 7.5e-321 
Amino acid motofs identified by MEME analysis (Bailey and Elkan, 1994). Hydrophobic residues are 
shown in blue, polar, non-charged residues in green, acidic residues in pink and positively charged 
residues in red. The frequency is the percentage of motif occurrences within the 198 analyzed CIR 
sequences. The E- values refer to the significance of each motif found within the CIR sequences.  
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Motifs 1 and 3 were the most conserved, being present in 72% of CIRs, and containing 
particular residue conservation. Motif 1 contained the almost unanimous YK residues, 
corresponding to the start of the third cir exon and part of the predicted CIR trans-
membrane domain. Motif 3 was found within the second cir exon and contained the 
highly conserved sequence YAILWLSY. Motif 10, present in 59% of CIRs, contained 
some degeneracy, but a clear conserved methionine indicated the N-terminus of all CIR 
proteins. All CIRs possessing motif 10 also contained a cysteine six residues into the 
sequence. Conserved cysteine residues were also located within motifs 5, 7 and 14.  
CIR motifs were arranged according to their phylogenetic sub-group to determine 
whether any motifs were sub-family specific, shown in Figure 17. Motif 10 was found 
at the N-terminus of all CIR proteins. Motifs 9, 3 11, 5, 4 and 1 were also found in 
members of all sub-families, indicating that these amino acid sequences may be 
essential for all CIR proteins. The remaining motifs appeared to have sub-family 
specific distributions, with motif 2 specifically, and motifs 6 and 7 predominantly found 
within sub-families A-F.  By contrast, motifs 8, 12, 13 and 14 were specific to CIR sub-
family U. Motif 8 lies within the predicted TM domain, which indicates that CIR sub-
family U proteins may have different functions than the other CIRs, such as perhaps 
spaning a different membrane. 
 
2.3.3  Diversity in the cir family generated by recombination  
The detection of similar CIR sequences, with conserved and sub-family specific amino 
acid motifs indicates that genetic exchange can occur between members of this multi-
gene family, most likely by recombination. 
Different types of recombination exist, several of which may affect pir genes. 
Homologous recombination occurs between similar sequences, typically alleles of the 
same gene, which could extend further within the pir repertoire to include any pir 
containing similar sequence. This may therefore occur during mitosis (within the 
mammalian host) as well as meiosis (within the mosquito), since the haploid genome 
present in all mammalian stages of the Plasmodium lifecycle does not necessarily 
preclude recombination between similar pir genes. During homologous recombination, 
genetic material may be exchanged in a reciprocal manner or one chromosome may 
donate genetic material without itself being changed. This phenomenon is called gene 
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conversion, and is likely to affect all multi-gene families. For simplicity, and since it is 
difficult to distinguish between these events bio-informatically, both reciprocal 
recombination and gene conversion will be referred to as ‘recombination’. 
Visualization of CIR sequence relationships using network methodology indicated that 
recombination may have occurred within the CIR repertoire, as many box-like 
structures (or reticulations) were present, Figure 16. Generally, tree-like structures 
within the network indicate linear evolution; whilst reticulations may represent 
recombination (Morrison, 2005). However, the interpretation of networks is more 
complex than interpretation of dichotomous trees. In fact, reticulations may represent 
one of three possibilities (Morrison, 2005):  
- Uncertainty or ambiguity in the data (for example: mistaken sequence 
homology, mis-alignment, or a poor fit of the data to the model used) 
- Analogy events in evolution (for example: convergent evolution giving rise to 
similar residues in sequences without shared origins) 
- True genetic exchange events in evolutionary history (for example: 
recombination, lateral transfer or hybridization) 
The second possibility may be ruled out, as all cir genes studied here were present 
within the same genome. Reticulations within the CIR networks were thus most likely 
to represent either poor alignment of the amino acid sequences or recombination events.  
To determine whether recombination had occurred within the cir repertoire of P. 
chabaudi AS, a closer examination was carried out using a variety of bio-informatic 
methods. An example is illustrated in Figure 18. Sub-family E was chosen since this 
appeared to be the most conserved of CIR clades, with a longer branch separating this 
from the other families within this major subgrouping than families A, B, C, D or F 
(Figure 16b). The members of this sub-family were aligned, and a network generated, as 
described previously, Figure 18a. The sequence similarity is shown in Figure 18b.  
There appeared to be two conserved clades within subfamily E, of which only one 
retained a significant probability of recombination (P = 0.0) using the PHI test within 
Splitstree (Huson, 1998) when the other clade was removed. This clade was present in 
the left hand region of Figure 18a, from which four cir DNA sequences were chosen: 
PCHAS_000100, PCHAS _000310, PCHAS _120060 and PCHAS _040040. These 
were aligned as previously described for CIR sequences, Figure 18c.  
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The program ‘tree TOPology-related analysis of ALignments interface’ [TOPALi; 
(Milne et al., 2009, Milne et al., 2004)] was used to produce a phylogenetic profile 
along the length of these sequences, iteratively removing sequence information from 
either the C-terminus or N-terminus end. By this approach, it may be possible to find 
areas of recombination between the cir sequences, as the tree topology would change 
when a recombination break-point was exposed. Phylogenetic inconsistencies were 
observed, indicating that different regions of the genes displayed different relationships 
with each other, Figure 18c. PCHAS_000100 is shown as an example, Figure 18d, 
containing similarity to different cirs along its length. Therefore it is likely that the 
PCHAS_000100 gene has undergone several recombination events. 
In fact, no part of the cir repertoire appeared exempt from recombination. All sequences 
investigated produced significant results from the PHI test and indicated possible break-
points by TOPALi analysis, they do indicate that recombination has played a strong role 
in shaping the cir repertoire.  
 
2.3.4 The context of CIR within the PIR super-family 
Since the PIR super-family is present in many Plasmodium species, it is likely that these 
proteins play similar roles, although functional differences may have emerged after 
speciation. PIR sequences that are conserved between different species may be subject 
to functional constraint, thus further investigation of such proteins may indicate the 
conserved role of PIR proteins. 
Firstly, a selection of PIR representing many different sub-groups was aligned as 
before, and used for creation of a NeighborNet network to illustrate the overall 
sequence diversity within the PIR super-family, Figure 19a (Cunningham et al., 2010). 
Here, PIR proteins were clearly most similar to PIR from parasites which had 
undergone the least phylogenetic separation, with VIR and KIR sequences being fairly 
divergent, and rodent PIRs clustering together, especially the BIR and YIR sequences.  
Some CIR sequences appeared to display similarities with BIR and YIR family 
members, so a larger proportion of the rodent PIR repertoire was analysed according to 
the same methodology, Figure 19b. Notably, these alignments were of lower quality 
than those created using only the CIR sequences, so only cautious interpretation may be 
attempted from this figure. The sub-families represented in these alignments are listed 
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in Table 8. CIR sequences preferentially clustered with themselves forming two large 
clades, as seen previously (Figure 16). CIR sub-family U was particularly distinct from 
the other rodent PIR. Other clades that could be easily distinguished corresponded to 3 
of the 5 previously identified YIR sub-groups: G2, G4a, and G5 (Fonager et al., 2007). 
Each YIR sub-group contained a few similar BIR sequences, but no CIRs. The rest of 
YIR and BIR sequences clustered together, and contained less distinctive sequences. 
 
Table 8: PIR sequences analyzed in Figure 19, and their respective sub-families. 
PIR sequences Rodent PIR sequences 
 Number of 
sequences 
Sub-families of 
sequences 
Number of 
sequences 
Sub-families of 
sequences 
VIR 29 B, C, E, I, J, K & nc - - 
KIR 16 * - - 
BIR 31 * 83 * 
YIR 32 G1, G2, G3a, G5 & nc 274 G1, G2, G3, G4, G5 & nc 
CIR 28 B, C, D, E, F & U 143 A, B, C, D, E, F & U 
Total 136  500  
Where sequences that were not clustered in previous analyses are labelled nc, and PIR repertoires for 
which sub-families have not been identified are labelled *. Sub-families that were not analysed are 
labelled -. 
 
2.3.5 Similarities between CIRs and RIFINs  
Whilst the CIR repertoire displayed some similarity with other PIR sequences (Figure 19), 
CIR sub-family U was distinct from the other rodent PIRs. The identification of two major 
CIR sub-families (Figure 16) was similar to the organization of the RIFIN repertoire in P. 
falciparum (Petter et al., 2007, Joannin et al., 2008). Accordingly, more comparisons of the 
CIR and RIFIN repertoires were undertaken.  
The RIFIN sub-family A is defined by the presence of a 25 amino acid sequence, which 
is absent from RIFIN-B types (Petter et al., 2007, Joannin et al., 2008). A relatively 
conserved insertion was detected only in CIR sub-family U members between position 
220 and 316 of the alignment of 183 CIRs. This region of the alignment is shown in 
Figure 20a, comparing representative CIR sub-family U and sub-family A-F sequences. 
The same region is also displayed as a weblogo (Crooks et al., 2004), created from all 
members of CIR sub-family U and sub-families A-F (Figure 20b). Figure 20c shows an 
enlargement of a section of the CIR sub-family U specific sequence, which displayed 
some similarities with the A-type RIFIN sequence, included in Figure 20d (Petter et al., 
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2007, Joannin et al., 2008). Notably, both sequences included two conserved cysteine 
residues. Approximately a third of the residues in each insertion sequence were 
hydrophobic and very few basic residues were present.   
The two RIFIN sub-families have been shown to display different sub-cellular 
localizations (Petter et al., 2007). A- and B-type RIFINs are thus predicted to have 
undergone functional divergence, which has been supported by bio-informatic analyses 
of the whole RIFIN repertoire in the P. falciparum clones 3D7, DD2 and HB3 
(Abhiman and Sonnhammer, 2005). To investigate whether the members of each major 
CIR sub-family could also have functionally diverged, a similar analysis was performed 
to that described by Joannin and colleagues (Joannin et al., 2008). The method used for 
function shift prediction, ‘FunShift’, has been developed using families of enzymes 
which were known to have different substrates (Abhiman and Sonnhammer, 2005). This 
method requires identification of rate shifting sites (RSS) and conservation shifting sites 
(CSS). These parameters correspond to residues that are either differentially conserved 
between the two sub-families (RSS), or positions that are equally conserved, but with 
different amino acids in each sub-family (CSS). 
The alignment of 183 CIRs was split into the major sub-families U and A-F; RSS and 
CSS were compared between the sub-families (significant sites are attached in 
Appendices 2.16 and 2.17). 77 RSS (15.4% of all positions) and 158 CSS (31.8% of all 
positions) were identified along the alignment, strongly suggesting that functional 
divergence between the CIR sub-families may have occurred according to the criteria 
generated with protein families of known function (Abhiman and Sonnhammer, 2005). 
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Figure 14: Comparison of alignments using CIR amino acid sequences 
At each of the three stages of cir gene annotation, the CIR amino acid sequences were 
aligned using Muscle (Edgar, 2004). Sequences that aligned poorly were removed from 
each alignment, leaving 107, 117 and 183 CIRs in the alignments at the first, second 
and third stages of annotation, respectively.  
Sequence similarity was plotted for the three alignments of CIR amino acid sequences 
using Plotcon (http://emboss.bioinformatics.nl/cgi-bin/emboss/plotcon).  
As the earliest identified CIRs were more similar, the alignment of 107 sequences was 
shorter than the subsequent alignments. Gaps present in the alignment are indicated by 
low sequence similarity.  
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Figure 15: Analysis of 
the CIR repertoire by 
different phylogenetic 
methods. 
Phylogenetic trees 
created using the 
following methods are 
shown:  
a) un-weighted pair 
group method with 
arithmetic mean 
(UPGMA)  
b) neighbour joining 
c) minimum evolution  
d) maximum 
parsimony, all 
implemented by 
MEGA (Kumar et al., 
2004) 
e), maximum 
likelihood, 
implemented by 
PhyML (Guindon and 
Gascuel, 2003, 
Guindon et al., 2005). 
Clades are highlighted 
with the colour 
accorded to each 
subfamily: A) red, B) 
green, C) yellow, D) 
pink, E) dark blue, F) 
light blue and U) 
black.  
The gene names 
indicated in e) were 
from the first stage of 
annotation.  
An electronic version 
of this figure is 
attached in Appendix 
2.4. 
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Figure 16: Relationships between CIR amino acid sequences. 
Similarities between CIR sequences were visualized using both a Maximum Likelihood 
tree [left, (Guindon et al., 2005)] and a NeighborNet network [right, (Bryant and 
Moulton, 2004)].  
These phylogenies and networks are shown without branch support values, for ease of 
view, therefore branches with high confidence [which comprise the majority of 
branches: defined as >60% calculated by aLRT (Anisimova and Gascuel, 2006) within 
the phylogenetic trees, and >70% of 1000 bootstrap replicates for networks] are shown 
in bold, and the figures including branch support values are attached in appendices. 
The six sub-families identified using the alignment of 117 CIRs, shown in a), were also 
seen when more CIR sequences were analyzed, 183 CIRs, shown in b). 
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Figure 17: Arrangement of conserved amino acid motifs within CIR sub-families 
Amino acid motifs identified by Multiple EM for Motif Elicitation (MEME) analysis 
[(Bailey and Elkan, 1994), Table 7], were aligned to their position within the encoded 
protein. A typical CIR is represented at the bottom of the figure, along with the motif 
key.  
To determine whether motifs were specific to CIR subfamilies, they were aligned to the 
maximum likelihood tree produced using 183 CIRs, Figure 16, which is represented 
here in a linear fashion. 40 sequences from sub-family U were not analyzed by MEME, 
this region of the tree is excluded. 
The subfamilies A-F are shown in colour at the bottom of the tree: A) red, B) green, C) 
yellow, D) pink, E) dark blue, F) light blue, whilst subfamily U is black, at the top of 
the tree.  
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Figure 18: Evidence for recombination between members of CIR sub-family E. 
A NeighborNet network (Bryant and Moulton, 2004), generated using aligned amino 
acid sequences from CIR sub-family E, a). Sequence identities of the amino acid 
alignment for CIR sub-family E members were generated in Plotcon 
(http://emboss.bioinformatics.nl/cgi-bin/emboss/plotcon), b) 
An example TOPALi profile (Milne et al., 2009, Milne et al., 2004), c), showing the 
three possible phylogenetic arrangements of sequences PCHAS_000100, 
PCHAS_000310, PCHAS_120060 and PCHAS_040040 (previously named 
PCAS_000970, PCAS_000120, PCAS_120060 and PCAS_040040, respectively). The 
phylogenetic profile indicates how the relatedness of the four analyzed sequences 
changes along their length. An example phylogenetic reconstruction is found to the 
right of each profile window, displaying the topology of that relationship.  
A reconstruction of PCHAS_000100, d), according to the phylogenetic profile shown 
above. Each block represents the cir sequence which displays closest homology with 
that region of PCHAS_000100, such that effectively this gene is a mosaic of the other 
three.  
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Figure 19: Relations of the CIR repertoire with the PIR super-family.  
Adapted from (Cunningham et al., 2010). Networks were created using the 
NeighborNet algorithm (Bryant and Moulton, 2004), in Splitstree v4.0 (Huson, 1998, 
Huson and Bryant, 2006). PIR sequences were either downloaded from PlasmoDB 
(KIR, YIR, & BIR) or kindly provided by Prof. Jane Carlton, New York University 
(VIR).  
136 sequences from the entire PIR superfamily, a), and 500 rodent PIR sequences, b), 
were compared. The previously identified YIR sub-groups: G2, G4a and G5 (Fonager et 
al., 2007) and CIR sub-families identified in chapter 2.3.2 are indicated. 
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Figure 20: Identification of similarities between the CIR and RIFIN repertoires.  
a) Ten representative CIR sequences from subfamilies A-F or U are shown, from an 
excerpt of the alignment of 183 CIRs. Between the conserved DY and YK residues at 
the N terminus and C terminus of this region, there are striking differences between 
these sets of CIRs.  
b) A weblogo (Crooks et al., 2004) was created using the sequences in a). The most 
conserved amino acids found in this region of CIR subfamily U, and subfamilies A-F 
are shown. A striking motif was observed within subfamily U sequences, highlighted by 
a dotted line. 
The subfamily U motif was detected from an alignment of 96 CIR sub-family U 
sequences, c), and compared to the insert present in the RIFIN subfamily A (Petter et 
al., 2007), d). 
Polar residues are shown in green, basic residues in blue, acidic residues in red and 
hydrophobic residues in black.    
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2.4 Discussion  
In total, 198 cir genes were identified in the P. chabaudi AS genome, with the majority 
being located in sub-telomeric sites and 6% in central locations which could be close to 
the centromere of those chromosomes. The majority of cir genes (96.5 %) retained the 
typical pir gene structure (Del Portillo et al., 2001, Janssen et al., 2002, Janssen et al., 
2004, Fonager et al., 2007), consisting of a short first exon, long second exon and 
highly conserved final exon. 
Three long cir genes were identified that were approximately double the length of the 
other cirs. These could potentially have been artefacts since DNA sequencing in the 
sub-telomeres, which are exceptionally AT-rich in Plasmodium genomes, is prone to 
errors (Scherf et al., 2004). For this reason, available transcriptome data was used to 
confirm the annotation of these cir genes. The motif arrangement within these amino 
acid sequences appears to show a repeated segment, which suggests that these genes 
were produced by tandem gene duplication events. 
Gene duplication and recombination events between members of the cir family are 
likely to have shaped the cir repertoire, as observed in other Plasmodium multi-gene 
families including var and sicavar [for example (Corredor et al., 2004, Frank et al., 
2008, Pain et al., 2008)]. Duplication events arise principally from mis-alignment of 
repetitive DNA, following which the genes evolve in concert by mutation and 
reciprocal or non-reciprocal recombination, also known as gene conversion. 
Recombination can either homogenize multi-gene families by promoting shared 
sequence, or increase polymorphism by the creation of mosaics (Petes et al., 1991, 
Weill and Reynaud, 1996, Hogstrand and Bohme, 1999, Martinsohn et al., 1999, Kudla 
et al., 2004, Nikolaidis and Nei, 2004, Maizels, 2005, Jackson, 2007); both mechanisms 
may act upon the cir repertoire. 
Fluorescent in situ hybridization analyses have demonstrated that chromosome 
telomeres cluster in the nuclear periphery of P. falciparum, enhancing the opportunities 
for sub-telomeric VSA genes to recombine with one another (Freitas-Junior et al., 2000, 
Taylor et al., 2000b). Similar localization of telomeres has also been observed in other 
Plasmodium species [reviewed by (Scherf et al., 2008)]. It has been postulated that the 
frequent recombination allowed by such spatial organization could allow VSA family 
members to evolve throughout infection, thus maintaining chronicity (Scherf et al., 
2008). 
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Comparison between the genomes of different P. falciparum isolates has identified a 
hierarchy of var genes, whereby certain variants appear restricted in their recombination 
potential (Pain et al., 2008). This suggests that certain PfEMP1 variants are more 
indispensible than others for maintenance of infection. Attempts were made to identify 
any cir genes similarly exempt from recombination, using comparable methodology to 
that applied to the sicavar genes for identification of recombination events (Pain et al., 
2008). No part of the cir repertoire appeared exempt from recombination. This could 
indicate that no such restriction of recombination exists for cir genes, as observed for 
vars. More probable though, is that cir genes displaying restricted recombination 
potential were not identified, as the repertoire from only one P. chabaudi clone was 
available for analysis. Whilst bio-informatic measures to identify recombination are 
crude, particularly within a single genome, they do indicate that recombination has 
played a strong role in shaping the cir repertoire. These observations are consistent with 
what has been shown in other multi-gene families such the VIR and RIFIN repertoires 
(Carlton et al., 2008, Joannin et al., 2008). 
A crucial question is how frequently recombination occurs between cir genes, 
particularly during mitosis, as the majority of studies using P. chabaudi investigate the 
asexual stages. If recombination occurs frequently in asexual stages, then many 
analyses of the cir repertoire could be meaningless. Attempts to confirm the break-
points identified by TOPALi using other methods, such as the recombination detection 
program [RDP, (Martin and Rybicki, 2000)] were inconsistent (data not shown). This 
suggests that many of the potential recombination events detected by TOPALi were not 
recent, and may have been of ancient origin, thus mitotic recombination between cir 
genes may be relatively infrequent. Further analysis of cir sequences from other P. 
chabaudi clones and sub-species, including clones that have experienced mosquito-
transmission, would be required for a confident estimation of recombination frequency 
within mitotic and meiotic stages. 
The detection of recombination between cir family members means that phylogenetic 
analysis is not an accurate way to analyze PIR sequences as they have not followed a 
path of linear evolution. Instead, both phylogenetic and non-assumptive methods were 
employed for this study, to provide a simple overview of the relationships between CIR 
sequences. Groups of highly similar sequences were identified using information 
derived from both methodologies. As described above, different tree topologies could 
arise from different regions of the protein. For example, alignments using only the C-
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terminus of CIR sequences may yield very different compatibility results than those 
using the N terminus. To eliminate this possibility, the whole protein sequences were 
used for the comparison of relationships between CIRs, with only uninformative regions 
of the alignments being removed. 
Six sub-groups named A-F were initially identified, comprising 75.7% of the 107 CIRs 
analyzed, whilst the remainder of CIR sequences remained un-clustered. Sub-families 
have also been identified in the VIR and YIR repertoires. Six VIR sub-families were 
initially described, and were detected in patient isolates (Del Portillo et al., 2001, 
Merino et al., 2006). Upon sequencing the whole P. vivax genome a further six were 
identified, meaning that 76% of the VIR repertoire was able to cluster into subfamilies 
(Carlton et al., 2008, Fonager et al., 2007). Similarly, 56% of the YIR repertoire was 
able to cluster into five sub-families, 44% of YIRs remaining un-clustered (Fonager et 
al., 2007).  Some of the yir sub-families were also detected in P. berghei, indicating 
that, for these closely related parasites at least, some sub-families were shared (Fonager 
et al., 2007). 
In order to detect possible conservation of sub-families, relationships between members 
of the PIR super-family were compared as described above for the CIRs. PIR proteins 
were clearly most similar to those from parasites that had undergone the least 
phylogenetic separation. This supports the original analyses of the PIRs carried out by 
Janssen and colleagues (Del Portillo et al., 2001, Janssen et al., 2002, Janssen et al., 
2004, Fonager et al., 2007).  CIR sequences preferentially clustered with themselves, 
forming two large clades, as seen previously. In particular, sub-family U appeared to be 
distinct from the other rodent PIRs. These data do not indicate any sharing of sub-
families between the cir and other pir repertoires, and suggest that no sequences are 
exempt from recombination. 
Upon identification of the more divergent cir genes by HMM analysis, the proportion of 
the CIR repertoire represented by the sub-families A-F was reduced to 44.3% of the 183 
CIRs analyzed. The remainder of CIR sequences remained un-clustered, comprising 
55.7% of the repertoire. Within these sequences, more conserved clades were observed, 
although due to time constraints these were not investigated separately. Thus the un-
clustered group was named sub-family U, and the previously identified sub-groups: A, 
B, C, D, E and F were defined as the other major sub-family. Given that the two major 
sub-families each represented almost half of the CIR repertoire, and each contained 
smaller clades of closely related CIRs, the composition of this family displayed 
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parallels with that of the RIFINs (Sevier and Kaiser, 2002). Consequently, a more 
detailed comparison of the CIR and RIFIN families was undertaken. 
The RIFIN sub-family A is defined by the presence of a 25 amino acid sequence, which 
is absent from RIFIN-B types (Petter et al., 2007, Joannin et al., 2008). An insertion 
was also observed within CIR sub-family U, a section of which contained two highly 
conserved cysteine residues. The close position of the cysteine residues was similar 
between the RIFIN and CIR motifs. Cysteine residues often participate in the formation 
of disulphide bridges [reviewed by (Sevier and Kaiser, 2002)], which suggests that the 
differential cysteine compositon of CIR and RIFIN sub-families could affect their 
tertiary structure. 
If the members of the CIR and RIFIN sub-families have different protein structures, 
they could perform distinct functions. This has been predicted to be the case for the A- 
and B-type RIFINs, using criteria for functional divergence developed using enzymes of 
known altered substrate specificity (Abhiman and Sonnhammer, 2005, Joannin et al., 
2008). This analysis was applied to the CIR repertoire, finding high proportions of rate 
and conservation shifting sites between the two major sub-families. As for the RIFINs, 
these data suggest that functional divergence between the CIR sub-families may have 
occurred.  
Notably, no function shift has been predicted for PIR super-family members using the 
domains curated by Pfam, (http://funshift.sbc.su.se/cgi-bin/stksub.cgi?domain=PF06022 
&ac=Cir_Bir_Yir&desc=Plasmodium%20variant%20antigen%20protein%20Cir/Yir/Bi
r). Pfam uses conservative annotation in order to define orthology groups (Sonnhammer 
et al., 1998, Finn et al., 2010), which means that 86 homology clusters had been defined 
at the time of writing. Therefore, the definition of two major CIR sub-families by 
whole-family analysis as presented here may be more informative than identification of 
many, smaller, highly related clusters of sequences. 
In-depth analysis of multi-gene families is time-consuming, particularly when 
phylogenetic analyses must be carried out in order to identify which sequences are 
members of each major sub-family. In order to facilitate the identification of A- and B- 
type RIFINs from field data, a tool has been developed by Joannnin and colleagues: 
RIFIN subfamily predictor [RSPRED, (Del Portillo et al., 2001, Joannin et al., 2010); 
available at http:// www.ifm.liu.se/bioinfo/]. This tool was unable to classify CIR 
sequences within the RIFIN-A or B sub-families. However, if functional similarities 
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were observed between these protein families, the criteria for classification of CIR sub-
types could be included in a similar tool to facilitate their categorization. 
Similarities between the CIRs and RIFINs have been previously identified by Janssen 
and colleagues, who predicted their secondary structures would comprise alpha helices 
of 12-20 amino acids, separated by coiled-coil regions (Janssen et al., 2004). In 
addition, rif genes were identified by an HMM designed using the rodent pir sequences, 
although at low significance levels (Janssen et al., 2004). Finally, similar amino acid 
motifs were identified within both repertoires, however these were not consistent across 
each repertoire. 
Motifs have been previously identified in PIR sequences (Janssen et al., 2004, Merino et 
al., 2006, Carlton et al., 2008). The CIR sequences were searched for evidence of these 
motifs, but the only motif with detectable similarity was M3 (Janssen et al., 2004), 
which corresponds to the conserved CIR motif 3. The motifs identified within VIR 
sequences were not investigated for presence within the CIR repertoire, owing to the 
lack of detection of other PIR motifs, and the clear divergence of the VIR and CIR 
repertoires. Pain and colleagues proposed the existence of a PIR protein domain, which 
may be repeated up to three times beyond the TM domain (Pain et al., 2008). This is 
likely to also be present within the CIR proteins.  
Within the CIR repertoire, 14 conserved amino acid sequence motifs were identified by 
MEME analysis (Bailey and Elkan, 1994). Sequences similar to the CIR motifs were 
also detected in a selection of rodent PIR, KIR and VIR sequences. Notably, one of the 
CIR motifs detected as specific to CIR sub-family U (motif 12) was detected in some 
rodent PIR sequences. This motif corresponds to the end of the predicted PIR TM 
domain at the conserved C-terminus. 
The majority of PIR proteins are predicted to contain at least one TM domain, a feature 
which has led to predictions that the C-terminus of most PIR proteins is intra-cellular, 
whilst the N-terminus is exposed at the iRBC surface (Del Portillo et al., 2001, Del 
Portillo et al., 2004). Certainly, PIR proteins can be fairly divergent at the N-terminal 
end, with amino acid identities of only 20-30% between VIR family members (Carlton 
et al., 2008), supporting the idea that these regions of the proteins are exposed to 
selective forces. Within a single cir gene, evidence for recombination was more 
pronounced at the 5’ end, supporting the idea that recombination here particularly 
facilitates the generation of diversity. Recombination within the conserved 3’ region of 
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cir genes may be inhibited due to functional constraints, such as the requirement for 
maintenance of the TM domain. Nonetheless, some CIRs belonging to sub-family U 
possessed a unique amino acid motif at the beginning of the predicted TM domain, 
which may give their TM domain different properties to the rest of the CIRs. Possession 
of a different TM domain may influence the function of these CIRs, perhaps altering 
which membrane the proteins are able to span.  
The lack of typical export sequences questions whether PIR proteins are truly exposed 
at the iRBC surface. Few PIR proteins contain a predicted signal sequence and a 
Plasmodium export element (PEXEL) / vacuolar transport signal (VTS) motif, which 
have been shown to be essential for export of certain proteins in P. falciparum (Marti et 
al., 2004, Hiller et al., 2004). The CIR repertoire fits this pattern with only 18 PEXEL 
motifs detected. However, approximately half of the VIRs contain a PEXEL-like 
sequence (Pain et al., 2008), and a different possible export motif has been described in 
the KIR repertoire (Pain et al., 2008). Within the CIR repertoire, 39 PEXEL-like motifs 
and 2 ZLPS motifs could be detected, found in both major sub-families. It is possible 
that PIR proteins are exported in a PEXEL-independent manner, which may even 
require species-specific signals.  
Intergenic analyses have been performed already for the cir repertoire (Janssen et al., 
2002, Janssen et al., 2004). Because VSA genes are known to be flanked by relatively 
conserved DNA sequences (Voss et al., 2003, Flueck et al., 2010, De Silva et al., 2008), 
these were not repeated for the present study. Janssen and colleagues suggested that the 
intron of some rif genes shared ancestry with the rodent pir genes’ second intron 
(Janssen et al., 2004). However, no homology was observed with the other pir intron, or 
any introns of the kir and vir genes.  
Transcripts derived from the intron act to silence var genes, in concert with different 
nuclear sub-localisation (Voss et al., 2003, Ralph et al., 2005, Duraisingh et al., 2005, 
Dzikowski et al., 2007), the silent information regulator 2 protein (PfSIR2) and 
different degrees of chromatin modification [reviewed by (Dzikowski and Deitsch, 
2009, Scherf et al., 2008)]. It is possible that this could also be the case for pir genes, as 
a conserved motif has been identified in vir introns, near the donor splice site (Janssen 
et al., 2004, Merino et al., 2006, Carlton et al., 2008). P. vivax telomeres also localize to 
distinct regions of the nuclear periphery (Scherf et al., 2004), and yir genes were found 
to have different intronic types (Fonager et al., 2007). If the second intron is involved in 
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elements of pir regulation, then rif gene expression could also be controlled by the same 
mechanism due to the conservation found between their introns. 
In previous studies, motifs have been identified outside of the pir coding sequence, 
implying there are different aspects of regulatory control for pir genes. A motif was 
identified upstream of yir genes (Fonager et al., 2007), which is present in all rodent pir 
promoters. This motif could not play a role in differential expression of individual pir 
genes, but could act perhaps as a transcription enhancer. A brief search of the regions 
500 nucleotides upstream and downstream of cir genes identified some motifs with 
similarity to those identified for yirs, such as the M2 motif found in 58% of yirs and 
43% of cirs (Fonager et al., 2007). 
Recently, the discovery of the first class of Plasmodium transcription factors (having an 
Apetala ‘AP2’ domain similar to the plant AP2/ERF DNA-binding proteins (Balaji et 
al., 2005), has enabled mapping of some of their substrates (Voss et al., 2003, Flueck et 
al., 2010, De Silva et al., 2008). Some of these sites could also be detected in cir 
intergenic regions (Table 9), indicating that cir transcription could in part be regulated 
by binding of AP2 transcription factors, as proposed for members of the upsB and upsC 
var gene subfamilies by the AP2 transcription factor PF14_0633 (De Silva et al., 2008), 
and PfSIP2, which has been shown to be involved in var gene silencing (Voss et al., 
2003, Flueck et al., 2010, De Silva et al., 2008) 
 
Table 9: Detection of Plasmodium ApiAP2 transcription factor DNA binding sites 
upstream of cir genes.  
Feature Sequence Proportion of cir Reference 
PF14_0633 (P. falciparum) 
Active in intra-erythrocytic stages CATGC 15.7% (Yuda et al., 2009) 
AP2-O (PB000572.01.0 P. berghei 
/PF11_0442 P. falciparum) 
Active in ookinete stages 
TAGCTA 38.6% (De Silva et al., 2008) 
PfSIP2 (PFF0200c P. falciparum) 
Active in intra-erythrocytic stages 
GTGCA 
[GCA]TGCA & 
[ACG]GTGC[GA] * 
22.8% 
100% & 29.1% 
(De Silva et al., 
2008) 
* PfSIP2 has a bipartite DNA binding site (Flueck et al., 2010), both sequences were searched 
independently in the cir upstream regions. 
 
As yet the significance of the identified CIR sub-families and amino acid or potential 
regulatory motifs are unknown. Microarray analyses have previously shown no 
correlation between phylogenetic sub-group and pir transcription (Bozdech et al., 2008, 
Cunningham et al., 2009). However, the similarities observed here between the two 
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major CIR sub-families and the RIFINs, suggest that the CIRs may display differential 
expression and localization as has been shown for the A- and B- type RIFINs (Petter et 
al., 2007). 
The data presented here provide an ideal starting point for experimental investigation of 
the cir family, including association of potential regulatory motifs with their expression, 
and validation of the identified sub-families. The identification of similar CIR 
sequences, and conserved amino acid motifs inform the design of reagents to carry out 
such investigations, which are presented in this thesis as follows: 
- Based upon the cir gene annotation presented here, primers were designed for 
the measurement of cir transcription by quantitative reverse-transcription PCR, 
described in chapter 3. 
- The amino acid sequences of particular cir genes were chosen for expression as 
recombinant proteins, described in chapter 4. 
- Synthetic peptides corresponding to conserved and sub-family specific amino 
acid motifs were synthesized, and anti-sera raised to these, which were used for 
detection of CIR proteins in iRBC, described in chapter 5.  
- In addition, the antibody responses to these peptides were measured in P. 
chabaudi infected mice, described in chapter 6.  
The repertoires of different P. chabaudi AS clones, and different P. chabaudi strains 
should be compared, to enable detection of changes such as recombination events, and 
their frequency. In addition, efforts should be made to determine the extent of 
recombination occurring between cir genes during meiosis, which would require 
mosquito transmission of the parasite.  
Since frequent recombination events could potentially confound further investigations 
of these genes, knowledge of the recombination frequency, and if indeed any cir are 
exempt, would allow better experimental design. The extensive diversity in VSA genes 
observed in the field may also be better understood by detailed analysis of the variant 
gene families present in laboratory models such as P. chabaudi AS.  
Little is known about the extent of vir sequence diversity, short of the amplification by 
PCR of particular sub-family members (Del Portillo et al., 2001, Joannin et al., 2010). 
In P. falciparum the VSA repertoires are extremely diverse, with different copy 
numbers of rif genes existing in different parasite isolates (Kraemer et al., 2007) and 
only three var genes which are consistently shared between isolates [for example: (Bull 
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et al., 2008)]. An approach taken by Bull and colleagues was to create networks using 
var gene sequence ‘tags’ from different patient isolates (Bull et al., 2008).  By 
comparing whole var gene sets between different parasite populations, they were able to 
find blocks of highly polymorphic sequence, shared between different var genes. By 
connecting var genes which contained these blocks, and connecting these to var with 
similar sequences, a network was created that spanned the majority of the var sequence 
tags used (Bull et al., 2008). The authors identified putative groups of var genes which 
have recombined, and suggest that the var genes have mosaic structures due to the 
problem of maximising antigenic diversity, minimising epitope sharing between 
variants whilst maintaining the protein binding function. Such an analysis could be 
feasible in the future for vir genes, as sequencing data from field studies accumulate. 
The mechanisms of pir repertoire structuring could be supported by dissection of the cir 
genes in the rodent model P. chabaudi, under known selective conditions. 
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Chapter 3: Analysis of cir transcription  
3.1 Introduction      
Characterization of the cir gene family, described in chapter 2, raised the question of 
which cirs were transcribed during the blood stages of P. chabaudi infection. Several 
studies have investigated pir transcription during blood stages of the Plasmodium 
lifecycle. In vitro analysis of vir expression during the 48h erythrocytic growth cycle 
has indicated that at least 59% of virs were transcribed (Bozdech et al., 2008, 
Cunningham et al., 2009). Similarly, 42% of the larger yir family was transcribed in 
vivo, during infection of immuno-deficient mice (Cunningham et al., 2009). Different 
yirs were more highly transcribed in ring / trophozoite stages and in schizonts 
(Cunningham et al., 2009),  supporting the observation of two waves of vir and Pvtrag 
transcription detected during P. vivax intra-erythrocytic development (Bozdech et al., 
2008, Cunningham et al., 2009). These studies were carried out using microarrays, 
which allow an insight into the transcription of the whole multi-gene family at a given 
time.  
More recently, with the advent of highly efficient DNA sequencing technologies, it has 
become feasible to apply genome level analyses to the transcriptome, by methodologies 
known as RNA sequencing. This technique has several benefits compared to the use of 
microarrays for measuring the expression of multi-gene family members, particularly 
since the design of gene specific probes is not required and data may be re-analyzed 
upon improvements to the genome annotation status. RNA sequencing has been used in 
a pioneering study of the P. falciparum transcriptome, comparing different time-points 
within the intra-erythrocytic development cycle (Otto et al., 2010). Not only did this 
methodology confirm results from microarrays performed in tandem, but more low 
abundance transcripts and other gene features could also be detected including splice 
variants. The application of this technology to other Plasmodium species would be 
extremely useful, particularly for the measurement of multi-gene family transcription. 
Reverse transcription followed by quantitative PCR has also been used to address yir 
transcription: to validate the expression of individual yir genes detected by microarray 
(Cunningham et al., 2009, Shi et al., 2005), and to detect transcription of yir sub-family 
members (Fonager et al., 2007). This technique enables the detection of pir transcripts 
from small quantities of RNA, even from individual iRBCs (Fernandez-Becerra et al., 
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2005). Individual P. yoelii iRBCs have thus been shown to transcribe 1-3 yir transcripts 
(Cunningham et al., 2009), whilst members of at least two vir sub-families have been 
detected from individual P. vivax iRBCs (Fernandez-Becerra et al., 2005). 
The objectives of the work described in this chapter were to: 
i) Design primers within cir genes and to validate their specificity and utility 
for RT-qPCR analyses.  
ii) Measure cir transcription during P. chabaudi infection by RT-qPCR. 
iii) Investigate whether whole transcriptome RNA sequencing analysis could be 
applied for detection of the whole cir repertoire during P. chabaudi 
infection. 
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3.2 Methods     
3.2.1 Mice and parasites 
All experiments used female BALB/c mice, using either wild-type mice or mice with a 
targeted disruption in the RAG2 gene [RAG2-/-, (Shinkaia et al., 1992)]. Mice were of 5 
- 8 weeks of age at the time of experiment initiation and were kept in living conditions 
according to the Home Office animal act (1980) regulations.  
P. chabaudi AS parasites were cloned and maintained at the National Institute for 
Medical Research (Slade and Langhorne, 1989), with only four passages in wild-type 
mice from the original isolate provided by Professor D. Walliker (University of 
Edinburgh). As further cloning would give rise to stochastically different populations of 
parasites following their expansion, all infections were initiated using P. chabaudi AS 
expanded in RAG2-/- mice from a reference stabilate produced by limited serial passage 
in the same mouse strain. This procedure was carried out such that all infections could 
be initiated with a highly similar parasite population, since the passage of parasites 
within immuno-competent mice was expected to place them under lymphocytic 
selection (Cunningham et al., 2005).  
All infections were initiated by intraperitoneal (i/p) injection with P. c. chabaudi AS 
iRBC. Blood samples were taken from mice either under terminal anaesthesia, for 
collection of the total blood volume by cardiac puncture, or by removal of the tail tip, 
for samples less than 100 µl. Blood samples were taken into Krebs saline (114 mM 
NaCl, 4.57 mM KCl, 1.15 mM MgSO4 (Krebs and Eggleston, 1940), containing 0.2% 
glucose and 25 U/ml heparin (Leo Pharmaceuticals). Blood was either used 
immediately for flow cytometry, reticulocyte depletion experiments, to make thin blood 
films, or stored at -80 °C in TRIZOL reagent (Invitrogen) for subsequent RNA 
extraction.  
 
3.2.2 Preparation and counting of thin blood films  
Parasitaemia was monitored by daily microscopic analysis of methanol-fixed Giemsa-
stained thin blood smears. Standard thin blood films were prepared using 2 µl blood, 
which was drawn across the surface of superfrost-coated slides (Menzel Glazer), 
allowed to air dry, and fixed using methanol. After fixed slides were dry, they were 
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stained using Giemsa (VWR international), diluted to 2x concentration in buffer 
(comprising 20mM Na2HPO4 and 40mM KH2PO4, pH 7.4).    
For measurement of reticulocytes, Brilliant Cresyl Blue slides were prepared by coating 
the slide surface with 0.3% Brilliant Cresyl Blue (BDH) dissolved in absolute ethanol. 
Once dry, blood films were drawn across the surface of these slides, and incubated in a 
moist chamber for 15 minutes to allow RBCs to absorb the stain. Subsequently, these 
slides were allowed to dry, fixed and Giemsa stained, as standard thin blood films. This 
method has been adapted from previously described work (Zuckerman, 1957). 
Slides were counted using a Zeiss Axioplan microscope, with a 25x eyepiece and 100x 
objective lens (Zeiss), under oil immersion (Zeiss). At low parasitaemia, the number of 
RBCs in each field was enumerated, and the number of iRBCs was recorded in each 
field until an estimated 10,000 RBCs were counted. When parasitaemia surpassed 5 % 
of RBCs infected, the number of iRBCs in a representative field of 200 RBCs was 
recorded. Enumeration of reticulocytes was carried out as a proportion of total RBCs, as 
described for iRBC counts at low parasitaemia (ie the number of reticulocytes present in 
approximately 10,000 RBCs). 
 
3.2.3 Primer design 
Primers were designed to amplify 150 – 250 nucleotides within selected cir genes using 
Primer3 software (Rozen and Skaletsky, 2000), with default settings except: 18 - 30 
nucleotide primer length and 55 - 65 °C primer melting temperature. Two pairs of 
primers were designed in the same way to amplify Mus musculus haemoglobin beta 
chain, to determine the extent of host RNA contamination in extracted parasite RNA for 
full transcriptome sequencing. 36 primer pairs were synthesized by Sigma Aldrich, 
listed in Appendix 3.1. 
 
3.2.4 Endpoint-polymerase chain reaction 
Primer efficacy was screened via endpoint PCR, using genomic DNA as the template. 
One µl each of forward and reverse primers were used at 10 pMol / µl concentration, in 
the presence of 2.5 µl 10x buffer, 1.5 µl 25 mM magnesium chloride, 1.25 units Taq 
polymerase (New England Biosciences), 0.1 µl 10 mM dNTPs, 50 ng gDNA template, 
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and sterile water to 25 µl final volume. Amplification conditions were 94 °C for 2 
minutes, followed by 35 cycles of: 94 °C for 1 minute, 65 °C for 1 minute and 72 °C for 
1 minute, with a final extension of 72 °C for 7 minutes, before cooling to 4 °C. 
Amplified products were resolved on a GelRed stained (Biotium), 2% agarose gel for 
30 minutes at 90 V. Product sizes were resolved using hyperladder IV (Invitrogen). 
These data are attached in Appendix 3.2. 
 
3.2.5 Primer specificity determination  
Primer specificity to the intended cir genes was determined by direct ligation of PCR-
amplified products into the TA cloning vector pCR2.1 (Invitrogen) followed by 
transformation into competent E. coli, according to manufacturer’s instructions. Briefly, 
the ligation reaction used a 3:1 ratio of fresh PCR product diluted in sterile water (3 ng) 
to vector (25 ng), in a final volume of 10 µl in the presence of 1 µl of 10x reaction 
buffer and 400 units of T4 ligase (New England Biosciences). Ligation reactions were 
incubated overnight at 14 °C. 
Two Escherichia coli strains were used for transformation, first DH5α (Sigma Aldrich), 
and secondly Epicurian coli gold super efficient cells (Stratagene). For DH5α cells, 15 
µl cell aliquots were thawed on ice to which 2 µl ligation reaction was added, and 
incubated for a further 10 minutes on ice. Cells were heat-shocked for 30 seconds at 42 
°C, allowed to recover on ice, before 100 µl SOC medium (Invitrogen) was added and 
cells incubated, shaking at 37 °C for one hour. 50 µl cells were then plated onto Luria 
Bertani (LB)-agar plates containing 50 µg/ml ampicillin and 1 mg/ml x-galactose (both 
Sigma) and incubated overnight at 37 °C. The super efficient cells followed the same 
protocol as the DH5α cells, except for a 10 minute incubation on ice with of 1 µl β 
mercaptoethanol solution (Stratagene) before addition of the ligation reaction, and the 
requirement of 100 µM Isopropyl β-D-1-thiogalactopyranoside (IPTG) presence in the 
LB-agar plates to allow blue-white screening. 
Between three and five transformants were selected, which were cultured overnight in 
LB broth containing 50 µg / ml ampicillin (Invitrogen), and plasmid DNA was extracted 
via miniprep (Qiagen), according to manufacturers instructions. Plasmid inserts were 
sequenced using the M13 forward primer (Source Biosciences), and sequences were 
verified by basic local alignment tool searches [BLAST, (Altschul et al., 1990)] against 
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the cir database (curated at http://www.genedb.org/blast/submitblast/GeneDB_ 
Pchabaudi, by the Wellcome Trust Sanger Institute). 
 
3.2.6 RNA extraction     
Blood stored at -80 °C in at least 10 volumes of TRIZOL reagent (Invitrogen) was 
defrosted on ice, and 40% of the TRIZOL volume of chloroform: isoamyl alcohol (24:1; 
Sigma Aldrich) was added. After incubation on ice for five minutes, samples were 
centrifuged at 13,000 x g for 30 minutes at 4 °C and the aqueous phase removed. RNA 
was precipitated by addition of an equal volume of isopropanol (Invitrogen) and 
incubation on ice for one hour. Samples were centrifuged as before, and the RNA pellet 
washed with 70% ethanol (Invitrogen). Samples were centrifuged as before, 
supernatants removed and the RNA pellets air-dried, inverted, for five minutes before 
re-suspension in DEPC-treated water (Invitrogen). Nucleic acid concentration was 
estimated by spectrophotometry (Nanodrop; ThermoFisher).  
500 ng RNA was DNAse digested, by addition of 2 µl Turbo DNAse buffer and 1 µl 
Turbo DNAse (both Ambion) and sterile water added to a final volume of 17 µl. 
Samples were heated at 37 °C for 30 min, and the reaction terminated by addition of 2 
µl Turbo DNAse inactivation reagent (Ambion). Samples were mixed gently, 
centrifuged at 10,000 x g for 2 minutes, and the RNA transferred to fresh tubes, before 
storage at -80 °C.  
All RNA concentrations were estimated using spectrophotometry (NanoDrop, 
ThermoScientific) after extraction via the phenol-chloroform method (Sambrook and 
Russell, 2001). The ratio of the absorbance at 260 and 280nm (A260/280) was determined 
(Appendix 3.3), which allows estimation of nucleic acid purity, whereby un-
contaminated RNA should have an A260/280 approximately equal to 2. The ratio for pure 
DNA should be 1.8, therefore RNA samples contaminated with DNA would have 
A260/280 ratios closer to 1.8 than 2. Lower A260/280 ratios could also be attributed to 
protein contamination, since amino acids absorb strongly at 280 nm (Bustin et al., 
2009). However there are limitations to the extent which spectroscopy can determine 
nucleic acid quality, therefore formamide-gel electrophoresis was also performed on all 
RNA samples to ensure the absence of degraded material (Appendix 3.3). 
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3.2.7 Reverse transcription 
Reverse transcription uses primers within RNA sequences to generate the 
complementary DNA sequence (cDNA), a more stable template for subsequent 
investigation. All cDNA samples used for estimation of cir and beta globin 
transcription throughout this thesis were reverse transcribed at the same time. This was 
carried out using 250 ng of DNAse digested RNA, to which 0.52 µg random hexamers 
(Promega), 1 µl 10 mM dNTPs (Invitrogen) and sterile water were added to a final 
volume of 12 µl. Samples were heated at 65 °C for 5 minutes before addition of: 4 µl 
first strand synthesis buffer, 1 µl 0.1 M dithiothreitol (DTT), 0.5 µl RNAsin and either 
0.5 µl Superscript II (Invitrogen) for RT positive or 0.5 µl H2O for RT negative 
controls. Samples were heated at 42 °C for 50 min, followed by 70 °C for 15 min, and 4 
°C overnight, before storage at -20 °C.  
 
3.2.8 RT-qPCR 
Quantitative PCR uses fluorescent dyes or sequence tags to detect PCR products as they 
accumulate throughout the reaction. The principle of this technique is that fluorescence 
intensity is measured on a logarithmic scale against cycle number as the PCR reaction 
progresses. A threshold value is set such that background fluorescence is excluded, and 
the cycle when sample fluorescence reaches the threshold is recorded as the 
quantification cycle (Cq). The design of RT-qPCR experiments was carried out 
according to the minimum information for the publication of quantitative PCR (Bustin 
et al., 2009), guidelines which attempt to standardize the reporting and design of RT-
qPCR experiments, including the use of a universal nomenclature. 
All quantitative PCR was carried out using 12.5 µl SYBR green ROX mastermix 
(Fermentas) with primers at 0.2 µM concentration, in a final volume of 25 µl. All 
reactions were carried out in triplicate, with every primer containing no template control 
and positive control (gDNA for cir primers, cDNA pool for beta tubulin primers) 
samples on each plate.  
Primer sensitivity was determined using gDNA template titration, diluted in sterile 
water (Gibco) to give 0.5 ng, 1 ng or 5 ng DNA per 25 µl total reaction volume. 
Thereafter RT-qPCR was carried out using all samples at 5 ng cDNA per 25 µl total 
reaction volume, with all RT- and positive controls at the same concentration. 
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Quantitative PCR conditions were 50 °C for 2 minutes, 95 °C for 15 minutes, followed 
by 35 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Because all samples were 
quantified in relation to internal plate controls, two qPCR machines were used in 
parallel: the 7000, using SDS 2.0 software and the 7900, using SDS 2.0 and 2.2.2 
software (both ABI). Quantification cycle numbers (Cq) were determined using the 
automatic threshold level of 0.2 within the SDS software, then all Cq values were 
exported into excel for further analysis (all data analysis is contained in Appendix 3.4). 
To validate the entire plate, samples were only analyzed further if the no template 
control (NTC) and RT- samples gave the maximal Cq values, and if the positive 
controls (gDNA / cDNA reference sample) were similar to those measured previously.  
 
3.2.8 i) Analysis of cir transcription 
Nucleic acid quantification can be achieved either by comparison with standards 
containing known amounts of the target gene, known as absolute quantification or by 
relative quantification, where the differences between samples are compared, after 
normalization to a control constitutively expressed gene. As no standards were 
available, the latter approach was used here. cir gene expression was normalized to 
another P. chabaudi reference gene, beta tubulin, and analyzed using the efficiency 
corrected ratio method (Pfaffl, 2001). Such normalization permits comparison between 
samples whose RNA concentration, efficiency of reverse transcription and amplification 
efficiencies are slightly different, assuming that the reference gene is expressed equally 
in the different samples (Bookout et al., 2006). 
Beta tubulin primers have been described elsewhere: AGCAGGCCAATGTGGTAATC, 
Forward; ACCTGCACGAACACTATCCA, Reverse (Cunningham et al., 2009). 
For each sample, the mean and standard deviation (SD) of the three technical replicates 
was measured (Raw data and analyses are contained in Appendix 3.4). Outlier points 
were discarded according to standard methodology (Bookout et al., 2006). Samples 
were analyzed where the confidence values were 99%, 95%, 90%, 85% and 80% (SDs 
of 0.3, 0.4, 0.525, 0.650 and 0.775, respectively). Samples were excluded if the 
confidence value was less than 80%. 
PCR efficiency was calculated using the logarithm of the gDNA amounts used in a 
titration experiment, measured by qPCR. The linear regression was determined from 
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these data, and slope values inputted into the equation: E=10(-1/slope) (Bookout et al., 
2006). However, since the beta tubulin primers spanned an exon: exon boundary, the 
product size from a gDNA template was too large to be efficiently amplified by qPCR. 
For this reason, comparison of PCR efficiencies between these reference primers and 
the cir primers required cDNA template titration.  
The ratios of the Cq difference between the cir transcripts present in different samples, 
normalized to the reference gene beta tubulin, were calculated according to the method 
described by Pfaffl (Pfaffl, 2001). This methodology was used because the cir primers 
did not have equal efficiencies of amplification with the reference primers for beta 
tubulin. The following equation was used to calculate the ratio of cir transcripts, where 
E is the PCR efficiency for each primer pair and ΔCq refers to the Cq difference 
between the two samples under comparison:  
Ratio = (Ecir) ΔCq of cir (control-sample) / (Ebeta tubulin) ΔCq of beta tubulin (control-sample) 
The standard deviation (SD) for the ratio of cir transcripts detected, relative to the 
control sample, was determined using the following equation:  
SD ΔCq = √[(SDbeta tubulin)2 + (SDcir)2] 
 
3.2.8 ii) Analysis of beta globin mRNA contamination  
A measure of M. musculus contamination of P. chabaudi mRNA was defined using the 
mean Cq values from the three technical replicates. The reciprocal Cq for beta globin 
was calculated as a percentage of the reciprocal Cq of beta tubulin to determine whether 
beta globin mRNA levels were higher in the sample than those of P. chabaudi mRNA. 
No correction for differences in qPCR amplification efficiency was performed here, 
thus the detected M. musculus mRNA contamination may in fact be higher than 
indicated by the ratios, as the beta globin primers had a lower amplification efficiency 
than the beta tubulin primers. Nonetheless, this method serves as a simple indicator of 
whether P. chabaudi mRNA samples contained substantial host contamination. 
Standard deviation was calculated using the equation above. All related information is 
attached in Appendix 3.6. 
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3.2.9 RNA sequencing 
Blood of a P. chabaudi AS infected BALB/c mouse on day 7 of infection was collected 
as described above (section 3.2.1), diluted 15-fold in PBS prior to filtration through 
commercially available Plasmodipur filters (Euro Diagnostica), and the RNA extracted. 
Two samples were prepared in this way, from separate infections. For cDNA synthesis, 
a combination of random oligonucleotide and oligo(dT) primers was used as previously 
published (Bozdech et al., 2003), followed by treatment with Terminator™ 5′-
Phosphate-Dependent Exonuclease (Epicentre) for removal of un-5’ capped mRNA, 
ribosomal RNA and transfer RNA species, following manufacturer’s recommendations. 
P. chabaudi AS RNA samples were prepared according to the methods described by 
Otto and colleagues (Otto et al., 2010). Firstly, a cDNA library was created by 
nebulisation (35 psi for 6 minutes) to shear the template, followed by end-repair using 
T4 polynucleotide kinase to blunt-end the DNA fragments, Klenow polymerase and T4 
DNA polymerase. A single 3′ adenosine was added to the cDNA using Klenow exo-
polymerase and dATP. 
Complementary DNA library fragments were ligated to adaptor oligonucleotides, 
containing primer sites for sequencing and flowcell surface annealing. Gel-
electrophoresis was used to separate library DNA fragments of 200-250 bp in size from 
unligated adapters, followed by gel extraction at room temperature to avoid under-
representation of AT-rich sequences (Quail et al., 2008). The QIAquick kit (Qiagen) 
was used for this purpose, according to manufacturer’s instructions. Hybridization of 
the adaptors to complementary sequences attached to the flowcell surface used an iso-
thermal DNA polymerase to amplify bound DNA fragments into clusters of identical 
molecules on the flowcell surface. Libraries were amplified by 18 cycles of PCR with 
Phusion DNA polymerase (Finnzymes Reagents), for sample 1, and Herculase II DNA 
polymerase (TwistDX), for sample 2. This process is known as solid phase bridge 
amplification, and can create up to 1000 identical copies of each DNA molecule 
(Technology Spotlight: Illumina® Sequencing, http://www.illumina.com/support/ 
literature.ilmn).  
The Illumina GA II platform, initially developed by Solexa, is based on the sequencing-
by synthesis reaction. Sequencing-by-synthesis incorporates a reversible terminator 
nucleotide, each labeled with a different fluorophore fluorescently labeled, at every step 
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of the sequencing reaction. At each step only one base may be incorporated and 
subsequent imaging enables determination of which nucleotide bound. The 3’ end of the 
nucleotides may then be un-blocked for the next sequencing step to occur. Following 
completion of the synthesis reaction, the sequence of each cluster may be determined by 
analysis of the images. P. chabaudi sequencing libraries were diluted to 2 nM, 
denatured with sodium hydroxide and diluted to 3.5 pM in hybridisation buffer 
(Illumina). Following this, libraries were loaded onto a single lane of an Illumina GA 
flowcell. Cluster formation, primer hybridisation and sequencing reads from 54 cycles 
were performed using the manufacturer’s recommended reagents and protocol 
(Illumina, https://icom.illumina.com/).  
The programs Sequence Search and Alignment by Hashing Algorithm 2 [SSAHA2, 
(Ning et al., 2001)] and SSAHA_ pileup were used to align the Illumina reads against 
the P. chabaudi AS reference genome curated at http://www.genedb.org/ 
Homepage/Pchabaudi.  During SSAHA2 mapping, reads were only included if one end 
of the pair aligned uniquely to the genome and the distance between the pairs was 
within the expected insert size. The output of SSAHA_ pileup was used to create the 
coverage plots over the genome. Uniqueness plots for all possible windows of 50 base 
pairs (bp) over the genome were generated, and repeat regions longer than the gene read 
length were ignored for the expression calculation. The expression levels of each gene 
were calculated based on the geometric mean depth of sequencing coverage of the gene. 
These data are attached in Appendix 3.5. 
 
3.2.10 Flow cytometry  
P. chabaudi AS iRBCs from RAG2-/- and wild-type BALB/c mice were washed three 
times in PBS, using centrifugation at 1500 xg at 4 ˚C for 5 minutes. Total cell counts 
were performed using a haemocytometer (NeuBauer), and blood diluted accordingly to 
give a final concentration of 1x107 RBCs per ml in flow cytometry buffer (PBS 
containing 1% BSA (w/v), 2 mM ethylene-diamine-tetra-acetic acid (EDTA) and 0.01% 
sodium azide).  
The RBCs (1x106) were plated in triplicate into V-bottom plates (Nunc), centrifuged at 
1200 x g for 1 minute at 4 ˚C and the supernatant removed. Cells were then stained with 
a combination of two dyes, of which thiazole orange (Sigma-Aldrich) binds both DNA 
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and RNA, whilst DRAQ5 (Biostatus Limited) binds DNA only. Thiazole orange 
(Sigma-Aldrich) was used at 1 mg/ml and DRAQ5 (Biostatus Limited) was used at 50 
µM, diluted in blocking buffer, and incubations performed in a volume of 100 µl for 10 
minutes on ice. Following this incubation step, cells were re-suspended twice in 150 µl 
blocking buffer, followed by centrifugation at 1200 x g for 1 minute at 4 ˚C. Cells were 
re-suspended in 150 µl flow cytometry buffer for data acquisition. 
Single colour and unstained controls were also performed for all samples, to allow 
calibration of the flow cytometer. Immediately prior to data acquisition, samples were 
passed through a 45 µm filter (Nunc), to ensure no aggregates were present. At least 
300,000 events were acquired within a defined region, which excluded very small or 
dead cells. Data were acquired using the CyAN flow cytometer (Dako Cytomation), 
using default filter settings, with Summit™ software (Dako Cytomation). Following 
data collection, information was further analyzed using FlowJo software version 8.8.6 
(Tree Star). A region including all live RBC was drawn in FlowJo software (version 
8.8.6.2), followed by a region excluding DNA positive cells (DRAQ5+). As mature 
reticulocytes are the only cell type to be RNA positive but DNA negative, remaining 
thiazole orange positive cells were enumerated. 
 
3.2.11 Reticulocyte depletion by magnetic cell separation  
Blood was taken from P. chabaudi AS infected RAG2-/- and wild-type BALB/c mice, as 
described above. Packed iRBCs were obtained by centrifugation at 2500 xg for 5 
minutes at 4 ˚C and 500 µl taken. iRBCs were diluted in 10 ml of MACS buffer 
(comprising 2 mM EDTA and 2% foetal calf serum in PBS) and passed through a 50 ml 
XS magnetic cell separation column (MACS, Miltenyi Biotechnology), mounted on a 
SuperMACS™II Separator magnet (Miltenyi Biotechnology).  
Before use, the XS column was washed extensively: with 50 ml distilled water applied 
against gravity from the top of the column and again from the bottom of the column, to 
remove air bubbles and contaminants, followed by 50 ml MACS buffer, for 
equilibration. The column was then mounted upon the magnet, and iRBCs slowly 
allowed to bind the column matrix, by limiting the flow-rate to less than 2 ml/minute. 
Following this, the column was washed with 100 ml MACS buffer, before the column 
was removed from the magnet and iRBCs were eluted.  
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Elution comprised three steps, all applied from a 50 ml syringe: 50 ml MACS buffer, 50 
ml air to remove residual liquid, and a final 50 ml MACS buffer to remove outstanding 
iRBCs. All iRBCs collected from the initial binding and wash steps were applied again 
over the column, to ensure that the maximal number of iRBCs were purified by this 
method. In total, 500 µl of packed iRBCs were applied to the column three times. 
Columns were re-used after extensive washing under gravity using at least 200 ml 0.15 
M NaOH, followed by at least 100 ml distilled water, and stored in absolute ethanol. 
Eluted iRBCs were pelleted by centrifugation at 1200 xg for 10 minutes at 4 ˚C. The 
supernatants were removed and iRBCs were used to make thin blood smears or at -80 
°C in TRIZOL reagent (Invitrogen) for subsequent RNA extraction. 
 
3.2.12 Reticulocyte depletion by saponin lysis of RBC 
Blood was taken from P. chabaudi AS infected RAG2-/- and wild-type BALB/c mice, as 
described above. Packed iRBCs were obtained by centrifugation at 2500 x g for 5 
minutes at 4 ˚C and 100 µl taken. iRBCs were washed three times with 900 µl PBS, 
followed by centrifugation as before. iRBCs were then re-suspended in 900 µl PBS 
containing 0.015% saponin (Sigma)  and incubated, with gentle shaking, for 10 minutes 
on ice. Un-lysed cells and cellular compartments were present in the pellet fraction after 
further centrifugation, as before. These were used to make thin blood smears or at -80 
°C in TRIZOL reagent (Invitrogen) for subsequent RNA extraction. 
Analysis of globin transcript depletion after MACS purfication or saponin lysis was 
assessed by RT-qPCR, all related information is attached in Appendix 3.6. 
 
3.2.13 Removal of leukocytes via cell filtration  
Blood was taken from P. chabaudi AS infected RAG2-/- and wild-type BALB/c mice, as 
described above (section 3.2.1). Blood samples were diluted 15-fold in PBS prior to 
filtration. 
CF11 columns were prepared according to the methods of Sriprawat and colleagues 
(Sriprawat et al., 2009), using 10 ml syringes filled with CF11 cellulose (Whatman 
Biosciences). Filtration using CF11 and Plasmodipur filters, required that the columns 
be pre-wetted with at least 3 ml PBS, following which, the diluted blood was applied to 
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the column and allowed to filter through under gravity. As leukocytes remain trapped 
within the column matrix, all blood was collected as the eluate. To ensure all iRBC 
were eluted, a further 20 ml PBS was applied to the columns, under gravity. Eluates 
were then centrifuged at 1200 x g for 5 minutes at 4 ˚C, and iRBC collected for further 
use.  
To compare leukocyte removal by blood filtration using CF11 cellulose or 
commercially available Plasmodipur filters (Euro-Diagnostica), the total blood volume 
of three representative P. chabaudi AS infected BALB/c mice were filtered using each 
method. The proportion of cell types in the blood samples before and after filtration 
were quantified using the Vetscan II platform (Abaxis).  
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3.3 Results   
3.3.1 Measurement of cir transcription by RT qPCR 
For this study, primer pairs were designed to amplify cir genes within cDNA 
synthesized from P. chabaudi RNA, based upon the cir annotation described in chapter 
2.3.1. In order to design primers that would specifically target the different annotated 
cir sub-families A, B, C, D, E, F and U, over two hundred potential primer sequences 
were investigated bio-informatically, before 36 appropriate primers were synthesized 
(Appendix 3.1).  
Primer efficacy was first screened using end-point PCR, to determine which primers 
were able to amplify a product of the expected size. Of the 36 primer pairs, 15 
successfully amplified products (Appendix 3.2). 14 of the PCR positive primers were 
designed using the same strategy: to amplify a region within cir exon 2, hence these 
were comparable and further validation was carried out for these 14 primers.  
The sensitivity of primer pairs was then tested via qPCR using gDNA template titration 
to ensure that no dimers or other artifacts were observed that could hinder the 
measurement of cir gene expression. Template titration also allowed determination of 
amplification efficiencies for each primer pair during qPCR, shown in Table 10. 
Unfortunately, analysis of the dissociation curve for each of the primer sets revealed 
strong evidence for primer-dimer formation in primers D2 and U3. This would likely 
interfere with quantification of cir transcription so these primers were excluded at this 
point and are not shown in Table 10. 
 
Table 10: Determination of cir primer efficiency by quantitative PCR using P. 
chabaudi gDNA titration and linear regression analysis.  
Primer 
pair: A1 A2 B1 B2 C1 C2 D1 E1 E2 U1 U2 U4 
Slope -3.85 -4.30 -3.07 -3.87 -4.05 -4.28 -4.46 -2.14 -4.67 -4.36 -7.01 -3.71 
r²  0.93 0.87 0.67 0.92 0.85 0.93 0.95 0.33 0.81 0.95 0.73 0.89 
E 1.82 1.71 2.12 1.81 1.77 1.71 1.68 2.93 1.64 1.70 1.39 1.86 
Slope refers to the gradient of the regression line, whilst E refers to PCR efficiency. Primers are listed in 
Appendix 3.1 
 
The slope of the line given in Table 10 reflects the rate of product amplification at the 
exponential phase of the qPCR reaction. A slope of -3.3 would indicate that the 
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of the cir primers had different gradients for the linear regression lines, indicating that 
they were not equally efficient.  
The specificity of designed primers was next determined, to be sure that the primers 
targeted the expected cir gene groups. This was achieved first via BLAST searches of 
the P. chabaudi AS genome during primer design, and then verified experimentally. 
Experimental validation involved cloning PCR-amplified products into competent E. 
coli and extraction of plasmid DNA by minipreps (Qiagen). Plasmid inserts were 
sequenced from the M13F primer site within the vector, and mapped via BLAST. The 
primer specificities determined by both methods are shown in Table 11. 
 
Table 11: Experimentally determined specificities of cir primers. 
Bio-informatic investigation: Experimental investigation: 
Primer 
pair 
Sequences identified by BLAST* 
Number of 
clones 
sequenced 
Sub-family specificity of 
sequenced clones 
A1 Pc_000270, Pc_000030, Pc_000120 2 A (Pc_000270) & B (Pc_001110) 
A2 Pc_000270, Pc_000030, Pc_000120 5 A (Pc_000270) & B (Pc_001110) 
B1 Pc_040020, Pc_000400, Pc_000080, Pc_001070 0 Too few clones sequenced 
B2 Pc_040020, Pc_000400, Pc_000080, Pc_001070 1 Too few clones sequenced 
C1 Pc_000140, Pc_114750 5 C 
C2 Pc_030030, Pc_070090, Pc_070160 3 Too few clones sequenced 
D1 Pc_001130, Pc_120070 3 D (Pc_001130) & A (Pc_000090)  
D2 Pc_100040, Pc_120050 4 D (Pc_100040) & A (Pc_000090) 
E1 Pc_120060, Pc_104230, Pc_000100 3 E (Pc_000100) 
E2 Pc_000100, Pc_000420 0 Too few clones sequenced 
U1 Pc_040050, Pc_001050 4 U (Pc_040050) 
U2 Pc_042030, Pc_060110 3 Too few clones sequenced 
U3 Pc_042030, Pc_030210 2 Too few clones sequenced 
U4 Pc_040110, Pc_060140, Pc_042030 3 U (Pc_040110) 
Primer sequences are given in Appendix 3.1.* BLAST searches carried out in November 2010. The 
species identifier PCHAS was abbreviated to Pc. The primer specificity was not certain where fewer than 
four clones were sequenced. The predominant cir gene detected experimentally within each sub-family 
for each primer pair is shown in brackets, although the majority of BLAST matches could be detected 
experimentally.  
 
 
Given the high sequence similarity between cir genes, described in chapter 2.3.2, none 
of the primers were completely specific, but recognized 2 - 4 cir genes, Table 11. This 
means that any transcriptional differences detected with these primers may include 
changes in a number of closely related genes. In total four primer pairs were used for 
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investigation of cir transcription, which were sub-family specific, did not produce 
primer-dimers and had similar amplification efficiencies during qPCR (except for 
primer pair E1, which was less efficient than the other cir primers, but was sub-family 
specific). A summary of their qualities is shown in Table 12. 
 
Table 12: Summary of primers used to measure cir transcription 
Primer 
pair 
Tm of 
primers 
Experimentally 
determined 
specificity 
Number of 
clones 
sequenced 
Predicted number of 
folds in target RNA 
sequence + 
PCR 
efficiency 
C1 64.4 ºC 63.0 ºC 
PCHAS_000140 
PCHAS_114750 5 
8 
(Using PCHAS_000140) 1.77 
E1 63.5 ºC 62.0 ºC 
PCHAS_120060 
PCHAS_104230 
PCHAS_000100 
3 7 (Using PCHAS_000100) 1.64 
U1 64.2 ºC 64.0 ºC 
PCHAS_040050 
PCHAS_001050 4 
10 
(Using PCHAS_040050) 1.70 
U4 63.9 ºC 59.9 ºC 
PCHAS_040110 
PCHAS_060140 
PCHAS_042030 
3 6 (Using PCHAS_040110) 1.86 
The names hereafter used for these primers are given in brackets underneath their number. Tm refers to 
the melting temperature for each primer. + Number of predicted RNA folds in amplified target sequence 
predicted by Mfold (http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-form1-2.3.cgi) using 
default settings. Primer sequences are listed in Appendix 3.1. 
 
The feasibility of measuring cir gene transcription using the four primer pairs: U1, U4, 
C1 and E1 described above (Table 12), was investigated in three experiments shown in 
Figure 21 and Figure 22. Immuno-competent (BALB/c) and immuno-deficient (RAG2-/-) 
mice were infected intra-peritoneally with 1x105 P. chabaudi iRBCs. Blood was 
harvested immediately prior to schizogony (11.30 - 12.00 in reverse light conditions) at 
the peak of infection, on day 7 after infection. As these were pilot experiments, only 
three mice per group were analyzed. RT-qPCR reactions having low confidence values 
were excluded from these figures (marked with x, and tabulated in Appendix 3.4), which 
in conjunction with the small group size, prevented statistical analyses since no changes 
were observed in all mice. 
Levels of cir transcripts were compared relative to the mouse in which parasites were 
expanded (the donor), normalized to beta tubulin. Changes in cir transcript levels were 
expressed as a ratio between the donor and recipient mice. Ratios approximately equal to 
one indicated no change or only very small changes in cir transcription, thus only ratios 
with more than two-fold change were considered. A ratio of 2 would indicate a two-fold 
increase in cir transcripts (1:2), in the recipient compared to the donor P. chabaudi 
parasite population. Conversely, a ratio of 0.5 would indicate a two-fold decrease (2:1), 
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in the recipient compared to the donor. For ease of view, these data are represented using 
a log2 scale, where a two-fold change in either direction is displayed at an equal scale. 
Figure 21a shows cir transcription in each of three BALB/c mice, which were infected 
from a RAG2-/- donor mouse. The P. chabaudi populations present in all BALB/c mice 
appeared to display minor (less than two-fold) changes compared to the donor RAG2-/- 
mouse. The only substantial differences were observed in one or more of the genes 
targeted by the U4 primers: PCHAS_040110, PCHAS_060140 and PCHAS_042030. 
These primers detected 2-12 -fold lower cir levels in all three P. chabaudi infected 
BALB/c mice, compared to the donor RAG2-/- mouse. 
In a second experiment, three RAG2-/- mice were infected with parasites from a 
BALB/c mouse (mouse 1 from the previous experiment); Figure 21b. This experiment 
aimed to determine whether cir expression changed during P. chabaudi infection in the 
absence of lymphocytic selection. As previously observed, few differences were 
detected in comparison to the donor mouse. The only substantial changes were observed 
in the genes targeted by U1 primers: PCHAS_040050 and PCHAS_001050, which 
detected almost four-fold higher cir levels in two of the three RAG2-/- mice.  
To determine whether cir transcription changed during a single 24-hour intra-
erythrocytic growth cycle, RT-qPCR was carried out using blood samples taken at four 
points during the cycle, Figure 22. The time-points contained parasites that were 
predominantly ring or trophozoite stages (defined in Table 13) examples of each stage 
are shown in Figure 22a. Mature P. chabaudi schizonts are rarely found in the periphery 
because they sequester (Cox et al., 1987, Gilks et al., 1990). 
 
Table 13: Parasite stages observed during intra-erythrocytic development. 
Stage composition of P. chabaudi iRBC (%): Time-point 
Ring stage Trophozoite stage Schizont stage 
Mouse 1 2 3 1 2 3 1 2 3 
Early trophozoite 
8.30 h 25.75 18.23 22.50 74.25 81.77 77.50 0.00 0.00 0.00 
Mid trophozoite 
10.30 h 12.04 12.50 13.59 87.04 86.67 85.87 0.93 0.83 0.54 
Late trophozoite 
12.30 h 13.82 20.86 10.52 83.87 76.26 86.91 2.30 2.88 2.58 
Ring  
22.30 h 89.72 58.82 91.54 9.35 41.18 6.34 0.93 0.00 2.11 
Blood samples were taken at the indicated time-points on day 7 of a P. chabaudi infection of three 
BALB/c mice, kept in reverse light conditions (where schizogony occurred between 11.30 and 12.30 
daily). Each time-point corresponded to a particular stage of parasite development, for the majority of 
iRBCs. Counts were performed by microscopy, enumerating the parasites observed within 10,000 RBCs.  
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Here, cir transcription was compared within the same mouse between the time-points 
representing predominantly: mid trophozoites, late trophozoites and ring stages, relative 
to the first time-point, early trophozoites; all normalized to beta tubulin. It is likely that 
cir genes were least transcribed in early trophozite stage parasites, as the trend observed 
in Figure 22 was for increased levels of cir transcripts in other stages of parasite 
development, compared to this time-point. However, further transcriptional patterns 
could not be identified for any particular time-point or sub-set of cir genes, indicating 
that cir transcription is a dynamic process in vivo during intra-erythrocytic parasite 
development. 
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3.3.2 Measurement of cir transcripts by RNA sequencing  
A major limitation for the use of RT-qPCR analysis to measure cir transcript levels 
during P. chabaudi infection was that very few of the cir family members could be 
effectively analyzed (as observed in section 3.3.1). Recent advances in high throughput 
sequencing technologies have enabled their application to transcriptome level analyses, 
and may outcompete the use of microarrays for this purpose (Shendure, 2008). To 
determine whether Solexa / Illumina whole transcriptome sequencing could be applied 
to P. chabaudi for the measurement of cir transcription, two trial RNA samples were 
prepared. The RNA was extracted directly from the whole blood volume of two 
BALB/c mice, taken at the peak of separate P. chabaudi infections. The results are 
summarized in Table 14. 
 
Table 14: Statistics for trial P. chabaudi RNA sequencing samples. 
 BALB/c sample 1 BALB/c sample 2 
Parasitaemia 42.93 40.78 
Sample composition: 
    Mus musculus * 23.23% 81.33% 
    rRNA 3.10% 0.01% 
    P. chabaudi mRNA 73.67% 18.66 
P. chabaudi statistics: 
    Total number of sequence reads 3038218 2825036 
    Mapped sequence reads 20% 34% 
    Reads with 40 bp overlap 269111 169499 
    Number of perfectly mapping reads ^  163363 18771 
    Reads which contained repetitive sequence 6% 21% 
    Unique reads, matching a single gene 14% 18% 
    Total bp mapped to P. chabaudi AS genes 16612855 15923935 
    Proportion of genes not covered by any reads + 89% 99% 
The parasitaemia of each mouse is shown on the day blood was taken and RNA extracted. Read lengths 
of 54 nucleotides were generated. * Including DNA and all RNA species.  ^ Containing no mis-matches 
with the genome sequence. + The total length of mapped transcripts as a percentage of all annotated genes 
(covering 18832209 base pairs). 
 
Both RNA samples contained high levels of host (mouse) RNA: 23.23 - 81.33% of the 
total sample (Table 14). One of the samples also contained a substantial percentage of 
ribosomal RNA (rRNA) contamination (3.10%, Table 14). These sequences were 
excluded bio-informatically and the remaining sequences were used to determine P. 
chabaudi AS specific statistics for the two samples. Between 1 and 10 million P. 
chabaudi sequence reads were obtained, with a read length of 54 base pairs (bp). After 
mapping these reads to the P. chabaudi genome sequence, the majority of the genome 
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was not covered by a single sequence read (89-99%; Table 14, the list of cir genes 
detected is attached in full in Appendix 3.5). Thus, it is likely that not all P. chabaudi 
transcripts were detected from these samples, and the levels of each transcript could not 
be determined with confidence.  
Nonetheless, Figure 23 shows that approximately two thirds of cir genes could be 
detected from these two RNA samples. Dominant cir genes were expressed at between 
four and ten times the level of the next most highly transcribed cir. Whole 
transcriptome sequencing data from the first sample were obtained during the second 
stage of cir gene annotation (described in chapter 2.2.1). Sequencing reads for 73 cir 
genes were detected, corresponding to approximately 62% of the cir repertoire. 
Subsequently, data were obtained for the second sample after cir gene annotation was 
complete, thus more cir genes could be detected in this sample: 122 of the total 199 cir 
genes. Notably, in both samples one transcript dominated the expressed cirs: 
PCHAS_010120 in sample 1 (excluded from CIR phylogenetic analyses), and 
PCHAS_110030 in sample 2 (CIR sub-family U).  
The detection of a dominant cir transcript in both P. chabaudi RNA samples could be 
due either to the majority of iRBCs transcribing that cir gene at low levels or a few 
iRBCs transcribing that cir at very high levels. Other highly expressed cir genes (with 
greater than 200 sequence reads detected) were also detected in the second sample: 
PCHAS_070130, PCHAS_083690 and PCHAS_040060. All highly expressed cir genes 
are indicated with stars in Figure 23. 
The ability to detect many cir transcripts, including a dominant cir, by RNA sequencing 
of P. chabaudi infected blood was encouraging. However, there was considerable room 
for improvement. The proportion of the genome covered by sequence reads was low, 
even to 1x coverage, Table 14. Transcriptome coverage to at least 4x redundancy is 
required in order to confidently identify transcripts and other phenomena that may be 
detected by RNA sequencing, such as novel splice variants (Trapnell et al., 2009). An 
RNA sequencing experiment is able to detect a finite number of reads, so the presence 
of high abundance mouse and rRNAs would have reduced the capacity for detection of 
P. chabaudi transcripts. Therefore, the further use of RNA sequencing technology 
required removal of high abundance contaminating RNA species, which precluded the 
detection of P. chabaudi transcripts. 
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Efforts were first made to investigate the source of the Mus musculus contaminating 
RNA, which comprised both rRNA and mRNA species. In fact, the host contamination 
was visible by agarose gel electrophoresis of the P. chabaudi RNA samples (prior to 
rRNA digestion), shown in Figure 24. Whilst mRNA and several rRNA species from P. 
chabaudi and M. musculus were indistinguishable on the gel, one rRNA species was 
detected solely in P. chabaudi infected samples (labelled band 2 in Figure 24). By 
contrast, band 1 was present at higher concentration in RNA samples from naïve mice 
than P. chabaudi infected mice, compared to the other rRNA bands (Figure 24a and b). 
Thus, a high degree of host contamination in P. chabaudi RNA samples could be 
visualized after gel electrophoresis by the presence of rRNA band 1. Lymphocytes were 
unlikely to be the source of this host contamination, as bands of equal intensity were 
observed in both BALB/c and RAG2-/- mice, Figure 24b. The source of host 
contamination was also not induced by P. chabaudi AS infection, as host RNA could be 
clearly seen in naïve mice, Figure 24c.  
To deplete leukocytes present in P. chabaudi infected blood, filtration of blood samples 
was carried out using CF11 columns and commercially available Plasmodipur filters 
(EuroProxima), Table 15.  
 
Table 15: Leukocyte depletion by filtration of P. chabaudi infected blood.  
Total leukocyte counts (x107): 
 Plasmodipur CF11 
Mouse 1 2 3 1 2 3 
Before filtration 4.29 4.56 3.00 4.28 4.35 6.03 
After filtration 0.04 0.12 0.05 0.47 0.48 1.22 
Total loss (%) 99.07 97.37 98.50 89.02 88.97 79.77 
Total RBC counts (x109): 
 Plasmodipur CF11 
Mouse 1 2 3 1 2 3 
Before filtration 7.71 5.58 6.00 6.50 6.08 5.95 
After filtration 7.66 5.40 5.64 4.98 4.43 5.03 
Total recovery (%) 99.35 96.77 94.00 76.62 65.15 84.54 
The proportion of leukocytes and RBCs present in each sample of P. chabaudi infected blood, from three 
BALB/c mice at day 7 of infection, was enumerated using the VetScan II (Abaxis), before and after 
filtration using either a Plasmodipur filter (EuroProxima) or a CF11 column. 
 
Plasmodipur filtration consistently removed a higher proportion of leukocytes from P. 
chabaudi infected blood samples (12.39% more than after CF11 filtration, Table 15), 
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with a greater recovery of RBCs (21.27% more than after CF11 filtration, Table 15). 
However, after more than 97% leukocyte depletion by Plasmodipur filtration, host RNA 
contamination was still visible upon gel electrophoresis of P. chabaudi RNA samples, 
Figure 24d. Thus, it was concluded that leukocytes were not the source of the host RNA 
contamination. 
The contribution of RNA from red blood cells was then investigated as a potential 
source of contamination for P. chabaudi RNA samples. High numbers of reticulocytes 
could be observed in the blood of both uninfected and P. chabaudi AS infected mice, 
Table 16. Reticulocytes in the blood of BALB/c and RAG2-/- mice were detected using 
two methods. First, flow cytometry was performed using the same blood samples, using 
the stain DRAQ5 (Biostatus Limited), which only detects DNA, and thiazole orange 
(Sigma-Aldrich), which detects all nucleic acids; Figure 25a. In addition, thin blood 
films were counter stained with Cresyl brilliant blue (BDH) to detect the reticular 
material and Giemsa (VWR international) to detect nuclei, Figure 25b. Two hundred 
RBCs were counted, and the proportion of reticulocytes recorded. In both strains of 
mice the reticulocyte numbers were similar (with a mean of 0.84% in naïve and 1.94% 
in P. chabaudi infected mice), within the acceptable range for healthy mice, up to 3% 
(McGarry et al., 2010).  
 
Table 16: The proportion of reticulocytes in the blood of naïve and P. chabaudi 
infected mice. 
% Reticulocytes (enumerated by:) Parasitaemia Mouse strain 
(Age, weeks) Cresyl blue  Flow cytometry   
Mouse 1 2 3 1 2 3 1 2 3 
BALB/c (9) 0.67 0.34 0.83 0.76 0.72 0.77 Naïve Naïve Naïve 
BALB/c (5) 1.19 3.00 1.00 2.76 3.91 2.88 19% 19% 17% 
RAG2-/- (5) 2.00 0.60 1.10 1.00 0.54 0.72 Naïve Naïve Naïve 
RAG2-/- (10) 3.50 1.50 1.33 5.32 1.19 1.08 25% < 1% 2% 
Tabulated data showing the percentage of RBC that were reticulocytes in different strains of naïve and P. 
chabaudi infected mice, counted using either microscopy or flow cytometry. Three individuals were 
analyzed per group, samples taken on day 7 of infection. The parasitaemia of infected mice is also given.  
 
Table 16 shows that reticulocyte numbers were increased in P. chabaudi infected mice 
compared to naïve mice, and that RAG2-/- mice appeared to have slightly higher 
numbers of reticulocytes than BALB/c mice. However, a large degree of variation 
between mice made conclusions difficult to draw. This may have been due to different 
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definitions of ‘a reticulocyte’ by the two methods, whereby DNA positive P. chabaudi 
infected reticulocytes were excluded by flow cytometry analysis, but could be detected 
by microscopy. Equally, the proportion of reticular material detected by each method 
may have been different. To minimize variation, mice aged between 6-8 weeks were 
used in all subsequent experiments.  
To measure the amount of host mRNA contamination in P. chabaudi RNA samples, all 
transcripts identified from the initial RNA sequencing samples were examined (data not 
shown). The majority of these host contaminants were globin transcripts, in agreement 
with the high percentages of reticulocytes observed in the blood of P. chabaudi infected 
mice. Primers were designed to amplify Mus musculis beta globin, to determine the 
extent of P. chabaudi RNA contamination by RT-qPCR.  
Beta globin primers were validated as described for cir primers (section 2.2.5, 
Appendix 3.6). Their specificity was assessed by cloning of PCR-amplified products; 
all three clones analyzed contained the beta globin gene. RT-qPCR was then used for 
determination of primer efficiency. As these primers spanned the first exon: exon 
boundary of the beta globin gene, PCR efficiency was calculated by titration of a 
pooled cDNA standard rather than using gDNA. This indicated that the beta globin 
primers were ten fold less efficient than those for the P. chabaudi gene beta tubulin: 
having PCR efficiencies of 20.09, and 2.00, respectively (calculated using the equation 
given in section 3.2.8.i). However, different levels of these transcripts may have been 
present in the cDNA pool used for estimation of primer efficiency and for this reason, 
correction for PCR efficiency was not applied in the estimation of their transcript levels. 
This meant that the relative levels of beta globin measured by RT-qPCR could have 
been actually ten-fold higher than the beta tubulin transcript levels in the analyses 
described below. Thus, any detection of beta globin transcripts by RT-qPCR would 
indicate substantial host contamination of P. chabaudi mRNA.  
Different methods were carried out in an attempt to reduce reticulocytes from infected 
blood. The first approach was to use a high dose infection as it is known that P. 
chabaudi infection with the standard intra-peritoneal (i/p) inoculum of 1x105 iRBC 
induces an efflux of reticulocytes from the bone marrow, known as reticulocytosis, 
around the peak of infection (Podoba and Stevenson, 1991). Reticulocyte numbers were 
compared between mice given the standard inoculum (1x105 iRBCs) and mice given a 
high dose inoculum of 1x108 iRBCs, with the idea that sufficient parasite material might 
be collected before induction of reticulocytosis. The percentage of reticulocytes in the 
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blood of these mice was counted by both cresyl blue microscopy and flow cytometry, 
Table 17. However, no differences were observed in the proportion of reticulocytes for 
the two groups.  
RT qPCR was used to measure the level of mouse beta globin contamination in P. 
chabaudi RNA samples, as a proportion of the constitutively expressed P. chabaudi 
gene beta tubulin (used to represent the level of P. chabaudi transcripts present). Figure 
25c shows that host contamination of parasite material was reduced in mice infected 
with 1x108 compared to 1x105 iRBCs, however there was still more beta globin than 
beta tubulin RNA present in the sample. Given that such a high dose infection was not 
practical for most P. chabaudi experiments, and that the early rise of parasitaemia did 
not sufficiently reduce the globin to parasite RNA ratio, this avenue was not pursued in 
further experiments. 
 
Table 17: The proportion of reticulocytes in the blood of P. chabaudi infected mice.  
% Reticulocytes (enumerated by:) 
Strategy 
Cresyl blue Flow cytometry 
Parasitaemia 
Mouse 1 2 3 1 2 3 1 2 3 
105 infectious dose 0.80 0.41 0.85 0.93 0.75 0.89 12.0% 10.4% 12.8% 
108 infectious dose 1.70 0.92 4.55 1.33 0.74 0.92 27.6% 28.8% 37.6% 
Tabulated data showing the percentage of RBC that were reticulocytes in BALB/c mice infected with 
different doses of P. chabaudi iRBCs. Three individuals were analyzed per group, samples were taken on 
day 7 of infection for mice given the 105 infectious dose, and day 4 of infection for mice given the 108 
infectious dose. Reticulocytes were counted using either microscopy or flow cytometry.  
 
 
Several investigators have made use of the magnetic property of haemozoin to enrich 
Plasmodium iRBCs and deplete other cell types [described by (Paul et al., 1981)]. This 
approach was explored for P. chabaudi using a large MACS column in combination 
with the SuperMACSII magnet (Miltenyi Biotechnology). Whilst the proportion of 
reticulocytes in blood was lower in the MACS purified blood samples, there was a 
substantial loss of material, Table 18. A volume of 100 µl packed RBCs was purified 
over the column twice, for three individual mice, yet only 3-10 µl of packed RBCs were 
recovered. Not only were the purified cells less uniform than is usual for Giemsa-
stained iRBC, but despite extensive washing of the column, uninfected cells, including 
reticulocytes, were still present in the purified iRBC fraction (48 - 64% of cells were 
RBCs, and 0.77 – 5.88% of these were reticulocytes). An example of purified cell 
morphology is shown in Figure 25d. The proportion of beta globin relative to beta 
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tubulin was again measured by RT-qPCR, but there was no difference between the 
samples before and after MACS purification, Figure 25d.  
Enrichment of the intra-erythrocytic parasites was attempted using saponin lysis of 
erythrocyte membranes. This process forms pores in both the erythrocyte and PV 
membranes of Plasmodium iRBC, as they are derived from the same source (Pouvelle et 
al., 1994, Ward et al., 1993), but leaves the developing parasites and their nuclei intact 
(Christophers and Fulton, 1939). Using this method, the proportion of reticulocytes 
decreased substantially relative to the number of parasites counted in two samples. 
However, in the other sample there was virtually no difference (denoted * in Table 18), 
indicating that the lysis process was highly variable for P. chabaudi iRBCs. Similarly to 
MACS purification, saponin mediated cell lysis resulted in approximately ten-fold loss 
of material, Table 18, yet no difference was observed in the proportion of beta globin 
relative to beta tubulin found in the extracted RNA, Figure 25d. This signified that 
neither method was able to reduce the proportion of M. musculus contamination in the 
P. chabaudi RNA samples. 
 
Table 18: The proportion of reticulocytes in P. chabaudi infected blood samples, 
subjected to purification by MACS or saponin lysis. 
Before separation: After MACS separation: After saponin lysis: 
Reticulocytes Parasitaemia P:R ratio  
Volume of 
eluted iRBC 
P:R 
ratio  
Volume of 
eluted iRBC 
P:R 
ratio  
1.50 % 
1.50 % 
2.00 % 
16.5% 
12.5% 
14.0% 
70.92 
18.00 
24.01 
10 ul 
6 ul 
3 ul 
11.00 
8.33 
7.00 
8 ul 
16 ul 
12 ul 
100.00 
9.52 * 
66.67 
The percentage of RBC that were reticulocytes and iRBC, before and after treatment, were counted by 
microscopy. As many uninfected cells were lost after treatment, the number of reticulocytes was counted 
within fields containing 200 parasites, and this was divided by the number of reticulocytes counted to 
give a ratio of parasites per reticulocyte (P:R). Three BALB/c mice were analyzed per group, samples 
taken on day 7 of infection. 100 µl packed RBC were used for all experiments and the volume of packed 
RBC recovered after treatment was noted as the volume of eluted iRBC. *Poor lysis, discussed above. 
 
 
In conclusion, although a major source of P. chabaudi mRNA contamination was 
derived from host cells, specifically reticulocytes, attempts to deplete these cells from 
infected blood samples were unsuccessful. The identification of improved methods, 
both to remove host mRNA contamination, and to reduce the levels of the other major 
contaminant (rRNA) from P. chabaudi RNA samples, will be required in order to carry 
out future RNA sequencing experiments. 
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Figure 21: RT qPCR analysis of cir transcription during P. chabaudi AS infection. 
a) P. chabaudi infection of three BALB/c mice (labelled M1, M2, M3), infected with 
parasites expanded in a RAG2-/- donor mouse.  
b) P. chabaudi infection of three RAG2-/- mice (labelled M1, M2, M3), infected with 
parasites expanded in a BALB/c donor mouse. 
5 ng RNA was analyzed from P. chabaudi infected blood, taken on Day 7 of infection. 
The ratio of cir transcription normalized to the parasite reference gene, beta tubulin, is 
shown for each mouse, relative to the P. chabaudi donor mouse. For ease of view, these 
data are represented using a log2 scale, where a two-fold change in either direction is 
displayed at an equal scale. Ratios are not displayed as log2 values however. 
Primers used were: U1, U4, C1 and E1, given under the respective graphs, beneath 
which the cir genes amplified by each primer pair are listed. 
In all graphs the mean of three technical replicates is plotted, data are tabulated in 
Appendix 3.4. Error bars represent standard deviation.  
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Figure 22: RT qPCR analysis of cir transcription in different stages of P. chabaudi.  
a) A representitive P. chabaudi iRBC is shown for the following stages of intra-
erythrocytic development: early trophozoite (8.30), mid trophozoite (10.30), late 
trophozoite (12.30), and ring (22.30), as described in Table 13. 
5 ng RNA was analyzed from three P. chabaudi infected BALB/c mice, on Day 7 of 
infection. cir transcription was measured in each mouse, shown in b), c) and d).  
The ratio (arbitrary units) of cir transcription is shown for the stages: early trophozoite, 
late trophozoite and early ring, relative to cir transcription in the same mouse at the late 
ring stage of iRBC development. All cir transcription was normalized to the parasite 
reference gene, beta tubulin. For ease of view, these data are represented using a log2 
scale, where a two-fold change in either direction is displayed at an equal scale. Ratios 
are not displayed as log2 values however. 
In all graphs the mean of three technical replicates is plotted. Error bars represent 
standard deviation. Mice were excluded where the standard deviation between technical 
replicates exceeded 0.775 (80% confidence), indicated by x. All data are tabulated in 
Appendix 3.4. 
Primers used were: U1 (white bars), U4 (hashed bars), C1 (yellow bars) and E1 (blue 
bars). These are given under the respective graphs, beneath which the cir genes 
amplified by each primer pair are listed. 
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Figure 23: Detection of cir transcription by Solexa/ Illumina RNA sequencing. 
The total number of sequence reads detected for each cir gene is plotted.  
a) Sample 1 shows all cir genes for which sequence reads were detected.  
b) Sample 2 shows cir genes for which more than 5 sequence reads were detected. 
Highly expressed cir genes, where at least 200 transcripts were detected, are indicated 
by *. All cir transcripts are tabulated in Appendix 3.5. 
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Figure 24: Host contamination in P. chabaudi AS RNA despite leukocyte depletion. 
a) P. chabaudi RNA extracted from infections in two RAG2-/- and BALB/c mice. 
Arrows represent the different RNA species resolved on this gel: 1), 3) and 4) Mus 
musculus ribosomal (r) RNA, 2), 3) and 4) P. chabaudi rRNA, 5) mRNA. RNA from 
both species was observed in bands 3), 4) and 5), where the word species was 
abbreviated to spp.  
b) RNA extracted from three uninfected BALB/c mice. 
c) P. chabaudi RNA extracted from infections of two BALB/c mice before and after 
leukocyte depletion by Plasmodipur filtration (the efficiency of which was assessed 
by microscopy, where no leukocytes were counted in more than 25,000 RBCs). 
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Figure 25: Strategies for depletion of reticulocytes from P. chabaudi infected 
blood. 
Reticulocyte numbers were estimated using two methodologies, outlined below: 
a) Example analysis of flow cytometry data. Dead cells were excluded according to their 
size (forward scatter, FSc) and granularity (side scatter, SSc) as defined by the red 
shape, shown in the left panel. DNA positive cells were excluded on the basis of 
DRAQ5 staining (a DNA specific dye), as defined by the red reactangle, centre panel. 
Remaining RNA positive cells were enumerated according to Thiazole Orange 
staining (staining both RNA and DNA), as defined by the red rectangle, right panel.  
b) Examples of RBCs from P. chabaudi infected blood, stained with Giemsa and 
counter-stained with cresyl blue. Reticulocytes are denoted by R. 
The expression levels of beta globin (M. musculus) and beta tubulin (P. chabaudi) were 
determined for the experiments outlined in c), d) and e) by RT-qPCR. The mean ratios 
of beta globin : beta tubulin transcripts present in the blood of P. chabaudi infected mice 
are plotted. Error bars represet the standard error of the mean. 
c) Three mice were infected with P. chabaudi i/p, with an infectious dose of either 105 
or 108 iRBCs. Blood samples were taken on day 7 and 4 of infection, respectively.  
Blood samples taken on day 7 of a standard P. chabaudi infection (105 infectious dose 
i/p), were analyzed by RT-qPCR before and after the following treatment: iRBC 
enrichment by MACS, d), and lysis of uninfected RBCs using saponin, e). Three mice 
were analyzed per group. 
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3.4 Discussion  
In this chapter, cir transcripts were measured in P. chabaudi infected blood samples 
using both RT-qPCR and RNA sequencing. Four pairs of primers were designed that 
could specifically amplify cir genes within the sub-families C, E and U. These primers 
were used in preliminary RT-qPCR analyses of cir transcription during P. chabaudi 
infections of BALB/c and RAG2-/- mice, finding variable levels of cir transcripts 
between mice. In addition, RNA sequencing detected transcription of two thirds of the 
cir repertoire at the peak of P. chabaudi infection, despite high levels of host 
contamination. One cir gene appeared to dominate each P. chabaudi infection, which 
was expressed at 4-10 times the level of the next most highly transcribed cir. The 
dominant cir may be transcribed by the majority of iRBCs at low levels, or by fewer 
cells at high levels. In both RNA sequencing experiments, the dominant cir belonged to 
sub-family U, although members of all the cir sub-families identified in chapter 2.3.2 
were detected in both samples. Members of the sub-families C, E and U were also 
detected during the blood stages of P. chabaudi infection by RT-qPCR. This has also 
been reported in another rodent model, P. yoelii, using group specific primers for RT-
qPCR (Fonager et al., 2007).  
A dynamic profile of cir expression was observed throughout the blood stages of 
parasite development, although one trend could be observed. The lowest levels of cir 
transcripts were detected in early trophozoite stage iRBCs, as all other stages had 
comparably higher cir detection. This agrees in part with previously published Northern 
blot data, which detected the highest levels of cir transcripts in late trophozoite stages 
(Janssen et al., 2002). Increased levels of some cir transcripts, notably those targeted by 
the primer pair U4, could also be detected in ring stage parasites, compared to the early 
trophozoite time-point. This may be explained by increased parasite biomass in this 
time-point after RBC invasion, compared to the trophozoite stages.   
An important consideration for RT-qPCR experiments is the choice of reference gene 
against which normalization is performed to provide a relative calculation of transcript 
abundance. In rodent-infecting species of Plasmodium, very few primers have been 
designed and validated for quantitative PCR, giving a limited choice of possible 
reference genes. Primers targeting beta tubulin have been used previously in this regard 
to normalize transcriptional measurements of yir genes (Cunningham et al., 2009). 
Expression data for beta tubulin throughout the erythrocytic growth cycle has been 
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collected for both P. falciparum (Le Roch et al., 2003, Llinás et al., 2006, Otto et al., 
2010, Bozdech et al., 2003a) and P. vivax (Bozdech et al., 2008), whose results were 
almost identical. A diagram of the P. vivax beta tubulin expression pattern in three 
patient isolates is shown in Figure 26.  
 
 
Figure 26: Transcriptional profile throughout the P. vivax 48 h intra-erythrocytic 
development cycle.  
 
Adapted from (Bozdech et al., 2008). Best fit Pearson correlations were used to correlate P. vivax beta 
tubulin expression intensity to the expression data in time-points 9, 13, 17, 20, 23, 29, 35, 40, and 43 h 
post RBC invasion in the P. falciparum transcriptome. This graph shows an approximate average from 
the values obtained from 3 patient samples (Bozdech et al., 2008). 
 
 
Whilst beta tubulin transcription remained fairly constant during the erythrocytic cycle, 
Figure 26 (Bozdech et al., 2008), the percentages were slightly lower at the early time-
points post RBC invasion (approximately 90 - 95% of the transcription observed for 
other P. vivax genes). A similar pattern of beta tubulin transcription is also likely to be 
observed during P. chabaudi intra-erythrocytic development. This may have 
contributed to the higher levels of cir transcripts detected in ring stage iRBCs compared 
to other stages of development. 
Therefore, as the normalization would be slightly different at these early stages it would 
be more accurate in future experiments to compare cir expression relative to beta 
tubulin within the equivalent stage of iRBC development, rather than between stages. 
The cir primers validated here may be used for further experiments where differences in 
transcription would be expected in particular cir genes, or where the quantities of 
material available would be too low for analysis of the whole transcriptome. For 
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example, analyses of cir transcription could be performed at several time-points during 
a chronic P. chabaudi infection to investigate whether cir transcription changes in line 
with the antigenic properties of the iRBC surface [as described by (McLean et al., 1982, 
McLean et al., 1986)]. In addition, cir transcription could be measured within individual 
iRBCs. Different sub-types of rif and pir genes can be co-expressed within individual 
iRBCs (Fonager et al., 2007, Petter et al., 2007, Bozdech et al., 2008), whilst infections 
of RAG2-/- mice with individual P. yoelii iRBCs have given rise to parasites expressing 
different yir profiles (Cunningham et al., 2009), indicating that the parasites must 
display plastic pir transcription.  
Early experiments have shown that yir transcription changes substantially during a 
secondary P. yoelii infection of immuno-competent mice, but not in immuno-
compromised animals (Cunningham et al., 2005), indicating that the YIR proteins could 
be involved in antigenic variation. During P. chabaudi infection of immuno -competent 
and  -deficient mice however, few substantial differences were detected by RT-qPCR. It 
is possible that some cir genes re-capitulated the altered yir profile in immuno-
competent mice, but which escaped detection due to the limited primers available. Thus, 
RT-qPCR is not an ideal method for analysis of such a large gene family, by necessity 
focussing on transcription of a few cir genes.  
Whole transcriptome analyses are invaluable for the investigation of multi-gene family 
expression patterns, in order to see the whole picture. For example, differences in the 
transcription of different yir sub-familes were observed during blood stage P. yoelii 
infection by RT-qPCR (Fonager et al., 2007), but not by the subsequent microarray 
study (Cunningham et al., 2009). Neither could correlations be identified by microarray 
between the pattern of vir transcription during intra-erythrocytic development and the 
previously identified VIR sub-families (Bozdech et al., 2008). These data indicate that 
members of the sub-families identified on the basis of sequence similarity were not co-
expressed during P. yoelii infection or P. vivax intra-erythrocytic development. Instead, 
two waves of vir and Pvtrag transcription were detected during P. vivax intra-
erythrocytic development (Bozdech et al., 2008), which may indicate that two 
functionally related VIR sub-families exist.  
Differences in pir transcription have also been detected from microarray studies: 
between mice susceptible and resistant to the development of cerebral malaria 
(Lovegrove et al., 2006), and in mice immunized with MSP-8, thus inhibiting the 
invasion of mature erythrocytes (Shi et al., 2005). These results may indicate the 
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involvement of PIR proteins in RBC invasion, processes leading to the development of 
cerebral malaria, or could reflect changes in the whole transcriptome as a result of 
altered parasite behaviour. This illustrates the power of whole transcriptome analyses, 
since differences in yir transcription were detected without prior expectation that the 
expression of these genes would change. Unfortunately, due to the complex analysis 
required, many micro-array studies simply exclude sub-telomeric regions and the multi-
gene families they encode [for example (Liew et al., 2010)], potentially meaning that 
differences in VSA expression are not detected.  
The future application of RNA sequencing technologies will likely facilitate analysis of 
VSA genes from whole Plasmodium transcriptome studies, as gene-specific probes are 
not required. During their analysis of the P. falciparum transcriptome, Otto and 
colleagues were able to provide near-complete genome coverage of RNA transcripts at 
single base pair resolution, and detect alternative splicing events, novel transcripts and 
low abundance transcripts (Otto et al., 2010). Periodic gene expression patterns during 
the erythrocytic cycle (Le Roch et al., 2003, Bozdech et al., 2003a) were also detected 
using RNA sequencing (Otto et al., 2010). Comparison of the same samples by micro-
array and RNA sequencing correlated well and furthermore, whole transcriptome 
sequencing was able to detect lower abundance transcripts giving an expanded 
transcriptome (Otto et al., 2010). It is anticipated that similar investigations will be 
possible for P. chabaudi once methods for improved sample preparation are defined.  
P. chabaudi RNA samples contained high abundance contaminants, of both ribosomal 
RNA and host-derived mRNA. None of the investigated reticulocyte depletion strategies 
could provide enough material from an individual P. chabaudi infected mouse for cDNA 
library preparation, which requires approximately 10 µg RNA for the methods used here. 
Whilst pooling of samples from several individuals is acceptable for certain applications, 
this is not informative for analysis of cir transcription dynamics; since the parasite 
populations arising in each mouse may be diverse, with different cir gene transcription 
in different infections. Recently, methods requiring much smaller quantities of template 
for RNA sequencing have been described (Ozsolak et al., 2010), which may be able to 
resolve this problem.  
It may be also be possible to specifically deplete the high abundance contaminants 
directly from P. chabaudi RNA samples, because they were predominantly rRNA and 
globin mRNA transcripts. To do this, biotinylated oligonucleotides could be designed to 
hybridize to each of the contaminating transcripts, which could then be removed from 
    Chapter 3: Analysis of cir transcription 
 149 
the RNA samples using streptavidin-coated beads. This was done for 26 rRNA species 
and 32 of the most abundant mRNA transcripts, including those encoding histones, 
during analysis of the P. falciparum transcriptome (Otto et al., 2010). More recently, 
another approach has been published, where rRNA contamination was excluded at the 
stage of cDNA template preparation (Vignali et al., 2011). Here, Vignali and colleagues 
used a ‘not so random’ priming strategy for cDNA synthesis, where any hexamers that 
would bind to rRNA transcripts were selectively removed from the random primers 
before cDNA synthesis (Vignali et al., 2011). Either or both of these approaches could 
be used to exclude rRNA and globin mRNA contamination from P. chabaudi cDNA 
samples prior to RNA sequencing. 
The application of whole transcriptome analysis methods, such as RNA sequencing, to 
the rodent model P. chabaudi will enable the investigation of parasite responses during 
growth in different host genetic backgrounds and under different treatments and is also 
likely to identify genes not previously known to be involved in such processes. For 
future studies, investigations should repeat the comparison of P. chabaudi infected 
immuno-competent and immuno-deficient mice to determine whether cir transcription 
is reduced in the absence of lymphocytes, as previously observed by RFLP analysis for 
the yirs (Cunningham et al., 2005). If a sub-set of cir transcripts were reproducibly 
detected at lower levels by RNA sequencing in the absence of lymphocytic selection 
(such as during P. chabaudi infection of RAG2-/- mice), this would strongly suggest that 
CIR proteins are under immune selection during the blood stages of infection.  
Subsequently, analysis of P. chabaudi transcription during parasite passage in mice of 
the same strain would identify differences in the cir transcription pattern. Analysis of 
the whole cir repertoire from these experiments will allow determination of the extent 
to which cir transcription changes between P. chabaudi infected individuals, compared 
to the donor mouse, identifying which transcripts become dominant in each infection. If 
a restricted number of cirs were more likely to dominate P. chabaudi infection, these 
family members should provide the basis of investigations into CIR function. 
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Chapter 4:  Generation of recombinant CIR proteins 
4.1 Introduction 
In order to investigate beyond the transcriptional analyses described in chapter 3 and 
explore the possible functions of CIR proteins, efforts were made to express 
recombinant CIR proteins. These proteins could then potentially be used for analyses of 
CIR protein structure, and as tools for investigation of CIR function. 
Plasmodium genes are notoriously difficult to express as recombinant proteins because 
of their A+T rich nature, containing an average of 80.6% A+T in P. falciparum and 
74.5% in P. chabaudi (Gardner et al., 2002, Janssen et al., 2001). This is unlike the 
typical A+T content, closer to 50%, found in common expression systems, and often 
leads to premature transcription termination during heterologous expression of 
Plasmodium genes [for example (Yadava and Ockenhouse, 2003)]. The pir genes are no 
exception, and the presence of at least one trans-membrane domain and other 
hydrophobic regions make them less likely to be soluble if expression is achieved.  
Insoluble proteins form irreversible aggregates, but soluble proteins can also form 
aggregates, such as inclusion bodies (Carrio and Villaverde, 2002), which must be 
disrupted by denaturing conditions before the proteins can undergo solubilization and 
re-folding. After such treatment, proteins may not accurately represent the native 
protein structure. The structure of recombinant proteins should be equivalent to the 
native protein, especially for immunological investigations, where improper protein 
folding may result in the loss of conformational determinants that are recognised by 
antibodies. 
Few attempts have been made to express recombinant PIR proteins. Initial endeavors by 
groups using E. coli managed with varying degrees of success to produce VIR GST-
fusion proteins (Del Portillo et al., 2001, Fernandez-Becerra et al., 2005, Oliveira et al., 
2006). Whilst all of these were insoluble and not necessarily representative of the 
endogenous protein structure, nonetheless some VIR proteins were recognized by Abs 
present in immune sera from P. vivax infected patients by western blot, indicating that 
non-conformational determinants of Ab specificity were present.  
To enhance the likelihood of expressing soluble CIR proteins, a eukaryotic protein 
expression system was used for this study, Pichia pastoris. The yeast P. pastoris 
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contains chaperones to facilitate protein folding and machinery required for post-
translational modifications. In this system it is also possible to secrete recombinant 
proteins directly into the culture medium, reducing lengthy protein purification 
strategies. Our laboratory has previously successfully expressed the 21 kDa P. chabaudi 
equivalent of P. falciparum MSP119 using this expression system (Hensmann et al., 
2004). 
The objectives of the work described in this chapter were to: 
i) Design synthetic cir genes, removing the trans-membrane domain and 
predicted intracellular domains in concert with gene re-codonisation for 
optimal expression in the methylotropic yeast P. pastoris. 
ii) Generate P. pastoris clones capable of expressing recombinant CIR proteins, 
to determine optimimal expression conditions for each recombinant CIR and 
to purify the recombinant CIRs via metal-chelate chromatography. 
iii) Conduct initial analyses of protein structure to assess the likelihood of 
recombinant CIRs having equivalent protein structures to native CIRs, and 
the feasibility of crystallisation of these proteins.  
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4.2 Methods 
4.2.1 Cloning and expression of CIR 
The DNA sequences of three cir genes chosen for protein expression: PCHAS_000100, 
PCHAS_070130 and PCHAS_040110 were downloaded from Genedb 
(http://www.genedb.org/Homepage/Pchabaudi). The predicted TM and intracellular 
domains were removed and restriction sites were inserted to flank the remaining 
sequences corresponding to the predicted extracellular region. The nucleotide sequences 
were further modified by re-codonization for optimal expression in Pichia pastoris and 
addition of a 3’-tag encoding six-histidine residues, which would facilitate protein 
purification. In addition, asparagine residues predicted by the NetNGlyc 1.0 Server to 
undergo N-glycosylation in P. pastoris (http://www.cbs.dtu.dk/ services/NetNGlyc/), 
were altered either to amino acids found at the same position in other CIR sequences or 
to amino acids with similar properties, since N-glycosylation occurs only rarely in 
Plasmodium (Gowda and Davidson, 1999). 
Following synthesis by GeneART™, the cir genes were sub-cloned into EcoRI or AvrII 
and NotI sites of the expression vector pPIC9K (Invitrogen). This vector contains the α-
factor mating signal sequence to enable protein expression directly into the culture 
medium, located directly 5’ of the multiple cloning site. Briefly, restriction digestion 
was carried out using either EcoRI or AvrII and NotI in buffer 3 (New England 
Biosciences), for 2 hours at 37 ˚C, according to manufacturer’s instructions. The 
pPIC9k vector was digested in the same way, in parallel, and digested products were 
size separated by agarose gel electrophoresis. Bands corresponding to the synthetic cir 
gene and the pPIC9K vector backbone were excised and purified using a Qiaquick gel 
extraction kit (Qiagen), according to manufacturer’s instructions. These products were 
then ligated together using the rapid ligation kit (Roche), according to manufacturer’s 
instructions and transformed into TOP10F E. coli cells (Invitrogen), as described 
previously (chapter 3.2.5). Several transformants were selected for a repeat double-
restriction digestion to confirm which cells contained the full cir gene and vector. A 
clone containing the expected cir gene was then inoculated into 500 ml cultures of LB 
broth (1% tryptone, 0.5% yeast extract, 1% NaCl, pH 7.0) containing 50 µg/ml 
ampicillin, and cultured overnight, shaking, at 37 ˚C. Plasmids containing the synthetic 
cir genes were then purified from the culture by maxiprep (Qiagen), according to 
manufacturer’s instructions. Plasmids were eluted in distilled water and their 
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concentrations were estimated using a Nanodrop spectrophotometer (ThermoFisher). 
The plasmids were sequenced using M13 primer sites flanking the cir gene insertion, 
for confirmation that the expected gene was present and in frame with the α-factor 
signal sequence. 
Electroporation of GS115 P. pastoris cells  (Invitrogen) was carried out according to 
methods adapted from the pPIC9k manual (Invitrogen). Between 1 and 5 µg of 
linearized vector was added to 60 µl P. pastoris cell suspension (containing 
approximately 1.2 x 109 cells, re-suspended in buffer comprising 270 mM sucrose, 10 
mM Tris-HCl, 1 mM MgCl2, pH 7.5), in an 0.2 cm electroporation cuvette (BioRad). 
This was placed in the gene pulser (BioRad) and electroporated using 1.5kV, 400Ω, 
25µF. Recombinants were selected by growth firstly on minimal medium- (containing 
1.34% yeast nitrogen base, 4x10-5% biotin and 2% dextrose), which selected for 
complementation of histidine auxotrophy in the GS115 P. pastoris cells, by the histidine 
biosynthesis open reading frame (ORF) present in the vector pPIC9k. Secondly, 
recombinants were selected by growth on yeast extract peptone medium- (containing 
1% yeast extract, 2% peptone and 2% dextrose) agar plates containing increasing 
concentrations of Geneticin ® (Invitrogen) selection. This allowed selection of 
recombinants with high Geneticin ® resistance, which correlates with an increased copy 
number of integrated constructs, thereby leading to higher levels of recombinant protein 
expression (Clare et al., 1991a). 
Clones growing at the highest concentration of Geneticin ® (1 mg/ml) were isolated, 
and used to create glycerol stocks, made by addition of 0.15 ml glycerol to 0.85 ml of P. 
pastoris culture, grown in yeast extract peptone medium. These were ‘snap frozen’ on 
dry ice for storage at -80 ˚C. In addition, the clones were transferred to BMGY medium 
(liquid broth containing 1% yeast extract, 2% peptone, 100 mM potassium phosphate 
pH 6.0, 1.34 % yeast nitrogen base, 4x10-5 % biotin and 0.5 % glycerol); and cultured at 
28 ˚C, in a shaking incubator set at 225 rpm, until the OD600 reached 2-6, indicating log 
phase growth.  
P. pastoris is able to use methanol as a sole carbon source, the first step in this pathway 
is the oxidation of methanol to formaldehyde using the enzyme alcohol oxidase. The 
enzyme responsible is produced by the AOX1 gene, whose promoter is encoded within 
the vector pPIC9k (Invitrogen), where it is fused to the α-factor secretion signal (Ellis et 
al., 1985, Koutz et al., 1989, Tschopp et al., 1987). Growth using methanol as the sole 
carbon source requires induction of the AOX1 gene (Cregg et al., 1989), and therefore 
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also induces expression of the recombinant cir gene inserted downstream of the α-factor 
signal sequence. 
Recombinant protein expression was induced by re-suspension of the cells in BMMY 
medium, where glycerol was replaced with methanol as the sole carbon source, 
according to methods adapted from the pPIC9k manual (Invitrogen). Cells were 
otherwise cultured in the same conditions as described above, adding a further 0.5% v/v 
methanol to maintain protein expression after every 24h of culture. For standard trials of 
protein expression, cells were re-suspended in BMMY to an OD600 of 1, in order to 
maintain log phase growth. Protein expression was optimized by addition of 5 µg/ml 
chymostatin (Sigma) every 24 h or re-suspension of P. pastoris in minimal methanol 
medium (Liquid broth containing 1.34% yeast nitrogen base, 4x10-5% biotin and 0.5% 
methanol) instead of BMMY. Both strategies inactivate host proteases, thus preventing 
the degradation of full-length recombinant proteins during protein expression (Clare et 
al., 1991b, Brierley et al., 1994). To favour slow methanol metabolism in clones where 
the AOX1 gene may have been replaced (resulting in poor utilisation of methanol as the 
sole carbon source) cells were re-suspended in BMMY at 20% of the original culture 
volume. 
 
4.2.2 Purification of recombinant CIR 
Recombinant CIR proteins containing hexa-histidine tags were purified by immobilised 
metal-affinity chromatography on Ni2+-nitrilotriacetic acid (Ni2+-NTA) agarose 
(Invitrogen), under native conditions, according to methods adapted from the Ni2+-NTA 
manual (Invitrogen).  Briefly, 45 volumes of culture supernatant were allowed to bind 
one volume of Ni2+-NTA agarose in the presence of complete protease inhibitors 
(Roche) and five volumes of binding buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole, pH 8.0) for one hour, rotating, at 4 ˚C. Non-specifically bound proteins were 
removed using 25 volumes of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole, pH 8.0), and bound protein eluted with three volumes of elution buffer 
(50mM NaH2PO4, 300 mM NaCl, 200 mM imidazole, pH 8.0). Centrifugation steps 
were carried out at 4 ˚C, using 3,000 x g for volumes greater than 1.5 ml and 13,000 x g 
for volumes smaller than 1.5 ml. 
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During the initial screens of protein expression, proteins were eluted from the Ni2+-NTA 
agarose using one volume of three elution buffers, each containing a higher imidazole 
concentration: 250 mM; 500 mM and 1 M imidazole, to determine whether all the 
protein had been eluted.  
Protein concentration was analysed using the bicin-choninic acid assay (BCA, Pierce), 
with bovine serum albumin (BSA) diluted in the appropriate buffer to form a standard 
curve. The absorbance of samples at 562 nm was measured using a Nanodrop 
spectrophotometer (Thermo Scientific). For subsequent studies, recombinant protein 
was dialyzed into PBS using either Dialyzer cassettes (Pierce) or desalted into PBS 
using PD10 columns (Amersham Biosciences).  
 
4.2.3 CIR detection via SDS-PAGE and immuno-blotting 
Time-course experiments were carried out, consisting of one ml samples collected every 
24 hours during induction of protein expression, which were analysed by 12% sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Concentration of all 
protein samples was necessary, achieved by centrifugation at 13,000 x g, 4 ˚C, using 
Vivaspin concentrating columns with a MWCO pore size of 10 kDa (Vivascience), until 
the volume of each sample was reduced ten-fold. 
Proteins were resolved on NuPAGE 12% bis-Tris gels (Invitrogen) in NuPAGE 1x 
morpholine-ethane-sulfonic acid sodium dodecyl sulphate buffer (Invitrogen), 
according to the manufacturer’s directions. Reducing conditions were used throughout, 
where samples contained 100 mM DTT and the running buffer also contained 0.5 ml 
NuPAGE antioxidant. Proteins were run alongside 1x SeeBlue Plus2-prestained 
standard (Invitrogen). Gels were either directly stained with coomassie blue or used for 
immuno-blotting. Coomassie blue staining was carried out overnight (0.25% w/v 
coomassie brilliant blue R250, 45% ethanol, 10% acetic acid) and gels were 
subsequently destained for several hours (45% ethanol, 10% acetic acid). Once fully 
destained, gels were washed in distilled water, and dried using the GelAir system 
(BioRad). 
For immuno-blotting, the proteins were electrophoretically transferred to Hybond C 
membrane (Amersham Biosciences) in buffer containing 10% methanol, 0.025 M Tris 
base (Sigma) and 0.2 M Glycine (BDH Biosciences) for 3 h at 30 V. Membranes were 
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blocked at 4 ˚C overnight in Odyssey blocking buffer (Licor Biosciences), and washed 
for 10 minutes three times with PBS containing 0.05% Tween 20. Specific proteins 
were detected using the anti-six his tag monoclonal antibody (Novagen) at 0.5 µg/ml 
concentration, membranes were washed as before. Bound antibodies were detected 
using secondary Alexa 680-conjugated goat anti-mouse IgG (Licor Biosciences) used at 
0.13 µg/ml concentration. Membranes were washed as before and stored in PBS in the 
dark. The bound secondary antibody was detected by scanning the probed membranes 
in the Odyssey scanner (Licor Biosciences), exciting the Alexa flurochrome at 680nm, 
and detected at 700nm. 
 
4.2.4 Biochemical measurements of recombinant CIR  
Dynamic light scattering was carried out with 20 µl protein samples, using a Viscotek 
spectrophotometer in conjunction with Omnisize 3.0 software. 
Circular dichroism and aromatic absorbance spectra were carried out as follows: ‐ Uncorrected fluorescence emission spectra were recorded using a Jasco FP-6300 
spectrofluorimeter equipped with an ETC-273T temperature controller with 
excitation at 280 nm (bandwidth 1.5 nm) and emission scanned from 290 to 400 
nm (bandwidth 5 nm). All measurements were made at 20 oC in Tris HCl pH 
7.2, to which 500 mM L-proline (Sigma) was added for one sample of 
PCHAS_000100 to enable concentration of the protein [the use of proline for 
this purpose has been reviewed by (Alibolandi and Mirzahoseini, 2011), and 
used for example by (Schobert and Tschesche, 1978)]. ‐ Far-UV CD spectra were recorded on a Jasco J-715 spectropolarimeter equipped 
with a PTC-348WI temperature controller. All measurements were made in Tris 
HCl pH 7.2 at 20 oC using 1 mm quartz cuvettes and appropriate baselines were 
subtracted. Spectra are presented as the CD absorption coefficient calculated on 
a mean residue weight basis (DeMRW). Secondary structure content was 
estimated using previously described methods (Sreerama and Woody, 2000).  
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4.3 Results 
4.3.1 Selection of cirs for recombinant protein expression 
Three cir genes were chosen for expression in P. pastoris according to their 
transcription level during blood stage P. chabaudi infection. Transcription of 
PCHAS_000100 and PCHAS_040110 was identified by RT-qPCR, using primers 
designed to amplify these genes (described in chapter 3.3.1), and all three cirs were also 
identified from the trial Illumina RNA sequencing experiments (described in chapter 
3.3.2). PCHAS_070130 was highly transcribed in both samples used for RNA 
sequencing.  
The locations of the chosen cir genes within the whole family are shown within a 
network in Figure 27a. The design of synthetic cir genes is summarized in Figure 27b, 
as a flow chart, i), and with the DNA sequences for each synthetic cir also shown, ii). 
The encoded amino acid sequences of all synthetic cir genes are shown in Figure 28a. 
These three recombinant CIRs had different predicted protein characteristics, for 
example, Figure 28b shows the hydrophobicity profile of each protein (Gasteiger et al., 
2005). This indicated that PCHAS_070130 contained more hydrophobic residues than 
the other CIRs, which may affect solubility of the expressed protein. In addition, the 
predicted protein characteristics are shown in Table 19, calculated using Expasy 
ProtParam (Gasteiger et al., 2005). The instability index is based upon the presence of 
particular dipeptides found in proteins known to be degraded in solution, where a score 
greater than 40 indicates the protein is likely to be degraded (Guruprasad et al., 1990). 
Only PCHAS_070130 was predicted to be stable so this protein was expected to be less 
prone to degradation than the other CIRs.  
 
 
Table 19: Statistics predicted for each recombinant CIR protein. 
1] Extinction 
coefficient  CIR protein 
Amino 
acid no.  
Molecular 
weight 
(Da) 
Isoelectric 
point 1. 2. 
Instability 
index 
2] 
GRAVY 
Pc_000100 239 28758.2 5.46 41510 41260 47.99 ‘unstable’ -0.964 
Pc_070130 257 29361.2 5.91 28350 27850 38.67 ‘stable’ -0.400 
Pc_040110 284 32871.1 6.07 42580 41830 44.86 ‘unstable’ -0.6888 
The species identifier PCHAS_ was abbreviated to Pc_. All predictions were made using ProtParam 
(Gasteiger et al., 2005). 1] Extinction coefficients (M-1 cm-1 at 280 nm in H2O) were calculated on the 
basis that either 1. all cysteine residues appear as ½ (ie all participate in disulphide bonding), or 2. no 
cysteine residues appear as ½. 2] The ‘grand average of hydropathy’ was abbreviated to GRAVY. 
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4.3.2 Expression of recombinant CIR 
Figure 29 shows the cloning strategy employed for generation of recombinant Pichia, 
and the resulting maps of cloned synthetic cir sequences within the pPIC9k vector. The 
flow-diagram depicted in Figure 29c was followed to generate recombinant P. pastoris 
clones. The clones that grew on high Geneticin ® concentration plates were assumed to 
have integrated more copies of the vector and so would be likely to express higher 
yields of protein. Selected clones were screened for protein expression (data not shown) 
and the highest expressers were used to determine the optimal length of protein 
expression. 
Figure 30 shows a time-course of protein expression for the three synthetic CIRs. 
Coomassie stained SDS-PAGE gels show the presence of bands at the expected size of 
approximately 29 kDa for PCHAS_000100 and PCHAS_070130. Bands above 40 kDa 
in size were also visible for both proteins, appearing at higher concentration for 
PCHAS_070130. The composition of these high molecular weight bands was unknown. 
PCHAS_000100 and PCHAS_070130 were the expected size, at 29 kDa, although 
PCHAS_070130 appeared as a doublet along with a slightly higher molecular weight 
band. PCHAS_070130 clearly aggregated forming high molecular weight bands visible 
by coomassie blue staining of SDS-PAGE gels, which were no longer recognized by 
anti-his antibody in western blots, Figure 30b. The presence of a doublet at the expected 
size and slightly larger may be the result of post-translational modifications that caused 
the protein to migrate differently in SDS-PAGE. Since N-glycosylation sites were 
removed from the synthetic CIR sequences, a likely post-translational modification of 
PCHAS_070130 is phosphorylation. Because of time constraints, this was not 
investigated further.  
By contrast, PCHAS_040110 expression resulted in a smaller than expected protein, 
Figure 30. The PCHAS_040110 observed was half the expected size, at 16 kDa, and the 
fragment was not recognized by the anti-his antibody in Western blot. Either the 
secreted protein was not CIR PCHAS_040110, or it was PCHAS_040110 but degraded 
or not fully transcribed, such that the C-terminal his tag was missing. To determine 
which of these was the case, protein expression was induced in a range of conditions to 
inactivate yeast proteases, shown in Figure 31. In parallel, samples were taken from an 
un-induced culture, to determine whether the 16 kDa protein was also expressed in the 
absence of methanol induction, and therefore likely to be a secreted host protein. This 
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was not the case. The full size PCHAS_040110 protein could be obtained by expression 
under conditions which inactivated neutral pH host proteases (Brierley et al., 1994), 
indicating that protease degradation led to the smaller than expected product. 
Specifically these conditions used minimal, un-buffered culture media and BMMY 
culture media containing the protease inhibitor chymostatin (Sigma).  
 
4.3.3 Purification and yield of recombinant CIR 
All three recombinant CIRs could be purified using metal chelate chromatography, 
producing clean proteins of the expected sizes (PCHAS_000100 28.7 kDa, 
PCHAS_070130 29.3 kDa and PCHAS_040110 32.8 kDa), Figure 32. Elution of the 
proteins from the Ni2+NTA agarose used three buffers, which contained increasing 
strengths of imidazole, to elute the majority of recombinant protein from the beads. 
PCHAS_000100 appeared to be expressed at higher levels than the other CIRs, and the 
majority of this protein was eluted using the lowest imidazole concentration, 250 mM. 
By contrast, PCHAS_070130 and PCHAS_040110 had lower protein yields to start 
with, and these proteins were most successfully eluted with the highest strength 
imidazole, 1M. All purified CIR proteins also contained high molecular weight 
products, which were also recognized by the anti His-tag Abs via Western blot. These 
could have been aggregated CIR proteins, as their molecular weights were 
approximately double the size of the recombinant CIRs. 
The protein yields were estimated from large-scale expression and purification of the 
recombinant proteins. This was carried out to predict the culture quantity required for 
protein production and use in subsequent assays. Optimal protein yields from 100 ml 
culture are shown in Figure 33a. Both PCHAS_070130 and PCHAS_040110 were 
expressed at much lower levels than PCHAS_000100, producing approximately 0.3, 0.5 
and 5 mg protein from 100 ml culture, respectively. Therefore, protein yields under 
different culture conditions were compared. For PCHAS_040110, growth in minimal 
medium or BMMY containing 5 µg/ml chymostatin was compared (Figure 33b), where 
the latter method produced a higher yield of recombinant protein measured by BCA 
assay. For PCHAS_070130, there was no suggestion of proteolytic cleavage since the 
full-length product was expressed in BMMY media without the addition of protease 
inhibitors. Low protein yields may have been a result of impaired methanol metabolism 
by the P. pastoris clone, for example if the AOX1 methanol utilization gene was 
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deleted. This was not the reason for poor protein expression, since no difference in 
protein yield was observed after growth in conditions favourable to methanol-slow (Mut 
S) or wild type (Mut +) P. pastoris (Figure 33c). 
 
4.3.4 Behaviour of recombinant CIR proteins in solution 
As one of the aims of expressing recombinant CIR proteins was to investigate their 
structural characteristics, measurements were taken to determine whether crystallization 
of the proteins would be feasible, to allow X-ray crystallographic determination of their 
structures.  
Spectroscopy techniques can be used to determine certain features of proteins in 
solution, such as dynamic light scattering (DLS). This technique uses 
spectrophotometry to analyse protein particles as they move through solution [reviewed 
by (Dahneke, 1983, Podzimek, 2011)]. When the laser is deflected by a protein particle, 
the Brownian motion of particles causes a fluctuation in the scattering intensity over 
time. From these measurements, the average particle radius may then be determined, 
and the molecular weight calculated. Thus it can be determined whether the proteins 
exist as monomers, dimers or aggregates in solution. DLS was carried out for all three 
proteins to determine whether it would be possible to crystallize them for structural 
studies.  
Figure 34a shows an example of DLS analysis using PCHAS_000100. First, OmniSIZE 
3.0 (Viscotek) software calculated a baseline of radius counts using 100 measurements. 
Ten measurements were then taken, and used to calculate the results and error (panel i); 
the combined correlation function (panel ii) was the average from these readings. The 
residuals of the combined correlation function (plotted in panel iii against time) showed 
an even distribution both above and below zero, indicating that the solution was equally 
dispersed. The mass distribution (panel iv) showed that the major particle in solution 
had a radius of 2.5nm, which equated to a molecular weight of 29.58 kDa. This was 
correct for the recombinant PCHAS_000100 CIR protein, indicating that in PBS this 
protein existed as a monomer in solution.  
Table 20 summarizes the DLS measurements taken from several different preparations 
of each recombinant protein. The number of peaks detected indicates how many protein 
species were present in solution. When combined with the SD and residuals of the 
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combined correlation function, this gives a measure of how well dispersed the protein 
was in solution. Finally, the molecular weight of each protein species is given, allowing 
the determination of whether each protein species was present as a monomer, aggregate, 
or as degraded material. 
Neither PCHAS_040110 nor PCHAS_070130 samples contained proteins of the 
expected molecular weight. Instead all samples measured for these proteins included 
small particles; likely degradation products, and large molecular weight aggregates, 
which probably comprised both full length and degraded CIR proteins. Protein solutions 
containing a mixture of species are unsuitable for determination of protein structure, 
hence PCHAS_000100 was the only protein preparation for which structural analyses 
could be undertaken.  
 
Table 20: Dynamic light scattering measurements of the three recombinant CIRs. 
Concentration (mg/ml) Peak % Area SD % RSD MW (kDa) 
PCHAS_000100: 
0.79 * 1 100 0.23 9.2 29.58 
2.16 * 1 100 1.06 30.4 62.53 
7.25 +  1 100 18.24 48.7 1.70 x 104 
PCHAS_070130: 
0.44 1 2 
93.1 
6.9 
0.15 
14.37 
6.9 
55.7 
20.47 
7175.03 
0.56 
1 
2 
3 
91.2 
8.4 
0.4 
0.00 
0.08 
0.76 
0.0 
6.1 
9.9 
0.02 
7.02 
408.67 
PCHAS_040110: 
0.12 
1 
2 
3 
75.0 
21.2 
3.8 
0.02 
0.56 
16.28 
3.4 
10.2 
43.6 
1.22 
181.60 
1.49 x 104 
0.94 1 2 
95.4 
4.6 
1.07 
13.23 
35.3 
59.8 
47.27 
4987.14 
DLS measurements of the three recombinant CIR proteins, taken using different protein preparations: 
prepared either in 1 M imidazole buffer, * in PBS, or + in PBS containing 0.5 M Proline. For each protein 
preparation, between 1 and 3 peaks could be measured, where peak refers to the number of species 
observed in solution. Area is the proportion of each species in the total sample, SD is standard deviation, 
% RSD is the percentage of residuals and MW is the molecular weight of each species. 
 
Unlike the other recombinant CIRs, PCHAS_000100 was completely monomeric in 
solution, at low concentration (less than 1 mg/ml, Figure 34), suggesting that it likely 
exists as a monomer in vivo. Unfortunately, as the protein preparations were 
concentrated, the size of the protein particles increased, indicating aggregation. The 
formation of aggregates could be due to multimerization or stochastic particle 
combination, the latter of which would be incompatible with further structural 
characterization by X-ray crystallography.  
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4.3.5 Conformation of recombinant PCHAS_000100 
supports bio-informatic prediction  
No monoclonal antibodies have been generated against native CIR proteins, hence few 
methods were available to determine whether the recombinant proteins were correctly 
folded. One indicator was to assess the secondary protein structure by circular 
dichroism spectrometry (CD), and compare this to predicted secondary protein fold 
analyses.  
CD analysis of a low concentration sample of PCHAS_000100, Figure 35a, revealed 
that the secondary structure contained 41.8% alpha helices and 11.8% beta sheets, with 
linking elements comprised of 16.9% tight turns and 28.3% random coils. 
PCHAS_000100 samples of higher concentration required the addition of 0.5 M proline 
to maintain protein solubility, which was unfortunately incompatible with CD analysis. 
To compare the PCHAS_000100 samples of both low and high concentration, 
measurements of the aromatic spectrum were made instead of CD, Figure 35b. These 
results were highly similar, both fluorescence spectra having maximal emission at 
approximately 324 nm, signifying that both the samples were folded and that the 
tryptophan residue was deeply buried in the hydrophobic core [solvent exposed 
tryptophan has an emission maximum at 356 nm, explained by: (Shirley, 1995)] 
Together, these results indicated that PCHAS_000100 was folded similarly to the native 
protein, as the percentage of random coil measurements was low and the tryptophan 
residue was not solvent-exposed. In addition, the fact that both samples retained highly 
similar fluorescence spectra suggests that the secondary structure of this protein was not 
impaired even when the protein existed in high molecular weight particles, Figure 34. 
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Figure 27: Choice of cirs for synthetic gene design. 
a) Three highly transcribed cirs were chosen for synthetic gene design, for recombinant 
protein expression. Their locations within the CIR family PhyML tree are highlighted 
with circles.  
b) Synthetic gene design. i) Flow chart describing the criteria applied to each cir gene. 
A mean hydrophobicity profile was created for each translated cir gene (Kyte and 
Doolittle, 1982), with a scan window of 13, in the program Bioedit 7.0.9.0 (Hall, 1999). 
In blue is shown the hydrophobicity profile of the orginal CIR, and in red, the profile 
after design of the synthetic cir gene PCHAS_000100. ii) The DNA sequences of each 
synthetic cir, before re-codonisation. These sequences were sent to GeneArt™ for re-
codonisation and synthesis.  
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Figure 28: Comparison of the three synthetic CIR. 
a) The amino acid sequences of the three synthetic CIRs obtained from GeneArt. 
Sequences are shown unaligned to enable comparison of the protein length. 
b) The hydrophobic regions of each translated cir gene were determined using a Kyte 
and Doolittle mean hydrophobicity profile (Kyte and Doolittle, 1982), with a scan 
window of 13, in the program Bioedit 7.0.9.0 (Hall, 1999).  
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Figure 29: Synthetic cir cloning strategy. 
a) Vector map of the features of pPIC9k (Invitrogen). * represents the SacI linearization 
site at position 209. The multiple cloning site is indicated by a red arrow. 
b) Vector maps of the synthetic cir after sub-cloning into the pPIC9k vector via EcoRI 
or AVRII and NotI restriction sites. 
c) Flow chart of the cloning strategy and selection of recombinants in P. pastoris. 
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Figure 30: Recombinant CIR expression in P. pastoris. 
Samples taken at induction (0) and at 24, 48 and 70 hours during a time-course of 
protein expression in P. pastoris for each recombinant CIR. Gels were loaded with 20 
µl P. pastoris culture supernatant. T refers to the time in hours since induction of 
protein expression, x10 indicates that the sample was concentrated ten-fold prior to 
loading on the gel. 
a) Coomassie stained SDS-PAGE gels. Arrows indicate proteins of the expected size 
for each recombinant CIR. 
b) Immuno blot detection of the His-tags of recombinant CIRs, present in P. pastoris 
culture supernatants. Controls for the anti-His Ab are attached in appendices. 
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Figure 31: Optimisation of PCHAS_040110 expression. 
Samples taken at induction (0) and at 24, 48 and 70 hours during a time-course of 
protein expression in P. pastoris for PCHAS_040110. A range of growth conditions 
was used: un-induced culture (complete ‘BMGY’ medium, lacking methanol), minimal 
medium, complete ‘BMMY’ medium, containing methanol plus either complete 
protease inhibitor tablets (Roche) added to 1% concentration every 24 h, or chymostatin 
(Sigma) added to 5 µg/ml concentration every 24 h. 
Gels were loaded with 20 µl P. pastoris culture supernatant, all samples concentrated 
ten-fold prior to loading on the gel. T refers to the time in hours since induction of 
protein expression, with the exception of ‘BMGY’ culture which was un-induced but 
cultured for the same length of time. 
a) Coomassie stained SDS-PAGE gels. Arrows indicate proteins of the expected size 
for PCHAS_040110. 
b) Immuno blot detection of the His tag of PCHAS_040110 present in P. pastoris 
culture supernatants. Controls for the anti-His Ab are attached in appendices. 
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Figure 32: Purification of CIR proteins using metal chelate chromatography. 
One ml samples were taken during purification of recombinant CIR proteins and 
concentrated ten-fold prior to SDS-PAGE, where all gels were loaded with: 1) Culture 
supernatant, 2) Wash, 3) Eluate using 250 mM imidazole, 4) Eluate using 500 mM 
imidazole, 5) Eluate using 1 M imidazole, 6) NiNTA2+ agarose.  
a) Coomassie stained SDS-PAGE gels. Arrows indicate eluted proteins of the expected 
size for each CIR. 
b) Immuno blot detection of His tags of recombinant CIRs present after protein 
purification. Controls for the anti-His Ab are attached in appendices. 
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Figure 33: Comparison of protein yield for the three recombinant CIRs. 
a) Estimation of protein yield from 100ml culture for each of the 3 recombinant CIRs. 
b) Comparison of protein yield from PCHAS_040110 grown in either minimal medium 
(MM) or complete medium containing 5 µg/ml chymostatin (BMMY+c).  
c) Comparison of protein yield from PCHAS_070130 grown under Mut S and Mut + 
conditions. 
The mean protein from three replicate cultures is plotted, with error bars representing 
the standard error of the mean. 
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Figure 34: Measurement of PCHAS_000100 protein behaviour in solution by 
dynamic light scattering spectrometry. 
An overview of the measurements made during DLS, using PCHAS_000100 as an 
example. Clockwise description of panels: a) The amplitude and error of ten 
measurements of the sample, plotted against time, b) The combined correlation function 
shows the average of these ten readings, c) Residuals, plotted against time, d) The mass 
distribution of the major species in solution.  
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Figure 35: Measurements of CIR secondary structure. 
a) A circular dichroism plot for PCHAS_000100, measured using a sample of 0.79 
mg/ml concentration in PBS. 
b) Comparison of PCHAS_000100 aromatic spectrum from different concentration 
samples: 0.79 mg/ml in PBS and 7.25 mg/ml in Tris-HCl containing 0.5 M proline. 
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4.4 Discussion  
The expression of all three recombinant CIRs presented here describes the first soluble 
expression of PIR proteins. Expression of VIR proteins in E. coli has been described by 
Del Portillo and colleagues, who were able to express glutathione S-transferase (GST) 
fusion proteins from the second exon of two vir subfamily C genes (Fernandez-Becerra 
et al., 2005). This approach was extended to produce 22 VIR ‘tags’, which were 
differentially recognized by antibodies in the sera of P. vivax infected patients 
(Fernandez-Becerra et al., 2005). Their recognition by patient immune sera indicate that 
some determinants of specific Ab binding were still present in the recombinant VIR. 
However, since the authors noted that all GST fusion proteins were found in inclusion 
bodies during protein expression and were insoluble, it could be that the recombinant 
VIR were mis-folded and therefore only recognized by anti-VIR Abs when the proteins 
were denatured for SDS-PAGE and western blot. 
In this study, a different expression system was chosen, P. pastoris, with the hope that 
the eukaryotic cellular machinery would directly produce correctly folded proteins. This 
expression system has been successfully used to express several merozoite proteins 
such as AMA1 (Kocken et al., 1999, Kocken et al., 2002), EBA-175 (Yadava and 
Ockenhouse, 2003) and MSP-1 (Brady et al., 2001, Hensmann et al., 2004) and the 
transmission-blocking mosquito-stage antigen Pfs25 (Zou et al., 2003). 
Highly expressed cir genes representing different sub-families or with different 
characteristics of the cir family were chosen for synthetic gene design (discussed in 
chapter 3). However, very few data were available to know which genes were 
consistently highly expressed in different P. chabaudi infections and life-cycle stages. 
The genes used were chosen on the basis of preliminary measurements of cir 
transcription, using RT-qPCR and / or RNA sequencing data from a total of five P. 
chabaudi infected mice. Expression of recombinant CIRs to represent all of the sub-
families and the most highly transcribed cirs would have been the optimal situation, in 
order to create a more representative library of CIRs. Since the assembly and annotation 
of the P. chabaudi AS genome sequence improved a great deal during this study, some 
early synthetic cir gene constructs were shelved as these no longer represented the real 
cir genes (data not shown). Under these experimental and time constraints, the 
expression of three recombinant CIRs was achieved, which could then be used to 
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investigate sub-group specific differences between the CIRs during P. chabaudi 
infection. 
Modifications were incorporated into synthetic cir genes to facilitate expression of the 
recombinant proteins; these included the removal of predicted N-glycosylation sites and 
re-codonization for optimal transcription and translation in P. pastoris. Of the three 
proteins described here: PCHAS_000100, could be expressed in amounts up to 5 mg 
from 100 ml culture; whilst expression of the other two, PCHAS_070130 and 
PCHAS_040110, yielded relatively smaller amounts of protein, less than 0.5 mg from 
100 ml culture. One possibility is that the low expression levels of both 
PCHAS_070130 and PCHAS_040110 was related to the inclusion of a TEV cleavage 
site to remove the six-his tag, which may have contributed to their poor protein yield 
(Kurz et al., 2006). This feature was not present in the design of PCHAS_000100. To 
address this in the future, the TEV cleavage site could be removed from the 
PCHAS_070130 and PCHAS_040110 constructs. 
Another explanation for the low yield of recombinant CIRs PCHAS_070130 and 
PCHAS_040110 is that the pPIC9k vector used here required antibiotic selection after 
electroporation, in order to select for recombinant clones. Since the vector was 
linearized before electroporation, multimers could form, which may then have been 
inserted into the yeast genome within the 5’ region of the AOX1 gene. Therefore 
increased antibiotic resistance was assumed to correlate with the number of plasmids 
acquired, and clones containing a higher copy number should have expressed the 
highest yields of the recombinant protein. However this may not always be the case, and 
highly resistant clones could have provided a false positive, where for example, 
resistance was acquired in the absence of multiple plasmid incorporation. In such 
instances, the clones that were highly antibiotic resistant would not correspondingly be 
the highest protein producers, which may have been the case for PCHAS_070130 and 
PCHAS_040110. 
Future plans to select recombinant P. pastoris clones should focus on the initial 
selection of clones containing high numbers of integrated constructs to facilitate the 
expression of high protein yields. Initial attempts to lyse the yeast cells were 
unsuccessful due to poor activity of the lyticase enzyme used. Further attempts should 
be made to lyse the cells, following which the size of the integrated plasmids could be 
determined by PCR amplification using primers that spanned the plasmid and insertion 
sites, followed by gel electrophoresis.  
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Since cloning the recombinant cir genes, a new P. pastoris vector ‘PINK-HC’ has been 
released (Invitrogen), which allows less subjective recombinant clone selection due to 
adenine auxotrophy complementation. Using this system may increase the chance of 
initially selecting a clone with high protein expression, and reduce lengthy protein 
optimization investigations. Another advantage of this system is that, if proteins fail to 
secrete into the culture medium, there is a choice of seven signal sequences besides the 
traditional alpha factor (present in pPIC9k) that can be easily assayed to find which aids 
secretion of a particular protein. 
Alternatively, a range of other eukaryotic expression systems exist, which may provide 
advantages over P. pastoris in the future production of recombinant CIR proteins; these 
have been used to express a range of Plasmodium proteins, illustrated in Table 21.  
 
Table 21: Eukaryotic systems available for expression of recombinant proteins 
 
Expression 
system: 
Example of soluble 
antigen expression: 
Efficacy of Plasmodium 
protein expression: 
Major advantage compared to 
other systems: 
Baculovirus-
infected 
insect cells 
The DBL3-X or the 
DBL5-ε domains of 
VAR2CSA 
(Mehlin et al., 2006) 
41% of 17 proteins 
insoluble in E. coli were 
produced and soluble by 
insect cells expression 
(Chang et al., 1992) 
Proteins are more likely to be 
folded than by yeast or E. coli 
expression. Yeast-expressed 
MSP119 was immunologically 
inactive; which was not true of 
MSP119 from this system 
(Lau et al., 2010) 
Arabidopsis 
Thaliana 
PfMSP142 
(Ghosh et al., 2002) 
No large-scale analyses 
described to date. 
May potentially be used as 
‘bioreactors’ for production of 
high protein yields for 
vaccination (Srivastava et al., 
2010) 
Mammalian 
cells 
The full-length 
extracellular region 
of var2CSA 
(Crosnier et al., 2010) 
The extracellular 
domains of 49 P. 
falciparum proteins were 
expressed (including 
EBA-175 and MSP1 
(Tsuboi et al., 2008) 
Proteins can be targeted to sub-
cellular compartments and the 
cell surface. Often used for 
investigation of ligand binding 
to host cells. 
Wheatgerm 
cell free 
system 
Pfs25, PfCSP, and 
PfAMA1  
(Tsuboi et al., 2008) 
65% of 93 expressed P. 
falciparum proteins were 
soluble using this system 
(Tsuboi et al., 2008) 
There is no detriment of toxic 
products on host cell growth and 
proteins may be selectively 
labelled during synthesis. 
 
Also listed in Table 21 is an expression system based on eukaryotic wheatgerm cell 
extract, this ‘cell-free’ system has been recently enhanced by Vinarov and colleagues to 
facilitate the expression of larger amounts of protein than previously possible (Vinarov 
et al., 2006). These different protein expression systems each have different advantages, 
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and which to use for future expression of CIR proteins would depend on the intended 
applications. For example, structural studies may require the incorporation of labels 
such as seleno-methionine to determine the protein fold, which would be facilitated by 
production of recombinant proteins using the wheatgerm cell free system. 
PCHAS_070130 was predicted to be stable by ProtParam, meaning that the protein 
structure should remain constant. However, low expression levels and a tendency to 
form large aggregates made many studies using this protein unfeasible. In order to 
increase the yield of PCHAS_070130 expression and reduce protein aggregation, it may 
be necessary to remove the 80 N-terminal amino acids from the synthetic CIR, which 
contained the most predicted hydrophobicity. Such modification may prevent the 
subsequent recombinant protein from representing its native CIR, and thus may limit 
the utility of this protein for analyses of CIR function and Ab recognition. 
PCHAS_000100 did initially consist of monomers in solution, which indicated that the 
protein was suitable for analyses of CIR structure. PCHAS_000100 secondary structure 
was observed to be 44% alpha helical by circular dichroism, suggesting that the 
recombinant protein was folded similarly to native CIRs, as unfolded proteins often 
predominantly contain random coils. This measurement also falls within the range 
predicted by Janssen and colleagues, that rodent PIR proteins would contain between 28 
and 53 % alpha helices, suggesting that indeed this protein was folded like native CIRs 
(Janssen et al., 2004). Interestingly, the aromatic spectrum of PCHAS_000100 indicated 
that the tryptophan residue in this protein was not exposed to the buffer containing the 
protein sample. This residue is in fact found within the conserved amino acid motif 3 
identified in chapter 2.3.3, present in the majority of CIR sequences. Such sequence 
conservation may arise from structural requirements, and the detection of one of these 
residues in the hydrophobic core of the protein indicates that this motif may be involved 
in maintenance of CIR protein structure. 
Unfortunately in higher concentration preparations PCHAS_000100 had a tendency to 
aggregate, supporting the prediction by ProtParam (Gasteiger et al., 2005) that this 
protein was unstable. PCHAS_000100 was desalted into several different solutions, 
including Tris HCl pH 7.5 and Tris HCl containing 500 mM proline, in an effort to 
increase protein concentration without the formation of aggregates, but this was in vain. 
Due to the presence of monomers visible by SDS-PAGE (even when non-reduced, data 
not shown), it was hoped that regular crystals might be produced, that would be suitable 
for X-ray crystallography. However, in an initial trial of many different conditions for 
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crystal formation attempted by Dr L. Haire (Division of Structural Biology, NIMR), the 
only crystals observed were salt, so this avenue was abandoned.  
To increase the chances of successful crystallisation, the tendency of the recombinant 
CIR proteins to aggregate must be addressed. This would probably include the removal 
of hydrophobic regions of the proteins, and regions that are predicted to self-
complement, likely by drastically decreasing the size of the CIR protein. In this case it 
would be important to consider which regions of the protein would be important for 
correct folding, such as the conserved motif 3 that contains a tryptophan residue deeply 
buried in the protein core. It is likely that the highly conserved nature of this region is a 
consequence of functional constraints on protein folding, and the ability to generate 
structural information on the CIR protein core may provide valuable insights into the 
function of CIR proteins.  
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Chapter 5: CIR localization in infected red blood cells 
5.1 Introduction  
In order to determine the function of CIR proteins it is necessary to be able to identify 
native CIRs and to determine their location within the parasite and/or the iRBC. The 
first step to characterization of CIR proteins is to generate specific Abs, which can then 
be used to determine the size of native proteins by Western blotting, and their cellular 
location by immuno-fluorescence studies. 
Polyclonal or monoclonal Abs can be generated using either the predicted extracellular 
domain of PIR proteins or to short peptides identified from the sequence data. In 
addition, recombinant proteins or peptides can be used to purify PIR-specific Abs 
induced by Plasmodium infection from the sera of immune individuals. These 
approaches have been used previously to generate specific Abs for the detection of 
native PIR, RIFIN, STEVOR and PfEMP1 proteins (Del Portillo et al., 2001, Janssen et 
al., 2004, Cunningham et al., 2005, Fernandez-Becerra et al., 2005, Petter et al., 2007, 
Niang et al., 2009, Joergensen et al., 2010, Khattab and Meri, 2011). 
During the initial description of the vir gene family, two GST-fusion VIR proteins were 
expressed in E. coli, and used to screen sera taken from patients infected with P. vivax 
(Del Portillo et al., 2001). Only three of 12 patients’ sera recognized either of these 
proteins. The expression of full-length PIR proteins has proved difficult, as discussed in 
chapter 4. As the two recombinant VIR proteins were insoluble, they may thus not have 
represented native VIR proteins, which could explain their poor recognition by Abs 
present in the sera of P. vivax patients. Serum from one patient was affinity purified 
against ‘VIR-C1-29’, belonging to the phylogenetic sub-family C, and used to 
determine the localization of VIR proteins within iRBCs (Del Portillo et al., 2001).  
An alternative solution to expressing full-length recombinant proteins is to synthesize 
short peptides and use these for the generation of polyclonal Abs. Whilst these peptides 
may represent amino acid residues hidden in nature due to the protein conformation, 
they are much easier to obtain. PIR peptide specific polyclonal Abs raised in rabbit, 
guinea-pig and mouse have been used in studies of VIR, YIR and CIR: to determine the 
molecular weights of native PIR proteins and to locate them near to or at the surface of 
iRBCs (Cunningham et al., 2005, Janssen et al., 2004, Fernandez-Becerra et al., 2005). 
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Janssen and colleagues generated Abs to the CIR peptide CSQKASEFVKSFKEL, 
found approximately in the centre of the CIR amino acid sequence (Janssen et al., 
2004). Although this peptide was described as semi-conserved, only one CIR, 
PCHAS_000020, contained greater than 50% identity to the peptide by BLAST search, 
according to current annotation (http://www.genedb.org/blast/submitblast/GeneDB_ 
Pchabaudi March 2011). These Abs were shown to recognize a protein of the expected 
size ~30kDa by western blot, and used to demonstrate that some CIR proteins appear to 
be located near the surface of fixed P. chabaudi trophozoite stage iRBCs (Janssen et al., 
2004). The exact localization was uncertain because cellular fixation can permeabilize 
the iRBC membrane, allowing the entry of Abs.  Thus, studies using fixed iRBC alone 
for protein localization may not distinguish proteins that are exposed at the iRBC 
surface from those which are located on the cytosolic face of the iRBC membrane. 
Immunofluorescence and flow cytometric analyses have been carried out on unfixed 
and fixed mouse RBC infected with Plasmodium yoelii (Cunningham et al., 2005) using 
anti-sera generated to the semi-conserved YIR peptides KLYDALQSLCNMYNEF and 
ISAGCLYLLDEFIKDC (found in 50% and 21% of YIRs, respectively). This 
demonstrated the presence of YIR on the surface of schizont iRBC as well as intra-
cellularly on fixed and permeabilized iRBC (Cunningham et al., 2005). 
The objectives of the work described in this chapter were to: 
i) Generate CIR-specific Abs using a peptide conserved within the CIR repertoire, 
and to use these Abs for: 
ii) Detection of CIRs expressed within iRBCs by SDS-PAGE and western blotting. 
iii) Determination of where and when CIR proteins were expressed in iRBCs using 
immunofluorescence confocal microscopy and flow cytometry. 
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5.2 Methods  
5.2.1 Preparation of P. chabaudi infected material  
Origins and housing of parasites and mice have been described previously, chapter 
3.2.4. Parasites expanded from frozen stabilate were passaged twice through BALB/c 
mice kept under normal or reverse light conditions to ensure maximal synchronicity. 
Late-ring and early-trophozoite iRBC stages were obtained from P. chabaudi infected 
mice housed under normal light conditions (light between 7 am and 7 pm), whilst all 
other stages of parasite development were obtained from P. chabaudi infected mice 
housed under reverse light conditions (light between 7 pm and 7 am), where schizogony 
occurred between 12pm and 1pm daily. 
Blood samples were taken from mice either under terminal anasthaesia, for collection of 
the total blood volume, or by removal of the tail tip, for samples less than 100 µl. Blood 
samples were taken into Krebs saline (128 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM 
MgSO4, 1 mM NaH2PO4, 25 mM NaHCO3, (Krebs and Eggleston, 1940) containing 
0.2% glucose and 25 U/ml heparin (Leo Pharmaceuticals). 
Saponin lysis of RBCs was performed in order to remove the abundant haemoglobin 
present within the cells, which may be recognized non-specifically by Abs during 
western blotting. Lysis was carried out using naïve or P. chabaudi infected blood as 
follows: Blood was first washed three times in PBS, using low-speed centrifugation at 
2000 x g for 5 minutes at 4 °C to pellet RBCs. Cells were then suspended in 0.15% 
saponin (Sigma), in PBS, for 10 minutes, followed by centrifugation at 2000 x g for 5 
minutes at 4 °C. The lyzed cellular fraction was found in the pellet from this step, 
hereafter referred to as the ‘parasite fraction’.  
After removal of the parasite fraction, the supernatant was then subjected to ultra-
centrifugation at 100,000 x g using the fixed angle rotor TLA 100.3 (Beckman) for 30 
minutes at 4 °C to pellet the lysed membranes, the ‘membrane fraction’. Both the 
parasite and membrane fractions were washed three times by re-suspension in PBS and 
further centrifugation at either 2000 x g for 5 minutes at 4 °C or 100,000 x g for 30 
minutes at 4 °C, respectively.  
Infected RBC membrane fractions are comprised both of the iRBC surface and PV 
membranes, as these are derived from the RBC membrane (Siddiqui et al., 1979). The 
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parasites’ own membranes are resistant to saponin lysis, at least in P. falciparum 
(Siddiqui et al., 1979). PV and iRBC membranes were used directly for electrophoresis.  
Membranes of uninfected RBCs were either used directly for electrophoresis or to 
absorb-out non-specific recognition of RBC surface proteins from the anti-1332 serum. 
 
5.2.2  CIR peptide design and synthesis 
A conserved amino acid motif identified within the CIR repertoire, chapter 2.3.3, was 
used as the basis for design of the conserved CIR peptide. The sequence 
AEYAILWLCYKIN, derived from the amino acid motif, was detected by BLAST in 
15.82% of CIR sequences, allowing 0 - 2 mis-matches. An N-terminal cysteine residue 
was added to facilitate peptide conjugation to the carrier proteins keyhole limpet 
haemocyanin (KLH) and bovine serum albumin (BSA). Peptide synthesis and 
conjugation of 5 mg peptide to each carrier protein was carried out by Jerini Peptide 
Technologies, Berlin, Germany.  
 
5.2.3 Generation of anti-sera  
Mouse anti-sera was prepared using 10 BALB/c mice, which were given three intra-
peritoneal immunizations of 50 µg of the KLH conjugated conserved CIR peptide in the 
presence of Sigma adjuvant (Sigma), prepared according to manufacturer’s instructions.  
In addition, two New Zealand White rabbits were immunized three times sub-
cutaneously with 250 µg of the KLH conjugated conserved CIR peptide in the presence 
of Titermax ® adjuvant (CytRx Corporation), carried out by Harlan laboratories, 
Loughborough, UK.  
Sera from immune and naïve mice and rabbits were prepared by collection of blood in 
the absence of heparin, which was allowed to clot at room temperature for 2 hours. Low 
speed centrifugation was then carried out at 2000 x g for 10 minutes to remove the clot, 
and supernatant was subjected to high speed centrifugation 13,000 x g for 5 minutes to 
remove aggregated material, debris and free erythocytes.  
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5.2.4 Detection of CIR-specific Ab titres in anti-sera 
96-well flat Polysorb plates (Nunc, Denmark) were coated with the BSA-conjugated 
CIR peptide at 5 µg/ml peptide concentration, diluted in PBS, and 50 µl was applied per 
well. Plates were incubated overnight at 4 ˚C, following which, the residual surface was 
blocked with 200 µl PBS containing 1% BSA, 0.3% Tween 20 and 0.05% Sodium azide 
(blocking buffer).  
Plates were washed three times with PBS containing 0.9% sodium chloride, and 10% 
Tween 20, pH 7.2. Sera from the immunized mice and rabbits were compared before 
and after immunization. Naïve and immunized mouse sera were pre-diluted to 1/100, 
whilst the initial dilution for rabbit sera was 1/10,000. Serial two-fold dilutions were 
performed in blocking buffer. Negative controls containing only blocking buffer were 
treated in the same way. The primary antibody was incubated for 1 h at 37 ˚C, followed 
by three washes with PBS containing 10% Tween 20, as described above.  
CIR-specific Abs were detected using alkaline phosphatase-conjugated goat anti-mouse 
Ig (Southern Biotechnology), diluted to 2 µg/ml, and incubated for 1h at 37 ˚C, 
followed by three washes in PBS alone. Bound antibodies were then visualised with 50 
µg of 1 mg/ml p-nitropheny-phosphate (p-NPP) in diethanolamine buffer (0.26 M 
diethanolamine, 8 mM magnesium chloride, pH 9.8). The optical density (OD) was 
measured at the reference wavelength 405 nm. 
The titres of specific Abs induced by immunization were calculated by interpolation of 
the titration curve, using non-linear regression analysis performed in Prism v5.0. Here, 
titre was defined as the dilution at which the pooled immunized sera reached the 
baseline OD 405 nm of the pooled sera prior to immunization.  
 
5.2.5 Preparation of anti-sera 
The anti-sera generated in mouse and rabbit were evaluated using western blots of naïve 
and P. chabaudi infected RBCs, to determine whether the Abs specifically recognized 
parasite proteins. The rabbit anti-serum was observed to contain higher proportions of 
Abs recognizing RBC proteins than the anti-sera generated in mice. For this reason, the 
sera were prepared differently for use in subsequent applications, using methods which 
had been found to remove RBC cross-reactivity.  
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Pre-immune sera and anti-sera to the conserved CIR peptide, generated in rabbit, were 
absorbed using RBC membrane fractions from uninfected mice, which were prepared as 
described above. 100 µl serum and 50 µg membrane fraction were incubated overnight, 
rotating, at 4 °C. To remove un-bound RBC membranes, samples were then subjected to 
ultra-centrifugation at 100,000 x g for thirty minutes at 4 °C.  
A simpler procedure was carried out for pre-immune and anti conserved CIR peptide 
sera generated in mice, whereby absorption was carried out using intact RBC from 
uninfected mice. 100 µl serum and 50 µl packed RBC were incubated overnight, 
rotating, at 4 °C. To remove un-bound RBCs, the samples were then subjected to 
centrifugation at 2000 x g for 5 minutes at 4 °C. To have adequate material, sera 
generated from a pool of 10 conserved CIR peptide-immunized mice was used for 
further investigation of CIR proteins. 
For simplicity, both RBC membrane-absorbed anti-sera generated in rabbit and RBC-
absorbed anti-sera generated in mice will be referred to as anti-CIR sera. 
 
5.2.6 SDS PAGE and immuno-blotting 
Proteins were resolved using 15% Tris-glycine gels, prepared according to Table 22, in 
running buffer containing 0.5% SDS (v/v, Invitrogen), 0.126 M Tris base (Sigma) and 1 
M Glycine (BDH Biosciences), at 200 volts for 40-60 minutes. Reducing conditions 
were used throughout, where samples contained 100 mM DTT. Proteins were run 
alongside 1x SeeBlue Plus2-prestained standard (Invitrogen).  
 
Table 22: Composition of 15% Tris glycine SDS-PAGE gels. 
Reagents Resolving gel Stacking gel 
Resolving buffer (1.5 M Tris, Invitrogen, pH 8.8)* 1.24 ml - 
Stacking buffer (0.5 M Tris, Invitrogen, pH 6.8)* - 0.75 ml 
Distilled water 1.24 ml 1.776 ml 
30% Acrylamide/Bis solution (29:1 ratio, BioRad) 2.48 ml 0.474 ml 
10% Ammonium persulfate (APS, Sigma-Aldrich) 0.03 ml 0.012 ml 
Tetramethylethylenediamine (TEMED, Sigma) 0.33 µl 3.9 µl 
Total composition of a single gel: 5 ml 3 ml 
* Buffers prepared using Tris base (Sigma) and containing 0.4% SDS (v/v from 20% stock, Invitrogen) 
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Total protein concentration in each sample was determined by BCA assay (Pierce), as 
described in chapter 4.2.2. For analysis of P. chabaudi infected- or uninfected RBC- 
derived material, 20 µg protein was loaded onto the SDS-PAGE gels. The recombinant 
CIR proteins PCHAS_000100 and PCHAS_040110, described in chapter 4, were 
compared with recombinant MSP1p21 (Hensmann et al., 2004), which was generated in 
the same expression system as the recombinant CIRs, P. pastoris, and contained an 
identical C-terminal six-histidine tag. For analysis of each recombinant protein, 500 ng 
of each was loaded onto the SDS-PAGE gels. 
All gels were used for immuno-blotting, where the proteins were electrophoretically 
transferred to Hybond C membrane (Amersham Biosciences) in buffer containing 20% 
methanol (v/v), 0.025 M Tris base (Sigma) and 0.2 M Glycine (BDH Biosciences) for 3 
h at 30 V. Membranes were blocked at 4 ˚C overnight in PBS containing 0.1% Tween 
20 (Sigma) and 3% bovine serum albumin (BSA), and washed for 10 minutes three 
times with PBS containing 0.01% Tween 20. 
Specific proteins were detected using a variety of Abs, diluted in PBS containing 0.1% 
Tween 20 and 3% BSA. P. chabaudi derived material was probed with the conserved 
CIR peptide rabbit anti-serum at 1:500 dilution, or a combination of the monoclonal 
Abs Ter119 and NIMP23, which recognize Glycophorin A and MSP1p21 respectively 
(Kina et al., 2000, Boyle et al., 1982, McKean et al., 1993), used at concentrations of 32 
pg/ml and 18 µg/ml. In addition, recombinant CIR were detected using conserved CIR 
peptide rabbit anti-serum, normal serum (NS) from the pre-immune rabbit, both at 
1:500 dilution; or an antibody which recognizes the six-histidine tag of the recombinant 
proteins, used at 0.5 µg/ml (Novagen). 
Bound antibodies were detected using secondary horseradish peroxidase (HRP)-
conjugated Abs: goat anti-rabbit IgG, goat anti-mouse IgG and goat anti-rat igG 
(Biorad) were used at 1:10,000 dilution. Membranes were washed as before, upon 
which SuperSignal West-Pico chemi-luminescent substrate (Thermo Scientific) was 
added, according to manufacturer’s instructions, and incubated in the dark for 5 
minutes. Light emission was detected by exposure to Biomax film (Kodak).  
 
5.2.7 Immuno-fluorescence assays 
P. chabaudi AS infected blood was collected from BALB/c mice on day 7 of infection, 
directly into Krebs saline (114 mM NaCl, 4.57 mM KCl, 1.15 mM MgSO4(Krebs and 
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Eggleston, 1940), containing 0.2% glucose and 25 U/ml heparin (Leo Pharmaceuticals). 
The iRBCs were centrifuged at 1500 x g at 4 ˚C for 5 minutes, and re-suspended in 
foetal calf serum. This material was used to make thin blood films on glass slides, 
which were allowed to dry, and then fixed using a solution containing 90% acetone and 
10% methanol, then dried. Slides were then incubated in PBS containing 3% bovine 
serum albumin (Sigma). All Abs were diluted in PBS containing 3% BSA, and 100 µl 
applied directly to the fixed iRBC on each slide, underneath a cover-slip. Primary 
reagents were rabbit anti-CIR serum (or pre-immune serum) diluted 1/50, NIMP23 at a 
concentration of 50 µg/ml and Ter119 conjugated to biotin (Biolegend) at 50 µg/ml. 
Secondary reagents were goat anti-rabbit IgG conjugated to Alexa 680, goat anti-mouse 
IgG conjugated to Alexa 594 and Streptavidin conjugated to Alexa 750-
Allophycocyanin (all Molecular Probes, used at 10 µg/ml). Incubations were carried out 
at 37 ˚C for one hour or 4 ˚C overnight in a humid chamber. Abs were applied 
sequentially, to prevent non-specific recognition of other Abs by the polyclonal 
antisera, in the following order: rabbit anti CIR Abs, goat anti-rabbit Alexa 680, 
followed by NIMP23 and Ter119 and their secondary reagents. 
Between each Ab incubation three washes were performed, by placing the slide into 50 
ml PBS for five minutes. Parasite nuclei were visualised using 1 mg/ml 4',6-Diamidino-
2-phenylindole (DAPI, Sigma Aldrich) in PBS. Slides were mounted in anti-fadent 
AFI™ (Citifluor), sealed using nail polish and stored at 4 ˚C in the dark. 
Immunofluorescence of iRBC was visualised using the Leica SP2 confocal microscope 
with total magnification of 2500 x, 405 nm, 488 nm, 594 nm and 750 nm lasers and 
Leica software. As the aim was to localize the signal of anti-CIR staining, the settings 
for gain and offset were determined empirically for each slide. 
 
5.2.8 Schizont culture 
P. chabaudi AS infected blood was collected from BALB/c mice on day 7 of infection, 
directly into Krebs saline (114 mM NaCl, 4.57 mM KCl, 1.15 mM MgSO4, (Krebs and 
Eggleston, 1940) containing 0.2% glucose and 25 U/ml heparin (Leo Pharmaceuticals). 
Blood was diluted 1:4 using RPMI 1640 medium (Gibco, to which 6 mM HEPES and 2 
mM L-glutamine (both Invitrogen) were added), pre-warmed to 37 oC. Diluted blood 
was immediately washed twice using 50 ml, pre-warmed to 37 oC, complete RPMI 
1640 medium [Gibco (containing 6 mM HEPES, 0.5 mM sodium pyruvate, 2 mM L-
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glutamine, 50 µM β-Mercapto-ethanol (Invitrogen) and 10% heat inactivated foetal calf 
serum (PAA laboratories, Pasching, Austria)], and followed by centrifugation at 600 x g 
for 5 minutes at 37 oC. 
Infected RBCs were then transferred to non-vented culture flasks (Becton Dickenson) 
containing 5 ml complete RPMI medium, pre-warmed to 37 oC, for every millilitre of 
iRBC. The gas composition was adjusted to 10% O2, 5% CO2, 85% N2 and iRBCs were 
incubated at 37 oC for between 3 and 4 hours until schizonts were observed to 
predominate in the culture and/or free merozoites started to appear. 
 
5.2.9 Flow cytometry 
P. chabaudi AS infected blood was collected from BALB/c mice on day 7 of infection, 
directly into Krebs saline (114 mM NaCl, 4.57 mM KCl, 1.15 mM MgSO4, (Krebs and 
Eggleston, 1940) containing 0.2% glucose and 25 U/ml heparin (Leo Pharmaceuticals). 
P. chabaudi AS iRBC were filtered through Plasmodipur filters (EuroProxima) to 
remove leukocytes and then washed three times in PBS, using centrifugation at 1500 xg 
at 4 ˚C for 5 minutes. Red blood cells were enumerated using a haemocytometer 
(NeuBauer), and blood diluted accordingly to give a final concentration of 1x107 RBCs 
per ml in PBS containing 1% BSA (w/v), 2 mM ethylene-diamine-tetra-acetic acid 
(EDTA) and 0.01% sodium azide (FACS buffer).  
The RBCs (1x106) were plated in triplicate into V-bottom plates (Nunc), centrifuged at 
1200 x g for 1 minute at 4 ˚C, and the supernatant removed. Cells were first incubated 
with mouse pre-immune sera or conserved CIR peptide anti-sera diluted 1/50, followed 
by goat anti-mouse IgG conjugated to FITC (Southern Biotechnology) used at 10 µg/ml 
concentration. All Abs were diluted in FACS buffer, and incubations performed in a 
final volume of 100 µl on ice for 30 minutes. Once fluorescently labelled Abs were 
added, all steps were performed in the dark. After all antibodies had been added, the cell 
suspensions were incubated with 10 µg/ml Hoechst 33342 (Invitrogen), prepared in 
FACS buffer, for 10 minutes on ice, to detect parasite DNA. Between each incubation 
step, cells were re-suspended twice in 150 µl FACS buffer, followed by centrifugation 
at 1200 x g for 1 minute at 4 ˚C. 
Single colour and unstained controls were included for all samples (including 
uninfected RBCs, data not shown). Immediately prior to data acquisition, all samples 
were passed through a 0.45 µm filter (Nunc), to ensure no cellular aggregates were 
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present. A minimum of 300,000 events were acquired using the LSR II flow cytometer 
(BD biosciences), using default filter settings, with FACSDIVA software (BD). 
Following data collection, information was further analyzed using FlowJo software 
version 8.8.6 (Tree Star).  
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5.3 Results   
5.3.1 Preparation of CIR-specific polyclonal Abs 
In order to detect native CIR proteins within P. chabaudi AS iRBCs, reagents were 
required that would recognize a large proportion of the CIR repertoire. The amino acid 
motif, identified as ‘motif 3’ in chapter 2.3.3, was present in the majority of CIR 
sequences and within the predicted extra-cellular domain of the proteins. In particular, 
the residues YAILWL within the amino acid motif were present in over 75% of CIRs. 
This is shown as a weblogo image (Crooks et al., 2004) in Figure 36a, where the 
proportion of CIRs containing each residue of the amino acid motif is depicted by the 
height of the letter. A consensus sequence was derived from this amino acid motif, 
Figure 36b, which was present in 64% of CIRs by basic local alignment tool analysis 
[BLAST, (Altschul et al., 1990)], allowing up to five mis-matches. A peptide was 
synthesized based upon the sequence AEYAILWLCYKIN, to which an N-terminal 
cysteine residue was added to facilitate conjugation of the peptide to the carrier proteins 
keyhole limpet haemocyanin (KLH) and bovine serum albumin (BSA).  
The KLH-conjugated peptide was used to immunize both rabbits and mice, for the 
generation of CIR-specific polyclonal Abs. Enzyme linked immunosorbent assays 
(ELISAs) were performed using the antisera to calculate the titre of Abs recognizing the 
peptide. Rabbit sera contained higher titres of anti-CIR Abs, with a mean titre of 5.12 x 
106 (+/- SEM of 1.36, calculated from triplicate titrations), than mouse sera, which had 
a mean titre of 1.04 x 105  (+/- SEM of 0.044, calculated from triplicate titrations). For 
this reason, the rabbit polyclonal anti-sera were preferentially used for detection of CIR 
proteins. 
Rabbit anti-CIR Abs were investigated via western blot, to confirm whether they 
exclusively recognized CIR proteins or could recognize other P. chabaudi proteins non-
specifically. Initial western blots using the polyclonal Abs resulted in the recognition of 
uninfected RBCs in addition to P. chabaudi iRBCs. To reduce this, the anti-serum was 
first absorbed on intact RBC, which did not entirely remove the observed cross-
reactivity for the Abs generated in rabbit. Subsequently the anti-1332 serum was 
absorbed against RBC membranes. This resulted in recognition of iRBC by the anti-
CIR Abs, without recognition of uninfected RBC, shown in Figure 37a. The P. 
chabaudi proteins recognized by the anti-CIR Abs were approximately 45, 35, 25 and 
20 kDA, within the size range predicted for native CIR proteins, based upon current cir 
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gene annotation. The majority of CIR proteins contain between 311 and 490 amino 
acids, which approximately equates to predicted molecular weights of between 34 and 
54 kDa, whilst the smallest predicted CIRs would have molecular weights ranging 
upwards from 15 kDa.  
In parallel, the same material was probed with a mixture of Abs (Figure 37b), as a 
loading control to ensure that equivalent amounts of infected and uninfected RBC 
membrane preparations were loaded onto the SDS-PAGE gel. The rat monoclonal Ab 
Ter119, which recognizes a Glycophorin A-associated protein, not glycophorin A itself 
on the RBC membrane (Kina et al., 2000), detected bands of approximately 30, 50 and 
64 kDa in both infected and uninfected RBC. These correspond with proteins of 32, 52 
and 60 kDa previously described for Ter119 (Boyle et al., 1982, McKean et al., 1993). 
In addition, the monoclonal Ab NIMP23, which recognizes the 21 kDa fragment of P. 
chabaudi MSP1 [the equivalent of P. falciparum MSP119, (Kina et al., 2000, Boyle et 
al., 1982, McKean et al., 1993)], detected MSP1 only in iRBCs. This indicates that the 
uninfected RBC material was not contaminated with parasites, as no MSP1 was 
detected. 
Figure 37b confirms that the sizes of proteins recognized by the anti-CIR Abs were not 
the same as the sizes of predominant parasite and RBC proteins. However, this did not 
necessarily indicate that the proteins recognized by anti-CIR Abs were indeed CIRs. To 
confirm that anti-CIR Abs recognized CIR proteins, western blots were carried out 
using two of the recombinant CIR described in chapter 4, PCHAS_040110 and 
PCHAS_000100, Figure 37c demonstrates that the anti-CIR serum recognized CIR 
proteins specifically, with no recognition of another recombinant P. chabaudi protein, 
MSP1p21, produced using the same expression system, P. pastoris (Hensmann et al., 
2004). Antibodies to the His-tag, present on all recombinant proteins, confirmed that 
equal amounts of protein were loaded on the gel, indicating that the failure of anti-CIR 
serum to recognize MSP1 was not due to different protein concentrations, but rather that 
it specifically recognized CIR proteins.  
In summary, the anti-CIR Abs generated in both mouse and rabbit were able to 
recognize proteins of the expected range of molecular weights for native CIR in P. 
chabaudi iRBC, by western blot. Importantly, these Abs also recognized recombinant 
CIR proteins from both of the major CIR subfamilies identified in chapter 2, Figure 
37c. Therefore these Abs appeared to be CIR-specific and able to detect a wide range of 
CIR proteins.  
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5.3.2 Localization of CIR proteins in P. chabaudi iRBCs 
To inform which stages of parasite development should be analyzed for the cellular 
localization of CIR proteins within iRBCs, blood samples were taken every two hours 
during the erythrocytic development cycle of P. chabaudi, which grows synchronously 
in vivo (Hawking et al., 1972). A representative Giemsa-stained iRBC from each time in 
the intra-erythrocytic development of P. chabaudi is depicted in Figure 38a. From these 
results, time-points corresponding to early- and late- phases of ring stage and 
trophozoite stage iRBCs were used for immunofluorescent analysis of CIR localization 
(Figure 38b). Infected RBCs were co-stained with Abs recognizing MSP1p21 and the 
iRBC surface, to allow some determination of CIR positioning. Controls ensuring that 
the Abs used did not bind to iRBCs non-specifically or cross-react with other reagents 
are attached in Appendix 5.1. 
In ring- and early trophozoite- iRBC stages, the pattern of immuno-fluorescence was 
similar. The parasitophorous vacuole (PV) around developing parasites could be clearly 
seen by MSP1p21 staining [as described by Smythe and colleagues (Smythe et al., 
1988)], Figure 38b. Anti-CIR staining remained close to the parasite nuclei in all 
iRBCs, in a similar but more diffuse pattern than MSP1p21. This indicates that CIR 
proteins were located within the PV membrane, and diffuse staining also occurred 
beyond the PV membrane in some ring- and early trophozoite- stage iRBCs. 
In late stage trophozoite iRBCs, CIRs were still detected close to the parasite nuclei, but 
in more than 50% of cells (of 25 counted), were also observed in the iRBC cytoplasm, 
Figure 38b. A small number of iRBCs were enumerated as cytoplasmic localization of 
CIRs was only clearly visible by confocal microscopy. A magnified view of an example 
trophozoite stage iRBC with such peripheral CIR staining is depicted in Figure 39a. 
Computationally, an axis was drawn across the trophozoite and the fluorescence 
intensity of anti-CIR, anti-MSP1 and nuclear staining were determined along this line, 
allowing the detailed study of the relative position of cellular components. The 
fluorescence intensity related to MSP1 appeared to define the edges of the PV, whilst 
CIR fluorescence was localized around the parasite nucleus, and in a discrete peak close 
to the edge of the iRBC. 
In addition, because the majority of P. chabaudi schizont stages sequester in the deep 
vasculature (Gilks et al., 1990, Mota et al., 2000), iRBCs at the late trophozoite stage 
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were cultured in vitro to reach schizogony and the release of free merozoites. These 
parasites were used for immunofluorescence analysis, shown in Figure 39b and c. 
Schizonts containing developing merozoites displayed the same CIR localization 
patterns as those found on free merozoites, which consisted of localization of CIR to the 
apical end of the merozoite. An axis was drawn computationally across a representative 
merozoite, as described above for the trophozoite stage iRBC. Here, the fluorescence 
intensity related to MSP1 defined the whole merozoite surface (Crooks et al., 2004). 
CIR fluorescence did not colocalize with MSP1, but rather appeared most intense at a 
discrete point at the apical end of the merozoite.  
Together, the data presented in Figure 39 indicated that CIR proteins were expressed in 
all parasites, at the apical end of merozoite stages, and within the PV of ring- and 
trophozoite iRBC stages. The detection of CIR close to the iRBC membrane of at least 
half of late-trophozoite stage parasites indicated that some CIR family members could 
be exposed at the iRBC surface. 
 
5.3.3 Detection of CIRs at the surface of live iRBCs 
To investigate the possibility that CIRs were exposed at the surface of some iRBCs, live 
(un-permeabilized) iRBCs at the late trophozoite stage were stained with anti-CIR Abs 
prepared in mouse. Flow cytometry was then used to determine the proportion of iRBC 
containing surface-exposed CIR during P. chabaudi infection, Figure 40.  
Data were analyzed using FlowJo software (Tree Star). Firstly, a region was drawn 
within the forward and side scatter parameters - to exclude very small, granular or other 
cells which were the wrong size or granularity for iRBC, Figure 40a. Subsequently, 
Hoechst 33342 was plotted against CIR fluorescence, and a region drawn to define the 
DNA positive iRBCs, Figure 40b. This definition may have also included some 
reticulocytes, as previously discussed in chapter 3. The percentage of CIR-positive 
iRBC is shown as a histogram in Figure 40c. Although the percentage of CIR positive 
iRBC was small, iRBC stained with pre-immune sera from the same mice were almost 
completely negative (0.01%). These data suggest that a small proportion of iRBCs 
expressed CIR at the surface, and confirm the localization of some CIRs at this position 
observed by immuno-fluoresence, described above.  
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Figure 36: Design of the conserved CIR peptide 
A highly conserved CIR amino acid motif was detected in CIR amino acid sequences, 
described in chapter 2 (Table 7).  
a) The weblogo image (Crooks et al., 2004) shows the proportion of all 198 CIR 
amino acid sequences containing each residue of this motif.  
b) A consensus sequence was taken from this motif, shown below the weblogo 
image. This sequence was synthesized as the conserved CIR peptide. 
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Figure 37: Specificity of polyclonal anti-CIR Abs.  
a) 20 µg of protein was loaded (left to right) from: total protein and membrane fractions 
extracted from P. chabaudi iRBC, and the membrane fraction of uninfected RBC. 
These were resolved using 15% Tris-glycine SDS-PAGE gels and used for western 
blots, which were probed with polyclonal anti-CIR Abs, generated in rabbit (left panel). 
Black arrows indicate CIR-specific bands in the iRBCs. The same membrane was 
stripped and re-probed with a combination of Ter119 and NIMP23 (right panel), which 
recognize the RBC membrane and MSP1p21, respectively (Kina et al., 2000, Boyle et 
al., 1982, McKean et al., 1993). Black arrows indicate bands recognized by Ter119, 
whilst a red arrow indicates bands recognized by NIMP23. 
b) The recombinant CIR proteins PCHAS_000100, PCHAS_040110 and recombinant 
MSP1p21 (Hensmann et al., 2004), were resolved using 15% Tris-glycine SDS-PAGE 
gels, onto which 500 ng of each recombinant protein was loaded. Western blots were 
carried out, probing the proteins with anti-CIR Abs, pre-immune serum from the same 
rabbit (NS), or an Ab recognizing the hexa-histidine tag present on all recombinant 
proteins (anti-His). Black arrows indicate CIRs, MSP1p21 is indicated by a red arrow.  
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Figure 38: CIR localization by indirect immunofluorescence and confocal 
microscopy during the erythrocytic growth cycle of P. chabaudi. 
a) A representative example of a Giemsa stained iRBC, taken every 2 hours during the 
24h erythrocytic growth cycle, from 09.00 hours until 07.00 hours the following 
day. 
 
b) Immunofluorescence analysis of specific stages of development: early ring (05.00 
h), late ring (11.00 h), trophozoite (17.00 h) and late trophozoite (23.00 h). 
P. chabaudi infected RBCs were probed with: DAPI, for detection of parasite nuclei; 
rabbit anti-serum to the conserved CIR peptide, detected using goat anti-rabbit Alexa 
488; NIMP23, which recognizes MSP1, detected using goat anti-mouse Alexa 594 and 
Ter119, which recognizes the RBC membrane, detected using streptavidin Alexa 750-
Allophycocyanin. These are shown from left to right, individually, followed by merged 
images (right).  
Images of control- stained iRBCs are attached in Appendix 5.1 
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Figure 39: CIR localization within individual P. chabaudi trophozoite, schizont and 
merozoite stages of development. 
Trophozoite stage iRBC, a), taken at 11.30 am from P. chabaudi infected mice kept 
under reverse light conditions (in darkness from 7am until 7pm). Schizont stage iRBC, 
b), and free merozoites, c), after 4 h ex vivo culture of iRBCs 
Infected RBCs were probed with: DAPI, for detection of parasite nuclei; rabbit anti-
serum to the conserved CIR peptide, detected using goat anti-rabbit Alexa 488; 
NIMP23, which recognizes MSP1, detected using goat anti-mouse Alexa 594 and 
Ter119, which recognizes the RBC membrane, detected using streptavidin Alexa 750-
Allophycocyanin. These are shown from left to right, followed by merged images.  
Graphs showing the intensity of fluorescence across an individual trophozoite stage 
iRBC and merozoite were produced, d) [using the merged images shown in a) and c)]. 
“Plot profiles” were created using Image J software (Abramoff et al., 2004), along the 
specified cellular axis shown with a white line. In these graphs, the fluorescence 
intensity of DAPI was represented with blue lines, the fluorescence intensity associated 
with MSP1-specific staining was represented with red lines and the fluorescence 
intensity associated with CIR-specific staining was represented with green lines. 
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Figure 40: CIR surface localization using flow cytometry of live iRBC. 
Live trophozoite stage P. chabaudi iRBCs were probed with: Hoechst 33342, for 
detection of parasite nuclei and mouse pre-immune serum (control) or anti-serum to the 
conserved CIR peptide (Anti-CIR), detected using a goat anti-mouse FITC conjugated 
secondary Ab. 
Live iRBCs were defined first using forward scatter (FSc) and side scatter (SSc) 
measurements, shown within the pink region, a). These cells were determined to be 
iRBCs, which had high levels of Hoechst 33342 staining, indicating the presence of 
nuclei, shown within the pink region, b). Histograms show the proportion of iRBC 
which were CIR positive, determined by positive staining in the FITC channel and 
shown by the black horizontal bar, c).  
 
 
  Chapter 5: CIR localization in infected RBCs 
 196 
5.4 Discussion 
The work described in this chapter was to detect CIR proteins expressed by 
Plasmodium chabaudi iRBCs, and their location within iRBCs. P. chabaudi proteins 
with a range of sizes were recognized by polyclonal anti-CIR Abs, which may represent 
several different CIR proteins expressed during this infection or the degradation 
products of one dominant CIR. All trophozoite stage iRBCs displayed CIR localization 
surrounding the parasite nuclei. At least half of trophozoite stage iRBCs also exhibited 
CIR staining close to the iRBC surface membrane. Flow cytometric analysis of live-
stained iRBCs suggested that a small proportion of iRBCs may have expressed CIR at 
the surface. Alternatively, CIR proteins could be located just underneath the iRBC 
membrane, and therefore were not exposed to Abs during staining of live iRBCs.  
VIR proteins have also been shown to localize near to the surface of trophozoite stage 
iRBC, via immuno-fluorescence analyses carried out using fixed P. vivax iRBCs (Del 
Portillo et al., 2001, Fernandez-Becerra et al., 2005). Exposure of YIR proteins at the 
iRBC surface has been confirmed using immuno-fluorescent staining of live, un-
permeabilized iRBCs (Cunningham et al., 2005), which may also be true for other PIR 
family members. Janssen and colleagues have provided preliminary evidence for similar 
CIR localization, using Abs generated against a peptide with closest homology to the 
CIR PCHAS_000020 (Janssen et al., 2004). The work described in this chapter aimed to 
determine whether the localization observed for PCHAS_000020 was characteristic of 
the majority of CIRs, and was comparable to that observed for other PIR.  
Immuno-fluorescence assays using fixed iRBCs, probed with Abs generated to the 
conserved CIR peptide, showed that CIR proteins were located around the parasite 
nuclei, probably within the PV. Confirmation of PV localization would require the use 
of a PV-specific marker, such as the monoclonal Ab MoAb 8E7/55, which recognizes 
P. falciparum EXP-1 (Lord et al., 1993), and an equivalent protein in P. chabaudi of 54 
kDa (Sam-Yellowe, 2009). CIRs were also detected in discrete dots throughout the 
cytoplasm of trophozoite stage iRBCs. It is tempting to speculate that these dots could 
represent CIR proteins in the process of export to the iRBC surface. Vesicular structures 
such as the Maurer’s clefts are thought to traffic proteins during export [reviewed by: 
(Sam-Yellowe, 2009)], and the Schüffner’s dots of P. vivax also comprise caveolar 
vesicle complexes (Alkawa et al., 1975), which may form part of the protein export 
pathway. In fact, 28 kDa P. vivax antigens have been identified within the Schüffner’s 
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dots (Matsumoto et al., 1988), which are within the predicted size range of the VIR 
proteins. 
A small number of P. chabaudi iRBCs also appeared to have CIR proteins at the 
surface, detected using live-staining followed by flow cyometry. The small number of 
these detected iRBCs may be a consequence of the anti-CIR peptide Abs used. The 
conserved CIR peptide corresponds to motif 3 identified in chapter 2.3.3, which appears 
to be located within the hydrophobic protein core (chapter 4.2.4). As previously 
discussed, this peptide is likely to play a role in maintenance of CIR protein structure, 
and may therefore not be accessible to the anti- CIR peptide Abs when the proteins 
were not denatured (in SDS-PAGE, under reducing conditions) or permeabilized by 
fixation. This would explain the apparent discrepancy between the detection of CIR 
close to the iRBC membrane in the majority of iRBCs by fixed immuno-fluorescence, 
and the detection of less than 1% of iRBCs appearing to contain surface exposed CIR 
by live staining and flow cytometry.  
Digestion of proteins exposed at the iRBC surface with trypsin could be used to verify 
the surface expression of CIR by mass spectrometry of the cleaved peptides. 
Alternatively, using a stronger digestion, such as proteinase K, all proteins would be 
lost from the iRBC surface. If the detection of a particular CIR following such treatment 
was then lost in comparison to un-treated control iRBCs, this would indicate that the 
CIR was indeed present at the iRBC surface.  
In addition to confirming the localization of CIR proteins in trophozoite stage parasites, 
the data presented here provide novel evidence for the localization of CIRs in other 
iRBC stages. All merozoites contained CIR localization at the apical end, in contrast to 
the presence of MSP1 on the whole merozoite surface. This agrees with previous data 
finding yir transcription in merozoites (Shi et al., 2005). The pattern of CIR localization 
observed in merozoites is strongly reminiscent of that described for members of the 
RIFIN A sub-family (Narum and Thomas, 1994), which were located adjacent to 
AMA1 proteins, found at the apical end of the merozoite (Narum and Thomas, 1994).  
This provides strong support to the similarities in CIR and RIFIN phylogenetic structure 
described in chapter 2.3.5. It is possible that the two major CIR sub-families identified 
in chapter 2 could also display differential cellular localizations, as observed for A and 
B type RIFINs (Narum and Thomas, 1994). A type RIFINs localize throughout the 
iRBC cytosol and at the iRBC surface in trophozoites, whilst B type RIFINs are found 
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only within the parasite. If anti-CIR Abs recognized both CIR sub-families, the 
detection of CIR within the PV and at the iRBC surface could have incorporated the 
differential localizations of both sub-families. To investigate whether this is the case, 
and whether P. chabaudi merozoites also display the different CIR localizations 
observed for RIFINs (Petter et al., 2007), reagents specific to each sub-family must be 
developed.  
The idea of differential localization of PIR sub-family members has already been 
investigated for the VIR proteins to some extent. Del Portillo and colleagues generated 
Abs to peptides representing the sub-families A, C and E [KKKKRKKRNYYDYGWC, 
QKDWRERKALYDYC and RKFARNLKNISTILNDC, respectively (Fernandez-
Becerra et al., 2005)]. Anti-C and E sera were used to investigate whether VIR proteins 
belonging to different sub-families displayed different cellular localizations. In 
schizonts, both VIRs appeared to be located in discrete points throughout the iRBC 
cytosol and each anti-serum produced an almost identical pattern (Fernandez-Becerra et 
al., 2005). The C- and E- specific Abs were shown not to recognize peptides belonging 
to the other families by Western blot (Fernandez-Becerra et al., 2005), nonetheless it is 
possible that they recognized other shared features of the different VIR sub-families.  
This illustrates an important caveat for the use of polyclonal anti-sera for such 
experiments; namely that a range of Ab specificities exists within the sera, some of 
which may recognize different sub-families.  
To investigate the possibility that members of different PIR sub-families may perform 
different functions, reagents to detect PIR sub-family members must therefore be highly 
specific, recognising few variants. As described above, the use of polyclonal Abs for 
this purpose is limited due to the range of Ab specificities and avidities. In contrast, 
monoclonal Abs (mAbs) are mono specific, therefore the acquisition of mAbs to CIR 
proteins would be useful for wide-ranging applications, including confident protein 
localization, because any detected cross-reactivity would be due to the presence of 
shared epitopes within proteins, rather than their recognition by different Abs within the 
polyclonal pool. The specificity of monoclonal Abs may also be mapped to determine 
the exact epitope that is recognized, allowing determination of which CIRs are 
recognized, and providing information about CIR protein folding. In addition, as 
monoclonal Abs are generated from a cell line, different batches can be safely assumed 
to contain the same specificity, unlike poly-clonal sera, whose range of specificities is 
highly dependent upon the antigen batch used and / or different animals’ responses.  
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An alternative approach for determination of CIR localization would be to genetically 
manipulate P. chabaudi by transfection with reporter constructs, such that CIR proteins 
within each major sub-family would be expressed along with a fluorescent tag. Fusion 
of BIRs to GFP has been used in two studies to investigate their cellular localization. 
Firstly, Di Girolamo and colleagues found that BIRs were associated with cholesterol 
rich membrane microdomains, exported into the iRBC cytosol and likely to the iRBC 
surface (Di Girolamo et al., 2008). Subsequently Sijwali and Rosenthal were able to use 
various BIR, RIFIN and STEVOR constructs, amongst others, to investigate the 
requirements for trafficking of these proteins (Sijwali and Rosenthal, 2010). This work 
also found that BIRs were exported to the iRBC cytosol and confirmed the localization 
of B-type RIFINs to the parasitophorous vacuole. It was suggested that the C-terminus 
of RIFIN and STEVOR proteins is important for their trafficking, since fusion proteins 
containing the PfEMP1 N-terminus, GFP and the RIFIN C-terminus were exported to 
the iRBC cytosol (Sijwali and Rosenthal, 2010). The N-terminus of a STEVOR protein 
has also been shown to enable trafficking to the iRBC cytosol (Saridaki et al., 2009), so 
the crucial signals that enable iRBC localization of STEVOR and RIFIN proteins are 
yet to be confirmed.  
Formerly, such transfection studies have not been feasible in P. chabaudi, however 
recent methodological advances have enabled the efficient generation of integrated 
transfectants expressing, for example, the reporter proteins M-cherry and luciferase 
(Spence et al., 2011). Following such improvement of P. chabaudi transfection 
methods, it should now be possible to tag CIR proteins in a similar way to the studies 
described above, allowing investigation of the cellular localization of individual CIR 
family members.  
A note of caution however is that the fusion of a large fluorescent protein to CIR may 
alter the native protein trafficking [observed for example by (Sijwali and Rosenthal, 
2010, Kuhn et al., 2010)]. An alternative to using a fluorochrome-CIR fusion protein 
would be to tag endogenous CIRs with a small tag, which could then be detected by 
IFA using Abs recognizing the tag. An example is the 10 amino acid TY1 tag, 
developed from the Saccharomyces cerevisiae Tyl virus-like particle (Bastin et al., 
1996), which is specifically recognized by two different monoclonal Abs (Brookman et 
al., 1995) and has been used to confirm localization and interactions for several P. 
falciparum and T. gondii proteins (Haase et al., 2008, Michelin et al., 2009, Treeck et 
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al., 2009). Such approaches could be used to confirm the CIR localization observed here 
by IFA, following which, investigations into their possible function(s) may proceed.  
A recent study by Carvalho and colleagues was able to make use of polyclonal Abs 
recognizing the A and E sub-groups (Fernandez-Becerra et al., 2005), to block the 
capacity for iRBCs to cyto-adhere to human lung endothelial cells by between 20 and 
40% compared to the extent of cyto-adhesion of iRBCs observed in the absence of 
specific Abs (Carvalho et al., 2010). Their data suggest that VIR proteins may be 
involved in sequestration to some extent, although only two P. vivax isolates were 
investigated so the implication of VIR proteins in cyto-adhesion remains to be 
substantiated. If confirmed, a role in mediating cyto-adhesion may also be true for 
members of the CIR family, since P. chabaudi is known to cyto-adhere to CD36 and to 
sequester, particularly in the liver (Gilks et al., 1990, Mota et al., 2000). 
To investigate the contribution of CIR proteins to the cyto-adhesion of P. chabaudi 
iRBCs, there are several possible approaches. Similar to the experiment described 
above in relation to VIR proteins (Carvalho et al., 2010), the anti-CIR Abs generated in 
this study could be used for inhibition of iRBC binding to mouse endothelial cells in 
vitro, using cell lines derived from known sites of sequestration, for example hepatic 
sinusoidal endothelial cells [which comprise the majority of endothelial cells in the 
liver, reviewed by (Huebert et al., 2010)], or to purified endothelial receptors such as 
CD36. Mota and colleagues have shown that Abs present in sera from P. chabaudi 
immune mice are able to disrupt the binding of iRBC both to CD36 and rat endothelial 
cells (Mota et al., 2000). 
In addition, the recent technical advances in P. chabaudi transfection in this laboratory 
have enabled the generation of luminescent P. chabaudi parasites (Spence et al., 2011). 
Firstly, these parasites could be used directly to investigate the sequestration behaviour 
of iRBC in vivo, using whole body imaging of P. chabaudi infected mice. This 
technique has been applied to another rodent malaria parasite, P. berghei, to compare 
the sequestration phenotype between wild-type and CD36 deficient mice (Franke-
Fayard et al., 2005). Use of luminescent P. chabaudi iRBCs to investigate the role of 
CIR proteins in sequestration could either use passive transfer of anti-CIR Abs to 
determine their effect on parasite sequestration, or the transgenic parasites could be 
further adapted to over-express particular CIR proteins either alone or in combination 
with luciferase. If this were possible, CIR over-expressing parasites could be used to 
initiate studies comparing the sequestration phenotype between parasites with high and 
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wild-type CIR expression both in vitro and in vivo. Over-expression of cir promoters 
may result in down-regulation of CIR expression, as has been observed for the rif, 
stevor and var genes (Howitt, Willnski et al. 2009); thus this strategy would require the 
use of strong, non-cir promoters to achieve high levels of CIR expression. 
CIR protein expression could also be determined in other stages of parasite 
development, such as gametocytes, ookinetes, oocysts, sporozoites and infected 
hepatocytes. RIFIN and STEVOR expression have been detected within gametocytes 
and sporozoites (Florens et al., 2002, McRobert et al., 2004, Petter et al., 2008). BIR 
peptides have also been detected within gametocytes and sporozoites and additionally in 
oocysts and ookinetes (Hall et al., 2005). It is likely therefore, that CIR proteins would 
also be expressed in other stages of the lifecycle beyond asexual erythrocytic growth, 
which could be elucidated by using the anti-CIR Abs generated here for 
immunofluorescent studies of these parasite stages. The detection of CIR proteins in 
multiple stages of parasite development would indicate, first, that these proteins mediate 
effects required for parasite survival in different environments, which may include 
evasion of mosquito immunity by oocysts. Second, if different CIR family members 
were found to be associated with particular stages of parasite development and / or 
different cellular localizations, the ‘sub-functionalization’ detected within the CIR 
family (described in chapter 2.3.5) could mean that these proteins have evolved to fulfil 
multiple functions. 
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Chapter 6: Immune recognition of CIR proteins 
6.1 Introduction  
The detection of CIRs at the apical end of P. chabaudi merozoites and possibly at the 
surface of some iRBCs (Chapter 5), indicates that these proteins could be targets for 
Ab-mediated immunity during P. chabaudi AS infection.  
Passive transfer of purified IgG from clinically immune adults has demonstrated that 
substantial protection against clinical malaria is afforded by Abs (Cohen et al., 1961, 
Edozien et al., 1962, McGregor and Carrington, 1963, Sabchareon et al., 1991). These 
results have been confirmed by experiments carried out in rodent models, including P. 
chabaudi (Diggs and Olser, 1969, Phillips and Jones, 1972, Boyle et al., 1982). In the 
model P. chabaudi adami, mice were unable to clear parasites in the absence of B cells 
(Grun and Weidanz, 1983, Meding and Langhorne, 1991, Rotman et al., 1998), 
indicating that Abs are crucial for resolution of infection and for immunity to re-
infection. In addition, Abs appear able to mediate parasite clearance even in the absence 
of Fcγ dependent effector functions (Rotman et al., 1998), which may include 
agglutination and / or neutralization (as described in section 1.3.2). Antibody production 
also reflects the nature of CD4+ help available, as different IgG isotypes are generated 
within the particular cytokine environments evoked by Th1 and Th2 responses (Paul et 
al., 1987, Purkerson and Isakson, 1992, Collins and Dunnick, 1993, Else and 
Finkelman, 1998). Therefore the measurement of Abs and their isotype distribution 
reflects several aspects of the immune response against malaria, particularly in model 
systems [for example: (Fairlie-Clarke et al., 2010)]. 
The crucial antigen targets of protective Abs are still largely unknown however, and it 
is imperative to investigate a wide range of antigens for this reason. Abs involved in 
parasite clearance are thought to target antigens expressed on the surface of merozoites 
or iRBCs, including ligands involved in iRBC invasion (Miller et al., 1975, Brown, 
1976, Cohen, 1979, Quinn and Wyler, 1979, Freeman et al., 1980, Jarra and Brown, 
1989, Snounou et al., 1989, Mota et al., 2001, Bull and Marsh, 2002, Good et al., 2004). 
The majority of studies investigating immune responses to Plasmodium have focussed 
on the recognition of conserved proteins, for example the merozoite stage antigens 
MSP1 and AMA1 which are not antigenically variant within a parasite strain. Both 
AMA1 and MSP1 are known to be immune targets (Egan et al., 1999, Hodder et al., 
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2001, O'Donnell et al., 2001), and several studies have shown a correlation between 
high titres of anti-AMA1 and / or MSP1 antibodies and protection from clinical malaria 
(Weir and Cockerham, 1984, Riley et al., 1992, Egan et al., 1996, Su and Wellems, 
1996, Branch et al., 1998, Anderson et al., 1999, Dodoo et al., 1999, Kitua et al., 1999, 
Conway et al., 2000, Metzger et al., 2003, Polley et al., 2004, Perrant et al., 2005, Nebie 
et al., 2008, Stanisic et al., 2009, Osier et al., 2010).  
Passive transfer of monoclonal anti-MSP1 and anti AMA1 Abs has been able to 
substantially reduce parasitaemia in rodent models (Boyle et al., 1982, Gozalo et al., 
1998, Narum et al., 2000, Vukovic et al., 2000, Lozano et al., 2011), and immunization 
studies using these antigens have also been able to generate protective immunity (Daly 
and Long, 1993, Ling et al., 1994, Crewther et al., 1996, Hirunpetcharat et al., 1997, 
Tian et al., 1997, Anders et al., 1998, Burns et al., 2003, Burns et al., 2004, Alaro et al., 
2010). For these reasons both antigens have been developed as vaccine candidates, 
although substantial obstacles to their efficacy have emerged. Not only are high titres of 
specific Abs required for protection (Hirunpetcharat et al., 1997, Ling et al., 1997), but 
the immunogenicity and activity of induced Abs can be substantially affected by the 
vaccine design [for example: (Hussain Reed et al., 2009)], delivery mechanism and 
adjuvant used [reviewed by: (Coler et al., 2009, Dey and Srivastava, 2011)]. In addition 
the correlation between naturally occurring Abs to AMA1 and MSP1 and protection is 
not completely clear (Dodoo et al., 1999, Sakihama et al., 1999, Corran et al., 2004, 
Okech et al., 2004), suggesting that immune responses, including the generation of Abs, 
to other antigens are also critical for development of protective immunity. 
Less is known about Ab responses to VSAs, although these are also thought to be 
targets of protective immunity (Marsh et al., 1989, Bull et al., 1998). The acquisition of 
Abs against PfEMP1 variants correlates with protection from severe malaria in Africa 
(Dodoo et al., 2001, Ofori et al., 2002, Kinyanjui et al., 2004b, Yone et al., 2005, 
Magistrado et al., 2007).  In particular, the acquisition of Abs recognizing sub-type A 
PfEMP1 variants appear particularly associated with protection against severe disease 
(Jensen et al., 2004, Bull et al., 2005b, Kaestli et al., 2006, Cham et al., 2009, Cham et 
al., 2010), whilst the presence of Abs to conserved regions of VAR2CSA correlate with 
immunity to PAM (Elliott et al., 2007, Rogerson et al., 2007). By contrast, there is no 
clear association of anti-RIFIN or STEVOR Abs with protection; with either no 
correlation to protection or perhaps even a link to developing a higher burden of 
parasitaemia or cerebral malaria (Abdel-Latif et al., 2003, Schreiber et al., 2006, 
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Schreiber et al., 2008). It is possible that the acquisition of Abs against the vast number 
of VSAs simply reflects the number of infections experienced, leaving much scope for 
understanding the connection between acquisition of Abs towards different VSA 
families and protection, either from severe disease or symptomatic infection. 
Whilst indirect evidence indicates that PIR expression is modulated by the presence of 
an intact immune response (Cunningham et al., 2005), only two studies to date have 
attempted to investigate immune recognition of PIR proteins. Both studies were carried 
out in northern Brazil using sera from a cohort of P. vivax symptomatically infected 
immigrant workers (Fernandez-Becerra et al., 2005). The first study used 22 
recombinant VIR fusion proteins corresponding to the second vir exon, and found 
differential recognition of these by immune sera from 32 patients. Approximately three 
quarters of patient serum samples were able to recognize at least one recombinant VIR 
by Western blot (Fernandez-Becerra et al., 2005), showing that VIR proteins are 
immunogenic during natural infection. The second study used seven of the recombinant 
VIR proteins and found VIR recognition by the immune sera of half of the 200 patients 
tested (Oliveira et al., 2006), the disparity was probably due to the lower number of 
recombinant VIR fragments tested in the second study (Oliveira et al., 2006).  
In both studies, the sera of patients with a primary P. vivax infection contained Abs 
recognizing a range of VIR proteins, including those from different phylogenetic sub-
families. There was no significant difference in the recognition of any VIR proteins by 
the sera of patients infected for the first time and those who had experienced several 
infections (Oliveira et al., 2006). Likely explanations for this phenomenon are that 
many VIR proteins are expressed during a primary P. vivax infection, and that Abs are 
able to recognize many VIRs. Transcriptional analyses of the pir family support the 
former scenario, whilst support for both hypotheses comes from the first study, where 
substantial cross-reactivity was observed between different VIR sub-families when 
polyclonal antisera were raised to different VIR peptides (Fernandez-Becerra et al., 
2005). The expression of multiple VIRs during infection and the induction of cross-
reactive Abs by VIR proteins may both contribute to the observed range of anti-VIR 
Abs induced in response to a primary P. vivax infection. 
The limited access to patient material and stochastic nature of natural infection means 
that the contribution of immune responses against PIR proteins is difficult to analyze in 
the field. Rodent models such as P. chabaudi AS allow the detailed investigation of 
immune recognition of PIR proteins, under controlled conditions including the ability to 
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initiate Plasmodium infections with a defined parasite population. Objectives of the 
present study were to: 
i) Confirm whether CIR proteins were recognized by immune sera, as previously 
observed for VIR (Fernandez-Becerra et al., 2005). 
ii) Investigate whether the presence of high anti-CIR Ab titres, induced by 
immunization, would influence the outcome and the parasite behaviour during a 
subsequent P. chabaudi infection. 
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6.2 Methods  
Origins and housing of parasites and mice have been described previously, along with 
measurement of parasitaemia during infection, chapter 3.2.4.  
 
6.2.1  Preparation of P. chabaudi immune-serum 
Serum samples were collected from 10 mice experiencing one, two or four P. chabaudi 
AS infections, normal (control) serum was collected from uninfected mice. Primary P. 
chabaudi AS infections were initiated intra-peritoneally, using 105 iRBC from a frozen 
stabilate that was expanded in RAG2-/- mice. Mice experiencing more than 1 infection 
were re-infected with 10 fold more parasites at each infection. Blood was allowed to 
clot at room temperature for 2 hours. Low speed centrifugation (1500 x g for 10 
minutes) was then carried out and the clot removed, and the serum subjected to high-
speed centrifugation (13,000 x g for 5 minutes) to remove aggregated material and free 
erythrocytes.  
 
6.2.2  SDS PAGE and immuno-blotting 
Proteins were resolved under reducing conditions using NuPAGE gels (Invitrogen), as 
previously described, chapter 4.2.3. 200 ng of the recombinant CIR proteins 
PCHAS_000100, PCHAS_070130 and PCHAS_040110 and MSP1p21 were loaded, as 
determined by BCA assay, described in chapter 4. 
All gels were used for immuno-blotting, where the proteins were electrophoretically 
transferred to Hybond C membrane (Amersham Biosciences) in buffer containing 10% 
methanol (v/v), 0.025 M Tris base (Sigma) and 0.2 M Glycine (BDH biosciences) for 3 
h at 30 V. Membranes were blocked at 4 ˚C overnight in PBS containing 0.1% Tween 
and 3% BSA, and washed for 10 minutes three times with PBS containing 0.01% 
Tween 20. 
The recombinant proteins were then probed with serum (diluted 1/50) from a naïve 
mouse or from a mouse which had experienced 1, 2 or 4 P. chabaudi AS infections. 
Antibodies directed against the histidine tag (Novagen), present on all recombinant 
proteins were used at 0.5 µg/ml concentration, as described in chapter 4.2.3 to ensure 
equal amounts of the recombinant proteins had been loaded. 
  Chapter 6: Immune recognition of CIR proteins  
 207 
Bound Abs were detected using horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG, (Southern Biotechnology, used at 1:10,000 dilution) as the secondary Ab. 
Membranes were washed as before, and SuperSignal West-Pico chemi-luminescent 
substrate (Thermo Scientific) added, according to manufacturer’s instructions, and 
incubated in the dark for 5 minutes. Light emission was detected by exposure of the blot 
to Biomax film (Kodak).  
 
6.2.3 Enzyme linked immuno-sorbent assays (ELISAs)  
The western blots described above surveyed a very limited number of CIR proteins, 
resolved under reducing conditions, which may have disrupted conformational 
determinants recognized by anti-CIR Abs present in the sera of P. chabaudi immune 
mice. Thus, ELISAs were carried out using these proteins, and with peptides 
representing a larger number of CIRs. The methodology used for these assays was the 
same as described in chapter 5.2.4, with the following exceptions:  
To measure CIR-specific Abs present in P. chabaudi immune sera, 96-well flat 
Polysorb plates (Nunc, Denmark) were coated with 50 µl of 5 µg/ml recombinant MSP-
1, CIR proteins or BSA conjugated CIR peptides (for which the approximate total 
protein coat for the conserved CIR peptide, CIR sub-family U peptide and CIR sub-
family A-F peptide respectively was 3.75 µg, 1.09 µg and 0.93 µg per well when the 
BSA conjugate was accounted for). The conserved CIR peptide was insoluble alone 
hence the BSA-conjugate was required for binding to the ELISA plate. For 
comparability, the other peptides were treated in the same manner. Antigens were 
diluted in PBS, and 50 µl was applied per well. Plates were incubated overnight at 4 ˚C, 
following which, the residual surface was blocked with 200 µl of blocking buffer (PBS 
containing 1% BSA, 0.3% Tween 20 and 0.05% Sodium azide). Recombinant MSP121, 
CIR proteins and peptides were probed with sera diluted 1/50 in blocking buffer from 
ten naïve mice or from ten individuals which had experienced 1, 2 or 4 P. chabaudi AS 
infections. The titres of specific Abs induced by immunization were calculated by 
interpolation of the titration curve, using non-linear regression analysis performed in 
Prism v5.0. The titre of Abs was defined as the dilution at which the sera from each P. 
chabaudi infected mouse would reach the OD405 nm of P. chabaudi-naïve mouse sera.  
To measure a known quantity of each antigen-specific Ig isotype, 96-well flat Polysorb 
plates (Nunc, Denmark) were coated with 50 µl of 5 µg/ml CIR sub-family U or A-F 
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specific peptides (not conjugated to a carrier protein, as these peptides were soluble in 
PBS). Each plate was also coated with 50 µl of a 5 µg/ml capture goat anti-mouse Ig 
(Southern Biotechnology), which may bind purified Ig of each isotype, used as a 
standard (Langhorne et al., 1989, Quin and Langhorne, 2001, Hensmann et al., 2004). 
Antigens were diluted in PBS, and 50 µl was applied per well. Plates were incubated 
overnight at 4 ˚C, following which, the residual surface was blocked with 200 µl PBS 
containing 1% BSA, 0.3% Tween 20 and 0.05% Sodium azide. CIR peptides were 
probed with sera diluted 1/50 in blocking buffer from a pool of ten naïve mice or from 
ten individuals which had experienced 4 P. chabaudi AS infections. In addition, a range 
of dilutions (in blocking buffer) of purified mouse IgM, IgG1, IgG2a, IgG2b, and IgG3 
(Sigma-Aldrich) were used to probe the capture Ab, as a standard curve. These bound 
antibodies, along with isotypes of Abs binding to CIR proteins on the plate were then 
detected using alkaline phosphatase-conjugated goat anti-mouse IgM, IgG1, IgG2a, 
IgG2b or IgG3 Abs (Southern Biotechnology). Antigen-specific Abs were ennumerated 
relative to the standard by interpolation of the titration curve, using non-linear 
regression analysis performed in Prism v5.0. 
In addition, ELISAs were also carried out to determine the titres of antigen-specific Abs 
induced by immunization of mice with recombinant MSP121, CIR proteins and peptides, 
described in section 6.2.4.  
 
6.2.4 CIR-immunization and P. chabaudi challenge  
Animals were immunised with 50 µg of antigen in the presence of 12 µg Abisco 
adjuvant (Iscanova). Antigens used were the recombinant proteins MSP1p21, CIRs 
PCHAS_040110 and PCHAS_000100 (generated in chapter 4); the conserved CIR 
peptide (described in chapter 5, Figure 36), and CIR sub-family U and A-F peptides 
(described in chapter 6.3.1, Figure 42). Here it must be noted that immunization with 
the CIR peptides required a carrier protein. For this purpose all peptides were 
conjugated to the carrier proteins BSA or KLH by Jerini Peptide Technologies, Berlin, 
Germany. Unfortunately, turbidity of the KLH conjugated peptide solutions prevented 
estimation of an accurate concentration. Instead, the BSA conjugated peptides were 
used for immunization as an accurate peptide dose could be administered.  
Mice immunized with CIR peptides received 50 µg of peptide, as peptides were 
conjugated to the carrier protein BSA, the total protein dose in these animals was 
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greater than 50 µg (approximately 747.96 µg, 217.23 µg and 185.50 µg, for mice 
immunized with the conserved CIR peptide, CIR sub-family U peptide and CIR sub-
family A-F peptide respectively). In addition, a group of mice were immunized with a 
CIR cocktail, who received 10 µg of each CIR antigen (CIR PCHAS_040110, 
PCHAS_000100, the conserved CIR peptide, and both CIR sub-family specific 
peptides) thus receiving 50 µg of CIR antigens in total (which equates to approximately 
330 µg of total protein). Immunizations were administered three times at 2-week 
intervals into different sites: intra-muscular (left hind leg), intra-muscular (right hind 
leg) and sub-cutaneous.  
The titres of antigen-specific Abs induced by immunization of mice with recombinant 
MSP121, CIR proteins and peptides were determined by ELISA. ELISAs were carried 
out according to the methods described above (in sections 5.2.4 and 6.2.3), with certain 
exceptions, which are described below.  
96-well flat Polysorb plates (Nunc, Denmark) were coated with 50 µl of 5 µg/ml 
recombinant MSP-1, CIR proteins or BSA conjugated CIR peptides (for which the 
approximate total protein coat for the conserved CIR peptide, CIR sub-family U peptide 
and CIR sub-family A-F peptide respectively was 3.75 µg, 1.09 µg and 0.93 µg per well 
when the BSA conjugate was accounted for). Antigens were diluted in PBS, and 50 µl 
was applied per well. Plates were incubated overnight at 4 ˚C, following which, the 
residual surface was blocked with 200 µl blocking buffer, as described above. 
Recombinant MSP1p21, CIR proteins and peptides were probed with serum samples 
from each mouse: compared before and after immunization. Naïve sera were diluted 
1/1000, whilst immunised sera were diluted 1/1000, 1/10000 and 1/100000, in blocking 
buffer. CIR-specific Abs were detected using alkaline phosphatase-conjugated goat 
anti-mouse Ig (Southern Biotechnology). The titres of Abs induced by immunization 
were calculated as described above, by interpolation of the titration curve, and were 
defined as the dilution at which the sera from each immunized mouse would reach the 
OD405 nm of sera from the same individual prior to immunization.  
Detection of peptide specific Ab responses would ideally have been carried out by 
ELISA using unconjugated peptides as the coating antigen, however the conserved CIR 
peptide was insoluble in PBS. Instead, the BSA-conjugated peptides were used as 
coating antigens for ELISA as described below. This is shown in Figure 41a. 
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In order to determine the relative titres of Abs recognizing the peptides, rather than the 
carrier protein BSA in the sera of CIR peptide immunized mice, purified BSA (Sigma 
Aldrich), or BSA conjugated CIR peptides were used as coating antigens for ELISA. 
Solutions containing the same molarity of BSA were prepared in PBS and used to coat 
the wells, so the antigens would be approximately comparable. The molarity used was 
the equivalent of a 5 µg/ml BSA solution, 74.88 nM, and 50 µl was applied per well.  
ELISAs were otherwise performed as described above, for determination of the titres of 
CIR-specific Abs induced by immunization, Figure 41b. 
Finally, to confirm that immunization with the CIR peptides did result in the generation 
of Abs recognizing the peptides, rather than the carrier protein BSA, the PBS soluble 
unconjugated CIR sub-family specific peptides were used as coating antigens for 
ELISA. The antigens were prepared at 5 µg/ml concentration in PBS and 50 µl applied 
per well. ELISAs were otherwise performed as described above, for determination of 
the titres of CIR-specific Abs induced by immunization, shown in Figure 41c. 
Whilst these three methodologies were different and thus not able to provide an exact 
calculation, three points may be observed. First, the sera of all groups of mice 
immunized with BSA-conjugated CIR peptides had similarly high titres of Abs 
recognizing their cognate antigen, crossing the background OD405 nm of pre-immune 
sera at titres of approximately 1x105, Figure 41a. Second, the sera of all mice had higher 
titres of Abs recognizing the BSA-conjugated peptide than to BSA alone, Figure 41b. 
From this it may be inferred that the majority of Abs were generated against the CIR 
pepides. Finally, for the two peptides that were soluble in PBS, it was possible to 
confirm that titres of Abs recognizing the un-conjugated peptide were of a similar titre 
to those generated against the BSA conjugated peptide, of 1.28 x105, Figure 41c. This 
was likely to also be the case for the mice immunized with the PBS insoluble, 
conserved CIR peptide. 
One important caveat here was that BSA was used both as a carrier protein for 
immunization and to block the ELISA plates. Whilst Abs were diluted in an excess of 
BSA to remove BSA-reactive Abs, it is possible that some BSA-reactive Abs were able 
to bind to the BSA block. ELISAs were thus carried out using the same strategy for the 
sera of all mice immunized with CIR peptides, with un-conjugated CIR sub-family 
specific peptides as coating antigens (Appendix 6.3).  
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Figure 41: Titres of Abs induced after immunization with CIR peptides, 
conjugated to the carrier protein BSA. 
Sera from mice immunized with the conserved CIR peptide (purple), CIR sub-family U 
peptide (orange), or CIR sub-family A-F peptide (blue), were compared with pre-
immune sera from the same animals.  
The mean absorbance OD405 nm of the ELISA substrate is plotted against the dilution 
of sera, from triplicate titrations. Bars represent the standard error of the mean. The sera 
of mice immunized with CIR peptides are represented by filled symbols and solid lines, 
whilst pre-immune sera are represented by empty symbols and dashed lines. 
The coating antigens used for ELISAs were: BSA-conjugated CIR peptides, a), BSA-
conjugated CIR peptides and BSA alone, b), or unconjugated CIR peptides, c).  
 
 
The only Abs recognizing each CIR peptide were found in the sera of mice immunized 
with those same peptides (Appendix 6.3). Thus, it was concluded that any BSA reactive 
Abs had been absorbed on the excess BSA during dilution of the sera. Therefore, 
although Abs were also generated against the carrier protein BSA, mice did make Abs 
recognizing the CIR peptide with which they were immunized, at least for the CIR sub-
family specific peptides. 
Control mouse groups of the same age were immunised with either saline alone, or 
saline plus adjuvant, using the same routes of administration. Before immunisation, pre-
immune serum was collected from all of these animals. Twelve days after the last 
immunisation, sera were collected from clotted blood, aliquotted and stored at -20 ˚C.  
Two days later, all mice were infected intra-venously with 103 P. chabaudi AS from a 
frozen stabilate that was expanded in a RAG2-/- mouse. Infections were monitored by 
daily blood smear. At the peak of infection (day 8), 50 µl blood was taken from each 
mouse, collected in 100 µl Krebs saline, containing 25 U/ml heparin (Leo Laboratories). 
To each sample 250 µl Trizol (Invitrogen) was added, and material stored at -80 ˚C.  
This material was processed for RNA using phenol-chloroform extraction followed by 
cDNA synthesis and RT-qPCR, carried out as described in chapter 3.2 (Appendix 3.4), 
using cir primers listed in Table 12. Transcription of cir genes was analyzed for three 
mice from each group immunized in the presence of Abisco adjuvant. Ratios of cir 
transcription were calculated relative to the donor RAG2-/- mouse and normalized to 
beta tubulin. These data are tabulated in Appendix 6.7. 
  Chapter 6: Immune recognition of CIR proteins  
 213 
6.3 Results   
6.3.1  Reagents used for detection of anti-CIR responses 
 
In order to detect anti-CIR responses that may occur during P. chabaudi infection, CIR 
protein reagents were required. The recombinant CIR proteins PCHAS_000100 and 
PCHAS_040110, generated in chapter 4, were expressed in sufficiently high quantities 
that they could be used for this purpose. These proteins represented each of the major 
sub-families identified in chapter 2: U (PCHAS_040110) and A-F (PCHAS_000100). 
Although neither cir gene was dominant in the samples analyzed by RNA sequencing 
(Figure 23), each P. chabaudi infection appeared to have a different dominant cir 
transcript, and RT-qPCR analyses had shown that both genes were expressed during P. 
chabaudi infection (Figure 21 and Figure 22).  
In addition, the identification of conserved and sub-family specific amino acid motifs 
within the CIR repertoire in chapter 2 provided a route for investigation of CIR 
proteins, by the synthesis of CIR peptides. Three amino acid motifs were chosen for 
peptide design. The first of these has been described in chapter 5, representing a highly 
conserved amino acid sequence expected to represent the majority of CIRs, illustrated 
in Figure 36. In addition, a motif specific to each of the major CIR sub-families was 
chosen for peptide synthesis, to enable functional comparisons between the CIRs and 
whether there were further similarities with the RIFINs of P. falciparum. The peptides 
were designed using the CIR sub-family U amino acid motif (identified in Figure 20d), 
and a motif found only in CIR sub-families A-F (motif 11, Table 7). These peptides are 
depicted in Figure 42. 
 
 
6.3.2 CIRs are recognized by immune sera 
To investigate the Ab response to CIR proteins following P. chabaudi AS infection, 
sera were prepared from mice experiencing one or more P. chabaudi infections. CIR-
reactive Abs were detected using recombinant proteins and peptides representing 
different CIR sub-families and regions of the proteins, as described above. The anti-CIR 
Ab response was compared with the Ab response to the C-terminal fragment of MSP1, 
a protein coded for by a single copy gene, and known to induce Ab responses in a P. 
chabaudi infection [for example (Langhorne et al., 1989, Quin and Langhorne, 2001, 
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Hensmann et al., 2004).]. Recombinant MSP1p21 was generated within the same 
expression system as the recombinant CIRs, using the same C-terminal His-tag 
(Hensmann et al., 2004).  
P. chabaudi infection in mice induced Abs which recognized more than one of the 
recombinant CIRs as determined by Western blot, even after a single infection, Figure 
43. After two infections Abs were present that recognized all CIR proteins, albeit at 
lower levels than anti- MSP1p21 Abs. Recognition of all proteins increased after four 
infections.  
The titres of CIR specific Abs were estimated from the sera of 10 mice using ELISAs, 
Figure 44. In addition to the recombinant proteins, three CIR peptides were used as 
coating antigens (described in chapter 2.3.6). The conserved CIR peptide represents 
64% of CIR proteins, as revealed by BLAST analysis, whilst CIR sub-family U and A-F 
peptides were exclusively found in each of the major sub-families identified in chapter 
2.3.2. Titres of Abs recognizing MSP1p21, recombinant CIR PCHAS_040110 and the 
CIR sub-family U and A-F specific peptides significantly increased after four P. 
chabaudi infections, compared to the sera of mice experiencing only one infection, 
Figure 44.  
In addition, Figure 44 shows that the titre of Abs recognizing any CIR proteins or 
peptides were approximately 100-fold lower after each infection than those from the 
same mice recognizing MSP1p21. These differences were significant at the 99.9% 
confidence level, when assessed by one-tailed Mann-Whitney tests. The lower 
quantities and greater range of anti-CIR Abs observed in comparison to anti- MSP1p21 
Abs were likely to be due to the differential expression of CIR variants within each 
mouse’s P. chabaudi infection. This is unlike MSP1, which is expressed from a single 
gene, present in all iRBCs.  
Since antibody responses to the sub-family specific CIR peptides were reproducibly 
higher than those to both recombinant CIR proteins, these peptides were used for 
investigation of the isotype distribution of anti-CIR Abs in mice that had experienced 
four P. chabaudi AS infections. Figure 45 shows that the Ab isotypes recognizing these 
peptides were predominantly IgM & IgG2a, with no differences observed in the 
distribution of isotypes recognizing either CIR peptide.  
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6.3.3 CIR-immunization and P. chabaudi challenge 
To investigate whether pre-existing anti-CIR Abs at high concentration might affect the 
course of a subsequent P. chabaudi AS infection (also referred to as challenge), an 
immunization experiment was carried out. The experimental design is shown in Figure 
46. Groups of five mice were immunized three times with 50 µg of CIR proteins or 
peptides, MSP1p21, or saline, in the presence of 12 µg Abisco adjuvant (Iscanova). In 
addition a negative control of saline without adjuvant was performed to enable detection 
of adjuvant-based effects. Fourteen days after the final immunization, mice were 
infected with P. chabaudi AS. Parasitaemia was monitored by thin-blood smear every 
other day after the first observation of parasites, and also at the peak of parasitaemia.  
Several key variables were measured, outlined below:  
- Anti-CIR Ab titres after immunization, to ensure that responses were made to 
the appropriate antigen in each individual.  
- Parasitaemia during P. chabaudi challenge, to measure the potential effect of 
CIR-immunization upon parasite growth.  
- Patterns of cir transcription at the peak of parasitaemia, to investigate likely 
changes in the population of parasites and their transcriptional responses in the 
presence of anti-CIR Abs.  
Before carrying out the immunization and challenge experiment, it was important to to 
confirm that the CIR proteins and peptides were capable of inducing Abs that 
recognized native P. chabaudi proteins. As described in chapter 5 for the conserved 
CIR peptide, rabbits were immunized with each CIR protein or peptide for the 
generation of polyclonal anti-sera. These sera were used to confirm that immunization 
with any of the recombinant CIR protein or CIR peptides contained Abs capable of 
recognizing native P. chabaudi proteins by Western blot (Appendix 6.1).  
 
6.3.3 i) CIR immunization and P. chabaudi challenge 
Following immunization of mice for the challenge experiment, serum from each mouse 
was compared to pre-immune sera from the same individuals by ELISA. Both saline 
control groups had no Abs recognizing antigens above a threshold of approximately 1 x 
103, thus sera containing titres above this level were deemed to contain Abs recognizing 
CIR proteins or peptides, or MSP1p21 (Appendix 6.4). The titres of Abs induced by CIR 
  Chapter 6: Immune recognition of CIR proteins  
 216 
immunization are shown in Figure 47. The standard errors of the mean are shown, but 
were masked by the log scale of the graphs. 
Sera from mice immunized with PCHAS_040110 contained similar titres of Abs 
recognizing both recombinant CIR proteins (titres of approximately 1 x 106), shown in 
the left panel of Figure 47a. Some cross-reactivity could potentially have been due to 
cross-reactive recognition of the His tag present at the C-terminus of both proteins; 
however, there was no recognition of the same His tag present on recombinant 
MSP1p21. Instead it is likely that the two recombinant CIRs shared several 
conformational determinants, which could be recognized by Abs induced by 
immunization with either protein. Upon P. chabaudi challenge, mice immunized with 
PCHAS_040110 displayed a significant difference from saline-controls on day 7 of 
infection, assessed by one-tailed Mann Whitney test, shown in the right panel of Figure 
47a. 
The sera of mice immunized with the CIR sub-family U peptide had high titres (of 
approximately 1 x 107) of Abs to this peptide, Figure 47b. Surprisingly, Abs were also 
detected that recognized the conserved CIR and sub-family A-F peptides, although at 
low titres (less than 1.6 x 104). As immunization with all CIR peptides used BSA 
conjugates, there was a strong likelihood that such apparent cross-reactivity was in fact 
due to Ab recognition of the carrier protein by ELISA. To confirm that this was the 
case, ELISAs were carried out to measure the recognition of BSA alone and, where 
possible, to determine anti-peptide Ab titres using un-conjugated peptides. This was 
addressed in detail in section 6.2.4, where specific responses were detected in all cases 
to the cognate peptide (Figure 41). In addition, ELISAs were carried out to measure the 
degree to which sera from mice immunized with each CIR peptide recognized either of 
the un-conjugated peptides (Appendix 6.3). No cross-reactivity was detected; hence all 
apparent cross reactivity between the sera of mice immunized with CIR peptides 
(presenting as Ab titres less than or equal to 1 x 104) could be attributed to recognition 
of the carrier protein BSA.  
Recognition of PCHAS_040110 by the sera of CIR sub-family U peptide immunized 
mice however, was likely not to be an artefact but recognition of the exact sub-family U 
peptide sequence: LPELTLPEGLYDCKTE, found within this recombinant CIR protein. 
Despite high titres of Abs recognizing the CIR sub-family U peptide and some cross-
reactivity with PCHAS_040110 in these mice, there was no difference in parasitaemia 
compared to the control groups during P. chabaudi challenge infection, Figure 47b. 
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Similarly to mice immunized with the recombinant CIR PCHAS_040110, mice 
immunized with recombinant PCHAS_000100 also made Abs recognizing the other 
recombinant CIR. However, the mice immunized with PCHAS_000100 made 100 fold 
higher titres of Abs to the protein they were immunized with than to PCHAS_040110 (1 
x 107 and 8.5 x 104 respectively), Figure 47c. In addition, low-level responses were 
detected against the sub-family A-F peptide (less than 1x 104), which is likely due to 
recognition of the peptide by Abs generated to a similar sequence within 
PCHAS_000100: KLSVDFYDSYIERNEYY (identical residues and those with similar 
properties are highlighted). Upon P. chabaudi challenge, mice immunized with 
PCHAS_000100 displayed the most significant differences in parasitaemia of all the 
groups tested, compared to saline- immunized controls. On day 3 and 7 of infection 
PCHAS_000100 immunized mice had significantly higher parasitaemia, followed by 
significantly reduced parasitaemia on days 11 and 13 of infection, Figure 47c. This 
suggests that the immunized mice were initially less able to control the growth of 
parasites, but after the peak of parasitaemia the mice were able to clear parsites slightly 
faster than control mice. 
Sera from mice immunized with the CIR sub-family A-F peptide contained high titres 
of Abs to this peptide (1 x 106), shown in Figure 47d. A low level response was 
detected against the sub-family U peptide, Figure 47d, which was actually directed 
against the carrier protein BSA as described above (Figure 41, Appendix 6.3). In 
addition, mice immunized with the CIR sub-family A-F peptide made low titres of Abs 
(less than 1.4 x 104) recognizing both recombinant CIR proteins. As described above, 
PCHAS_000100 contained a sequence similar to this peptide, however the reason for 
recognition of the recombinant CIR PCHAS_040110 by mice immunized with a peptide 
not present in this protein is unclear. No differences were detected during the course of 
parasitaemia upon P. chabaudi challenge, Figure 47d, although one mouse died after 
the peak of infection, suggesting that these mice may have suffered from more acute 
pathology. 
Mice immunized with the conserved CIR peptide were expected to generate Abs 
recognizing the majority of CIR proteins. The sera of these mice contained high titres 
(of 1 x 106) of Abs to this peptide, Figure 47e; and low-level responses to the sub-
family A-F peptide (less than 1x 104), which were actually directed against BSA (Figure 
41, Appendix 6.3). Similarly to the mice immunized with the CIR-sub-family A-F 
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specific peptide, no differences were detected during the course of parasitaemia upon P. 
chabaudi challenge, yet one mouse died after the peak of infection, Figure 47e. 
Finally, the sera of mice immunized with the CIR-cocktail made low titres (less than 3.5 
x 104) of Abs to each CIR antigen, Figure 47f. These mice displayed a significantly 
higher parasitaemia upon day 7 of P. chabaudi challenge than saline controls, (Figure 
47f) similarly to the mice immunized with PCHAS_040110. Since PCHAS_040110 
was present in the CIR cocktail, both groups of mice may have experienced Ab: parasite 
interactions leading to increased parasitaemia just prior to the peak of infection. 
For comparison, a group of mice was immunized with recombinant MSP1p21, as 
indicated in Figure 46. Like the recombinant CIR proteins, MSP1p21 was generated in 
the same expression system, P. pastoris, and contained an identical C-terminal hexa-
histidine tag for protein purification and identification (Hensmann et al., 2004). Mice 
immunized with recombinant MSP1p21 made high titres of Abs (1 x 108) only 
recognizing this protein, yet these mice experienced no difference in parasitaemia upon 
P. chabaudi challenge, compared to saline controls (Appendix 6.4).  
Due to the scope of this immunization and challenge experiment, measurement of 
pathology during the P. chabaudi challenge infection was impractical. A comparison of 
anaemia was however undertaken at the beginning and at the peak of infection, to 
determine whether any of the groups appeared more susceptible to this complication of 
malaria. No difference in anaemia was detected between groups (Appendix 6.5), except 
for the mice immunized with PCHAS_000100, whose rapid increase in parasitaemia 
after infection resulted in anaemia prior to the other groups.  
 
6.3.3 ii) Measurement of cir transcripts by RT-qPCR 
P. chabaudi infected blood samples were taken for analysis of cir transcription by RT-
qPCR both from the donor RAG2-/- mouse, and from all challenged mice at the expected 
peak of parasitaemia (day 8 post infection). The ratio of cir transcript levels relative to 
the donor mouse was calculated for three mice per group and normalized to beta tubulin 
as described in chapter 3. The three mice chosen for this analysis were those whose 
parasitaemias were closest to the median parasitemia of the group on day 8 of P. 
chabaudi challenge.  
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The majority of P. chabaudi challenged mice displayed no difference in cir transcript 
levels compared to the donor mouse, with ratios of cir transcription being close to 1, 
shown in Figure 48. All RT-qPCR data are tabulated in Appendix 6.7. Greater than two-
fold differences in cir transcript levels were observed in some P. chabaudi challenged 
mice, compared to the donor mouse, and are described below. 
P. chabaudi challenge of mice immunized with the conserved CIR peptide resulted in 
lower levels of all cir transcripts measured, particularly those targeted by the primers 
U4 (PCHAS_040110, PCHAS_060140 and PCHAS_042030), Figure 48b and E1 
(PCHAS_120060, PCHAS_104230 and PCHAS_000100), Figure 48d. These 2 - 8 fold 
decreases in cir detection, compared to the saline controls, were significant at the 95% 
confidence level, assessed by one-tailed Mann Whitney test.  
The only other significant change in cir transcript levels was detected in MSP1p21 
immunized mice, which had a small (less than two-fold) decrease in the levels of cir 
genes targeted by primer pair E1, Figure 48d. In general, differences in cir transcript 
levels were variable between mice, meaning that few changes were significantly 
different from those observed in the saline controls. A clear trend was observed in P. 
chabaudi challenged mice immunized with the CIR sub-family A-F specific peptide, 
which had approximately 4-fold increased levels of cirs targeted by both sub-family U 
specific primers, Figure 48a and b.  
Conversely, mice immunized with the CIR sub-family U specific peptide had increased 
levels of E1 cir transcripts, Figure 48d. This was also detected in mice immunized with 
the sub-family U recombinant protein, PCHAS_040110. In addition, the primer pair U4 
detected lower levels of the equivalent cir gene in PCHAS_040110 immunized mice, 
compared to saline controls, Figure 48b.  
The opposite trend appeared to occur in mice immunized with recombinant 
PCHAS_000100, as increased levels of the equivalent cir gene sub-set was detected, 
targeted by primer pair E1, Figure 48d. However, only one mouse could be analyzed for 
this result, thus further substantiation is required. 
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Figure 42: Design of CIR sub-family specific peptides. 
 
The amino acid motifs corresponding to CIR sub-family U and CIR subfamilies A-F 
were found in 29.8% and 100.0% of the respective sub-family members. The proportion 
of CIR amino acid sequences containing each residue of the motifs are depicted as 
weblogo images (Crooks et al., 2004).  
Peptides were designed using the sequences given above each amino acid motif. The 
sequences are given below each Weblogo image. The CIR sub-family U peptide was 
present in 37.0% of this sub-family, and the CIR subfamilies A-F peptide was present in 
23.1% of these sub-families by BLAST search, allowing 5 mis-matches. 
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Figure 43: Recombinant CIR recognition by sera from a mouse experiencing one, 
two or four P. chabaudi AS infections. 
500 ng of the recombinant CIR proteins: PCHAS_070130, PCHAS_000100, 
PCHAS_040110, and MSP1p21 (Hensmann et al., 2004), were loaded onto a 12% SDS-
PAGE gel and resolved under reducing conditions, where samples contained 100 mM 
DTT and the running buffer also contained 0.5 ml NuPAGE antioxidant. 
Western blots were probed using serum from either a naïve BALB/c mouse (0 P. 
chabaudi infections), or a mouse that had experienced one, two or four P. chabaudi 
infections. In addition, antibodies recognizing the C-terminal His-tag present on all 
recombinant proteins were used as a positive control and as a loading control.  
All blots show the recombinant CIR proteins at approximately 30 kDa, highlighted with 
black arrows, and recombinant MSP1p21 at 14 kDa, highlighted with red arrows. 
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Figure 44: Titres of CIR-specific Abs, present in the sera of mice experiencing one, 
two or four P. chabaudi AS infections. 
ELISAs were performed to measure the recognition of CIR and MSP1p21 by Abs 
present in mouse sera. The recombinant CIR proteins PCHAS_000100, 
PCHAS_040110, or recombinant MSP1p21, and the conserved CIR, CIR sub-family U 
and CIR sub-family A-F peptides were used as coating antigens.  
The CIR proteins and peptides and MSP1p21 were probed using serum from 10 BALB/c 
individuals that had experienced one, two or four P. chabaudi infections. Each protein 
was also probed with sera from a pool of 10 P. chabaudi naïve individuals, the 
absorbance of which was calculated as the ‘baseline of non-specific Ab recognition’. 
This baseline was removed from the absorbance of P. chabaudi immune sera before Ab 
concentrations were approximated according to a known standard present on each 
ELISA plate: affinity purified mouse anti-PCHAS_000100 Abs.  
These results are shown as box and whisker plots showing CIR or MSP1p21 recognition 
by P. chabaudi immune sera from the 10 mice. The median and 5-95 percentile are 
shown, meaning that 90% of Ab titres are plotted [computed in Prsim v5.0 using the 
equations: 5*(N+1)/100 and 95*(N+1)/100)]. 
For each antigen, one-tailed Mann-Whitney tests were performed to determine whether 
Ab titres were significantly higher after four P. chabaudi infections, compared to one. 
Significance to the 99% confidence level is denoted by **.  
 
  Chapter 6: Immune recognition of CIR proteins  
 223 
 
Figure 45: The isotype distribution of CIR-specific Abs present in sera from mice 
experiencing four P. chabaudi AS infections. 
ELISAs were performed using the CIR sub-family U peptide, a), and the CIR sub-
family A-F peptide, b), as coating antigens.  
The isotype distribution was analyzed using immune sera from mice that had 
experienced four P. chabaudi infections, from the same 10 individuals used to estimate 
the concentration of total anti-CIR Ig, Figure 44. Each isotype concentration was 
estimated from a titration of purified mouse immunoglobulin for that isotype.  
The concentration of CIR-specific Abs present in serum from each P. chabaudi immune 
mouse is plotted individually, each point representing a different mouse. Bars represent 
the geometric mean and 95% confidence intervals. 
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Figure 46: The experimental outline for CIR immunization and P. chabaudi 
challenge experiments.  
Mice were immunized three times with 50 µg of CIR protein or peptide, MSP1p21 or 
saline, in the presence of 12 µg Abisco adjuvant (Iscanova), according to the schedule 
shown in black. In addition a negative control of saline without adjuvant was performed 
to ensure no adjuvant-based effects were observed. The full list of groups is shown, 
along with the colour code used in all figures relating to this experiment.  
Serum samples were taken prior to immunization, and 12 days after the final 
immunization to enable determination of induced Ab titres. 14 days after the final 
immunization, mice were infected with P. chabaudi AS, shown in red. Blood samples 
were taken for measurement of anaemia shortly after infection, and at the expected peak 
of parasitaemia, shown in blue. Blood samples were also taken at the expected peak of 
parasitaemia for analysis of cir transcription by RT-qPCR, shown in red. 
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Figure 47: The titres of specific and cross-reactive Abs induced by immunization 
with CIR proteins. 
Groups of mice were immunized with the following: the recombinant CIR protein 
PCHAS_040110, a), CIR sub-family U peptide, b), recombinant CIR PCHAS_000100, 
c), the CIR sub-family A-F peptide, d), conserved CIR peptide, e), CIR cocktail, f).  
Left panels: Sera from all mice were compared before and after immunization, for their 
ability to recognize: recombinant MSP1p21, the conserved CIR peptide, the CIR sub-
family U and A-F specific peptides, the recombinant CIRs PCHAS_040110 and 
PCHAS_000100 (present in CIR sub-families U and E, respectively). Titre was defined 
as the dilution of immunized serum at which it reached the OD405 nm of serum from 
the same mouse prior to immunization, calculated using the mean of two technical 
replicates. Error bars represent the standard error of the mean. 
Right panels: The courses of parasitaemia, are shown for mice infected with 103 P. 
chabaudi AS iRBC following immunization. All graphs show the courses of 
parasitaemia for the two negative control groups, mice immunized with saline only or 
saline in the presence of Abisco adjuvant (Iscanova). The geometric mean parasitaemia 
for each group of 5 mice is shown, excluding an individual that did not receive a full 
infectious dose in two groups. Error bars represent the standard error of the mean. One-
tailed Mann-Whitney tests were performed to determine whether parasitaemias of CIR-
immunized mice were significantly different from control mice. Significance to the 95% 
confidence level by comparison to both saline-immunized groups is denoted by *.  
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Figure 48: The patterns of cir transcription observed in CIR-immunized mice 
challenged with P. chabaudi AS infection.  
RT-qPCR was used to analyze 5 ng RNA from P. chabaudi infected blood samples 
taken on Day 8 of infection. The ratio (arbitrary units) of cir transcription normalized to 
the parasite reference gene, beta tubulin, was calculated for three immunized mice, 
relative to the P. chabaudi donor RAG2-/- mouse. For ease of view, these data are 
represented using a log2 scale, where a two-fold change in either direction is displayed at 
an equal scale. Ratios are not displayed as log2 values however. 
Primer pairs used were: U1 (white bars), which target the cir genes PCHAS_040050 and 
PCHAS_001050 a), U4 (hashed bars), which target the cir genes PCHAS_040110, 
PCHAS_060140 and PCHAS_042030  b), C1 (yellow bars), which target the cir genes 
PCHAS_000140 and PCHAS_114750 c), and E1 (blue bars), which target the cir genes 
PCHAS_120060, PCHAS_104230 and PCHAS_000100 d).  
The mean ratio of three mice analyzed per group is plotted. Mice were excluded if the 
SD between technical replicates exceeded 0.775 (80% confidence), attached in 
Appendix 6.7. Error bars represent the standard error of the mean.  
One-tailed Mann-Whitney tests were performed to determine whether the ratios of cir 
transcripts detected in CIR-immunized mice, relative to the donor mouse, were 
significantly different from saline-immunized controls. Significance to the 95% 
confidence level by comparison to the group immunized with saline in the presence of 
adjuvant is denoted by *. 
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6.4 Discussion 
In this chapter, efforts were made to determine whether CIR proteins were 
immunogenic during P. chabaudi infection, and the effect that induced immunity to 
CIRs could have upon subsequent infection. To accomplish these aims, CIR reagents 
were required. The generation of recombinant CIR proteins to represent each major CIR 
sub-family was described in chapter 3. In addition, a peptide was designed from a 
conserved CIR amino acid motif, found in the majority of CIR sequences, as described 
in chapter 5.  
Antibodies to this peptide detected many features of CIR localization within iRBCs and 
merozoites which appeared similar to that described for the RIFINs of P. falciparum 
(Petter et al., 2007). The A and B-type RIFINs display different cellular localizations 
(Petter et al., 2007), which may be re-capitulated by the two major CIR sub-families. If 
this were truly the case, then members of CIR sub-family U would be predicted to 
localize at the iRBC surface like A-type RIFINs as they contain a similar insertion 
sequence (described in chapter 2.4). As such, members of the CIR U and A-F sub-
families might experience different levels of immune pressure, and sub-family specific 
peptides were designed to determine whether this was the case. Briefly, the CIR sub-
family U specific peptide contained similar features to the RIFIN A-type insertion 
sequence, and was present within the recombinant CIR PCHAS_040110; whilst the CIR 
sub-family A-F peptide corresponded to a similar sequence in the recombinant CIR 
PCHAS_000100. 
All CIR proteins and peptides were recognized by the immune system after P. chabaudi 
infection; with the exception of the conserved CIR peptide, which is found within the 
hydrophobic core of CIR proteins (discussed in chapter 5). Titres of Abs recognizing 
CIRs were approximately 100 fold lower than those recognizing recombinant MSP1p21. 
Even after four P. chabaudi infections, the majority of Abs recognizing the CIR sub-
family specific peptides comprised IgM and IgG2a isotypes. Immunization with CIR 
proteins and peptides was successful in that the sera of all mice contained Abs 
recognizing their cognate antigen. CIR immunization did not affect parasitaemia upon 
P. chabaudi challenge, apart from a slight increase in certain immunized groups on day 
7 of infection. The exception was for the mice immunized with PCHAS_000100, which 
experienced an earlier peak of infection, and earlier parasite clearance than all other 
groups. Infected RBCs from these mice did not display any difference in cir transcript 
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levels, relative to the donor mouse, compared to the saline controls. Infected RBCs from 
mice immunized with PCHAS_040110 however, had significantly lower levels of the 
corresponding cir gene or cirs closely related to it. 
The titre of Abs present in the sera of P. chabaudi immune mice recognising CIRs was 
lower and displayed larger variation than Abs recognizing MSP1p21. MSP1 is expressed 
by all parasites and is therefore probably more exposed to the immune system than 
individual CIR proteins, which are predicted to be differentially expressed. This 
difference in protein expression probably led to the stronger Ab response detected 
against MSP1p21 than any of the CIRs tested. It has been hypothesized that the majority 
of CIR proteins are expressed at levels below the threshold sufficient for induction of 
successful immune responses, thus providing a smoke-screen behind which parasites 
may continue to replicate (Cunningham et al., 2009). The transcription of many cir 
genes during P. chabaudi infection supports this idea (described in chapter 3.3.2), as do 
the low level Ab responses observed to CIRs even after four P. chabaudi infections. 
The highest Ab responses were to the CIR sub-family A-F specific peptide and 
PCHAS_000100 (sub-family E), followed by the CIR sub-family U specific peptide and 
the corresponding recombinant CIR PCHAS_040110. 
The Ab isotypes recognizing both sub-family specific CIR peptides were predominantly 
IgM and IgG2a, in the sera of mice which had experienced four P. chabaudi AS 
infections. IgM are usually the first Abs which appear during infection and do not 
undergo affinity maturation or somatic hypermutation to improve the specificity of 
antigen binding (Janeway, 2007). Nonetheless, the pentameric structure of IgM ensures 
high avidity binding to antigen, enables efficient complement fixation and can promote 
the lysis and / or agglutionation of pathogens (Janeway, 2007). The high levels of IgM 
Abs detected in response to CIR proteins have two plausible explanations. First, that 
few CIR-specific memory B cell responses were induced following P. chabaudi 
infection thus IgM provided an early defence at each infection. Or second, that memory 
did develop against CIRs, but that fewer CIR-specific B cells underwent maturation into 
IgG2a production, thus memory responses remained producing IgM.  
By contrast, IgG2a Abs are only produced after affinity maturation, somatic 
hypermutation and class switching, and are thus characteristic of a memory response 
(Janeway, 2007). As IgG2a was the predominant IgG isotype detected for CIRs after 
four P. chabaudi infections, this likely represents a memory response, as also detected 
for MSP1p21 in CB57Bl/6 mice [where the the equivalent isotype is IgG2c (Jouvin-
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Marche et al., 1989, Morgado et al., 1989)]. This Ab isotype has been shown to induce 
complement activation and bind Fcγ receptors more effectively than other IgG isotypes 
(Nimmerjahn and Ravetch, 2006, Nimmerjahn and Ravetch, 2005, Nimmerjahn et al., 
2005). Passive transfer of IgG2a Abs from Plasmodium-immune mice to naïves have 
also been shown to provide more protection than other isotypes, for example; delaying 
the onset of parasitaemia for P. yoelii infection (White et al., 1991), and inhibiting RBC 
re-invasion for P. chabaudi AJ (Cavinato et al., 2001), compared to IgG1 Abs. The 
contribution of IgG2a Abs recognizing CIR proteins to these effects is as yet unknown. 
The immune recognition of other PIRs has only been investigated in two studies to date, 
focussing on the VIRs. Fernandez-Becerra and colleagues found that approximately 
three quarters of P. vivax infected patients had generated Abs recognizing at least one of 
the 22 VIR proteins analyzed, showing that VIR proteins were immunogenic in natural 
infection (Fernandez-Becerra et al., 2005). This work was extended by Oliveira and 
colleagues, who surveyed the reactivity of 200 patients’ sera against seven recombinant 
VIRs (Oliveira et al., 2006). Approximately half of all P. vivax patients had a 
measurable IgG or IgM response to at least one of the seven VIRs, measured by ELISA.  
By contrast, 90.5% of individuals had measurable IgG responses against MSP119. 
Similarly, titres of Abs in the sera of P. chabaudi infected mice were consistently higher 
against MSP1p21 than CIRs.  
IgG and IgM Abs recognizing at least one of the 7 recombinant VIRs were found 
respectively in the sera of 26% and 29.6% of P. vivax infected individuals. The high 
proportion of IgM recognizing VIRs appears similar to what was detected for CIRs, 
however, a definitive comparison cannot be made as no distinction was made between 
the number of P. vivax infections experienced by the patients (Oliveira et al., 2006).  
Unlike Ab responses to CIR proteins, which increased after each P. chabaudi infection, 
the proportions of patients making a positive IgG response to VIR did not increase with 
the number of P. vivax infections experienced (Oliveira et al., 2006). There was no bias 
in the isotype of IgG Abs in patient sera recognizing recombinant VIR proteins from 
each sub-family (Oliveira et al., 2006). This suggests that, unlike for the CIRs, anti-VIR 
Ab responses were not dominated by a particular IgG isotype, although again, 
comparison is difficult owing to the varying number of P. vivax infections experienced 
by the different patients surveyed. 
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Dissection of anti-PIR immunity is complicated in the field, due to variation between 
individuals and the infecting parasites. Equally, the presence of Abs recognizing PIR 
proteins does not inform whether they have any role in protection against either 
infection or disease. In fact many ‘blocking Abs’ can be induced in response to 
particular epitopes of Plasmodium proteins, which prevent effector Abs from reaching 
their target [for example, (Uthaipibull et al., 2001)]. P. chabaudi challenge of CIR-
immunized mice was thus carried out to determine whether immunity generated against 
CIR proteins could play a role in the outcome of the infection. Immunization to induce 
high titres of anti-CIR Abs was carried out in the presence of Abisco adjuvant, which 
was derived from saponin. Adjuvants influence the titre of induced Abs, their isotypes 
and avidities, and can mediate other effects (Oda et al., 2000).  Saponin based adjuvants 
are useful as they can stimulate cell mediated immunity in addition to enhancing Ab 
production (Oda et al., 2000). Due to time constraints, the isotype distribution of Abs 
induced by CIR-immunization was not investigated, and should be ascertained. 
However, it is known that immunization in the presence of saponin based adjuvants 
often induces high titres of IgG1 and IgG2a Abs [for example (Fleck et al., 2006), 
http://www.isconova.com/products/abisco-research-reagent/abisco-100.aspx]. This was 
likely to also be the case for the CIR-immunized mice. 
All immunized mice made Ab responses to the antigen they were immunized with. Abs 
present in the sera of mice immunized with sub-family specific CIR peptides also 
recognized the corresponding recombinant CIR protein, probably due to recognition of 
the equivalent peptide within the recombinant CIRs by these Abs. The two recombinant 
CIR proteins, whilst representing different major sub-families, were likely to share 
conformational determinants, which would induce cross-reactive Abs after 
immunization. This may explain why sera from mice immunized with one recombinant 
CIR contained Abs that could also recognize the other one.  
Upon challenge of all other CIR-immunized mice there were few differences in 
parasitaemia compared with saline immunized controls. This could have been due to 
several reasons. The first, that induced Ab titres were too low to have an effect, may 
have applied to mice immunized with the CIR cocktail, as the sera of these mice 
contained very low titres of Abs against all CIR antigens. The second explanation could 
be that the CIR targets were not exposed to the immune system for induced anti-CIR 
Abs to have an effect. This is the most likely explanation for mice immunized with the 
conserved CIR peptide, as the hydrophobic core of CIR proteins was probably 
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inaccessible to these Abs. The relevant CIRs in other immunized mice may also have 
remained within the iRBC or were not expressed by many parasites in the infecting 
population. In the latter case, iRBCs expressing CIRs not recognized by the induced 
Abs would have a selective growth advantage in the immunized mice.  
Anti-CIR Abs induced by immunization could only contribute to protective effects if 
their protein target were exposed during P. chabaudi infection. Some CIR proteins were 
detected near to or at the iRBC surface (described in chapter 5), which may correlate to 
the members of CIR sub-family U, if the CIR sub-families do display similar 
localizations to those of the A- and B- type RIFINs. Thus, mice immunized with the 
CIR sub-family U peptide and protein PCHAS_040110 were expected to be protected 
better than mice immunized with the CIR sub-family A-F peptide or PCHAS_000100. 
Surprisingly however, the reverse was observed, and mice immunized with 
PCHAS_000100 experienced earlier parasite clearance than all other groups. The reason 
for this is unclear. It could be that PCHAS_000100 was simply more representative of 
native CIRs than PCHAS_040110, that the higher titres of Abs recognizing this protein 
were able to cross-react with other members of the CIR repertoire, that PCHAS_000100 
was the dominant CIR protein expressed during the P. chabaudi challenge infection, or 
a combination of these.  
Another interesting possibility comes from the observation in chapter 5, that CIRs were 
located at the apical end of merozoites. Cavinato and colleagues have suggested that 
Abs present in the sera of P. chabaudi AJ ‘hyper-immune’ mice could predominantly 
reduce parasite numbers at the RBC re-invasion stage rather than, for example, by 
opsonization of iRBCs (Cavinato et al., 2001). This is likely to act upon merozoite 
proteins such as MSP1 and AMA1, but it is possible that CIRs are also affected by such 
mechanisms. However, as the effect of Abs recognizing PCHAS_000100 was only 
apparent after day 7 of P. chabaudi challenge, it is likely that they did not act to inhibit 
RBC invasion. Instead, other mechanisms may have contributed to parasite clearance in 
PCHAS_000100 immunized mice, which may have involved Ab recognition of 
merozoites rather than iRBCs. 
A trend for increased parasitaemia was observed on day 7 of infection in four of the 
CIR immunized groups. Peripheral parasitaemia was measured at 9pm in the challenged 
mice (housed under normal light conditions, where schizogony would be expected to 
occur at midnight). It is possible that Abs induced by CIR-immunization were able to 
prevent sequestration of late-trophozoite iRBCs at this time, causing an efflux of iRBC 
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in the periphery, compared to control mice where the iRBCs were able to sequester in 
the deep vasculature. The VIR proteins have recently been implicated in cyto-adhesion 
of some P. vivax iRBCs, albeit in a preliminary experiment where not all anti-VIR anti-
sera produced equivalent effects (Carvalho et al., 2010). If the ability of VIR proteins to 
mediate cyto-adhesion is substantiated, other PIR proteins could also play a role in 
sequestration. Then, the above mechanism could explain the higher parasitaemia 
observed in mice immunized with conserved CIRs or those predicted to be at the iRBC 
surface. 
No substantial differences between the MSP1p21 and saline immunized mice were 
observed, confirming similar results obtained during P. chabaudi challenge of mice 
immunized with the recombinant C-terminus of MSP1 (O'Dea et al., 1996, Hensmann et 
al., 2004). This can be explained by the fact that low numbers of CD4 T-cells recognize 
the C-terminal region of MSP1 (Quin and Langhorne, 2001). During infection, CD4 T-
cells recognizing epitopes in the central region of MSP1 provide necessary help to 
mount an effective Ab response against the C-terminus (Quin and Langhorne, 2001). 
However, after immunization with only the C-terminal region, such help may be 
lacking. Low proliferative T cell responses have also been observed in relation to VIR 
proteins (Oliveira 2006). This may indicate that PIR proteins, like MSP1p19 and its 
equivalents, fail to induce effective CD4 help for Ab production, which would also 
explain the high levels of IgM observed in response to CIR proteins, after four P. 
chabaudi AS infections, Figure 45. 
Since parasitaemia was expected to be too crude a measure to detect changes in the 
parasite response to anti-CIR immunity, parasite transcription was measured at the 
expected peak of infection. Whilst the majority of parasites displayed no substantial 
changes in cir expression compared to the donor mouse, there were some differences. 
For example, significantly lower levels of cir sub-family E and U transcripts were 
detected in mice immunized with the conserved CIR peptide, than in control mice, 
immunized with saline. Non-significant, but substantial changes were also observed 
upon P. chabaudi challenge of mice immunized with sub-family specific reagents. The 
detection of cir sub-family U transcripts increased after immunization with the opposite 
CIR sub-family A-F specific peptide. The converse, increased levels of cir transcripts 
belonging to sub-family E, was observed in mice immunized with the sub-family U 
specific peptide and the recombinant sub-family U CIR protein PCHAS_040110. In 
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addition, iRBCs isolated from mice immunized with PCHAS_040110, had reduced 
levels of the corresponding transcript.  
These data suggest that in the face of a CIR protein or sub-family specific immune 
response, iRBCs expressing less of those cirs (and instead transcribing others) were 
able to dominate the P. chabaudi infection. This could have been due to immune-
mediated destruction of iRBCs expressing the corresponding CIR protein(s), and 
subsequent expansion of an iRBC population expressing different CIRs. Alternatively, 
switching of cir / CIR expression could have allowed iRBCs to evade specific 
immunity. This phenomenon was characterized for the VSAs of P. knowlesi and is also 
known to occur in P. chabaudi, permitting establishment of chronic infection (Brown 
and Brown, 1965, McLean et al., 1982, McLean et al., 1986). Whilst no change was 
observed in the majority of iRBCs, this may reflect the limited detection of cir family 
members by RT-qPCR and cir switching events may have occurred without detection. 
It is also possible that other related cir gene transcripts may have increased, which were 
not detected by RT-qPCR. The limited number of cirs that could be analyzed by this 
methodology means that whole transcriptome sequencing of the parasites in P. 
chabaudi challenged mice may be more informative than RT-qPCR. If the sensitivity of 
RNA sequencing methods were improved (as discussed in chapter 3.4), this would 
allow detection of the switch in dominant cir transcript between the infections of donor 
and challenge mice. Similarly, proteomic techniques could be used for the detection of 
dominant CIR proteins.  
The experiments presented here indicate that not only are CIR proteins recognized by 
the immune response following P. chabaudi infection, but immunization with CIR can 
affect both the parasitaemia during a P. chabaudi challenge and also the parasite 
transcriptional response, whether by immune selection of different parasites or by active 
alteration of cir transcription in the face of a specific Ab response. Future experiments 
should be carried out to elucidate the true effect of CIR immunization, using larger 
group sizes and a lower infectious dose of P. chabaudi to enable clearer observation of 
the effects of anti-CIR Abs. In addition, it is feasible that immunization with CIR 
proteins could reduce the proportion of iRBC in the population that are associated with 
parasite virulence, without affecting total parasitaemia. To investigate this possibility, 
measures of pathology such as weight loss, reduction in temperature, lethargy, and 
anaemia in the mice should be implemented. 
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The recent development of technologies to permit effective P. chabaudi transfection 
(Spence et al., 2011) has allowed the generation of luminescent P. chabaudi in our 
laboratory. These parasites could be used to indicate sites of P. chabaudi sequestration 
by whole body imaging and subsequent dissection of organs. If CIR proteins are 
involved in sequestration, CIR-immunized mice may display differences in the parasite 
distribution during challenge infection.  
Another application of P. chabaudi transfection (Spence et al., 2011) could be to 
manipulate CIR expression in these parasites. Unfortunately, given the large family 
size, cir ‘knock-outs’ would not be practical to attempt, meaning that subsequent 
complementation with a single cir would not be possible. Thus, analysis of a single cir 
in isolation would probably be infeasible. An alternative strategy could be to over-
express a particular cir gene, such that all transfectants would display the same CIR at 
the iRBC surface, as discussed in chapter 5. Immunizing mice with that CIR protein 
may then permit the detection of specific immune responses more clearly.  
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Chapter 7: Final perspectives
 
The work presented in this thesis has sought to characterize the cir multi-gene family of 
P. chabaudi, by analysis of their sequences, transcription, protein structure, cellular 
localization and immune recognition. 198 cir genes were identified in the P. chabaudi 
genome, 86% of which clustered to form two major sub-families and six minor ones, on 
the basis of sequence similarity. Reagents were designed to analyze cir gene and CIR 
protein expression during the blood stages of P. chabaudi infection. Transcripts 
belonging to all cir sub-families were detected at low levels by RT-qPCR and RNA 
sequencing. Each RNA sequencing sample contained a dominant cir transcript, both of 
which were members of cir sub-family U. CIR localization in blood stage parasites was 
determined by confocal microscopy and flow cytometry, detecting CIRs at the apical 
end of merozoites and located within the PV of iRBCs. In addition, CIRs were also 
found at the infected erythrocyte surface of some mature trophozoites. After P. 
chabaudi infection, low titres of Abs were detected, which were predominantly IgG2a 
and IgM isotypes. Immunization with CIRs mostly did not influence subsequent P. 
chabaudi challenge either by altering parasitaemia or the levels of cir transcripts. 
However, one of the recombinant proteins resulted in significantly earlier parasite 
clearance, and whilst the other did not, the corresponding transcript was reduced.  
Many similarities to other members of the PIR super-family were detected in the CIR 
repertoire, in their amino acid sequence features and the identification of sub-families 
containing similar sequences [chapter 2, (Del Portillo et al., 2001, Janssen et al., 2002, 
Janssen et al., 2004, Merino et al., 2006, Fonager et al., 2007)]. Other features shared by 
CIRs and other PIRs included the detection of many transcripts during the blood stages 
of infection [chapter 3, (Bozdech et al., 2008, Cunningham et al., 2009)], localization of 
proteins near to or at the surface of trophozoite stage iRBCs [chapter 5, (Del Portillo et 
al., 2001, Janssen et al., 2004, Cunningham et al., 2005, Fernandez-Becerra et al., 2005, 
Petter et al., 2007, Niang et al., 2009, Joergensen et al., 2010, Khattab and Meri, 2011)], 
and relatively low titres of Abs recognizing these proteins detected in the sera after 
Plasmodium infection [chapter 6, (Oliveira 2006)].  
The PIR super-family had previously been proposed to include the RIFINs of P. 
falciparum, however, evidence to support this beyond similarities of the intron and 
amino acid sequences was lacking (Janssen et al., 2004). Several features observed in 
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common for the RIFIN and CIR repertoires, presented in this thesis, suggest that indeed 
the PIR and RIFIN proteins may form part of a Plasmodium-wide multi-gene family. 
Notably, both CIR and RIFIN repertoires cluster to form two major sequence sub-
families, one of which is predicted to have undergone functional divergence, whose 
members contain an insertion containing two conserved cysteine residues (Petter et al., 
2007, Joannin et al., 2008). The close position of the cysteine residues was similar 
between the sub-family A RIFIN and CIR sub-family U amino acid motifs. Cysteine 
residues often participate in the formation of disulphide bridges [reviewed by (Sevier 
and Kaiser, 2002)], which suggests that the differential cysteine compositon of CIR and 
RIFIN sub-families could affect their tertiary structure. The structure of both PIR and 
RIFIN proteins was predicted to comprise alpha helices of 12-20 amino acids, separated 
by coiled-coil regions (Janssen et al., 2004). In this thesis, the first experimental 
evidence for PIR protein structure was presented, using the recombinant CIR protein 
PCHAS_000100. Circular dichroism detected 44% alpha helices within this protein, a 
measurement which falls within the range predicted by Janssen and colleagues (Janssen 
et al., 2004), and also suggests that PCHAS_000100 was folded similarly to native CIR 
proteins. 
The majority of PIR proteins are predicted to contain at least one TM domain, a feature 
which has led to predictions that the C-terminus of most PIR proteins is intra-cellular, 
whilst the N-terminus is exposed at the iRBC surface (Del Portillo et al., 2001, Del 
Portillo et al., 2004). Pain and colleagues have proposed the existence of a PIR protein 
domain, which may be repeated up to three times beyond the TM domain (Pain et al., 
2008), and is likely to also be present within the CIR proteins. Informatic predictions 
have suggested that B-type RIFINs may contain two TM domains, whilst sub-type A 
proteins contain one (Bultrini et al., 2009). Modelling the structure of an A-type RIFIN 
from primary amino acid sequence has indicated the presence of an Armadillo fold 
(Bultrini et al., 2009), which is characterised by alpha-helices arranged to form a wide 
cleft with an extensive solvent-accessible surface and typically able to bind large 
substrates [reviewed by: (Coates, 2003)]. Further experimental analyses are required to 
verify this prediction, which may gain insight into potential binding partners. 
Members of the two RIFIN sub-families have been shown to display different cellular 
localizations (Petter et al., 2007). Whilst this has not shown for the two major CIR sub-
families, Abs recognizing a broad range of CIRs reproduced both patterns observed for 
the A and B-type RIFINs: within the iRBC cytoplasm and within the PV [chapter 5, 
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(Petter et al., 2007)]. If a similar distinction in protein localization were confirmed for 
the two CIR sub-families, this would provide strong support to the inclusion of PIRs 
and RIFINs in one super-family.  
The dedication of a large proportion of the Plasmodium genome to accommodate multi-
gene families indicates that their encoded proteins may be important for parasite 
survival. Similarities identified between the PIRs and RIFINs have suggested that these 
proteins are analogous, and may form a ubiquitous multi-gene family, present in all 
Plasmodium species sequenced to date. If this is the case, STEVOR and PfMC-2TM 
proteins may also be included due to their shared sequence characteristics (described in 
chapter 1.8). Thus, it is important to uncover the function(s) of these proteins, which 
would aid their classification, and fundamentally aid understanding of malaria parasites. 
The detection of CIR proteins exposed at the surface of some iRBCs in chapter 5, 
provides the first piece of evidence that CIRs may interact with the host immune 
response. YIR proteins have also been detected in this location, and yir transcription 
shown to change substantially during a secondary P. yoelii infection of immuno-
competent mice, but not in immuno-compromised animals (Cunningham et al., 2005). It 
has been hypothesized that the majority of PIR proteins are expressed at levels below 
the threshold sufficient for induction of successful immune responses, thus providing a 
smoke-screen behind which parasites may continue to replicate (Cunningham et al., 
2009). The transcription of many cir genes during P. chabaudi infection supports this 
idea (chapter 3), as do the low level Ab responses observed to CIRs even after four P. 
chabaudi infections (chapter 6). 
Any CIRs exposed at the iRBC surface could potentially mediate antigenic variation. P. 
chabaudi is known to express variant antigens during the late trophozoite stages of 
development in the bloodstream (Brannan et al., 1994), and to undergo immune evasion 
(McLean et al., 1982, McLean et al., 1986). Antigenic variation has also been shown to 
correlate with the ability of P. chabaudi iRBCs to sequester and to maintain chronic 
infection (Gilks et al., 1990). Whilst the antigens responsible have not been definitively 
characterized, early experiments were able to clone a P. chabaudi gene, of which the 
expressed fusion protein retained reactivity with variant specific anti-sera and induced 
some protection during an immunization and challenge experiment (Phillips et al., 
1997). The whole gene product was 597 amino acids (Phillips et al., 1997), within the 
size range of the cir repertoire.  
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Evidence that may support a role for cir genes in antigenic variation was observed 
during the P. chabaudi challenge experiment, presented in chapter 6. Mice immunized 
with CIR sub-family specific reagents had increased levels of cir transcripts belonging 
to the other major sub-family, and some decrease of the corresponding or similar cir 
transcripts, during a P. chabaudi challenge infection. It is likely that immune selection 
against iRBCs expressing the equivalent proteins favoured the growth of parasites 
expressing other CIRs, recapitulating the differences in P. chabaudi antigens previously 
observed between primary and recrusdescent peaks of infection (McLean et al., 1982, 
McLean et al., 1986). 
Another phenomenon observed during the P. chabaudi challenge experiment was a 
trend for increased parasitaemia on day 7 of infection in certain CIR-immunized groups. 
As parasitaemia was measured at 9pm, when parasites would be predominantly late 
trophozoite stage, it is possible that Abs induced by CIR-immunization were able to 
prevent sequestration at this time. This would cause an efflux of iRBCs into the 
peripheral blood, compared to control mice where the iRBCs were able to sequester in 
the deep vasculature. It is possible that PIR proteins could mediate cyto-adhesion in the 
deep vasculature in regions where less rapid blood flow occurs, as non P. falciparum 
species are known to sequester to some extent (Mota et al., 2000, Franke-Fayard et al., 
2005, Carvalho et al., 2010, Gilks et al., 1990). P. vivax iRBCs have recently been 
shown to bind endothelium with an equivalent strength to P. falciparum iRBCs, 
although the attachment process was slower (Carvalho et al., 2010). Preliminary data 
has implicated the VIR proteins in this process (Carvalho et al., 2010), although this 
awaits confirmation.  
Predictions based upon features of known adhesive proteins (Sachdeva et al., 2005), 
when applied to Plasmodium have suggested that PIR and RIFIN proteins could be 
potential parasite adhesins (Ansari et al., 2008). Besides sequestration, another role for 
adhesive proteins is during attachment and invasion of RBCs. The detection of CIR 
proteins at the apical end of merozoites (chapter 5), similar to A-type RIFINs and 
STEVORs (Blythe et al., 2008), suggests that these proteins mediate functions in 
several stages of parasite development. STEVOR proteins additionally appear to coat 
the merozoite surface (Khattab and Meri, 2011). Anti-STEVOR Abs have been 
postulated to inhibit RBC invasion (Garcia et al., 2005), however, to date the evidence 
is not clear. Different studies have shown anti-STEVOR Abs and peptides either to 
inhibit RBC invasion or to have no effect, according to the concentration used (Garcia 
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et al., 2005, Khattab et al., 2008). If STEVOR proteins are truly involved in RBC 
invasion, it has been postulated that their biological role could involve the deflection of 
specific immunity away from essential invasion machinery (Khattab et al., 2008).  
Potentially, the PIR proteins could also play a role in RBC invasion process, and in fact 
approximately 30 yir genes were found to be up-regulated during P. yoelii challenge of 
mice immunized with merozoite surface protein 8 [MSP8, (Shi et al., 2005)]. MSP8 
immunization is believed to protect mice from lethal P. yoelii 17XL infection by 
restricting parasite invasion to reticulocytes (Shi et al., 2005). Thus PIR proteins could 
conceivably act as the required alternative RBC invasion ligands or could shield the 
crucial ligands from the immune response.  
Although not investigated here, CIR proteins could also play a role in other stages of the 
P. chabaudi life-cycle. Transcription or protein expression has been detected for PIRs 
and RIFINs in gametocytes, sporozoites and mosquito stages, (Florens et al., 2002, Hall 
et al., 2005, Petter et al., 2008, Wang et al., 2010). Their function(s) in these stages may 
involve evasion of mosquito immunity for ookinetes and innate mammalian immunity 
for sporozoites, or adhesion of oocysts. Insects and innate vertebrate responses are 
known to share features of complement and immune signalling (the insect pathways 
Toll, Imd and Hop, are equivalent to the mammalian TLR, TNFα and JAK/STAT 
pathways [reviewed by (Vilmos and Kurucz, 1998, Pinheiro and Ellar, 2006)]. In 
addition, a role for PIR proteins during invasion of the mosquito mid-gut and 
mammalian hepatocytes is also possible, if also true within the blood stages of the 
lifecycle. These possibilities are speculative and await evaluation. 
The work presented in this thesis has raised several interesting lines of enquiry 
regarding the function of CIR proteins during the blood stages of P. chabaudi infection. 
A crucial question is whether proteins belonging to the two major CIR sub-families 
display differential sub-cellular localization, as observed for the RIFINs. Once 
answered, this will enable predictions about the role of CIRs during P. chabaudi 
infection, may illuminate results of the P. chabaudi challenge experiment and may 
strengthen the similarities observed between CIRs and RIFINs. The recombinant CIR 
proteins or sub-family specific peptides may be used to produce polyclonal Abs for this 
purpose.  
Tools generated here may also be used to investigate the role of CIR proteins in cyto-
adhesion, RBC invasion and antigenic variation during P. chabaudi infection. For 
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example, RNA sequencing could be used in combination with proteomic approaches, 
providing a powerful means of analysis for the whole cir repertoire. The sensitive 
nature of RT-qPCR could enable detection of certain cir transcripts in individual 
iRBCs, as shown previously for the yirs and virs (Fernandez-Becerra et al., 2005, 
Cunningham et al., 2009).  
If the PIR and RIFIN families are related, it is possible that the mechanisms regulating 
their expression are similar, and may incorporate features of var gene regulation 
(Howitt et al., 2009). Plasmodium VSAs often appear to be down-regulated during in 
vitro culture (Dzikowski and Deitsch, 2008, Howitt et al., 2009), thus functional 
analyses of VSA proteins would be best carried out in vivo. Investigations of VSA 
regulation in P. falciparum have focused on the var genes, which appear to require a 
substantial epigenetic contribution, as discussed in chapter 1.8.3. However, analyses of 
the regulation and functions of Plasmodium VSAs should also prioritize the PIR super-
family, which may include the RIFINs, given their ubiquitous nature and likely 
importance for parasite survival.  
VSAs encoded by Plasmodium multi-gene families are likely to mediate antigenic 
variation, in addition to other possible functions. Whilst antigenic variation has long 
been assumed to be responsible for chronic infection and the evasion of host immunity, 
evidence has only been generated recently, for the intestinal parasite Giardia lamblia. In 
this parasite, disruption of the RNA interference pathway, which regulates VSP 
expression (Prucca et al., 2008), resulted in simultaneous expression of all VSPs 
(Rivero et al., 2010). Immunization with purified VSPs from these parasites completely 
protected gerbils from G. lamblia infection, which may have applications for vaccine 
development. Similar disruption of antigenic variation in Plasmodium may also be 
possible if the mechanisms underlying VSA regulation were understood, which could 
have important applications to malaria vaccine design strategies.  
Clearly there is still a great deal to learn about the large multi-gene families present in 
all Plasmodium species, particularly with respect to their possible host-interactions such 
as sequestration and immune evasion. These investigations are most accessible in rodent 
models, following which mechanisms can be confirmed by patient studies. The cir 
multi-gene family of P. chabaudi may provide an ideal model system for such research.
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Appendices 
Appendix 2.1 Common Plasmodium splice sites 
Splice boundary DNA sequence Amino acid sequence 
Exon 1 / Intron 1 TG / GT EL or KL or LM or NV / - 
Intron 1 / Exon 2 AG / TG or AG / TA - / CG or CK or CD or CE 
Exon 2 / Intron 2 TG / GT YK / - 
Intron 2 / Exon 3 AG / TA - / YSLF 
 
The sequences above are commonly found at the boundaries of Plasmodium exons and 
introns (personal communication, Dr U. Böhme). During cir gene annotation (chapter 
2.2.1), where these sequences flanked regions without stop codons, this indicated the 
site of a potential ORF. 
 
 
Appendix 2.2  Comparison of PIR alignments  
136 PIR and 500 rodent PIR amino acid sequences were aligned using Muscle (Edgar, 
2004). Sequence similarity for each alignment was plotted using Plotcon 
(http://emboss.bioinformatics.nl/cgi-bin/emboss/plotcon). Gaps present in the alignment 
are indicated by low sequence similarity.  
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The following appendices for chapter 2 were not suitable for print due to their large 
size, however they are enclosed within the CD accompanying this thesis. Appendices 
2.2, 2.5, 2.7, 2.11 and 2.13 are FASTA files, which may be viewed using software such 
as Bioedit (Hall, 1999). The remaining appendices for chapter 2 are TIFF or PDF files, 
and may be viewed using software such as Adobe Photoshop. 
 
Appendix 2.3 Alignment of 107 CIR amino acid sequences.  
Appendix 2.4 Maximum likelihood tree of 107 CIRs.  
Appendix 2.5 NeighborNet network of 107 CIRs.  
Appendix 2.6 Alignment of 117 CIR amino acid sequences.  
Appendix 2.7 Maximum likelihood tree of 117 CIRs.  
Appendix 2.8 NeighborNet network of 117 CIRs.  
Appendix 2.9 Alignment of 183 CIR amino acid sequences.  
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Appendix 3.1 cir primer design  
 
Appendix 3.1.1 Location of cir primers within a typical cir gene  
This figure illustrates a typical cir gene and its encoded protein, with regions of 
sequence conservation highlighted by hashed lines. In order to amplify a small number 
of cir genes from different sub-families with different primer pairs, primer design was 
focussed within the variable sequence towards the 5’ end of cir genes. 
 
Two strategies were initially employed for cir primer design: The first, indicated above 
by blue arrows, used a forward primer that spanned an exon: exon boundary. These 
primers are listed in Appendix 3.1.2. The second, indicated above by red arrows, used 
both primers situated within the cir second exon. These primers are listed in Appendix 
3.1.3 
 
 Appendix 3.1.2 Strategy 1) Design of exon: exon boundary spanning primers 
Primer design was described in chapter 3. The cir sub-family targeted by the primers is indicated in the 
ID column. The forward (Fwd) and reverse (Rev) sequences are given for each primer pair, where the 
reverse primer sequence shown is the reverse complement (RC) of that present in the corresponding cir 
gene. Tm refers to the melting temperature of each primer. The product size is shown as length in 
nucleotides. 
 
 
 
 
 
ID Fwd. sequence Rev. sequence (RC) 
BLAST 
matches  
Predicted 
dimers 
Product 
size 
Tm 
Tm 
difference 
A ATGGCTGAAAATATGTGTAGAAG ACATTGTCGATTTGGCCATC 
PCHAS_073190 
PCHAS_100030
8 296
58.7 ºC 
64.7 ºC
6.0 ºC
B ATGTCTAAGGGAGTGTGTGAAG GCTCGAACATCACTAGCAACC 
PCHAS_000410 
PCHAS_000320
8 202
59.7 ºC 
63.7 ºC
4.0 ºC
B " TGTCCATTTCTCCCATTGTTC
PCHAS_000410 
PCHAS_000320
6 140
59.7 ºC 
63.6 ºC
3.6 ºC
C ATGTCTAAGAAAGTGTGTGAAGC ATTTTTCGGGATAGGGCAAT
PCHAS_120020 
PCHAS_130020
5 126
59.0 ºC 
63.1 ºC
4.1 ºC
D CTGCAGTGTGTAACGCAATTAAAG ATCACCATCGTAAACATCAACAAGAT PCHAS_070130 8 217
64.4 ºC 
65.2 ºC
0.8 ºC 
D ATGGCTTATGGAGTGTGTAACG GCGTATTCGGCAAGTTTATCA
PCHAS_120070 
PCHAS_001130
4 251
62.6 ºC 
63.7 ºC 
1.1 ºC
D " TCAATGCATGGTTAGGGGTAA
PCHAS_120070 
PCHAS_001130
4 100
62.6 ºC 
63.9 ºC 
1.3 ºC
E TAAGATTGAGGATGTGTATAATGA TCTTTTTCTTGTCTATCGTCGTAATG PCHAS_000100 7 137
56.8 ºC 
63.2 ºC
6.4 ºC
E
CAAGTTATAAGATTGAGGATGTGTATAAA
G
GCGTATTCGGCAAGTTTATCAT
PCHAS_120060 
PCHAS_000420 
PCHAS_000310
7 252
61.1 ºC 
63.7 ºC
2.6 ºC
U GTCTAAGGAATTGTGTCAAGGAA TCTATGGATTTACCATCTTCTCC PCHAS_040110 5 341
60.9 ºC 
59.9 ºC
1.0 ºC
U ATGTCTGAGGAATTGTGTGGAG TTCCTTTTCCATCCTTTCCA
PCHAS_120030 
PCHAS_030030
7 85
62.9 ºC 
63.2 ºC
0.3 ºC
Stra egy 1) Design of sub-group specific i tron spanning primers
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Appendix 3.1.3 Strategy 2) Design of primers within the cir second exon 
 Primer design was described in chapter 3. The cir sub-family targeted by the primers is indicated in the 
ID column. The forward (Fwd) and reverse (Rev) sequences are given for each primer pair, where the 
reverse primer sequence shown is the reverse complement (RC) of that present in the corresponding cir 
gene. Tm refers to the melting temperature of each primer. The product size is shown as length in 
nucleotides. 
 
  
ID Fwd. sequence Rev. sequence (RC) 
BLAST 
matches  
Predicted 
dimers 
Product 
size 
Tm 
Tm 
difference 
A GGTGAGGGGTATGAAACGTC TGCAATCTGGTGGGTCACTA 
PCHAS_000270 
PCHAS_000090 
PCHAS_000030 
2 180
63.2 ºC 
64.2 ºC
1.0 ºC
PCHAS_000270
PCHAS_000090 
PCHAS_000030
PCHAS_070030
PCHAS_011520 
PCHAS_104250
PCHAS_000410
PCHAS_000320 
B TGGATGCAGCAATATTCCAA GCAATCCCCAAGAAAAGTGA PCHAS_000130 2 236
63.9 ºC 
63.9 ºC 
0.0 ºC
B “ TGAACCCGTTTACCAAATCC PCHAS_000130 7 197
63.9 ºC 
63.4 ºC
0.5 ºC
B TGCGAGTTTCCATCTCTTCCA TGCCCCTCTATCTTTGTAGGG
PCHAS_000400 
PCHAS_000330 
PCHAS_040020
4 226
67.0 ºC 
64.0 ºC
3.0 ºC 
B CTGTTCGCAAAATGCTGAAG CATGACTTGGCGTAGAACCTT
PCHAS_000400 
PCHAS_000080 
PCHAS_001070
4 227
63.5 ºC 
63.0 ºC
0.5 ºC 
PCHAS_114750
PCHAS_000140
C CTTCCACCACTTCCAACGAT GAGCCCGTTTATCAAATCCA PCHAS_130020 1 237
63.9 ºC 
63.6 ºC
0.3 ºC
C CGAGATGCTCAAGATTTTGCT CGATGAACTTGGTGGTGCTT
PCHAS_030030 
PCHAS_000350 
PCHAS_110020
4 249
63.3 ºC 
65.0 ºC
1.7 ºC
C CAAGGATGAGGAAGGCACAT GCTTCACCAGACATTTTCTCAA PCHAS_030030 6 198
64.0 ºC 
63.1 ºC
0.9 ºC
D CGCAATTAAAGCGATCGATAA TCCCTTTTTGTGGGTTTTGA PCHAS_070130 7 280
63.6 ºC 
64.1 ºC
0.5 ºC 
PCHAS_120070
PCHAS_000300
PCHAS_001130
PCHAS_100040
PCHAS_001130
PCHAS_120070
PCHAS_100040 
D GGCTTCTGCAGTGTGTGGT GCGTATTCGGCAAGTTTAGC PCHAS_100040 2 248
64.2 ºC 
63.5 ºC
0.7 ºC
E TTGATGAGGATGAAAATGATGG CAAATGAATAACACCAGAACTAGTCA PCHAS_000100 6 140
63.5 ºC 
62.0 ºC
1.5 ºC
PCHAS_000100
PCHAS_000420 
PCHAS_000340
PCHAS_104230
PCHAS_030040
PCHAS_040040 
PCHAS_000340
PCHAS_104230
PCHAS_030040
PCHAS_040040
U TGGCCTAAAAATTGGCTCTG TCTATGGATTTACCATCTTCTCC PCHAS_040110 -2.16 213
63.9 ºC 
59.9 ºC
4.0 ºC 
PCHAS_040050
PCHAS_001050 
U GTGCTGCTTCGTATCGTTCA CTGCCTTCGGTGCGTATATT PCHAS_070100 1 249
64.0 ºC 
63.8 ºC
0.2 ºC
U " TTCCTTCTGGTGGCTTCAAT PCHAS_070100 0 149
64.0 ºC 
63.5 ºC
0.5 ºC
U CTGACTTGTATCGCGCATGT
ACACTGGCTTTATGCCGTTC
PCHAS_042030 
PCHAS_040110 
PCHAS_030210 
PCHAS_060060
3 199
63.9 ºC 
63.9 ºC
0.0 ºC
U GAACGGCATAAAGCCAGTGT TCGCCATACGGGTGTTAAAT
PCHAS_040230 
PCHAS_146770 
PCHAS_030210 
PCHAS_060060 
PCHAS_060050 
PCHAS_040110
4 207
63.9 ºC 
63.9 ºC
0.0 ºC
Strategy 2) Design of sub-group specific non-intron spanning primers
TTACCCCTAACCATGCATTGA GCGTATTCGGCAAGTTTATCA D 5 171
3 138
A CACCAGATTGCACCAAACAT GGGGGATATTGTCACAACCA 3
0.4 ºC 
0.9 ºC
0.5 ºC
0.2 ºC 
0.9 ºC
8.0 ºC 
1.1 ºC 
0.2 ºC 
0.5 ºC
188
63.5 ºC 
64.4 ºC
B CATTCCTTAATAATAATGATGTTG GTCGTTGGAAGGAGTGGAAA 
56.0 ºC 
64.0 ºC
C GAATGCACCGAACTTCCAAC GCAAATCCCAAGAAAATTGG 5 142
64.4 ºC 
63.0 ºC
63.9 ºC 
63.7 ºC
D ACCCCTAACCATGCATTGAA GCGTATTCGGCAAGTTTAGC 3 169
64.0 ºC 
63.5 ºC
63.6 ºC 
63.2 ºC
E 
TGGTGGTGATGGTCTGACTT
TTTTCGCAATCCGGATGT 0 152
63.2 ºC 
64.1 ºC
E CATCCCTCCCAGTTTATCCA TGGAATAATCCCTCTCTTCGAG 6 218
64.1 ºC 
63.6 ºC
U AACGTCGTTTTGGACTCAGC CATCTTCGCAGTTCCCCTAA 3 233
64.2 ºC 
64.0 ºC
E ACATCCGGATTGCGAAAA TGGATAAACTGGGAGGGATG 3 177
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Appendix 3.2 cir primer efficacy tested using PCR  
  
 
 
Appendix 3.2.1 Strategy 1) exon: exon boundary spanning primers 
This figure shows the amplification products of primers listed in Appendix 3.1.2, after 
endpoint PCR. Only one of the primers from strategy 1 (D2) showed marked 
amplification of any product. Primers designed using strategy 1 could thus either poorly 
amplify their target genes or the target cir genes may not have been expressed in the 
cDNA template. Since it would be difficult and lengthy to investigate which of these 
was the case, and in addition, extensive primer dimer formation (bands less than 100 bp 
in size) was observed for most primers, the use of all strategy 1 primers was 
discontinued at this point. 
 
 
Appendix 3.2.2 Strategy 2) primers within cir exons 
This figure shows the amplification products of primers listed in Appendix 3.1.3, after 
endpoint PCR. The majority of primers from strategy 2 amplified products of the 
expected size, between 150 and 250 bp. Primers that successfully amplified products are 
listed in Appendix 3.2.3 
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Appendix 3.2.3 Primers that amplified products by endpoint PCR. 
 
 
 
 
 
 
Pair 
no:
ID Fwd. sequence Rev. sequence (RC) 
BLAST 
matches  
Predicted 
dimers 
Product 
size 
Tm 
Tm 
difference 
1 A1 GGTGAGGGGTATGAAACGTC TGCAATCTGGTGGGTCACTA 
PCHAS_000270 
PCHAS_000090 
PCHAS_000030 
2 180
63.2 ºC 
64.2 ºC
1.0 ºC
3 B1 TGCGAGTTTCCATCTCTTCCA TGCCCCTCTATCTTTGTAGGG
PCHAS_000400 
PCHAS_000330 
PCHAS_040020
4 226
67.0 ºC 
64.0 ºC
3.0 ºC 
4 B2 CTGTTCGCAAAATGCTGAAG CATGACTTGGCGTAGAACCTT
PCHAS_000400 
PCHAS_000080 
PCHAS_001070
4 227
63.5 ºC 
63.0 ºC
0.5 ºC 
6 C2 CGAGATGCTCAAGATTTTGCT CGATGAACTTGGTGGTGCTT
PCHAS_030030 
PCHAS_000350 
PCHAS_110020
4 249
63.3 ºC 
65.0 ºC
1.7 ºC
9 E1 TTGATGAGGATGAAAATGATGG CAAATGAATAACACCAGAACTAGTCA PCHAS_000100 6 140
63.5 ºC 
62.0 ºC
1.5 ºC
12 U2 TGGCCTAAAAATTGGCTCTG TCTATGGATTTACCATCTTCTCC PCHAS_040110 5 213
63.9 ºC 
59.9 ºC
4.0 ºC 
13 U3 CTGACTTGTATCGCGCATGT
ACACTGGCTTTATGCCGTTC
PCHAS_042030 
PCHAS_040110 
PCHAS_030210 
PCHAS_060060
3 199
63.9 ºC 
63.9 ºC
0.0 ºC
14 U4 GAACGGCATAAAGCCAGTGT TCGCCATACGGGTGTTAAAT
PCHAS_040230 
PCHAS_146770 
PCHAS_030210 
PCHAS_060060 
PCHAS_060050 
PCHAS_040110
4 207
63.9 ºC 
63.9 ºC
0.0 ºC
2
PCHAS_000270
PCHAS_000090 
PCHAS_000030
PCHAS_070030
PCHAS_114750
PCHAS_000140
PCHAS_120070
PCHAS_000300
PCHAS_001130
PCHAS_100040
142
64.4 ºC 
63.0 ºC
1.1 ºC 
A2 CACCAGATTGCACCAAACAT GGGGGATATTGTCACAACCA 3 188
63.5 ºC 
64.4 ºC
0.9 ºC
C1 GAATGCACCGAACTTCCAAC GCAAATCCCAAGAAAATTGG 5
PCHAS_001130
PCHAS_120070
PCHAS_100040
63.9 ºC 
63.7 ºC
0.2 ºC 
D2 ACCCCTAACCATGCATTGAA GCGTATTCGGCAAGTTTAGC 3 169
64.0 ºC 
63.5 ºC
0.5 ºC
D1 TTACCCCTAACCATGCATTGA GCGTATTCGGCAAGTTTATCA 5 171
E2 CATCCCTCCCAGTTTATCCA TGGAATAATCCCTCTCTTCGAG 6
PCHAS_000100
PCHAS_000420
233
64.2 ºC 
64.0 ºC
0.2 ºC 
63.6 ºC 
63.2 ºC
0.4 ºC 218
U1 AACGTCGTTTTGGACTCAGC CATCTTCGCAGTTCCCCTAA 3
PCHAS_040050
PCHAS_001050
5
8
7
10
11
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Appendix 3.3 RNA integrity   
 
Three experiments were carried out in chapter 3 to measure cir transcript levels during 
P. chabaudi infection by RT-qPCR. All mice were labelled with their cage number: 
 
• Figure 22a used P. chabaudi parasites expanded in a RAG2-/- mouse (JL1014) to 
infect three BALB mice (JL1017-1, 2 and 3). As the whole blood volume of 
these mice was taken, RNA was extracted from two or three aliquots per mouse. 
• Figure 22b used P. chabaudi parasites from the BALB/c mouse JL1017-1 to 
infect three RAG2-/- mice (JL1018-1, 2 and 3). As the whole blood volume of 
these mice was taken, RNA was extracted from two or three aliquots per mouse. 
• Figure 23 re-capitulated the experiment described in Figure 22b, using P. 
chabaudi parasites expanded in a BALB/c mouse to infect three RAG2-/- mice 
(JL1043 M1, M2 and M3). Samples were taken from these mice at 8.30 am, 
10.30 am, 12.30 pm and 10.30 pm. 
 
Appendix 3.3.1 Spectroscopy measurements of extracted RNA. 
 
Samples indicated with a * were pooled to produce a positive control for RT-qPCR 
(hereafter referred to as the cDNA pool). All other samples used to measure cir 
transcription in individual mice. 
Sample Tube
Concentration  
(ng/ul) 500ng A260/A280
Position in 
96 well plate
JL1014 RAG 1 213.63 2.34 1.92 D1
* 2 413.23 1.21 2.01 D2
* 3 232.95 2.15 1.94 D3
JL1017-1 BALB 1 341.09 1.47 1.96 D4
* 2 413.55 1.21 2.02 D5
JL1017-2 BALB * 1 592.93 0.84 1.87 D6
2 499.09 1.00 1.94 D7
JL1017-3 BALB * 1 510.49 0.98 1.75 D8
* 2 346.95 1.44 1.99 D9
3 334.6 1.49 2.00 D10
JL1018-1 RAG * 1 441.96 1.13 2.07 D11
2 457.95 1.09 2.10 D12
JL1018-2 RAG * 1 420.18 1.19 2.10 E1
2 415.23 1.20 2.08 E2
JL1018-3 RAG 1 591.55 0.85 2.07 E3
* 2 600.86 0.83 2.09 E4
JL1043 RAG 8-30am M1 232.02 2.15 1.87 E5
M2 260.55 1.92 1.91 E6
M3 334.55 1.49 1.98 E7
JL1043 RAG 10-30am M1 235.47 2.12 1.86 E8
M2 326.87 1.53 1.98 E9
M3 366.42 1.36 1.98 E10
JL1043 RAG 12-30pm M1 388.31 1.29 2.01 E11
M2 224.09 2.23 1.88 E12
M3 564.39 0.89 1.71 F1
JL1043 RAG 10-30pm M1 665.3 0.75 1.71 F2
M2 337.65 1.48 1.94 F3
M3 551.03 0.91 1.72 F4
* Samples pooled to make RNA pool (cDNA used as positive control for qPCR)
M refers to individual mouse from the specified cage (labelledJL…) 
All other numbers refer to aliquots extracted from the same mouse in different tubes.
 All other samples used to measure cir transcription in individual mice 
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Appendix 3.3.2 Gel electrophoresis of 500ng RNA. 
 
 
 
Where samples are numbered as follows: 
1) JL1014 M1-1 
2) JL1014 M1-2 
3) JL1017 M1-1 
4) JL1017 M1-2 
5) JL1017 M2-1 
6) JL1017 M2-2 
7) JL1017 M3-1 
8) JL1017 M3-2 
9) JL1017 M3-3 
10) JL1018 M1-1 
11) JL1018 M1-2 
12) JL1018 M2-1 
13) JL1018 M2-2 
14) JL1018 M3-1 
15) JL1018 M3-2 
16) JL1043 M1 8.30 
17) JL1043 M2 8.30 
18) JL1043 M3 8.30 
19) JL1043 M1 10.30 
20) JL1043 M2 10.30 
21) JL1043 M3 10.30 
22) JL1043 M1 12.30 
23) JL1043 M2 12.30 
24) JL1043 M3 12.30 
25) JL1043 M1 22.30 
26) JL1043 M2 22.30 
27) JL1043 M3 22.30 
 
Samples marked with * were precipitated and the concentrations re-measured prior to 
use for cDNA synthesis (data not shown). 
 
   
 
Appendix 3.4 RT-qPCR analysis    
 
Appendix 3.4.1 Process of analysis of raw Cq values from RT-qPCR data. 
  
Cq values obtained from RT-qPCR experiments were analyzed as outlined in chapter 3: 
 
1) Calculation of the mean Cq for each sample from three technical replicates. 
2) Calculation of the standard deviation for each mean Cq.  
3) Where one replicate caused the SD to increase above the 80% confidence level, 
this replicate was excluded. The mean and SD of the Cq values were re-
calculated from the two technical replicates.  
4) The following equation was used to calculate the ratio of change in cir 
transcript levels between the ‘control’ and ‘sample’ mice (Pfaffl, 2001):  
Ratio = (E cir) ΔCq cir (control - sample) / (E beta tubulin) ΔCq beta tubulin (control - sample) 
Where E represents primer efficiency. 
5) The standard deviation of differences in Cq between samples were calculated 
using the equation: SDΔCq = √ [(SD beta tubulin)2 + (SD beta globin)2] 
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The mean ratio, SD and number of technical replicates (N) used for figures 22 and 23 
are shown below, in appendices 3.5.2-4. The confidence interval (CI) is indicated by the 
following colour code. For example the maximum allowable SD that can distinguish a 
two-fold change in transcription levels with 99% confidence is 0.3. 
 
SD: < 0.3 < 0.4 < 0.525 < 0.650 < 0.775 > 0.775 
CI: 99% 95% 90% 85% 80% exclude 
 
 
Appendix 3.4.2 RT-qPCR data in Figure 21a (compared to donor mouse) 
 
U1 U4 C1 E1 
BALB/c 
mouse 
Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
1 0.33 0.04 2.00 0.24 0.28 2.00 1.31 0.21 3.00 0.69 0.15 3.00 
2 0.61 0.25 2.00 0.51 0.27 3.00 1.52 0.14 3.00 0.68 0.34 2.00 
3 0.61 0.10 3.00 0.08 0.32 2.00 1.12 0.28 2.00 0.29 0.41 3.00 
 
 
Appendix 3.4.3 RT-qPCR data in Figure 21b (compared to donor mouse) 
 
U1 U4 C1 E1 
Mouse 
Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
1 3.49 0.28 2.00 2.58 0.07 2.00 2.37 0.20 2.00 1.05 0.18 2.00 
2 1.89 0.36 3.00 2.07 0.12 2.00 0.76 0.18 3.00 1.81 0.25 3.00 
3 3.37 0.27 3.00 2.29 0.19 3.00 1.20 0.13 3.00 1.55 0.31 3.00 
 
 
Appendix 3.4.4 RT-qPCR data in Figure 22 (compared to 8.30h time-point) 
 
U1 U4 C1 E1 Time- 
point Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
10.30 M1 2.12 0.04 3.00 6.15 0.30 2.00 2.15 0.17 3.00 1.50 0.40 3.00 
10.30 M2 2.30 0.19 2.00 2.63 0.43 2.00 1.36 0.11 2.00 3.57 0.41 2.00 
10.30 M3 6.79 0.55 2.00 3.91 0.17 2.00 1.96 0.27 3.00 3.00 0.27 3.00 
12.30 M1 5.42 0.17 3.00 5.59 0.46 2.00 3.22 0.08 2.00 3.38 0.25 3.00 
12.30 M2 19.13 0.09 3.00 0.21 0.32 2.00 9.27 0.23 3.00 6.32 0.08 3.00 
12.30 M3 1.54 0.37 2.00 2.68 0.04 2.00 0.55 0.26 2.00 1.36 0.37 3.00 
22.30 M1 2.51 0.16 3.00 12.27 0.25 2.00 2.68 0.12 2.00 13.62 0.31 2.00 
22.30 M2 5.15 0.22 3.00 6.81 0.30 2.00 4.88 0.08 2.00 23.17 0.24 2.00 
22.30 M3 3.35 0.51 3.00 6.84 0.60 2.00 7.01 0.34 2.00 10.04 0.15 3.00 
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Appendix 3.5 RNA sequencing data    
 
Appendix 3.5.1 Sample 1  
 
For each cir gene, the total length is given, followed by length of the gene found to be 
unique to that cir, or present in other cirs. The number of RNA sequence reads that 
were mapped to each cir gene is given, along with the mean, geometric mean, median 
and the minimum and maximum errors of the mean. In addition, the product of each 
gene is given, as transcripts belonging to three highly divergent ‘cir-like’ genes were 
also detected. 
 
 
Name
Gene 
length
Non-unique 
sequence
Unique 
sequence
Number of 
reads mapping Max Min
Geometric 
Mean Mean Median Product
PCAS_010020 893 380 513 6 2 0 1.05 0.4 1 CIR protein
PCAS_010030 902 671 231 2 2 0 1 0.39 1 CIR protein
PCAS_010120 1055 509 546 1100 155 8 67.25 74.39 75 CIR protein
PCAS_011450 890 0 890 50 11 0 1.7 2.06 2 CIR protein
PCAS_011510 959 57 902 5 2 0 1.02 0.22 1 CIR protein
PCAS_011520 917 0 917 6 2 0 1.03 0.23 1 CIR protein
PCAS_011530 902 38 864 6 1 0 1 0.26 1 CIR protein
PCAS_030020 881 0 881 14 2 0 1.07 0.6 1 CIR protein
PCAS_030030 845 272 573 4 1 0 1 0.24 1 CIR protein
PCAS_030040 917 380 537 19 4 0 1.5 1.33 2 CIR protein
PCAS_030060 953 514 439 0 0 0 1 0 1 CIR protein
PCAS_030080 959 284 675 2 2 0 1.01 0.09 1 CIR protein
PCAS_030090 950 24 926 30 6 0 1.39 1.19 2 CIR protein
PCAS_030110 941 796 145 5 4 0 1.44 1.31 2 CIR protein
PCAS_030120 1079 922 157 0 0 0 1 0 1 CIR protein
PCAS_030150 1742 341 1401 2 1 0 1 0.05 1 CIR protein
PCAS_030180 2030 0 2030 2 1 0 1 0.04 1 CIR protein
PCAS_030220 959 0 959 37 6 0 1.54 1.42 2 CIR protein
PCAS_030210 959 0 959 37 6 0 1.54 1.42 2 CIR protein
PCAS_030270 1301 0 1301 116 9 0 2.77 3.31 4 CIR protein
PCAS_040010 941 315 626 20 6 0 1.4 1.18 2 CIR protein
PCAS_040020 1718 1480 238 3 2 0 1.03 0.44 1 CIR protein
PCAS_040030 947 35 912 15 7 0 1.1 0.6 1 CIR protein
PCAS_040040 914 573 341 14 6 0 1.6 1.56 2 CIR protein
PCAS_040050 980 257 723 6 2 0 1.04 0.31 1 CIR protein
PCAS_040110 941 214 727 22 5 0 1.32 1.09 2 CIR protein
PCAS_042030 950 86 864 3 2 0 1.01 0.13 1 CIR protein
PCAS_050020 932 0 932 60 17 0 1.73 2.4 2 CIR protein
PCAS_050060 857 0 857 16 4 0 1.15 0.68 1 CIR protein
PCAS_050070 917 16 901 12 3 0 1.1 0.48 1 CIR protein
PCAS_060040 950 0 950 14 3 0 1.08 0.54 1 CIR protein
PCAS_070020 974 487 487 3 3 0 1.06 0.25 1 CIR protein
PCAS_070030 932 478 454 6 2 0 1.07 0.45 1 CIR protein
PCAS_070050 893 465 428 11 6 0 1.22 0.98 2 CIR protein
PCAS_070100 1073 30 1043 26 5 0 1.24 0.92 2 CIR protein
PCAS_070130 893 50 843 166 20 0 6.23 7.29 8 CIR protein
PCAS_070160 902 41 861 4 2 0 1.02 0.16 1 CIR protein
PCAS_073160 896 0 896 15 5 0 1.14 0.62 1 CIR protein
PCAS_073180 932 0 932 15 5 0 1.11 0.6 1 CIR protein
PCAS_073190 905 0 905 14 4 0 1.11 0.59 1 CIR protein
PCAS_073200 929 0 929 51 8 0 1.85 2.02 3 CIR protein
PCAS_093820 731 717 14 0 0 0 1 0 1 CIR protein
PCAS_104000 1124 0 1124 92 11 0 2.39 3.03 3 CIR protein
PCAS_104110 917 0 917 15 3 0 1.13 0.61 1 CIR protein
PCAS_104100 917 0 917 15 3 0 1.13 0.61 1 CIR protein
PCAS_104120 920 0 920 38 12 0 1.49 1.53 2 CIR protein
PCAS_104130 926 0 926 29 12 0 1.39 1.18 1 CIR protein
PCAS_110020 845 0 845 108 18 0 3.73 4.72 5 CIR protein
PCAS_120020 929 0 929 17 6 0 1.17 0.66 1 CIR protein
PCAS_120030 953 0 953 25 4 0 1.28 0.97 2 CIR protein
PCAS_120040 986 0 986 8 2 0 1.03 0.31 1 CIR protein
PCAS_120050 914 0 914 8 2 0 1.04 0.34 1 CIR protein
PCAS_120060 911 0 911 18 4 0 1.26 0.72 1 CIR protein
PCAS_120070 881 0 881 11 3 0 1.05 0.44 1 CIR protein
PCAS_124630 1106 513 593 11 4 0 1.12 0.69 1 CIR protein
PCAS_124690 1100 0 1100 11 3 0 1.06 0.36 1 CIR protein
PCAS_130020 959 0 959 12 6 0 1.11 0.48 1 CIR protein
PCAS_130030 950 0 950 9 2 0 1.04 0.34 1 CIR protein
PCAS_130050 944 0 944 4 1 0 1 0.15 1 CIR protein
PCAS_130070 1985 0 1985 9 2 0 1.02 0.16 1 CIR protein
PCAS_130080 2318 0 2318 11 3 0 1.01 0.18 1 CIR protein
PCAS_137120 923 815 108 1 1 0 1 0.28 1 CIR protein
PCAS_137130 911 447 464 5 2 0 1.03 0.37 1 CIR protein
PCAS_137150 1058 0 1058 19 4 0 1.14 0.66 1 CIR protein
PCAS_137160 878 0 878 106 11 0 3.61 4.48 5 CIR protein
PCAS_140020 968 0 968 20 6 0 1.18 0.76 1 CIR protein
PCAS_140030 917 0 917 12 4 0 1.15 0.49 1 CIR protein
PCAS_140040 926 0 926 18 4 0 1.14 0.7 1 CIR protein
PCAS_140070 929 0 929 28 4 0 1.3 1.12 2 CIR protein
PCAS_140090 860 0 860 6 4 0 1.01 0.28 1 CIR protein
PCAS_140130 866 0 866 43 8 0 1.68 1.84 2 CIR protein
PCAS_146850 1082 0 1082 13 3 0 1.08 0.45 1 CIR protein
PCAS_146870 935 0 935 3 2 0 1 0.12 1 CIR protein
PCAS_052430 716 0 716 978 211 4 35.81 50.46 45 CIR-like protein
PCAS_090030 1199 0 1199 36 8 0 1.32 1.1 2 CIR-like protein
PCAS_146840 587 0 587 22 9 0 1.45 1.38 1 CIR-like protein
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Appendix 3.5.2 Sample 2  
 
Here, only the number of reads mapping to each cir gene is given, as full statistics for 
this sample had not been calculated at the time of writing. 
 
 
Name
Gene 
length
Non-unique 
sequence
Unique 
sequence
Number of 
reads mapping Max Min
Geometric 
Mean Mean Median Product
PCAS_010020 893 380 513 6 2 0 1.05 0.4 1 CIR protein
PCAS_010030 902 671 231 2 2 0 1 0.39 1 CIR protein
PCAS_010120 1055 509 546 1100 155 8 67.25 74.39 75 CIR protein
PCAS_011450 890 0 890 50 11 0 1.7 2.06 2 CIR protein
PCAS_011510 959 57 902 5 2 0 1.02 0.22 1 CIR protein
PCAS_011520 917 0 917 6 2 0 1.03 0.23 1 CIR protein
PCAS_011530 902 38 864 6 1 0 1 0.26 1 CIR protein
PCAS_030020 881 0 881 14 2 0 1.07 0.6 1 CIR protein
PCAS_030030 845 272 573 4 1 0 1 0.24 1 CIR protein
PCAS_030040 917 380 537 19 4 0 1.5 1.33 2 CIR protein
PCAS_030060 953 514 439 0 0 0 1 0 1 CIR protein
PCAS_030080 959 284 675 2 2 0 1.01 0.09 1 CIR protein
PCAS_030090 950 24 926 30 6 0 1.39 1.19 2 CIR protein
PCAS_030110 941 796 145 5 4 0 1.44 1.31 2 CIR protein
PCAS_030120 1079 922 157 0 0 0 1 0 1 CIR protein
PCAS_030150 1742 341 1401 2 1 0 1 0.05 1 CIR protein
PCAS_030180 2030 0 2030 2 1 0 1 0.04 1 CIR protein
PCAS_030220 959 0 959 37 6 0 1.54 1.42 2 CIR protein
PCAS_030210 959 0 959 37 6 0 1.54 1.42 2 CIR protein
PCAS_030270 1301 0 1301 116 9 0 2.77 3.31 4 CIR protein
PCAS_040010 941 315 626 20 6 0 1.4 1.18 2 CIR protein
PCAS_040020 1718 1480 238 3 2 0 1.03 0.44 1 CIR protein
PCAS_040030 947 35 912 15 7 0 1.1 0.6 1 CIR protein
PCAS_040040 914 573 341 14 6 0 1.6 1.56 2 CIR protein
PCAS_040050 980 257 723 6 2 0 1.04 0.31 1 CIR protein
PCAS_040110 941 214 727 22 5 0 1.32 1.09 2 CIR protein
PCAS_042030 950 86 864 3 2 0 1.01 0.13 1 CIR protein
PCAS_050020 932 0 932 60 17 0 1.73 2.4 2 CIR protein
PCAS_050060 857 0 857 16 4 0 1.15 0.68 1 CIR protein
PCAS_050070 917 16 901 12 3 0 1.1 0.48 1 CIR protein
PCAS_060040 950 0 950 14 3 0 1.08 0.54 1 CIR protein
PCAS_070020 974 487 487 3 3 0 1.06 0.25 1 CIR protein
PCAS_070030 932 478 454 6 2 0 1.07 0.45 1 CIR protein
PCAS_070050 893 465 428 11 6 0 1.22 0.98 2 CIR protein
PCAS_070100 1073 30 1043 26 5 0 1.24 0.92 2 CIR protein
PCAS_070130 893 50 843 166 20 0 6.23 7.29 8 CIR protein
PCAS_070160 902 41 861 4 2 0 1.02 0.16 1 CIR protein
PCAS_073160 896 0 896 15 5 0 1.14 0.62 1 CIR protein
PCAS_073180 932 0 932 15 5 0 1.11 0.6 1 CIR protein
PCAS_073190 905 0 905 14 4 0 1.11 0.59 1 CIR protein
PCAS_073200 929 0 929 51 8 0 1.85 2.02 3 CIR protein
PCAS_093820 731 717 14 0 0 0 1 0 1 CIR protein
PCAS_104000 1124 0 1124 92 11 0 2.39 3.03 3 CIR protein
PCAS_104110 917 0 917 15 3 0 1.13 0.61 1 CIR protein
PCAS_104100 917 0 917 15 3 0 1.13 0.61 1 CIR protein
PCAS_104120 920 0 920 38 12 0 1.49 1.53 2 CIR protein
PCAS_104130 926 0 926 29 12 0 1.39 1.18 1 CIR protein
PCAS_110020 845 0 845 108 18 0 3.73 4.72 5 CIR protein
PCAS_120020 929 0 929 17 6 0 1.17 0.66 1 CIR protein
PCAS_120030 953 0 953 25 4 0 1.28 0.97 2 CIR protein
PCAS_120040 986 0 986 8 2 0 1.03 0.31 1 CIR protein
PCAS_120050 914 0 914 8 2 0 1.04 0.34 1 CIR protein
PCAS_120060 911 0 911 18 4 0 1.26 0.72 1 CIR protein
PCAS_120070 881 0 881 11 3 0 1.05 0.44 1 CIR protein
PCAS_124630 1106 513 593 11 4 0 1.12 0.69 1 CIR protein
PCAS_124690 1100 0 1100 11 3 0 1.06 0.36 1 CIR protein
PCAS_130020 959 0 959 12 6 0 1.11 0.48 1 CIR protein
PCAS_130030 950 0 950 9 2 0 1.04 0.34 1 CIR protein
PCAS_130050 944 0 944 4 1 0 1 0.15 1 CIR protein
PCAS_130070 1985 0 1985 9 2 0 1.02 0.16 1 CIR protein
PCAS_130080 2318 0 2318 11 3 0 1.01 0.18 1 CIR protein
PCAS_137120 923 815 108 1 1 0 1 0.28 1 CIR protein
PCAS_137130 911 447 464 5 2 0 1.03 0.37 1 CIR protein
PCAS_137150 1058 0 1058 19 4 0 1.14 0.66 1 CIR protein
PCAS_137160 878 0 878 106 11 0 3.61 4.48 5 CIR protein
PCAS_140020 968 0 968 20 6 0 1.18 0.76 1 CIR protein
PCAS_140030 917 0 917 12 4 0 1.15 0.49 1 CIR protein
PCAS_140040 926 0 926 18 4 0 1.14 0.7 1 CIR protein
PCAS_140070 929 0 929 28 4 0 1.3 1.12 2 CIR protein
PCAS_140090 860 0 860 6 4 0 1.01 0.28 1 CIR protein
PCAS_140130 866 0 866 43 8 0 1.68 1.84 2 CIR protein
PCAS_146850 1082 0 1082 13 3 0 1.08 0.45 1 CIR protein
PCAS_146870 935 0 935 3 2 0 1 0.12 1 CIR protein
PCAS_052430 716 0 716 978 211 4 35.81 50.46 45 CIR-like protein
PCAS_090030 1199 0 1199 36 8 0 1.32 1.1 2 CIR-like protein
PCAS_146840 587 0 587 22 9 0 1.45 1.38 1 CIR-like protein
Name
Number of 
reads mapping Name
Number of 
reads mapping Name
Number of 
reads mapping
PCHAS_040030 124.4815679 PCHAS_011510 0 PCHAS_114700 13.20259054
PCHAS_040060 299.8874136 PCHAS_011520 49.03819342 PCHAS_114720 70.72816359
PCHAS_000320 0 PCHAS_011530 1.886084362 PCHAS_114750 0
PCHAS_070130 794.9845588 PCHAS_030020 1.886084362 PCHAS_120020 0
PCHAS_070160 0 PCHAS_030040 0 PCHAS_120040 0
PCHAS_041970 5.658253087 PCHAS_030070 1.886084362 PCHAS_120060 0.943042181
PCHAS_090030 120.7093992 PCHAS_030090 4.715210906 PCHAS_120070 1.886084362
PCHAS_060030 33.94951852 PCHAS_030110 3.772168725 PCHAS_130030 0
PCHAS_073180 76.38641668 PCHAS_030120 7.54433745 PCHAS_130060 1.886084362
PCHAS_000580 0 PCHAS_030140 0 PCHAS_130070 0
PCHAS_001120 0 PCHAS_030160 7.54433745 PCHAS_130080 24.51909671
PCHAS_000020 0 PCHAS_030190 0 PCHAS_130090 59.41165742
PCHAS_000040 9.430421812 PCHAS_030200 16.97475926 PCHAS_130100 1.886084362
PCHAS_000060 7.54433745 PCHAS_030210 9.430421812 PCHAS_130110 8.487379631
PCHAS_000070 9.430421812 PCHAS_030270 193.3236472 PCHAS_130120 15.0886749
PCHAS_000090 0 PCHAS_040080 3.772168725 PCHAS_130170 7.54433745
PCHAS_000100 22.63301235 PCHAS_040110 73.55729014 PCHAS_130220 1.886084362
PCHAS_000110 9.430421812 PCHAS_041950 0 PCHAS_130280 1.886084362
PCHAS_000120 12.25954836 PCHAS_041980 0 PCHAS_137030 58.46861524
PCHAS_000130 9.430421812 PCHAS_041990 0 PCHAS_137090 1.886084362
PCHAS_000140 0 PCHAS_042020 0 PCHAS_137110 0
PCHAS_000150 8.487379631 PCHAS_042030 5.658253087 PCHAS_140030 3.772168725
PCHAS_000170 1.886084362 PCHAS_042070 23.57605453 PCHAS_140040 1.886084362
PCHAS_000220 0 PCHAS_050020 5.658253087 PCHAS_140070 5.658253087
PCHAS_000270 0 PCHAS_050040 33.94951852 PCHAS_140090 3.772168725
PCHAS_000310 1.886084362 PCHAS_050060 1.886084362 PCHAS_140140 10.37346399
PCHAS_000340 0 PCHAS_050070 3.772168725 PCHAS_146770 7.54433745
PCHAS_000350 0.943042181 PCHAS_060060 0 PCHAS_146840 96.19030249
PCHAS_000360 0 PCHAS_060070 13.20259054 PCHAS_146860 0
PCHAS_000400 0.943042181 PCHAS_060100 20.74692799 PCHAS_146870 0
PCHAS_000410 0 PCHAS_060110 30.1773498 PCHAS_000180 0
PCHAS_000420 1.886084362 PCHAS_060120 102.7915978 PCHAS_041960 0
PCHAS_000470 9.430421812 PCHAS_060130 15.0886749 PCHAS_042010 0
PCHAS_000490 12.25954836 PCHAS_060160 1.886084362 PCHAS_060080 0
PCHAS_000500 11.31650617 PCHAS_070020 11.31650617 PCHAS_140130 0
PCHAS_000560 1.886084362 PCHAS_070030 1.886084362 PCHAS_001010 0
PCHAS_000570 0 PCHAS_070040 52.81036215 PCHAS_030150 0
PCHAS_000680 0 PCHAS_070070 11.31650617 PCHAS_040040 18.86084362
PCHAS_000720 8.487379631 PCHAS_070100 10.37346399 PCHAS_070090 14.14563272
PCHAS_000730 3.772168725 PCHAS_070170 1.886084362 PCHAS_073200 25.46213889
PCHAS_000770 2.829126544 PCHAS_073150 5.658253087 PCHAS_104250 0
PCHAS_000950 0 PCHAS_073160 0.943042181 PCHAS_130350 18.86084362
PCHAS_001040 5.658253087 PCHAS_073190 32.06343416 PCHAS_140020 18.86084362
PCHAS_001050 0 PCHAS_083690 370.6155772 PCHAS_030030 15.0886749
PCHAS_001060 0.943042181 PCHAS_083720 18.86084362 PCHAS_030060 0.943042181
PCHAS_001090 126.3676523 PCHAS_083760 0 PCHAS_030170 22.63301235
PCHAS_001100 35.83560289 PCHAS_090010 13.20259054 PCHAS_060140 16.97475926
PCHAS_001110 3.772168725 PCHAS_100040 0 PCHAS_070050 0
PCHAS_001130 0 PCHAS_100060 5.658253087 PCHAS_070060 49.03819342
PCHAS_010020 1.886084362 PCHAS_100110 1.886084362 PCHAS_073130 30.1773498
PCHAS_010040 0 PCHAS_104230 0 PCHAS_093820 17.91780144
PCHAS_010080 0.943042181 PCHAS_104260 13.20259054 PCHAS_104200 37.72168725
PCHAS_011330 26.40518107 PCHAS_104270 5.658253087 PCHAS_120050 1.886084362
PCHAS_011450 79.21554322 PCHAS_110020 115.0511461 PCHAS_130050 1.886084362
PCHAS_011480 7.54433745 PCHAS_110030 4238.974605 PCHAS_146790 0
PCHAS_011490 10.37346399 PCHAS_114600 13.20259054 PCHAS_146850 0.943042181
PCHAS_011500 0.943042181 PCHAS_114640 14.14563272
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Appendix 3.6 Beta globin primers and RT-qPCR analysis 
 
Appendix 3.6.1 Beta globin primers  
 
 
Primer design was described in chapter 3. The ID column indicates the names of the forward (F) and 
reverse (R) primers which successfully amplified beta globin transcripts. The reverse primer sequence is 
given as the reverse complement (RC) of that present in the beta globin gene. Tm refers to the melting 
temperature of each primer. The product size is shown as length in nucleotides. 
 
 
 
Appendix 3.6.2 Analysis of RNA quality by spectroscopy 
 
 
Where mice 
infected with 105 
and 108 iRBCs 
were labelled as 
10e5 and 10e8, 
respectively.
 
 
 
 
Appendix 3.6.3 Analysis of RNA quality by gel electrophoresis 
 
  
Samples were numbered as follows: 
1) 1x105 P. chabaudi infection: M1 
2) 1x105 P. chabaudi infection: M2 
3) 1x105 P. chabaudi infection: M3 
4) 1x108 P. chabaudi infection: M1 
5) 1x108 P. chabaudi infection: M2 
6) 1x108 P. chabaudi infection: M3 
7) Saponin lysis before: M1 
8) Saponin lysis before: M2 
9) Saponin lysis before: M3 
10) Saponin lysis after: M1 
11) Saponin lysis after: M2 
12) Saponin lysis after: M3 
13) MACS purification before: M1 
14) MACS purification after: M1 
15) MACS purification before: M2 
16) MACS purification after: M2 
17) MACS purification before: M3 
18) MACS purification after: M3 
ID Sequence Tm 
Product 
size
Tm 
difference
HBB-B2 F CTGCATGTGGATCCTGAGAA 64.0 ºC
HBB-B2 R 
(RC)
TCATTTCCCCACACTTGACA 64.1 ºC
NM_016956.2 (mus musculus 
hemoglobin, beta adult minor 
chain (Hbb-b2), mRNA) 
NM_008220.2 (Mus musculus 
230 (cDNA) 
858 (gDNA)
0.1 ºC
BLAST matches
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Appendix 3.6.4 Analysis of RT-qPCR data 
 
Cq values obtained from RT-qPCR experiments were analyzed by the following 
procedure, as outlined in chapter 3 and appendix 3.4.1, with the following exception: 
The reciprocal mean Cq of beta globin was divided by the reciprocal mean Cq of beta 
tubulin for each sample to create a ratio of beta globin: beta tubulin transcript levels. 
 
 
 
Appendix 3.6.5 beta globin: beta tubulin transcript levels in Figure 24. 
 
Mouse 1 Mouse 2 Mouse 3 
Sample Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
Differential dose experiment. Mice infected with: 
1x105 iRBCs 1.42 0.13 3 1.42 0.05 3 1.66 0.12 3 
1x108 iRBCs 1.11 0.07 3 1.35 0.17 3 1.28 0.14 3 
Saponin lysis experiment: 
Before 1.46 0.18 3 1.24 0.22 3 1.45 0.18 3 
After 1.40 0.61 2 1.48 0.01 3 1.41 0.08 3 
MACS purification experiment: 
Before 1.36 0.13 3 1.40 0.24 3 1.33 0.19 3 
After 1.33 0.11 3 1.43 0.10 2 1.29 0.08 3 
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Appendix 5.1 Controls for immuno-fluorescence assays 
 
Where:  
1) Primary Abs were Anti-CIR & Anti-Rabbit Alexa 488, with the secondary 
reagents Anti-Glycophorin A (Ter119)-biotin & Streptavidin-Texas Red 
2) Primary Abs were Anti-CIR & Anti-Rabbit Alexa 488, with the secondary 
reagents Anti-MSP1 (NIMP23) & Anti-Mouse Alexa 595 
3) No primary antibody, with the secondary reagents Anti-Rabbit Alexa 488 & 
Streptavidin-Texas Red 
4) No primary antibody, with the secondary reagents Anti-Rabbit Alexa 488 & 
Anti-Mouse Alexa 595 
5) Primary Abs were Anti-Glycophorin A (Ter119)-biotin only, with the secondary 
reagents Anti-Rabbit Alexa 488 & Anti-Mouse Alexa 595 
6) Primary Abs were Anti-MSP1 (NIMP23) only with the secondary reagents Anti-
Rabbit Alexa 488 & Streptavidin-Texas Red 
7) Primary Abs were Anti-CIR only with the secondary reagent Streptavidin-Texas 
Red 
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Appendix 6.1 Rationale for the use of CIR peptides and proteins in 
the immunization and P. chabaudi challenge experiment. 
 
Rabbits were immunized with the two CIR sub-family specific peptides, and the 
recombinant CIR proteins PCHAS_040110 and PCHAS_000100, as described for the 
conserved CIR peptide in chapter 5. To ensure that Abs generated in response to CIR 
immunization recognized P. chabaudi proteins, rabbit anti-sera were absorbed against 
uninfected RBC membranes and used to probe western blots (as described in chapter 5). 
 
The figure above shows that all rabbits immunized with CIR proteins or peptides made 
Abs that recognized P. chabaudi proteins (present in the iRBC lanes), which did not 
recognize proteins from uninfected RBCs. Immunization of mice was thus expected to 
produce Abs with similar reactivities. 
 
 
Appendix 6.2 Experimental mice 
In this appendix, mice were labelled according to their cage number, listed below: 
 
JL1041 Donor RAG2-/- mouse (in which P. chabaudi paraites were expanded 
prior to infection of the challenge mice). 
JL1031 Immunized with saline in the presence of adjuvant  
JL1032 Immunized with MSP1p21 
JL1033 Immunized with the conserved CIR peptide 
JL1034 Immunized with the CIR sub-family U peptide 
JL1035 Immunized with the recombinant CIR PCHAS_040110 
JL1036 Immunized with the CIR sub-family A-F peptide 
JL1037 Immunized with the recombinant CIR PCHAS_000100 
JL1038 Immunized with the CIR cocktail 
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Appendix 6.3 Peptide immunization cross-reactivity 
 
ELISAs were performed using the un-conjugated sub-family U and A-F peptides, to 
determine whether mice immunized with CIR peptides made cross-reactive Abs 
recognizing other peptides, as described in chapter 6. Mice immunized with a CIR 
peptide made Abs recognizing that peptide, but not the other CIR peptide(s).  
 
 
 
The reactivity of sera from mice immunized with the conserved CIR peptide, sub-
family specific peptides or the CIR cocktail is colour coded as follows, with filled 
symbols: conserved CIR peptide, purple; CIR cocktail, pink; CIR sub-family U peptide, 
orange; CIR sub-family A-F peptide, light blue.  
In addition, pre-immune sera from the same mice prior to immunization are plotted 
according to the same colour code, using hollow symbols. The mean of three technical 
replicates is plotted, as a two-fold titration from a starting sera dilution of 1/100. Error 
bars represent the standard error of the mean. 
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Appendix 6.4 P. chabaudi challenge of MSP1p21 immunized mice
  
 
Titres of Abs recognizing MSP1p21 and CIR proteins and peptides were measured in the 
sera of mice immunized with saline alone or in the presence of adjuvant, and MSP1p21 
in the presence of adjuvant, a). Titre was defined as the dilution of immunized serum at 
which it reached the OD405 nm of serum from the same mouse prior to immunization, 
calculated using the mean of two technical replicates. Error bars represent the standard 
error of the mean. 
The geometric mean parasitaemia for these three groups of 5 mice are shown, b). Error 
bars represent the standard error of the mean. 
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Appendix 6.5 Anaemia during P. chabaudi infection  
 
 
Blood samples were taken from challenge mice on day 3 and day 8 of P. chabaudi 
infection. These were used to calculate the haematocrit (HCT%) of the blood for all 
mice, which is a measure of anaemia. The mean HCT% and 95 percentiles are plotted 
for each group of 5 mice. The groups are labelled according to their cage numbers. 
 
 
Appendix 6.6 RNA integrity   
Appendix 6.6.1 Spectroscopy. (M refers to individual mice). 
  
 
 
Sample Tube
Concentration  
(ng/ul) 500ng A260/A280
Position in 
96 well plate
JL1031 challenge M1 225.59 2.22 1.92 F5
M2 143.36 3.49 1.86 F6
M5 111.19 4.50 1.83 F7
JL1032 challenge M3 197.38 2.53 1.87 F8
M4 214.41 2.33 1.85 F9
M5 147.41 3.39 1.88 F10
JL1033 challenge M2 196.92 2.54 1.93 F11
M3 172.33 2.90 1.87 F12
M4 163.15 3.06 1.92 G1
JL1034 challenge M1 222.11 2.25 1.92 G2
M3 109.61 4.56 1.96 G3
M4 78.32 6.38 1.84 G4
JL1035 challenge M1 226.15 2.21 1.89 G5
M4 108.19 4.62 1.82 G6
M5 603.73 0.83 1.74 G7
JL1036 challenge M1 230.97 2.16 1.89 G8
M3 178.79 2.80 1.92 G9
M5 95.48 5.24 1.82 G10
JL1037 challenge M1 305.13 1.64 1.99 G11
M2 231.43 2.16 1.92 G12
M3 235.86 2.12 1.93 H1
JL1038 challenge M1 95.48 5.24 1.81 H2
M2 127.39 3.92 1.86 H3
M3 145.02 3.45 1.90 H4
Donor JL1041-2 1 561.77 0.89 1.69 H5
2 601.67 0.83 1.82 H6
M refers to individual mouse from the specified cage (labelledJL…)
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Appendix 6.6.2 Gel electrophoresis of 500ng RNA 
 
RNA was extracted from these samples at the same time as those in Appendix 3.7.3 (the 
numbering continues from these).  
 
28) JL1031 M1 
29) JL1031 M2 
30) JL1031 M5 
31) JL1032 M3 
32) JL1032 M4 
33) JL1032 M5 
34) JL1033 M2 
35) JL1033 M3 
36) JL1033 M4 
37) JL1034 M1 
38) JL1034 M3 
39) JL1034 M4 
40) JL1035 M1 
41) JL1035 M4 
42) JL1035 M5 
43) JL1036 M1 
44) JL1036 M3 
45) JL1036 M5 
46) JL1037 M1 
47) JL1037 M2 
48) JL1037 M3 
49) JL1038 M1 
50) JL1038 M2 
51) JL1038 M3 
52) JL1041 M1
 
Appendix 6.7 RT-qPCR analysis 
Analyzed as described in chapter 3 and Appendix 3.5.1.  
 
U1 U4 C1 E1 
Mouse: Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
Mean 
ratio SD N 
JL1031-1 4.10 0.22 3.00 2.33 0.39 3.00 1.05 0.22 3.00 1.65 0.27 3.00 
JL1031-2 11.63 0.93 3.00 0.41 0.22 2.00 4.45 0.29 3.00 1.46 0.24 3.00 
JL1031-5 1.92 0.15 3.00 0.19 0.29 3.00 0.88 0.33 3.00 1.63 0.00 3.00 
JL1032-3 1.19 0.29 3.00 0.15 0.19 3.00 0.73 0.22 3.00 0.44 0.07 3.00 
JL1032-4 3.44 0.16 3.00 0.58 0.27 3.00 1.37 0.04 3.00 0.91 0.12 3.00 
JL1032-5 3.39 0.17 3.00 0.22 0.13 3.00 1.45 0.09 3.00 0.97 0.18 3.00 
JL1033-2 0.35 0.06 3.00 0.04 0.18 3.00 0.14 0.22 3.00 0.16 0.22 3.00 
JL1033-3 1.39 0.29 3.00 0.15 0.14 3.00 0.53 0.59 3.00 0.41 0.39 3.00 
JL1033-4 0.91 0.17 3.00 0.12 0.22 3.00 1.05 2.06 3.00 0.39 0.28 3.00 
JL1034-1 0.76 0.05 3.00 0.10 0.13 3.00 1.50 0.00 3.00 6.79 0.54 3.00 
JL1034-3 1.67 0.14 3.00 0.44 0.82 2.00 4.26 0.00 3.00 15.99 0.00 2.00 
JL1034-4 3.45 0.47 3.00 1.40 0.27 3.00 0.70 0.00 3.00 2.64 0.00 3.00 
JL1035-1 2.29 0.09 3.00 0.32 0.01 3.00 0.44 0.00 3.00 10.16 0.20 3.00 
JL1035-4 2.53 0.08 3.00 0.25 0.06 3.00 1.26 0.00 3.00 4.73 0.00 2.00 
JL1035-5 0.59 0.25 3.00 0.13 0.11 3.00 6.63 2.66 3.00 28.18 1.93 3.00 
JL1036-1 2.81 0.38 3.00 2.05 1.30 3.00 0.51 0.00 3.00 1.92 0.00 3.00 
JL1036-3 4.10 0.00 3.00 1.62 0.03 2.00 0.69 0.07 3.00 1.56 0.43 2.00 
JL1036-5 11.63 0.00 3.00 4.53 0.00 3.00 42.70 1.56 3.00 262.96 1.61 3.00 
JL1037-1 1.92 0.02 3.00 0.75 0.06 3.00 0.88 0.11 3.00 13.02 3.53 3.00 
JL1037-2 1.19 0.00 3.00 0.46 0.00 3.00 4.25 3.99 3.00 115.67 4.95 3.00 
JL1037-3 3.44 0.00 3.00 1.44 0.63 3.00 0.37 0.19 3.00 3.99 0.64 2.00 
JL1038-1 3.39 0.00 3.00 3.57 1.01 3.00 0.82 0.81 3.00 0.93 0.19 2.00 
JL1038-2 1.39 0.00 3.00 0.54 0.00 3.00 20.66 4.88 3.00 3.29 0.75 3.00 
JL1038-3 1.08 0.47 3.00 0.14 0.59 3.00 0.59 0.30 3.00 0.70 0.23 3.00 
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